



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Chinese herbal medicines for treating osteoporosis (Review)

Liu Y, Liu JP, Xia Y

Liu Y, Liu JP, Xia Y.

Chinese herbal medicines for treating osteoporosis.

*Cochrane Database of Systematic Reviews* 2014, Issue 3. Art. No.: CD005467.

DOI: [10.1002/14651858.CD005467.pub2](https://doi.org/10.1002/14651858.CD005467.pub2).

[www.cochranelibrary.com](http://www.cochranelibrary.com)

---

**Chinese herbal medicines for treating osteoporosis (Review)**

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**WILEY**

**TABLE OF CONTENTS**

ABSTRACT .....	1
PLAIN LANGUAGE SUMMARY .....	2
SUMMARY OF FINDINGS .....	4
BACKGROUND .....	11
OBJECTIVES .....	12
METHODS .....	12
RESULTS .....	14
Figure 1. ....	15
Figure 2. ....	17
Figure 3. ....	18
DISCUSSION .....	33
AUTHORS' CONCLUSIONS .....	34
ACKNOWLEDGEMENTS .....	34
REFERENCES .....	35
CHARACTERISTICS OF STUDIES .....	46
DATA AND ANALYSES .....	149
Analysis 1.1. Comparison 1 Chinese herbal medicines versus placebo, Outcome 1 New fractures. ....	150
Analysis 1.2. Comparison 1 Chinese herbal medicines versus placebo, Outcome 2 Bone mineral density (BMD). ....	151
Analysis 1.3. Comparison 1 Chinese herbal medicines versus placebo, Outcome 3 Oestradiol (E2). ....	151
Analysis 1.4. Comparison 1 Chinese herbal medicines versus placebo, Outcome 4 Symptoms including pain, muscle fatigue and limited mobility. ....	151
Analysis 2.1. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 1 Bone mineral density (BMD). ....	153
Analysis 2.2. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 2 Oestradiol (E2). ....	154
Analysis 2.3. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 3 Bone Gla protein (BGP). ....	155
Analysis 3.1. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 1 New fractures. ....	171
Analysis 3.2. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 2 Bone mineral density (BMD). ....	172
Analysis 3.3. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 3 T score in BMD measurement. ....	183
Analysis 3.4. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 4 Symptoms including pain, muscle fatigue and limited mobility. ....	184
Analysis 3.5. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 5 Oestradiol (E2). ....	186
Analysis 3.6. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 6 Serum calcium (Ca). ....	190
Analysis 3.7. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 7 Phosphorus (P). ....	193
Analysis 3.8. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 8 Alkaline phosphatase (ALP). ....	195
Analysis 3.9. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 9 Bone Gla protein (BGP). ....	200
Analysis 3.10. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 10 Interleukin-6 (IL-6). ....	201
Analysis 3.11. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 11 Parathyroid hormone (PTH). ....	202
Analysis 3.12. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 12 Computed tomography (CT). ...	204
Analysis 4.1. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 1 New fractures. ....	217
Analysis 4.2. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 2 Bone mineral density (BMD). ....	218
Analysis 4.3. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 3 T score in BMD measurement. ....	229
Analysis 4.4. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 4 Quality of life. ....	230
Analysis 4.5. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 5 Symptoms including pain, muscle fatigue and limited mobility. ....	230
Analysis 4.6. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 6 Oestradiol (E2). ....	231
Analysis 4.7. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 7 Serum calcium (Ca). ....	232
Analysis 4.8. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 8 Phosphorus (P). ....	234

Analysis 4.9. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 9 Alkaline phosphatase (ALP). .....	235
Analysis 4.10. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 10 Bone Gla protein (BGP). .....	237
Analysis 4.11. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 11 Interleukin-6 (IL-6). .....	238
ADDITIONAL TABLES .....	239
APPENDICES .....	251
HISTORY .....	262
CONTRIBUTIONS OF AUTHORS .....	262
DECLARATIONS OF INTEREST .....	263
SOURCES OF SUPPORT .....	263
DIFFERENCES BETWEEN PROTOCOL AND REVIEW .....	263
INDEX TERMS .....	263

[Intervention Review]

# Chinese herbal medicines for treating osteoporosis

Yunxia Liu<sup>1</sup>, Jian Ping Liu<sup>2</sup>, Yun Xia<sup>3</sup>

<sup>1</sup>Department of Epidemiology and Biostatistics, School of Public Health, Shandong University, Jinan, China. <sup>2</sup>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. <sup>3</sup>Science of Education, Beijing University of Chinese Medicine Subsidiary Dongfang Hospital, Beijing, China

**Contact:** Yunxia Liu, Department of Epidemiology and Biostatistics, School of Public Health, Shandong University, 44 Wenhua Xilu Road, Jinan, 250012, China. [lyx7677@hotmail.com](mailto:lyx7677@hotmail.com), [yunxialiu@163.com](mailto:yunxialiu@163.com).

**Editorial group:** Cochrane Musculoskeletal Group.

**Publication status and date:** New, published in Issue 3, 2014.

**Citation:** Liu Y, Liu JP, Xia Y. Chinese herbal medicines for treating osteoporosis. *Cochrane Database of Systematic Reviews* 2014, Issue 3. Art. No.: CD005467. DOI: [10.1002/14651858.CD005467.pub2](https://doi.org/10.1002/14651858.CD005467.pub2).

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Chinese herbal medicines have been used for a long time to treat osteoporosis. The evidence of their benefits and harms needs to be systematically reviewed.

### Objectives

To assess the beneficial and harmful effects of Chinese herbal medicines as a general experimental intervention for treating primary osteoporosis by comparing herbal treatments with placebo, no intervention and conventional medicine.

### Search methods

We searched the following electronic databases to January 2013: the Specialised Register of the Cochrane Complementary Medicine Field, CENTRAL, MEDLINE, EMBASE, LILACS, JICST-E, AMED, Chinese Biomedical Database and CINAHL.

### Selection criteria

Randomised controlled trials of Chinese herbal medicines compared with placebo, no intervention or conventional medicine were included.

### Data collection and analysis

Two authors extracted data and assessed risk of bias independently. Disagreement was resolved by discussion.

### Main results

One hundred and eight randomised trials involving 10,655 participants were included. Ninety-nine different Chinese herbal medicines were tested and compared with placebo (three trials), no intervention (five trials) or conventional medicine (61 trials), or Chinese herbal medicines plus western medicine were compared with western medicine (47 trials). The risk of bias across all studies was unclear for most domains primarily due to inadequate reporting of study design. Although we rated the risk of selective reporting for all studies as unclear, only a few studies contributed numerical data to the key outcomes.

Seven trials reported fracture incidence, but they were small in sample size, suffered from various biases and tested different Chinese herbal medicines. These trials compared Kanggusong capsules versus placebo, Kanggusong granule versus Caltrate or ipriflavone plus Caltrate, Yigu capsule plus calcium versus placebo plus calcium, Xianlinggubao capsule plus Caltrate versus placebo plus Caltrate, Bushen Zhuanggu granules plus Caltrate versus placebo granules plus Caltrate, Kanggusong soup plus Caltrate versus Caltrate, Zhuangguqiangjin tablets and Shujinbogu tablets plus calcitonin ampoule versus calcitonin ampoule. The results were inconsistent.

**Chinese herbal medicines for treating osteoporosis (Review)**

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

One trial showed that Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol had a better effect on quality of life score (scale 0 to 100, higher is better) than calcium carbonate tablets and alfacalcidol (mean difference (MD) 5.30; 95% confidence interval (CI) 3.67 to 6.93).

Compared with placebo in three separate trials, Chinese herbal medicines (Migu decoction, Bushen Yigu soft extract, Kanggusong capsules) showed a statistically significant increase in bone mineral density (BMD) (e.g. Kanggusong capsules, MD 0.06 g/cm<sup>3</sup>; 95% CI 0.02 to 0.10). Compared with no intervention in five trials, only two showed that Chinese herbal medicines had a statistically significant effect on increase in BMD (e.g. Shigu yin, MD 0.08 g/cm<sup>3</sup>; 95% CI 0.03 to 0.13). Compared with conventional medicine in 61 trials, 23 showed that Chinese herbal medicines had a statistically significant effect on increase in BMD. In 48 trials evaluating Chinese herbal medicines plus western medication against western medication, 26 showed better effects of the combination therapy on increase in BMD.

No trial reported death or serious adverse events of Chinese herbal medicines, while some trials reported minor adverse effects such as nausea, diarrhoea, etc.

### Authors' conclusions

Current findings suggest that the beneficial effect of Chinese herbal medicines in improving BMD is still uncertain and more rigorous studies are warranted.

## PLAIN LANGUAGE SUMMARY

### Chinese herbal medicines for osteoporosis

#### Review question

We conducted a review of the effects of Chinese herbal medicines for people with primary osteoporosis. We found 108 studies with 10,655 people.

#### Background: what is primary osteoporosis and what are Chinese herbal medicines?

Bone is a living, growing part of your body. Throughout your lifetime, new bone cells grow and old bone cells break down to make room for the new, stronger bone. When you have osteoporosis, the old bone breaks down faster than the new bone can replace it. As this happens, the bones lose minerals (such as calcium). This makes bones weaker and more likely to break even after a minor injury, like a little bump or fall.

Chinese herbal medicines are products made from any part of medicinal plants (leaves, stems, buds, flowers or roots). Sometimes non-plant based components (for example insects, deer horn, snake, various shells and powdered fossil) are included. These can be used in the form of raw plant materials, or water or alcohol extracts of raw plant materials. Herbs can also be taken by mouth as capsules, tablets or liquids, or as injections.

Chinese herbal medicines are widely used in China for primary osteoporosis but their benefits and harms have not been appraised in order to inform clinical practice.

#### Study characteristics

After searching for all relevant studies up to January 2013, we found 108 studies with 10,655 people with osteoporosis. Ninety-nine different Chinese herbal medicines were tested and compared with placebo (three trials), no intervention (five trials) or conventional medicine (61 trials), or Chinese herbal medicines plus conventional medicine were compared with conventional medicine (47 trials). The average length of treatment was 5.7 months (ranging from 3 to 12 months).

#### Key results: what happens to people with osteoporosis who take Chinese herbal medicines?

##### New fractures

We are uncertain whether Chinese herbal medicines reduce the chance of having a new bone fracture. Seven trials evaluated the incidence of fractures. However, these trials were small and had flaws in their methods.

##### Quality of life

People who took Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol rated their quality of life to be 5.30 points better on a scale of 0 to 100 after three months compared to people who did not take the herbal medicine.

People who took Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol rated their quality of life to be 56.05 on a scale of 0 to 100.

People who took calcium carbonate tablets and alfacalcidol rated their quality of life to be 50.75 on a scale of 0 to 100.

### Chinese herbal medicines for treating osteoporosis (Review)

---

**Serious side effects or deaths**

No serious side effects or deaths occurred in the trials.

We often do not have precise information about side effects and complications. This is particularly true for rare but serious side effects. Possible side effects may include a mild stomach ache or diarrhoea.

**Bone mineral density** (the amount and type of minerals in the bone)

We found studies that compared Chinese herbal medicines with placebo (fake treatment), with no treatment and with conventional medicine. We also found studies that compared Chinese herbal medicines plus conventional medication with just conventional medication.

Compared to placebo (fake treatment), three studies showed that bone mineral density increased slightly with Chinese herbal medicines.

Compared to no treatment or conventional medicine, some studies showed an increase in bone mineral density with Chinese herbal medicines while others did not.

When Chinese herbal medicines plus conventional medication was compared with just conventional medicine, some studies showed an increase in bone mineral density while others did not.

**Quality of the evidence**

In people with osteoporosis:

- Chinese herbal medicines may improve bone mineral density and quality of life slightly. Further research is likely to change this estimate of how Chinese herbal medicines affect bone mineral density and quality of life.
- We are uncertain whether Chinese herbal medicines reduce the chance of having a new bone fracture.
- No trial reported death or serious side effects.

## SUMMARY OF FINDINGS

### Summary of findings for the main comparison. Chinese herbal medicines versus placebo for osteoporosis

#### Chinese herbal medicines versus placebo for osteoporosis

**Patient or population:** patients with osteoporosis

**Settings:** inpatients

**Intervention:** Chinese herbal medicine versus placebo

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments (95% CI)
	Assumed risk	Corresponding risk				
	Control (placebo)	Chinese herbal medicine				
<b>New fractures</b> (Kanggusong capsule versus placebo)  Follow-up: 12 months	<b>185 per 1000</b>	<b>0 per 1000</b> (0 to 157)	<b>RR 0.05</b> (0 to 0.85)	104 (1 study)	⊕⊕⊕⊕ <b>very low</b> 1,2,3	We are uncertain about the estimate <sup>3</sup>
<b>Quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
<b>Death</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
<b>Serious adverse events</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
<b>BMD of lumbar spine</b> (Kanggusong capsule versus placebo)  Follow-up: 12 months Scale from: 0 to 4	The mean BMD in the control groups was <b>0.82 g/cm<sup>3</sup></b>	The mean BMD in the intervention groups was <b>0.06 higher</b> (0.02 to 0.1 higher)		140 (1 study)	⊕⊕⊕⊕ <b>low</b> 1,4	MD 0.06 g/cm <sup>3</sup> (0.02 to 0.10)  Absolute risk difference 2% (1% to 3%)  Relative per cent change 7% (2% to 12%)  NNT 5 (3 to 13)
<b>BMD of ulna</b>	The mean BMD in the control	The mean BMD in the intervention groups		59 (1 study)	⊕⊕⊕⊕ <b>low</b> 1,4	MD 0.06 g/cm <sup>3</sup> (0.02 to 0.10)

(Bushen Yigu soft extract versus placebo) Follow-up: 3 months Scale from: 0 to 4	groups was <b>0.59 g/cm<sup>3</sup></b>	was <b>0.06 higher</b> (0.02 to 0.1 higher)			Absolute risk difference 2% (1% to 3%)  Relative per cent change 10% (3% to 17%)  NNT 3 (2 to 8)
<b>BMD of radius</b> (Bushen Yigu soft extract versus placebo) Follow-up: 3 months Scale from: 0 to 4	The mean BMD in the control groups was <b>0.58 g/cm<sup>3</sup></b>	The mean BMD in the intervention groups was <b>0.06 higher</b> (0.03 to 0.09 higher)	59 (1 study)	⊕⊕⊕⊕ <b>low</b> 1,4	MD 0.06 g/cm <sup>3</sup> (0.03 to 0.09)  Absolute risk difference 2% (1% to 2%)  Relative per cent change 10% (5% to 16%)  NNT 3 (2 to 6)

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**BMD:** bone mineral density; **CI:** confidence interval; **MD:** mean difference; **NNT:** number needed to treat; **RR:** risk ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup>No information on adequate sequence generation and not all the outcomes that were of interest in this review were reported.

<sup>2</sup>The total population size is less than 300 (a threshold rule-of-thumb value).

<sup>3</sup>Seven trials reported on the outcome of fracture incidence, but these trials were small in sample size, suffered from various biases, tested different Chinese herbal medicines and the results were not consistent.

<sup>4</sup>The total population size is less than 400 (a threshold rule-of-thumb value).

## Summary of findings 2. Chinese herbal medicines versus no intervention for osteoporosis

### Chinese herbal medicines versus no intervention for osteoporosis

**Patient or population:** patients with osteoporosis

**Settings:** inpatients and outpatients

**Intervention:** Chinese herbal medicine versus no intervention

Outcomes	Illustrative comparative risks* (95% CI)	Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
----------	--	--------------------------	------------------------------	---------------------------------	----------



	Assumed risk	Corresponding risk				
	Control (no intervention)	Chinese herbal medicine				
<b>New fractures</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
<b>Quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
<b>Death</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
<b>Serious adverse events</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
<b>BMD of lumbar spine</b> (Bushen Shengsui principle versus no intervention)  Follow-up: 6 months Scale from: 0 to 4	The mean BMD in the control groups was <b>0.82 g/cm<sup>3</sup></b>	The mean BMD in the intervention groups was <b>0.07 higher</b> (0.06 lower to 0.2 higher)		61 (1 study)	⊕⊕○○ <b>low</b> 1,2	MD 0.07 g/cm <sup>3</sup> (-0.06 to 0.20)  Absolute risk difference 2% (-2% to 5%)  Relative per cent change 9% (-7% to 24%)  Not statistically significant
<b>BMD of femoral neck</b> (Shigu yin versus no intervention)  Follow-up: 6 months Scale from: 0 to 4	The mean BMD in the control groups was <b>0.60 g/cm<sup>3</sup></b>	The mean BMD in the intervention groups was <b>0.08 higher</b> (0.03 to 0.13 higher)		80 (1 study)	⊕⊕○○ <b>low</b> 1,2	MD 0.08 g/cm <sup>3</sup> (0.03 to 0.13)  Absolute risk difference 2% (1% to 3%)  Relative per cent change 13% (5% to 22%)  NNT 4 (3 to 8)
<b>BMD of femoral neck</b> (Shengu capsule versus no intervention)  Follow-up: 6 months Scale from: 0 to 4	The mean BMD in the control groups was <b>0.62 g/cm<sup>3</sup></b>	The mean in the intervention groups was <b>0.02 higher</b> (0.06 lower to 0.09 higher)		34 (1 study)	⊕⊕○○ <b>low</b> 1,2	MD 0.02 g/cm <sup>3</sup> (-0.06 to 0.09)  Absolute risk difference 1% (-2% to 2%)  Relative per cent change 3% (-10% to 15%)  Not statistically significant

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**BMD:** bone mineral density; **CI:** confidence interval; **MD:** mean difference; **NNT:** number needed to treat; **RR:** risk ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup>No information on adequate sequence generation and not all the outcomes that were of interest in this review were reported.

<sup>2</sup>The total population size is less than 400 (a threshold rule-of-thumb value).

### Summary of findings 3. Chinese herbal medicines versus western medicine for osteoporosis

#### Chinese herbal medicines versus western medicine for osteoporosis

**Patient or population:** patients with osteoporosis

**Settings:** outpatients and inpatients

**Intervention:** Chinese herbal medicine versus western medicine

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control (western medicine)	Chinese herbal medicine				
<b>New fractures</b> (Kanggusong granule versus calcium and vitamin D) Follow-up: 9 months	<b>0 per 40</b>	<b>0 per 31</b>	Not estimable	71 (1 study)	⊕⊕⊕⊕ <b>very low</b> <sup>1,2</sup>	We are uncertain about the estimate <sup>3</sup>
<b>Quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
<b>Death</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
<b>Serious adverse events</b>	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome

<p><b>BMD of lumbar spine</b> (Bushenjianpi Zhuangguayin versus Caltrate and calcium)</p> <p>Follow-up: 12 weeks Scale from: 0 to 4</p>	<p>The mean BMD in the control groups was <b>0.79 g/cm<sup>3</sup></b></p>	<p>The mean BMD in the intervention groups was <b>0.16 higher</b> (0.1 to 0.22 higher)</p>	<p>100 (1 study)</p>	<p>⊕⊕⊕⊕ <b>low</b><sup>1,2</sup></p>	<p>MD 0.16 g/cm<sup>3</sup> (0.10 to 0.22)</p> <p>Absolute risk difference 4% (3% to 6%)</p> <p>Relative per cent change 20% (13% to 18%)</p> <p>NNT 3 (2 to 4)</p>
<p><b>BMD of lumbar spine</b> (Liuwei Dihuang pills versus calcium and vitamin D)</p> <p>Follow-up: 6 months Scale from: 0 to 4</p>	<p>The mean BMD in the control groups was <b>0.89 g/cm<sup>3</sup></b></p>	<p>The mean BMD in the intervention groups was <b>0.05 higher</b> (0.03 to 0.07 higher)</p>	<p>71 (1 study)</p>	<p>⊕⊕⊕⊕ <b>low</b><sup>1,2</sup></p>	<p>MD 0.05 g/cm<sup>3</sup> (0.03 to 0.07)</p> <p>Absolute risk difference 1% (1% to 2%)</p> <p>Relative per cent change 6% (3% to 8%)</p> <p>NNT 3 (2 to 5)</p>
<p><b>BMD of femoral neck</b> (Kanggusong granule versus calcium and vitamin D)</p> <p>Follow-up: 9 months Scale from: 0 to 4</p>	<p>The mean BMD in the control groups was <b>0.71 g/cm<sup>3</sup></b></p>	<p>The mean BMD in the intervention groups was <b>0.01 higher</b> (0.03 lower to 0.05 higher)</p>	<p>71 (1 study)</p>	<p>⊕⊕⊕⊕ <b>low</b><sup>1,2</sup></p>	<p>MD 0.01 g/cm<sup>3</sup> (-0.03 to 0.05)</p> <p>Absolute risk difference 0.25% (-1% to 1%)</p> <p>Relative per cent change 1% (-4% to 7%)</p> <p>Not statistically significant</p>

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**BMD:** bone mineral density; **CI:** confidence interval; **MD:** mean difference; **NNT:** number needed to treat; **RR:** risk ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup>No information on adequate sequence generation and not all the outcomes that were of interest in this review were reported.

<sup>2</sup>The total population size is less than 400 (a threshold rule-of-thumb value).

<sup>3</sup>Only one trial out of 61 reported this outcome.

## Summary of findings 4. Chinese herbal medicines plus western medicine versus western medicine for osteoporosis

### Chinese herbal medicines plus western medicine versus western medicine for osteoporosis

**Patient or population:** patients with osteoporosis

**Settings:** inpatients

**Intervention:** Chinese herbal medicine plus western medicine versus western medicine

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control (western medicine)	Chinese herbal medicine plus western medicine				
<b>New fractures</b> (Yigu capsule plus calcium versus placebo plus calcium)  Follow-up: 6 months	<b>114 per 1000</b>	<b>0 per 1000</b> (0 to 114)	<b>RR 0.06</b> (0 to 1)	140 (1 study)	⊕⊕⊕⊕ <b>very low</b> <sup>1,2</sup>	We are uncertain about the estimate <sup>3</sup>
<b>New fractures</b> (Xianlinggubao capsule (low-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D)  Follow-up: 12 months	<b>17 per 1000</b>	<b>0 per 1000</b> (0 to 134)	<b>RR 0.33</b> (0.01 to 8.02)	120 (1 study)	⊕⊕⊕⊕ <b>very low</b> <sup>1,2</sup>	We are uncertain about the estimate <sup>3</sup>
<b>New fractures</b> (Bushen Zhuanggu granules plus calcium and vitamin D versus placebo granules plus calcium and vitamin D)  Follow-up: 5 years	<b>104 per 1000</b>	<b>46 per 1000</b> (14 to 149)	<b>RR 0.44</b> (0.13 to 1.43)	155 (1 study)	⊕⊕⊕⊕ <b>very low</b> <sup>1,2</sup>	We are uncertain about the estimate <sup>3</sup>
<b>New fractures</b> (Kanggusong soup plus calcium and vitamin D versus calcium and vitamin D)  Follow-up: 3 months	<b>33 per 1000</b>	<b>0 per 1000</b> (0 to 178)	<b>RR 0.22</b> (0.01 to 5.34)	75 (1 study)	⊕⊕⊕⊕ <b>very low</b> <sup>1,2</sup>	We are uncertain about the estimate <sup>3</sup>



<b>Quality of life</b> (Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol versus calcium carbonate tablets and alfacalcidol) Follow-up: 3 months Scale from: 0 to 100	The mean quality of life in the control groups was <b>50.75</b>	The mean quality of life in the intervention groups was <b>5.3 higher</b> (3.67 to 6.93 higher)	80 (1 study)	⊕⊕⊕⊕ <b>low</b> 1,4	MD 5.30 g/cm <sup>3</sup> (3.67 to 6.93)  Absolute risk difference 5% (4% to 7%)  Relative per cent change 10% (7% to 14%)  NNT 2 (2 to 3)
<b>Death</b>	See comment	See comment	Not estimable	0 (0)	See comment No trial reported this outcome
<b>Serious adverse events</b>	See comment	See comment	Not estimable	0 (0)	See comment No trial reported this outcome

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **MD:** mean difference; **NNT:** number needed to treat; **RR:** risk ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup>No information on adequate sequence generation and not all the outcomes that were of interest in this review were reported.

<sup>2</sup>The total population size is less than 300 (a threshold rule-of-thumb value).

<sup>3</sup>Five trials reported on the outcome of fracture incidence, but these trials were small in sample size, suffered from various biases, tested different Chinese herbal medicines and the results were not consistent.

<sup>4</sup>The total population size is less than 400 (a threshold rule-of-thumb value).

## BACKGROUND

### Description of the condition

Osteoporosis is a worldwide common public health problem with high prevalence (Cole 2008; Woolf 2003). It is defined as a progressive, systemic disease characterised by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased susceptibility to fractures (Diez 2002; NOF 2014; Wylie 2010). While osteoporosis is often thought of as an older person's disease, it can strike at any age (Cole 2008; NOF 2014). It is estimated that worldwide osteoporosis is currently a problem for 200 million middle-aged and elderly persons, and there are 75 million people with osteoporosis in America, Western Europe and Japan. In terms of its incidence rate osteoporosis has been ranked as seventh among common diseases worldwide (Nguyen 2000; Xue 2000). In China, there are already 50 million people with osteoporosis and a large-scale epidemiological study found that the prevalence in people over 50 years is 50% (Qiu 2001). As life expectancy increases, this number is expected to continue to grow (Bengner 1988; Cumming 1997; Kushner 1998).

Osteoporosis is a highly prevalent disorder associated with sequelae that often have devastating effects on the quality of life of those affected, and may be a high risk factor for death. Morbidity and mortality rates from osteoporosis-related injuries are high (Diez 2002; Holroyd 2008). Osteoporosis-related sequelae therefore have a major impact on healthcare costs, both direct and indirect, especially those related to hip fracture (Diez 2002; Holroyd 2008). Three kinds of major fractures are associated with osteoporosis: hip, vertebrae and the distal forearm (such as wrist) (Diez 2002; NOF 2014). Epidemiologic studies from several countries have reported the incidence and impact of hip fractures, and their absolute number is expected to double in the next 25 years, with a projected total of more than six million occurrences per year throughout the world by the year 2050 (Genant 1999). Some studies have found that the mortality rate associated with hip fracture is 15% to 25%, caused by complications such as pneumonia, other infections and cardiac insufficiency. The expense of therapy and hospitalisation is USD 25 billion each year (Xue 2000). It is difficult to calculate the incidence of spinal fractures because many are asymptomatic or may not be diagnosed, however they are also an important fracture in many elderly people (Diez 2002). Therefore, osteoporosis has become an important social and medical care problem.

Osteoporosis is often called the 'silent disease' because bone loss occurs gradually and without symptoms or warning signs until the disease is advanced (Cole 2008; NOF 2014; Wylie 2010). Some people may suffer from chronic or acute pain, muscle fatigue and limited mobility, but they may not know that they have osteoporosis until their bones become so weak that a sudden strain, bump or fall causes a fracture or a vertebra to collapse. Collapsed vertebrae may initially be felt or seen in the form of severe back pain, loss of height or spinal deformities such as kyphosis (stooped posture) (IOF 2014; Xia 2001).

At present, the pathogenesis of osteoporosis is still not clear, but may be associated with heredity, poor nutrition, malabsorption, gonadal insufficiency, inadequate physical activity, lack of sunlight irradiation and smoking (Diez 2002; Raisz 2005; Winsloe 2009; Zhou 2001b).

### Description of the intervention

Currently, there are a range of therapeutic approaches for osteoporosis. Conventional medicines include oestrogen, raloxifene, bisphosphonates (such as alendronate, etidronate, risedronate), calcitriol, calcitonin, Caltrate (Confavreux 2012; Diez 2002; Guo 2003a; Guo 2003b; Horst-Sikorska 2011; Leong 2002; Rizzoli 2012; Sambrook 2000; Silverman 2012; Wells 2008a; Wells 2008b; Wells 2008c; Zhang 2012). Although fluoride has the ability to increase bone mineral density (BMD) at the lumbar spine (Haugenauer 2005), it has been found ineffective for reducing vertebral fractures in postmenopausal women with osteoporosis. Oestrogen therapy has limited effectiveness and long-term use increases the risks of breast cancer, endometrial haemorrhage and endometrial cancer (Leong 2002). A Cochrane systematic review shows that exercise has the potential to be a safe and effective way to avert bone loss in postmenopausal women (Howe 2011). Although concerted research efforts have been made to identify safe and effective therapies, treatment options are still needed.

In China and other countries, people are looking for alternative modalities to treat osteoporosis and Chinese herbal medicines are one of the popular therapies used. Chinese herbal medicines are defined in this review as products derived from any part of medicinal plants (e.g. leaves, stems, buds, flowers, roots or tubers) used for the treatment of osteoporosis (Rates 2001) and some non-plant based component (e.g. insects, deer horn, snake, various shells and powdered fossil, etc.) are sometimes included. Chinese herbal medicines can be in the form of raw plant materials, or water or alcohol extracts of raw plant materials, or herbal formulations in capsules, tablets, decoctions or injections.

### How the intervention might work

In China, many herbs have been tested in clinical trials and claims made as to their effectiveness in treating osteoporosis (Cao GY 2010; Dong Y 2010; Jian QQ 2010; Wang JM 2008; Zhang XG 2011). For example, Zhang et al found that Zhuangguayin (a formula containing different herbs, such as common yam rhizome, red and white peony root, Chinese angelica, Radix codonopsis pilosulae, liquorice root, etc. plus dry powder of Placenta hominis) improved primary osteoporosis, and proposed that the therapy improved the BMD of the lumbar spine and femoral neck (Zhang XG 2011). One clinical trial found that Gujian capsule (studied and produced by Xiyuan Hospital under the Institute of Traditional Chinese Medicine) improved BMD, increased levels of calcitonin, oestradiol, testosterone, follicle-stimulating hormone and luteinising hormone, and decreased levels of parathyroid hormone (Meng 2003).

### Why it is important to do this review

Cochrane reviews have assessed the efficacy of Chinese herbal medicines in the treatment of many conditions such as atopic eczema (Gu 2013), cholelithiasis (Gan 2013), colorectal cancer (Guo 2012), gastric cancer (Yang 2013), endometriosis (Flower 2012), heart failure (Chen 2012), osteoarthritis (Cameron 2013) and nephrotic syndrome (Chen 2013; Feng 2013), but not osteoporosis. Chinese herbal medicines are widely used in China for the treatment of osteoporosis and many herbal drugs have been approved by the China State Food and Drug Administration (SFDA) for the market. Each year, many clinical trials are published in China, however, there is no critical appraisal of the evidence on

the potential benefits and harms of Chinese herbal medicines for treating osteoporosis. The purpose of this review is to systematically identify available randomised clinical trials of Chinese herbal medicines for primary osteoporosis to appraise their benefit and harm in order to inform clinical practice.

## OBJECTIVES

To assess the beneficial and harmful effects of Chinese herbal medicines as a general experimental intervention for treating primary osteoporosis by comparing herbal treatments with placebo, no intervention and conventional medicine.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

Randomised clinical trials were included irrespective of blinding, publication status or language. For adverse effects associated with medicinal herbs in osteoporosis treatment, we planned to include data from cohort studies for the evaluation of safety.

#### Types of participants

Study participants with primary osteoporosis or osteopenia regardless of age, gender or ethnic origin were included. Those with secondary osteoporosis including corticosteroid-induced osteoporosis due to diseases affecting metabolism of bone and the liver, kidney and haematopoietic system, and disability of the heart and cerebral vessels, were excluded.

Osteoporosis could be diagnosed on the basis of one of the following criteria for bone mineral density (BMD) levels. BMD was detected by one of the following methods of examination: single photon absorptiometry (SPA), dual photon absorptiometry (DPA), quantitative computed tomography (QCT), dual energy X-ray absorptiometry (DXA) or peripheral dual energy X-ray absorptiometry (pDXA).

The World Health Organization (WHO) have recommended criteria for primary osteoporosis based on BMD levels (WHO 1994):

- Normal: BMD is within +1 or -1 standard deviations (SD) of the young adult mean.
- Osteopenia (low bone mass): BMD is between -1 and -2.5 SD below the young adult mean.
- Osteoporosis: BMD is -2.5 SD or more than the young adult mean.
- Severe (established) osteoporosis: BMD is more than -2.5 SD and one or more osteoporotic fractures have occurred.

The Chinese diagnostic criteria for primary osteoporosis based on BMD levels (Osteoporosis 1999):

- Normal: BMD is within +1 or -1 SD of peak bone mass of the same race, gender and region.
- Osteopenia (low bone mass): BMD is between -1 and -2 standard deviations below peak bone mass of the same race, gender and region.
- Osteoporosis: BMD is -2 SD or more than the peak bone mass of the same race, gender and region.

- Severe (established) osteoporosis: BMD is more than -2 SD and one or more osteoporotic fractures have occurred.

### Types of interventions

The experimental interventions included single herbs, combinations of herbs or Chinese proprietary medicines. There was no standard for the classification of Chinese herbal medicines. Therefore, to make it easier, we classified Chinese herbal medicines into two major types: a) Chinese proprietary medicine which was approved by the China State Food and Drug Administration (SFDA) and produced by pharmaceutical companies with good manufacture practices; b) herbal formulae prescribed by Chinese medicine practitioners based on a Chinese medicine diagnosis (i.e. pattern differentiation of symptoms). This type of medicine was usually cooked as decoction by the patients themselves or prepared by a hospital pharmacy. As we predicted great variation in the type, timing, dosage and administration of herbs and their combination with other interventions, we did not limit any of these aspects.

The control intervention could be no treatment, placebo or conventional pharmaceutical medicine (such as hormone replacement therapy, bisphosphonate, calcitonin, calcium and vitamin D), as well as non-pharmaceutical interventions such as exercise. Co-intervention was allowed as long as all groups from the randomised allocation received the same co-intervention.

We excluded studies in which the duration of herbal treatment was less than three months.

### Types of outcome measures

#### Major outcomes

Major outcome measures sought at the end of treatment or at maximal follow-up:

1. Number of individuals with fractures and type of fractures (lumbar spine, radius, femoral neck).
2. Quality of life or symptoms including pain, muscle fatigue and limited mobility.
3. Death directly or indirectly attributed to osteoporosis.
4. Adverse effects including serious adverse events and withdrawals: serious adverse events are defined as any untoward medical occurrence that resulted in death or fracture, was life-threatening, resulted in persistent or significant disability, or any important medical event which may have jeopardised the patient or required intervention to prevent it (ICH GCP 1997). All other adverse effects were considered non-serious. We recorded reports of adverse effects associated with the herbs used in the treatment of osteoporosis from any type of study in order to evaluate harms.

#### Minor outcomes

Minor outcomes at the end of treatment or at maximal follow-up:

1. Bone mineral density (BMD).
2. Biochemical indicators: serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), oestradiol (E2), parathyroid hormone (PTH), calcitonin (CT), bone Gla protein (BGP), interleukin-6 (IL-6).

## Search methods for identification of studies

### Electronic searches

We searched the following electronic databases irrespective of language or publication status: the Cochrane Central Register of Controlled Trials (CENTRAL) in *The Cochrane Library* (2012, Issue 12), MEDLINE, EMBASE, LILACS, JICST-E (Japan Information Center for Science and Technology), AMED, the database of the Cochrane Complementary Medicine Field, Chinese Biomedical Database (CBM), CINAHL (Cumulative Index to Nursing and Allied Health Literature) and the Chinese Academic Conference Papers Database.

We used the following MeSH and free-text terms: osteoporosis, medicine-Chinese-traditional, plants-medicinal, drugs-Chinese-herbal, plants extracts and herbs. The full search strategies were in [Appendix 1](#) (MEDLINE), [Appendix 2](#) (EMBASE), [Appendix 3](#) (CENTRAL) and [Appendix 4](#) (CBM). All electronic searches were from inception to 9 January 2013.

### Searching other resources

We handsearched the following journals published in Chinese: *Chinese Journal of Integrated Traditional and Western Medicine* (1981 to 2012), *Chinese Journal of Osteoporosis* (1995 to 2012), *Chinese Journal of Geriatrics* (1982 to 2012) and *Journal of Clinical Orthopaedics* (1998 to 2012).

We screened reference lists of all retrieved articles and reviews for possible eligible trials.

## Data collection and analysis

### Selection of studies

Two authors (Y Liu, Y Xia) independently selected the trials to be included in the review according to the prespecified selection criteria. Any disagreement was resolved by discussion.

### Data extraction and management

Two authors (Y Liu, Y Xia) extracted data independently using a self developed data extraction form which was piloted for formal use. Disagreement was resolved by discussion.

We extracted the following characteristics and data from each included trial: primary author, study setting, methodology, mean age, gender and ethnicity of patients, number of randomised patients, reasons and number of patients who dropped out or were lost during the follow-up, patient inclusion and exclusion criteria, symptoms of the patients, diagnostic criteria, type of herb or herbs, route of administration, dosage and duration of the herb, details of comparison regime, outcome measures (end of treatment and follow-up), and number and type of adverse effects.

If the above data were not available in the trial reports, we sought further information by correspondence with the principal author. If the information was still lacking after the author was contacted, we recorded the last reported observed response.

### Assessment of risk of bias in included studies

Based on the recommendations in the *Cochrane Handbook for Systematic Reviews of Interventions* (Chapter 8: Assessing risk of bias in included studies), we made separate critical assessments for seven specific domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding

of outcome assessment, incomplete outcome data, selective outcome reporting and 'other' issues (the baseline comparability between groups) ([Higgins 2011](#)). Two authors (Y Liu, Y Xia) assessed the risk of bias independently and assigned a judgement of 'low' risk of bias, 'high' risk of bias or 'unclear' risk of bias. Any disagreement was resolved by discussion.

### Measures of treatment effect

We presented dichotomous data as risk ratio (RR) and continuous outcomes as mean difference (MD), both with 95% confidence intervals (CI).

### Unit of analysis issues

For a trial with multiple treatment groups, in order to overcome a unit of analysis error, we selected the following approaches accordingly.

- Combining groups of the same Chinese herbal medicine with different dosages to create a single pair-wise comparison.
- Selecting one pair of interventions and excluding the others.
- Splitting the 'shared' group into two or more groups with smaller sample size, and including two or more (reasonably independent) comparisons.

### Dealing with missing data

Based on the recommendations in the *Cochrane Handbook for Systematic Reviews of Interventions* (Chapter 16.1: Missing data), we used two options for dealing with missing data ([Higgins 2011](#)).

- Analysing only the available data when data were assumed to be missing at random (i.e. ignoring the missing data).
- Imputing the missing data with replacement values (such as a poor outcome) when data were not assumed to be missing at random.

### Assessment of heterogeneity

We assessed heterogeneity using the  $I^2$  statistic, which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) ([Higgins 2011](#)). A rough guide to interpretation of  $I^2$  is as follows:

- 0% to 40%: might not be important;
- 30% to 60%: may represent moderate heterogeneity;
- 50% to 90%: may represent substantial heterogeneity;
- 75% to 100%: considerable heterogeneity.

### Assessment of reporting biases

We planned to detect reporting biases with funnel plots, which is a simple scatter plot of the intervention effect estimates from individual studies against some measure of each study's size or precision ([Higgins 2011](#)).

### Data synthesis

We compared types of Chinese herbal medicines with each control (such as placebo) regardless of the treatment regimen. We performed meta-analysis within comparisons of the same herb versus the similar control intervention. Whenever there was significant heterogeneity ( $I^2 > 50\%$ ), we used the random-effects model; otherwise we reported fixed-effect models ([Altman 2003](#)).



We carried out the statistical analyses using Review Manager 5.2 (Cochrane software) ([RevMan 2012](#)).

We tabulated the following comparisons when data were available:

- Chinese herbal medicines versus no intervention or placebo;
- Chinese herbal medicines versus conventional medicine (such as hormone replacement therapy, bisphosphonate);
- Chinese herbal medicines versus non-pharmaceutical intervention.

We presented trials of herbs plus active intervention versus active intervention alone as a separate comparison.

### Subgroup analysis and investigation of heterogeneity

We performed subgroup analyses on different Chinese herbal medicines and on body parts of participants for BMD measurement. However, due to the limited number of randomised trials for individual Chinese herbal medicines, the following subgroup analyses were not performed: duration of the herbal treatment, types of osteoporosis (for example, senile or postmenopausal osteoporosis) and severity of osteoporosis.

### Sensitivity analysis

Similarly, due to the heterogeneity of the interventions, we were unable to pool results into a meta-analysis and therefore could not undertake a sensitivity analysis to explore the influence of trial methodological quality on effect estimates.

### 'Summary of findings' tables

We created 'Summary of findings' tables for different comparisons and included the following patient-important outcomes (fractures, quality of life, death, serious adverse events, BMD). We assessed the overall quality of the evidence by outcome using the GRADE approach and incorporated this in the tables.

## RESULTS

### Description of studies


#### Results of the search

Our initial searches identified 4427 references: 4378 from electronic searches and 49 from handsearches. After reading titles and abstracts, 4176 of these articles were excluded because they were duplicates, non-clinical studies, without a control group, traditional reviews, animal studies, case reports or had study objectives different from this review. We retrieved a total of 251 references published in Chinese or English for further assessment. Of these, 143 references were excluded because they did not meet our inclusion criteria. Reasons for exclusion were shown in the [Characteristics of excluded studies](#) table.

In this review, 108 randomised clinical trials met the inclusion criteria. All trials were conducted in China between 1996 and 2012. We did not find any cohort studies for the evaluation of the safety of Chinese herbal medicines for osteoporosis. The included studies reported random allocation of patients with osteoporosis to Chinese herbal medicines versus control (placebo in three trials, no treatment in five trials, conventional pharmaceutical medicine (such as calcium and vitamin D, calcium gluconate, tibolone tablets, nilestriol, calcitonin, alendronate, calcium, vitamin D, etc.) in 61 trials, Chinese herbal medicines plus co-intervention versus the same co-intervention in 47 trials). No trial compared Chinese herbal medicines with non-pharmaceutical interventions. Eighteen trials ([An SJ 2000](#); [Chen ZX 2002](#); [Dai Y 2007](#); [Gong L 2001](#); [Liao L 2004](#); [Miu JQ 2008](#); [Peng T 2002](#); [Ruan XY 2006](#); [Song XW 2000](#); [Wang XY 2000](#); [Wu MS 2007](#); [Xiong YH 2008](#); [Xu H 2010](#); [Xu M 2009](#); [Zhan HS 2009](#); [Zhang YS 2003](#); [Zhang YP 2007](#); [Zhu HM 2012](#)) had more than two arms. Attributes of the 108 included studies are shown in the [Characteristics of included studies](#) table. Four trials were published in English ([Deng WM 2012](#); [Qiu RB 2004](#); [Xie J 2004](#); [Zhu HM 2012](#)) and 104 studies were published in Chinese.

The study flow diagram is shown in [Figure 1](#).

**Figure 1. The study screening flow diagram.**



**Included studies**

**Participants**

A total of 10,655 patients with osteoporosis were randomised in the 108 trials, among which 65 trials included postmenopausal osteoporosis patients, eight trials included senile osteoporosis patients and 35 trials included primary osteoporosis patients unspecified as to life-stage or co-morbidity. The race/ethnicity of all patients studied was Chinese in all 108 trials. One hundred and five randomised clinical trials included adults with a mean age of 61.3 years. Three trials did not report data on gender or age or both (Lin W 2000; Xiong YH 2008; Zhao LN 2003). The average number of participants in the trials was 98, ranging from 20 to 600 patients per trial.

**Diagnosis**

Among the 108 included trials, the diagnostic criteria for osteoporosis in 18 trials were based on WHO criteria (An SJ 2000; Cao W 2010; Chen NQ 2006; Chen ZX 2002; Cui TH 1999; Dai Y 2007; Gang PH 2001; Hu J 2012; Li HW 2004; Li YH 2008; Miu JQ

2008; Wang SW 2003; Ye AN 1998; Zhang RH 2004; Zhang YL 1996; Zhao G 2002; Zheng WK 2007; Zhou LZ 2001), and in the others the Chinese diagnostic criteria for osteoporosis were used. BMD was detected by dual energy X-ray absorptiometry (DXA), single photon absorptiometry (SPA) or CUBA ultrasound bone densitometer in all of the studies.

**Interventions**

Ninety-nine different Chinese herbal medicines were tested in 108 randomised trials. Only eight Chinese herbal medicines were tested twice or more, including Kanggusong granule in two trials (An SJ 2000; Wu MS 2001), Bushen Qiangshen pill in two trials (Mu G 2001; Mu G 2001a), Migu tablets in two trials (Dai Y 2007; Xie J 2004), Gukang oral liquid in three trials (Chen JP 1999; Shao M 2003; Wang JM 2008), Gushukang granule in three trials (Chen ZX 2002; Wu MS 2007; Zhang YS 2003), Qianggu capsule in three trials (Ruan XY 2006; Wang J 2007; Xu H 2010), Liuwei Dihuang pills in two trials (Ma C 2011; Zhang J 2003) and Xianlinggubao capsule in seven trials (Dai Y 2007; Dong Y 2010; Qiu ZX 2010; Wu W 2005; Xu M 2009; Zhang XZ 2004; Zhu HM 2012). However, even when the same Chinese herbal medicines were tested, the control interventions were different for

each trial. Therefore, there was no trial which tested exactly the same Chinese herbal medicine and the same control in this review. Seven trials tested two or more different Chinese herbal medicines respectively (Dai Y 2007; Gong L 2001; Wu MS 2007; Xiong YH 2008; Zhan HS 2009; Zhang YS 2003; Zhang ZF 2011). According to the categories of medicinal herbs, two trials tested single herbs (Yang B 2007; Zhao LN 2003) and the remaining trials tested compounds of multiple herbs. Based on our standard classification for Chinese herbal medicines, 45 trials tested Chinese proprietary medicine and the others tested prescribed herbal formulae. The composition and treatment regimens of the Chinese herbal medicines varied (see Table 1: 'The preparation and composition of the Chinese herbal medicines in the included trials'). The median duration of treatment was 5.7 months (ranging from 3 to 12 months).

The control interventions included placebo in three trials and no treatment in five trials. In the other trials the control interventions were conventional pharmaceutical medicine or Chinese herbal medicines plus co-intervention versus the same co-intervention.

The interventions in the included trials are described in the [Characteristics of included studies](#) table.

### Outcomes

Seven trials reported fracture incidence (An SJ 2000; Deng WM 2012; Li ZP 2011; Zhang RH 2004; Zhang ZF 2011; Zhao HX 2001; Zhu HM 2012). None of the 108 trials reported death directly or indirectly caused by osteoporosis. The outcomes reported were mainly surrogate outcomes, including BMD, biochemical indicators (serum calcium, phosphorus, alkaline phosphatase, oestradiol, parathyroid hormone, calcitonin, bone Gla protein, interleukin-6, etc.), the improvement of lumbago and backache, and adverse effects. Only two trials reported quality of life and medical expenses (Liang DB 2012; Zhang ZF 2011). Adverse effects were reported in 44 trials and included nausea, diarrhoea, dry mouth, constipation, tiredness, dental ulcer, epigastric discomfort, breast pain, dizziness, stomach discomfort, etc. All the reported outcomes were measured at the end of treatment.

### Risk of bias in included studies

In this review, all 108 trials were reported as parallel-group randomised trials and three trials were multicentre randomised trials (Deng WM 2012; Xiong YH 2008; Zhu HM 2012). Of the 108, only 27 reported the methods used for the generation of the allocation sequence. Among them, four used random numbers generated by a computer or calculator (Xu YL 2007; Zhang RH 2004; Zhao HX 2001; Zhu HM 2012), 20 used a random numbers table (Chen XL 2010; Chen ZX 2002; Dai Y 2007; He N 2006; Hu J 2012; Li BL 2007; Li HW 2004; Li YH 2008; Ma C 2011; Qiu RB 2008; Wang CC 2005; Wu MS 2007; Wu W 2005; Xiong YH 2008; Xu H 2010; Xu M 2009; Zhang DS 2011; Zhang XZ 2004; Zhao G 2002; Zhu HJ 2011) and one used random drawings (Wang ZK 2004).

Only one trial (Zhu HM 2012) provided information about allocation concealment.

Double-blinding was reported in 10 trials (An SJ 2000; Lin W 2000; Wang SW 2003; Wang XD 2011; Xiong YH 2008; Zhan HS 2009; Zhao HX 2001; Zhao LN 2003; Zheng WK 2007; Zhu HM 2012). Eight trials reported use of single-blinding (Chen JP 1999; Chen NQ 2006; Mao YF 2011; Wang XY 2000; Xie YM 1997; Yuan YN 2000; Zhou ZK 2006; Zou JJ 2005).


Two trials (Deng WM 2012; Zhu HM 2012) reported a pre-trial estimation of sample size and reported performing intention-to-treat analysis. Nineteen trials reported withdrawals (Deng WM 2012; He MT 2007; Li SL 2004; Li YH 2010; Ma C 2011; Meng XD 2003; Peng T 2002; Ruan XY 2006; Wang CC 2005; Wang JM 2008; Xiong YH 2008; Xu YL 2007; Zhan HS 2009; Zhang XJ 2008; Zhang RH 2004; Zhang ZF 2011; Zhao HX 2001; Zheng WK 2007; Zhu HM 2012).

None of the 108 trials reported all outcomes of interest in this review.

Seventy trials appeared to be free of other sources of bias, while the 38 other trials did not report the baseline comparability between groups in detail.

The risk of bias in the included studies is shown in detail in [Figure 2](#) and [Figure 3](#).

**Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**



**Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.**

	Adequate sequence generation	Allocation concealment	Blinding	Incomplete outcome data addressed	Free of selective reporting	Free of other bias
An SJ 2000	?	?	+	+	?	+
Cao GY 2010	?	?	?	+	?	?
Cao W 2010	?	?	?	+	?	+
Chen FS 2001	?	?	?	+	?	?
Chen JP 1999	?	?	+	+	?	?
Chen NQ 2006	?	?	+	+	?	?
Chen X 2008	-	-	?	+	?	+
Chen XL 2010	+	?	?	+	?	+
Chen YQ 2001	?	?	?	+	?	?
Chen ZX 2002	+	?	?	+	?	+
Cui TH 1999	?	?	?	+	?	?
Dai Y 2007	+	?	?	+	?	?
Deng WM 2012	?	?	?	+	?	?
Dong Y 2010	?	?	?	+	?	+
Dong YF 2004	?	?	?	+	?	?
Fan HX 2004	?	?	?	+	?	?
Gang PH 2001	?	?	?	+	?	?
Gong L 2001	?	?	?	+	?	+
Guo JH 2008	?	?	?	+	?	+
Han XL 2007	?	?	?	+	?	+
He MT 2007	?	?	?	+	?	+
He N 2006	+	?	?	+	?	+
He XQ 2006	?	?	?	+	?	+
Huang JW 2008	?	?	?	+	?	+

Figure 3. (Continued)

	+	+	+	+	+	+
Huang JW 2008	?	?	?	+	?	+
Huang ZJ 2008	-	-	?	+	?	+
Hu J 2012	+	?	?	+	?	+
Jian QQ 2010	?	?	?	+	?	?
Lan ZX 2006	?	?	?	+	?	+
Liang DB 2012	+	?	?	+	?	+
Liao L 2004	?	?	?	+	?	+
Li BL 2007	?	?	?	+	?	?
Li HW 2004	+	?	?	+	?	+
Ling JY 2008	?	?	?	+	?	+
Lin W 2000	?	?	+	+	?	?
Li SL 2004	?	?	?	+	?	+
Liu JM 2012	?	?	?	+	?	+
Li YH 2008	+	?	?	+	?	+
Li YH 2010	?	?	?	+	?	+
Li ZP 2011	?	?	?	+	?	+
Li ZY 2006	?	?	?	+	?	+
Lv ZH 2002	?	?	?	+	?	+
Ma C 2011	+	?	?	+	?	+
Ma CZ 2011	?	?	?	+	?	+
Mao YF 2011	?	?	?	?	?	+
Ma YJ 2011	?	?	?	+	?	+
Meng XD 2003	?	?	?	+	?	+
Miu JQ 2008	?	?	?	+	?	+
Mu G 2001	?	?	?	+	?	+
Mu G 2001a	?	?	?	+	?	?
Ou L 2011	?	?	?	+	?	+
Peng T 2002	+	?	?	+	?	+
Qiu RB 2004	?	?	?	+	?	+
Qiu RB 2008	+	?	?	+	?	+
Qiu ZX 2010	?	?	?	+	?	?

Figure 3. (Continued)

Qiu ZX 2010	?	?	?	+	?	?
Qi ZX 1998	?	?	?	+	?	+
Ruan XY 2006	?	?	?	+	?	?
Shao M 2003	?	?	?	+	?	?
Shi CD 2012	?	?	?	+	?	+
Song XW 2000	?	?	?	+	?	?
Tang ZA 2012	?	?	?	+	?	+
Wang CC 2005	?	?	?	+	?	+
Wang H 2007	+	?	?	+	?	+
Wang J 2007	?	?	?	+	?	+
Wang JM 2008	?	?	?	+	?	?
Wang SW 2003	?	?	+	+	?	?
Wang XD 2011	?	?	+	+	?	?
Wang XY 2000	?	?	+	+	?	+
Wang YZ 2008	?	?	?	+	?	?
Wang ZK 2004	+	?	?	+	?	?
Wei RY 2011	?	?	?	+	?	+
Wu JZ 2010	?	?	?	+	?	+
Wu MS 2001	?	?	?	+	?	?
Wu MS 2007	+	?	?	+	?	+
Wu W 2005	+	?	?	+	?	+
Xiao W 2008	?	?	?	+	?	?
Xie J 2004	?	?	?	+	?	?
Xie YM 1997	?	?	+	+	?	?
Xiong YH 2008	?	?	?	+	?	+
Xu H 2010	?	?	?	+	?	+
Xu M 2009	?	?	?	+	?	+
Xu W 2005	?	?	?	+	?	+
Xu YL 2007	+	?	?	+	?	+
Yang B 2007	?	?	?	+	?	+
Ye AN 1998	?	?	?	+	?	?

**Figure 3. (Continued)**

	?	?	?	+	?	?
Ye AN 1998	?	?	?	+	?	?
Yuan YN 2000	?	?	+	+	?	?
Zhang DS 2011	?	?	?	+	?	?
Zhang J 2003	?	?	?	+	?	?
Zhang RH 2004	+	?	+	+	?	+
Zhang XG 2011	?	?	?	+	?	?
Zhang XJ 2008	?	?	?	+	?	?
Zhang XZ 2004	?	?	?	+	?	?
Zhang YL 1996	?	?	?	+	?	?
Zhang YP 2007	?	?	?	+	?	+
Zhang YS 2003	?	?	?	+	?	+
Zhang ZF 2011	?	?	?	+	?	+
Zhan HS 2009	?	?	+	?	?	+
Zhan ML 2007	?	?	?	+	?	+
Zhao G 2002	+	?	?	+	?	+
Zhao HX 2001	+	?	+	?	?	+
Zhao LN 2003	?	?	+	+	?	?
Zheng WK 2007	?	?	+	+	?	+
Zhong RQ 2007	?	?	?	+	?	+
Zhou LZ 2001	?	?	?	+	?	+
Zhou XT 2001	?	?	?	+	?	+
Zhou ZK 2006	?	?	+	+	?	+
Zhu HJ 2011	+	?	?	+	?	+
Zhu HM 2012	+	?	+	?	?	+
Zou JJ 2005	?	?	+	+	?	?

The poor availability of information about study design meant that we rated most items as having unclear risk of bias. Based on The Cochrane Collaboration's recommended summary assessments for risk of bias (Higgins 2011), the 'Risk of bias' assessment should be for the important outcomes, therefore for the outcome of fracture we evaluated the risk of bias as 'unclear' for sequence generation, allocation concealment, blinding and selective outcome reporting in those seven studies that reported it (Figure 3).

**Assessment of reporting biases**

Due to the small number of trials testing the same intervention and same outcome, a meaningful funnel plot analysis could not be conducted.

**Effects of interventions**

See: [Summary of findings for the main comparison](#) Chinese herbal medicines versus placebo for osteoporosis; [Summary of findings 2](#) Chinese herbal medicines versus no intervention for osteoporosis; [Summary of findings 3](#) Chinese herbal medicines



versus western medicine for osteoporosis; **Summary of findings 4** Chinese herbal medicines plus western medicine versus western medicine for osteoporosis

### Chinese herbal medicines versus placebo (Comparison 01)

Three trials (involving 219 patients) compared the effects of Chinese herbal medicines with placebo (Lin W 2000; Wang XY 2000; Zhao HX 2001). Based on our standard classification for Chinese herbal medicines, the tested Chinese herbal medicines included two prescribed herbal formulae (Migu decoction and Bushen Yigu soft extract), and one Chinese proprietary medicine (Kanggusong capsules). The reported outcomes included BMD of the lumbar spine, radius and ulna, and the levels of oestradiol (E2). We were not able to pool the data due to the heterogeneity of the Chinese herbal medicines that were studied.

Based on the included trials, we created a 'Summary of findings' table for patient-important outcomes (fractures, quality of life, death, serious adverse events, BMD) (see [Summary of findings for the main comparison](#)).

#### Fractures

In three trials of Chinese herbal medicines versus placebo, one trial reported new compression fractures of the backbone in the placebo group (0/50 versus 10/54) (RR 0.05; 95% CI 0.00 to 0.85) ([Analysis 1.1](#)) (Zhao HX 2001).

#### Quality of life or symptoms including pain, muscle fatigue and limited mobility

No trials reported quality of life.

One trial reported improvement in bone pain in the group treated with Chinese herbal medicines compared to placebo (49/50 versus 44/54) (RR 1.20; 95% CI 1.05 to 1.37) ([Analysis 1.4](#)) (Zhao HX 2001).

#### Death

No trials reported this outcome.

#### Adverse effects

In three trials of Chinese herbal medicines versus placebo, one trial reported some mild adverse effects in the Chinese herbal medicines group, including stomach/intestinal upset, headache and dizziness (Zhao HX 2001). Two trials did not report on adverse effects (Lin W 2000; Wang XY 2000).

#### Bone mineral density (BMD)

##### BMD of the lumbar spine

Compared with placebo, the group treated with Migu decoction showed a statistically significant increase in BMD of the lumbar spine after four months treatment (MD 0.16 g/cm<sup>3</sup>; 95% CI 0.06 to 0.26) ([Analysis 1.2](#)) (Lin W 2000). The group treated with Kanggusong capsules had a statistically significant increase in BMD when compared to the placebo group after 12 months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.02 to 0.10) ([Analysis 1.2](#)) (Zhao HX 2001).

##### BMD of the radius

The group treated with Bushen Yigu soft extract showed a statistically significant increase in BMD of the radius compared to a

group treated with placebo after three months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.03 to 0.09) ([Analysis 1.2](#)) (Wang XY 2000).

##### BMD of the ulna

Those treated with Bushen Yigu soft extract showed a statistically significant increase in BMD of the ulna when compared to a placebo group after three months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.02 to 0.10) ([Analysis 1.2](#)) (Wang XY 2000).

#### Biochemical indicators

The effects of the interventions on biochemical indicators are shown in [Appendix 5](#).

#### Summary: Comparison 01

In summary, compared with placebo, Migu decoction and Kanggusong capsule seemed to improve the BMD of the lumbar spine; Bushen Yigu soft extract improved the BMD of the radius and the ulna.

### Chinese herbal medicines versus no intervention (Comparison 02)

Five trials (involving 628 patients) compared seven different Chinese herbal medicines with no intervention (Gong L 2001; Liao L 2004; Peng T 2002; Zhang YP 2007; Zhang YS 2003). Two trials with two arms compared different herbs with no intervention (Gong L 2001; Zhang YS 2003). The tested herbs included Yishen Zhuanggu mixture, Shenggu capsule, Bushen Shengsui principle, Qianggu soft extract, Huoluo Gukang pills, Shigu yin and Gushukang granule. Based on our standard classification for Chinese herbal medicines, five herbs were Chinese proprietary medicine, and two were prescribed herbal formulae. The reported outcomes included BMD of the lumbar spine and femoral neck, and the levels of oestradiol (E2) and osteocalcin, also known as bone Gla protein (BGP), but we were not able to pool the data due to the heterogeneity of the Chinese herbal medicines that were studied.

Based on the included trials, we created a 'Summary of findings' table for patient-important outcomes (fractures, quality of life, death, serious adverse events, BMD) (see [Summary of findings 2](#)).

#### Fractures

None of the five trials reported the outcome fractures.

#### Quality of life or symptoms including pain, muscle fatigue and limited mobility

None of the five trials reported these outcomes.

#### Death

None of the five trials reported this outcome.

#### Adverse effects

Four trials reported some mild adverse effects, such as mild stomach discomfort, intestinal upset or constipation, but this did not affect the continuation of treatment (Gong L 2001; Peng T 2002; Zhang YS 2003; Zhang YP 2007). One trial reported no adverse effects (Liao L 2004).

## Bone mineral density (BMD)

### BMD of lumbar spine

Compared with no intervention, treatment with Bushen Shengsui principle showed no evidence of effect after six months treatment (MD 0.07 g/cm<sup>3</sup>; 95% CI -0.06 to 0.20) ([Analysis 2.1](#)) ([Liao L 2004](#)).

### BMD of femoral neck

Compared with no intervention, treatment with Bushen Shengsui principle did not increase the BMD of the femoral neck after six months (MD 0.10 g/cm<sup>3</sup>; 95% CI 0.00 to 0.20) ([Analysis 2.1](#)) ([Liao L 2004](#)), and nor did treatment with Yishen Zhuanggu mixture after six months (MD 0.05 g/cm<sup>3</sup>; 95% CI -0.01 to 0.11) ([Analysis 2.1](#)) ([Gong L 2001](#)) or Shengu capsule (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.06 to 0.09) ([Analysis 2.1](#)) ([Gong L 2001](#)). Treatment with Qianggu soft extract resulted in a statistically significant increase in the BMD of the femoral neck after six months treatment (MD 0.09 g/cm<sup>3</sup>; 95% CI 0.03 to 0.15) ([Analysis 2.1](#)) ([Peng T 2002](#)), as did Shigu yin after six months treatment (MD 0.08 g/cm<sup>3</sup>; 95% CI 0.03 to 0.13) ([Analysis 2.1](#)) ([Zhang YP 2007](#)).

### Biochemical indicators

The effects of the interventions on biochemical indicators are shown in [Appendix 5](#).

### Summary: Comparison 02

In summary, compared with no intervention, Qianggu soft extract appeared to improve the BMD of the femoral neck significantly. Shigu yin also seemed to improve the BMD of the femoral neck. However, some groups treated with Chinese herbal medicines showed no significant difference from those receiving no intervention, including Bushen Shengsui principle (BMD of the lumbar spine and femoral neck), Yishen Zhuanggu mixture (BMD of the femoral neck) and Shengu capsule (BMD of the femoral neck) after six months of treatment.

### Chinese herbal medicines versus western medicine (Comparison 03)

Sixty-one trials (involving 4805 patients) compared 56 different Chinese herbal medicines with western medicine ([An SJ 2000](#); [Chen JP 1999](#); [Chen NQ 2006](#); [Chen X 2008](#); [Chen ZX 2002](#); [Cui TH 1999](#); [Dong YF 2004](#); [Gang PH 2001](#); [He MT 2007](#); [He N 2006](#); [Huang ZJ 2008](#); [Lan ZX 2006](#); [Li BL 2007](#); [Li YH 2008](#); [Li YH 2010](#); [Li ZY 2006](#); [Liao L 2004](#); [Ling JY 2008](#); [Lv ZH 2002](#); [Ma C 2011](#); [Mao YF 2011](#); [Meng XD 2003](#); [Mu G 2001a](#); [Ou L 2011](#); [Peng T 2002](#); [Qi ZX 1998](#); [Qiu RB 2004](#); [Qiu RB 2008](#); [Ruan XY 2006](#); [Shao M 2003](#); [Shi CD 2012](#); [Song XW 2000](#); [Wang CC 2005](#); [Wang H 2007](#); [Wang J 2007](#); [Wang JM 2008](#); [Wang XY 2000](#); [Wang YZ 2008](#); [Wang ZK 2004](#); [Wei RY 2011](#); [Wu JZ 2010](#); [Wu MS 2001](#); [Wu MS 2007](#); [Xie YM 1997](#); [Xu H 2010](#); [Xu M 2009](#); [Xu W 2005](#); [Xu YL 2007](#); [Yang B 2007](#); [Yuan YN 2000](#); [Zhan ML 2007](#); [Zhang XG 2011](#); [Zhang YP 2007](#); [Zhang J 2003](#); [Zhang XJ 2008](#); [Zhang YL 1996](#); [Zhao LN 2003](#); [Zhong RQ 2007](#); [Zhou LZ 2001](#); [Zhou ZK 2006](#); [Zhu HJ 2011](#)). Among them, two trials compared herbs with two different Western pharmaceutical medicines ([An SJ 2000](#); [Song XW 2000](#)). One trial ([Wu MS 2007](#)) compared two herbs with western medicine.

The tested herbal preparations included Acupoint sticking of Migudan, Bugu Shengsui capsule, Bushen Huoxue capsules, Bushen Jianpi Huoxue recipe, Bushen Jianpi Jingu decoction,

Bushen Jianpi Migu prescription, Bushen Qianggutang, Bushen Qiangshen pill, Bushen Tianjing Huoxue therapy, Bushen Shengsui principle, Bushen Yangxue tang, Bushen Yigu soft extract, Bushen Zhuanggu tang, Bushenjianpi Zhuanggu yin, Erxian soup, Gujian capsule, Gukang decoction, Gukang oral liquid, Guli powder, Gumikang capsule, Gumiling granule, Gushen Yijing tang, Gushukang granule, Huangqi, Huangqi Sanxian tang, Jiangu capsule, Jiangu recipe, Jianshenfang granule, Jiawei Bushen Zhuangjintang, Jiawei Zhuangyao Jianshen tang, Jingujian granule, Jingujian granule (1,2,3), Kanggusong capsule, Kanggusong granule, Kangshu Jiangu granule, kidney-tonifying herbs, Liuwei Dihuang pills, prescription for tonifying kidney, Qianggu capsule, Qianggu paste, Qianggu soft extract, Radix rehmanniae preparata and Radix astragali, Shangke Jiegu tablet, Shenyao capsules, Shigu yin, Strong Bone capsule, TPF capsule, Tongbu Qianggutang, urinary bladder (Kidney) meridian sticking, Xianling Gusong capsules, Xianlinggubao capsule, Yanghuo Sanzi tang, Yinyanghuo, Herba epimedii prescription (including Herba epimedii, Fructus psoraleae, Cortex eucommiae, Concha ostreae, Radix aconiti preparata, Radix aconiti kusnezoffii, Radix angelicae sinensis and Rhizome chuanxiong), Yishen Yanggan mixture and Zishen Gukang pill. All these herbal preparations except Yinyanghuo and Huangqi (Radix Astragali) are mixtures of herbs. Based on our standard classification for Chinese herbal medicines, 22 herbs were Chinese proprietary medicine, and 34 were prescribed herbal formulae.

The reported outcomes included BMD of the lumbar spine, radius, ulna, femoral neck, Ward's triangle, trochanter, hipbone, distal radius and calcaneus. Levels of oestradiol (E2), serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), bone Gla protein (BGP), interleukin-6 (IL-6), parathyroid hormone (PTH) and calcitonin (CT) were also measured, as was the improvement of lumbago and backache.

We were not able to pool the data due to the variations in the herbal preparations and control interventions that were used in the studies.

Based on the included trials, we created a 'Summary of findings' table for patient-important outcomes (fractures, quality of life, death, serious adverse events, BMD) (see [Summary of findings 3](#)).

### Fractures

Of the 61 trials, one trial reported that no new fracture occurred ([An SJ 2000](#)).

### Quality of life or symptoms including pain, muscle fatigue and limited mobility

No trials reported the outcome of quality of life.

Twenty trials out of 61 reported the improvement of lumbago and backache. Among these 20 trials, eight reported that Chinese herbal medicines were better than western medicines without reporting the number of cases with ache improvement in each group ([Chen NQ 2006](#); [Dong YF 2004](#); [Ou L 2011](#); [Qi ZX 1998](#); [Wang ZK 2004](#); [Xie YM 1997](#); [Xu H 2010](#); [Zhang XJ 2008](#)). The other 12 trials reported as follows:

- 46/48 versus 24/42: RR 1.68; 95% CI 1.28 to 2.19 ([Analysis 3.4](#)) ([Lv ZH 2002](#));

### Chinese herbal medicines for treating osteoporosis (Review)

- 76/78 versus 11/21: RR 1.86; 95% CI 1.24 to 2.80 (Analysis 3.4) (Peng T 2002);
  - 24/30 versus 15/30: RR 1.60; 95% CI 1.07 to 2.39 (Analysis 3.4) (Wu MS 2001);
  - 53/60 versus 26/50: RR 1.70; 95% CI 1.28 to 2.25 (Analysis 3.4) (Xu W 2005);
  - 13/15 versus 9/10: RR 0.96; 95% CI 0.72 to 1.28 (Analysis 3.4) (Zhao LN 2003);
  - 15/15 versus 2/10: RR 4.26; 95% CI 1.43 to 12.72 (Analysis 3.4) (Gang PH 2001);
  - 25/29 versus 20/29: RR 1.25; 95% CI 0.94 to 1.66 (Analysis 3.4) (He N 2006);
  - 28/30 versus 22/30: RR 1.27; 95% CI 1.01 to 1.61 (Analysis 3.4) (Huang ZJ 2008);
  - 52/60 versus 11/40: RR 3.15; 95% CI 1.89 to 5.26 (Analysis 3.4) (Li YH 2008);
  - 18/21 versus 12/22: RR 1.57; 95% CI 1.03 to 2.39 (Analysis 3.4) (Li ZY 2006);
  - 43/48 versus 19/32: RR 1.51; 95% CI 1.12 to 2.04 (Analysis 3.4) (Wei RY 2011);
  - 56/60 versus 34/60: RR 1.65; 95% CI 1.31 to 2.08 (Analysis 3.4) (Qiu RB 2008).
- a few patients with nausea, stomach ache and dizziness in the western medicine group (Wu MS 2001);
  - two patients with dry and hard stools during treatment in the herbal group (Xie YM 1997);
  - five patients with nausea in the herbal group and three in the western medicine group (Xu H 2010);
  - two patients with nausea in the herbal group and three in the western medicine group (Xu M 2009);
  - three patients with gastrointestinal reactions in the western medicine group (Chen X 2008);
  - one patient with palpitations, two patients with constipation and four patients with stomach discomfort in the Jingujian granule group, and five patients with constipation and two patients with abdominal distention in the western medicine group (Li YH 2008); and
  - one trial (Zhang YP 2007) which reported patients with constipation in the control group without reporting data.

Six trials reported no adverse effects (Chen NQ 2006; Gang PH 2001; Xu YL 2007; Yuan YN 2000; Zhang XJ 2008; Zhou LZ 2001).

Most of the adverse effects did not affect continuation of treatment. Thirty-eight trials did not report adverse effects.

## Death

No trials reported this outcome.

## Adverse effects

Twenty-three trials out of 61 reported adverse effects. These included:

- two patients with midsection discomfort in the herbal group (Cui TH 1999);
- a few patients with dizziness, rash, nausea, vomiting and cardiopalmus at the beginning of therapy, but no significant difference in comparison groups (Dong Y 2010);
- 11 patients with dry mouth symptoms, five with stomach discomfort, two with constipation and one with cardiopalmus in the herbal group, and nine patients with stomach discomfort and one with constipation in the western medicine group (Li YH 2010);
- three patients with spotting vaginal bleeding at the beginning of treatment, which did not affect observation, and five cases with breast pain who withdrew from the western medicine group (Liao L 2004);
- six patients with constipation and five with dry mouth symptoms in the herbal group, which did not affect observation (Meng XD 2003);
- two patients with abdominal distention and sour regurgitation in the herbal group, and three with gastrointestinal symptoms in the western medicine group (Ma C 2011);
- three patients in the herbal group and one in the western medicine group with stomach discomfort (Peng T 2002);
- one patient with stomach discomfort in the western medicine group (Wang CC 2005);
- five patients with stomach discomfort in the herbal group and two in the western medicine group (Wang H 2007);
- two patients with mild constipation and one with dry mouth symptoms in the herbal group (Wang J 2007);

## Bone mineral density (BMD)

### BMD of the lumbar spine

No significant difference between groups in the BMD of the lumbar spine was reported for any of the following comparisons of treatment groups:

- Kanggusong granule versus ipriflavone plus Caltrate (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.05 to 0.05), Kanggusong granule versus Caltrate after nine months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI -0.02 to 0.10) (Analysis 3.2) (An SJ 2000);
- Strong Bone capsule versus Caltrate after three months treatment (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.08 to 0.06) (Analysis 3.2) (Cui TH 1999);
- Herba epimedii prescription versus vitamin D plus Caltrate after six months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI 0.00 to 0.06) (Analysis 3.2) (Dong YF 2004);
- Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone after six months treatment (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.12 to 0.12) (Analysis 3.2) (Liao L 2004);
- Bushen Jianpi Jingu decoction versus calcitonin after three months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.09 to 0.13) (Analysis 3.2) (Mao YF 2011);
- Gukang oral liquid versus alendronate after six months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.03 to 0.05) (Analysis 3.2) (Shao M 2003);
- kidney-tonifying herbs versus nilestriol (MD -0.02 g/cm<sup>3</sup>; 95% CI -0.09 to 0.05), kidney-tonifying herbs versus calcium (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.04 to 0.08) after six months treatment (Analysis 3.2) (Song XW 2000);
- Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.01 to 0.05) after six months treatment (Analysis 3.2) (He MT 2007);

- Huangqi Sanxian tang versus nilestriol after three months treatment (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.03 to 0.04) ([Analysis 3.2](#)) ([Zhou ZK 2006](#));
- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI -0.01 to 0.09) ([Analysis 3.2](#)) ([Wang J 2007](#));
- Jianshenfang granule versus alendronate sodium after six months treatment (MD 0.09 g/cm<sup>3</sup>; 95% CI -0.03 to 0.21) ([Analysis 3.2](#)) ([Li BL 2007](#));
- Jiangu recipe versus alendronate sodium after 12 months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI 0.00 to 0.04) ([Analysis 3.2](#)) ([Qiu RB 2008](#));
- Gukang fang versus alendronate sodium tablets after four months treatment (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.03 to 0.03) ([Analysis 3.2](#)) ([Chen X 2008](#));
- Qianggu capsule versus alendronate (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.04 to 0.05) after six months treatment ([Analysis 3.2](#)) ([Xu H 2010](#));
- Bushen Huoxue capsules versus Caltrate and calcitonin (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.05 to 0.09) after 12 months treatment ([Analysis 3.2](#)) ([Zhang XJ 2008](#));
- Yinyanghuo versus conjugated oestrogens (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.04 to 0.10) after six months treatment ([Analysis 3.2](#)) ([Zhao LN 2003](#));
- Shenyao capsules versus Caltrate (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.05 to 0.05) after six months treatment ([Analysis 3.2](#)) ([Chen NQ 2006](#));
- Guli powder versus Caltrate after three months treatment (male: MD 0.02 g/cm<sup>3</sup>; 95% CI -0.01 to 0.05; female: MD 0.04 g/cm<sup>3</sup>; 95% CI -0.07 to 0.15) ([Analysis 3.2](#)) ([Lan ZX 2006](#));
- Gushen Yijing tang versus Caltrate after six months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI -0.02 to 0.14) ([Analysis 3.2](#)) ([Zhong RQ 2007](#));
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD 0.12 g/cm<sup>3</sup>; 95% CI -0.01 to 0.26) ([Analysis 3.2](#)) ([Xie YM 1997](#));
- Xianling Gusong capsules versus Caltrate after six months treatment (MD -0.03 g/cm<sup>3</sup>; 95% CI -0.08 to 0.02) ([Analysis 3.2](#)) ([Li ZY 2006](#));
- Zishen Gukang pill versus Caltrate plus vitamin D after three months treatment (MD -0.00 g/cm<sup>3</sup>; 95% CI -0.05 to 0.04) ([Analysis 3.2](#)) ([Huang ZJ 2008](#));
- Gukang decoction versus alendronate sodium tablets after four months treatment (MD -0.00 g/cm<sup>3</sup>; 95% CI -0.03 to 0.03) ([Analysis 3.2](#)) ([Chen X 2008](#));
- Gumiling granule versus chewable bicarbonate calcium after six months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI -0.02 to 0.09) ([Analysis 3.2](#)) ([Gang PH 2001](#));
- Gujian capsule versus alfacalcidol after three months treatment (MD 0.08 g/cm<sup>3</sup>; 95% CI -0.02 to 0.18) ([Analysis 3.2](#)) ([Meng XD 2003](#));
- Xianlinggubao capsule versus alendronate after six months treatment (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.02 to 0.02) ([Analysis 3.2](#)) ([Xu M 2009](#));
- Bushen Tianjing Huoxue therapy versus Caltrate and calcitriol soft capsule after six months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.00 to 0.07) ([Analysis 3.2](#)) ([Zhu HJ 2011](#)).

In 13 trials Chinese herbal medicines were reported to have statistically significant better effects on the BMD of the lumbar spine when compared with western medicine (calcium supplementation, vitamin D, hormones or different combinations):

- Jiawei Bushen Zhuangjintang versus calcium granules after three months treatment (MD 0.10 g/cm<sup>3</sup>; 95% CI 0.05 to 0.15) ([Analysis 3.2](#)) ([Lv ZH 2002](#));
- Yishen Yanggan mixture versus calcium gluconate after three months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.01 to 0.07) ([Analysis 3.2](#)) ([Xu W 2005](#));
- Kanggusong granule versus Caltrate after six months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.02 to 0.11) ([Analysis 3.2](#)) ([Wei RY 2011](#));
- Bushen Qianggutang versus Caltrate after three months treatment (MD 0.09 g/cm<sup>3</sup>; 95% CI 0.01 to 0.17) ([Analysis 3.2](#)) ([Qi ZX 1998](#));
- Bushen Jianpi Migu prescription versus Caltrate after three months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.03 to 0.09) ([Analysis 3.2](#)) ([Wang ZK 2004](#));
- Bushen Zhuanggu tang versus alendronate sodium tablets after three months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.01 to 0.07) ([Analysis 3.2](#)) ([Ling JY 2008](#));
- Bushenjianpi Zhuanggu yin versus Caltrate and calcitonin after 12 weeks treatment (MD 0.16 g/cm<sup>3</sup>; 95% CI 0.10 to 0.22) ([Analysis 3.2](#)) ([Zhang XG 2011](#));
- Liuwei Dihuang pills versus Caltrate after six months (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.03 to 0.07) ([Analysis 3.2](#)) ([Ma C 2011](#));
- Gujian capsule versus alfacalcidol after six months treatment (MD 0.14 g/cm<sup>3</sup>; 95% CI 0.03 to 0.26) ([Analysis 3.2](#)) ([Meng XD 2003](#));
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.03 to 0.07) ([Analysis 3.2](#)) ([Ou L 2011](#));
- Kangshu Jiangu granule versus Caltrate after six months treatment (MD 0.11 g/cm<sup>3</sup>; 95% CI 0.01 to 0.21) ([Analysis 3.2](#)) ([Shi CD 2012](#));
- Erxian soup versus Caltrate after six months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.02 to 0.11) ([Analysis 3.2](#)) ([Wu JZ 2010](#));
- Shangke Jiegu tablet versus vitamin D2 plus calcium tablet after six months treatment (MD 0.25 g/cm<sup>3</sup>; 95% CI 0.11 to 0.39) ([Analysis 3.2](#)) ([Yuan YN 2000](#)).

#### BMD of the radius

Treatment with Liuwei Dihuang pills statistically significantly increased the BMD of the radius as compared to a group supplemented with calcium. The difference at 12 months between before and after treatment was MD 0.04 g/cm<sup>3</sup> (95% CI 0.03 to 0.05) ([Analysis 3.2](#)) ([Zhang J 2003](#)). Another trial of treatment with Gukang oral liquid as compared to treatment with calcium gluconate reported a significant increase in the BMD of the radius after six months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI 0.01 to 0.04) ([Analysis 3.2](#)) ([Chen JP 1999](#)). A third trial showed positive effects of herbal treatments when compared to vitamin D and Caltrate: compared with vitamin D plus Caltrate, Herba epimedii prescription statistically significantly increased the BMD of the radius after six months treatment (MD 0.07 g/cm<sup>3</sup>; 95% CI 0.04 to 0.11) ([Analysis 3.2](#)) ([Dong YF 2004](#)).

Other trials comparing herbal treatments to vitamin D and calcium showed no significant difference in the BMD of the radius, including:

- Bushen Yigu soft extract versus Alfacalcidol after three months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.02 to 0.04) ([Analysis 3.2](#)) ([Wang XY 2000](#));
- Bugu Shengsui capsule versus vitamin D2 and calcium tablets after six months treatment (MD 0.08 g/cm<sup>3</sup>; 95% CI -0.12 to 0.28) ([Analysis 3.2](#)) ([Xie YM 1997](#));
- Shangke Jiegu tablet versus vitamin D2 and calcium tablets after six months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.02 to 0.11) ([Analysis 3.2](#)) ([Yuan YN 2000](#)).

#### BMD of the ulna

Four trials showed no significant effects on the BMD of the ulna:

- Gukang oral liquid versus calcium gluconate (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.02 to 0.02) ([Analysis 3.2](#)) ([Chen JP 1999](#));
- Bushen Yigu soft extract versus Alfacalcidol after three months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.01 to 0.05) ([Analysis 3.2](#)) ([Wang XY 2000](#));
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablets after six months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI -0.01 to 0.13) ([Analysis 3.2](#)) ([Xie YM 1997](#));
- Shangke Jiegu tablet versus vitamin D2 plus calcium tablets after six months treatment (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.00 to 0.11) ([Analysis 3.2](#)) ([Yuan YN 2000](#)).

After 12 months treatment with Liuwei Dihuang pills, the BMD of the ulna was statistically significantly increased when compared with calcium supplementation (MD 0.02 g/cm<sup>3</sup>; 95% CI 0.01 to 0.03) ([Analysis 3.2](#)) ([Zhang J 2003](#)).

#### BMD of the femoral neck

Eight trials of Chinese herbal medicines compared with supplementation with calcium or calcium plus other western medicine showed a significant increase in the BMD of the femoral neck:

- Qianggu soft extract versus calcium gluconate after six months treatment (MD 0.07 g/cm<sup>3</sup>; 95% CI 0.02 to 0.12) ([Analysis 3.2](#)) ([Peng T 2002](#));
- Herba epimedii prescription versus vitamin D plus Caltrate after six months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.02 to 0.10) ([Analysis 3.2](#)) ([Dong YF 2004](#));
- Kangshu Jiangu granule versus Caltrate after six months treatment (MD 0.08 g/cm<sup>3</sup>; 95% CI 0.01 to 0.15) ([Analysis 3.2](#)) ([Shi CD 2012](#));
- kidney-tonifying herbs versus calcium after six months treatment (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.01 to 0.09) ([Analysis 3.2](#)) ([Song XW 2000](#));
- Qianggu paste versus calcium gluconate after six months treatment (MD 0.07 g/cm<sup>3</sup>; 95% CI 0.03 to 0.11) ([Analysis 3.2](#)) ([Wang H 2007](#));
- Yanghuo Sanzi Tang versus Caltrate after six months treatment (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.02 to 0.08) ([Analysis 3.2](#)) ([Qiu RB 2004](#));
- Jiangu capsule versus Caltrate after 12 months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.03 to 0.06) ([Analysis 3.2](#)) ([Wang YZ 2008](#));

- Gujian capsule versus alfacalcidol after six months treatment (MD 0.08 g/cm<sup>3</sup>; 95% CI 0.03 to 0.14) ([Analysis 3.2](#)) ([Meng XD 2003](#)).

Ten other trials showed no significant difference in the BMD of the femoral neck for those treated with Chinese herbal medicines when compared to control groups:

- Kanggusong granule versus Caltrate after nine months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.03 to 0.05), Kanggusong granule versus ipriflavone plus Caltrate after nine months treatment (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.04 to 0.02) ([Analysis 3.2](#)) ([An SJ 2000](#));
- Bushen Jianpi decoction versus calcitonin (MD 0.05 g/cm<sup>3</sup>; 95% CI -0.02 to 0.12) ([Analysis 3.2](#)) ([Mao YF 2011](#));
- Gumikang capsule versus calcium gluconate after six months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.04 to 0.08) ([Analysis 3.2](#)) ([Wang CC 2005](#));
- Yanghuo Sanzi Tang versus Caltrate after three months treatment (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.03 to 0.03) ([Analysis 3.2](#)) ([Qiu RB 2004](#));
- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.01 to 0.07) ([Analysis 3.2](#)) ([Wang J 2007](#));
- Shigu yin versus Caltrate after six months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.01 to 0.07) ([Analysis 3.2](#)) ([Zhang YP 2007](#));
- Bushen Huoxue capsule versus Caltrate plus calcitriol after 12 months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.06 to 0.10) ([Analysis 3.2](#)) ([Zhang XJ 2008](#));
- Bushenjianpi Zhuanggu yin versus Caltrate and calcitonin after 12 weeks (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.00 to 0.12) ([Analysis 3.2](#)) ([Zhang XG 2011](#));
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD 0.09 g/cm<sup>3</sup>; 95% CI -0.05 to 0.23) ([Analysis 3.2](#)) ([Xie YM 1997](#));
- Shangke Jiegu tablet versus vitamin D2 plus calcium tablet after six months treatment (MD 0.07 g/cm<sup>3</sup>; 95% CI -0.06 to 0.20) ([Analysis 3.2](#)) ([Yuan YN 2000](#)).

Three trials compared Chinese herbal medicines with western medicine and found no significant differences between groups on measurement of BMD of the femoral neck:

- Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone after six months treatment (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.11 to 0.09) ([Analysis 3.2](#)) ([Liao L 2004](#));
- kidney-tonifying herbs versus nilestriol after six months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.02 to 0.06) ([Analysis 3.2](#)) ([Song XW 2000](#));
- Qianggu capsules versus oestradiol valerate after six months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.02 to 0.06) ([Analysis 3.2](#)) ([Ruan XY 2006](#)).

#### BMD of Ward's triangle

Two trials showed no evidence of an effect on the BMD of Ward's triangle of Chinese herbal medicines when compared with alendronate after six months treatment:

- Qianggu capsule (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.02 to 0.03) ([Analysis 3.2](#)) ([Xu H 2010](#));
- Xianlinggubao capsule (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.02 to 0.02) ([Analysis 3.2](#)) ([Xu M 2009](#)).

Two other trials showed no evidence of an effect of Chinese herbal medicines when compared with vitamin D2 plus calcium tablet after six months treatment:

- Bugu Shengsui capsule (MD 0.07 g/cm<sup>3</sup>; 95% CI -0.05 to 0.19) ([Analysis 3.2](#)) ([Xie YM 1997](#));
- Shangke Jiegu capsule (MD 0.10 g/cm<sup>3</sup>; 95% CI -0.01 to 0.22) ([Analysis 3.2](#)) ([Yuan YN 2000](#)).

There was no significant difference between Chinese herbal medicine (Kanggusong granule) and ipriflavone plus Caltrate (MD -0.03 g/cm<sup>3</sup>; 95% CI -0.07 to 0.01), or Caltrate alone (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.04 to 0.04) after nine months treatment ([Analysis 3.2](#)) ([An SJ 2000](#)). Gujian capsule appeared statistically significantly better than alfacalcidol after six months treatment (MD 0.08 g/cm<sup>3</sup>; 95% CI 0.01 to 0.15) ([Analysis 3.2](#)) ([Meng XD 2003](#)).

The trial comparing kidney-tonifying herbs with treatment with nilestriol (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.02 to 0.10) or supplementation with calcium (MD 0.10 g/cm<sup>3</sup>; 95% CI 0.06 to 0.14) ([Analysis 3.2](#)) ([Song XW 2000](#)) found a significant improvement in the BMD of Ward's triangle.

#### BMD of the trochanter

One trial showed better treatment effects of Chinese herbal medicines on the BMD of the trochanter when compared with calcium supplementation:

- Shangke Jiegu tablet versus vitamin D2 plus calcium tablet after six months treatment (MD 0.19 g/cm<sup>3</sup>; 95% CI 0.04 to 0.33) ([Analysis 3.2](#)) ([Yuan YN 2000](#)).

However, two other trials showed no evidence of an effect of Chinese herbal medicines:

- Kanggusong granule versus ipriflavone plus Caltrate after nine months treatment (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.05 to 0.03) ([Analysis 3.2](#)) ([An SJ 2000](#)), or versus Caltrate alone (MD 0.03 g/cm<sup>3</sup>; 95% CI 0.00 to 0.06) ([Analysis 3.2](#)) ([An SJ 2000](#));
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD 0.11 g/cm<sup>3</sup>; 95% CI -0.04 to 0.27) ([Analysis 3.2](#)) ([Xie YM 1997](#)).

There was a significant difference between Gujian capsule and alfacalcidol after six months treatment (MD 0.14 g/cm<sup>3</sup>; 95% CI 0.07 to 0.20) ([Analysis 3.2](#)) ([Meng XD 2003](#)).

#### BMD of the hip bone

There was no significant difference between the Chinese herbal medicine Gushukang granule and Calcium carbonate with vitamin D chewable tablets in the BMD of the hip bone after six months treatment: the MD was 0.02 g/cm<sup>3</sup> (95% CI -0.02 to 0.06) ([Analysis 3.2](#)) ([Chen ZX 2002](#)). There was also no significant difference between the Chinese herbal medicine Guli powder when compared with Caltrate after six months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.05 to 0.11) ([Analysis 3.2](#)) ([Lan ZX 2006](#)).

#### BMD of the distal radius

TPF capsule compared to calcium granules statistically significantly increased the BMD of the distal radius (MD 0.20 g/cm<sup>3</sup>; 95% CI 0.17 to 0.23) ([Analysis 3.2](#)) ([Zhang YL 1996](#)).

#### BMD of the calcaneus

Jiawei Zhuangyao Jianshen tang compared to compound calcium amino acid chelate capsules statistically significantly increased the BMD of the calcaneus (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.01 to 0.11) ([Analysis 3.2](#)) ([He N 2006](#)).

#### T score in BMD measurement

Two trials reported T score in bone mineral density measurement:

- Jingujian granule versus Caltrate after three months treatment (MD 0.05; 95% CI -0.57 to 0.67) ([Analysis 3.3](#)) ([Li YH 2008](#));
- Jingujian granule versus Caltrate after three months treatment (MD 0.03; 95% CI -0.04 to 0.10) ([Analysis 3.3](#)) ([Li YH 2010](#)).

#### Biochemical indicators

The effects of the interventions on biochemical indicators are shown in [Appendix 5](#).

#### Summary: Comparison 03

In summary, 61 trials out of the 108 included trials evaluated Chinese herbal medicines compared with conventional western medicines.

The following Chinese herbal medicines increased the BMD of the lumbar spine: Jiawei Bushen Zhuangjintang Yishen Yanggan mixture, Kanggusong granule, Bushen Qianggutang, Bushen Jianpi Migu prescription, Bushen Zhuanggu tang, Bushenjianpi Zhuangguyin, Gujian capsule, Erxian soup, Shangke Jiegu tablet, Liuwei Dihuang pills, Kangshu Jiangu granule, Radix rehmanniae preparata and Radix astragali. However, the following did not increase the BMD of the lumbar spine: Kanggusong granule, Strong Bone capsule, Herba epimedii prescription, Bushen Shengsui principle, Bushen Jianpi Jingu decoction, Gukang oral liquid, kidney-tonifying herbs, Bushen Jianpi Huoxue recipe, Huangqi Sanxian tang, Qianggu capsule, Jianshenfang granule, Jiangu recipe, Gukang fang, Qianggu capsule, Bushen Huoxue capsules, Yinyanghuo, Shenyao capsules, Guli powder, Gushen Yijing tang, Bugu Shengsui capsule, Xianling Gusong capsules, Zishen Gukang pill, Gukang decoction, Gumiling granule, Gujian capsule, Xianlinggubao capsule and Bushen Tianjing Huoxue therapy.

Gukang oral liquid, Herba epimedii prescription and Liuwei Dihuang pills increased the BMD of the radius, while Bushen Yigu soft extract, Bugu Shengsui capsule and Shangke Jiegu tablet did not.

Liuwei Dihuang pills appeared to increase the BMD of the ulna, while Gukang oral liquid, Bushen Yigu soft extract, Bugu Shengsui capsule and Shangke Jiegu tablet did not.

The following Chinese herbal medicines appeared to improve the BMD of the femoral neck: Qianggu soft extract, Herba epimedii prescription, kidney-tonifying herbs, Qianggu paste, Yanghuo Sanzi tang, Jiangu capsule, Kangshu Jiangu granule and Gujian capsule. However, the following did not: Kanggusong granule, Bushen Jianpi decoction, Gumikang capsule, Yanghuo Sanzi Tang,

Qianggu capsule, Shigu yin, Bushen Huoxue capsule, Bushenjianpi Zhuanggu yin, Bugu Shengsui capsule, Shangke Jiegu tablet and Bushen Shengsui principle.

Gujian capsule and kidney-tonifying herbs seemed to increase the BMD of Ward's triangle, while Qianggu capsule, Xianlinggubao capsule, Bugu Shengsui capsule, Shangke Jiegu capsule and Kanggusong granule did not.

Shangke Jiegu tablet and Gujian capsule appeared to increase the BMD of the trochanter, while Kanggusong granule and Bugu Shengsui capsule did not.

Gushukang granule and Guli powder did not show statistically significant increases in the BMD of the hip bone.

TPF capsule appeared to increase the BMD of the distal radius.

Jiawei Zhuangyao Jianshen tang statistically significantly increased the BMD of the calcaneus.

Jingujian granule did not show a statistically significant increase in the T score of BMD.

#### Chinese herbal medicines plus western medicine versus western medicine (Comparison 04)

Forty-seven trials (involving 5529 patients) compared 42 different Chinese herbal medicines plus western medicine with western medicine (Cao GY 2010; Cao W 2010; Chen FS 2001; Chen XL 2010; Chen YQ 2001; Chen ZX 2002; Dai Y 2007; Deng WM 2012; Dong Y 2010; Fan HX 2004; Guo JH 2008; Han XL 2007; He XQ 2006; Hu J 2012; Huang JW 2008; Jian QQ 2010; Liang DB 2012; Li HW 2004; Li SL 2004; Liu JM 2012; Ma C 2011; Ma CZ 2011; Ma YJ 2011; Miu JQ 2008; Mu G 2001; Qiu ZX 2010; Ruan XY 2006; Tang ZA 2012; Wang SW 2003; Wang XD 2011; Wu W 2005; Xie J 2004; Xiong YH 2008; Xu H 2010; Xu M 2009; Yang B 2007; Ye AN 1998; Zhan HS 2009; Zhang DS 2011; Zhang RH 2004; Zhang XZ 2004; Zhang ZF 2011; Zhao G 2002; Zheng WK 2007; Zhou XT 2001; Zhu HM 2012; Zou JJ 2005).

The tested herbs included Antai capsule, Bushenhuoxue therapy, Bushen Qianggu Huoxue therapy, Bushen Qiangshen pill, Bushen Yangxue tang, Bushen Zhuanggutang, Bushen Zhuanggu granules, Bushen Kangsong pill, Bushenyiqihuoxue soup, Chinese medicine (combination of 10 herbs), Chinese medicine Bushenhuoxue recipe, Erxian Yanggu decoction, Gengnian Anyi tablet, Guben Zhuanggu capsules, Guilu Erxiantang, Gukang tablet, Gushen decoction, Gushukang granule, Gusongbao granule, Heche Dazao pill, Huangqi, Hugu capsule, Jiangu granule, Jiarong tablet, Jinwugutong capsules, Kanggusong soup, Liuwei Dihuang pills, Migu tablet, Qianggu capsule, Shangke Yishen Zhuanggu pill, Shengsuiyin recipe, Shugan zishen huoxue tang, traditional Chinese capsule, Xianlinggubao capsule, Xuduanzhuanggu capsule, Yigu capsule, Yishen Zhuanggu decoction, Yiyuanjiangu decoction, Zhuanggu capsule, Zhuangguqiangjin tablet, Zishen prescription and Ziyin Bushen Zhuanggu prescription. All these Chinese herbal medicines, except Huangqi, were mixtures of herbs. Based on our standard classification for Chinese herbal medicines, 17 herbs were Chinese proprietary medicine, and 25 were prescribed herbal formulae.

The reported outcomes included BMD of the lumbar spine, femoral neck, Ward's triangle, trochanter, hip bone and distal radius. Levels of oestradiol (E2), serum calcium (Ca), phosphorus (P), alkaline

phosphatase (ALP), bone Gla protein (BGP) and interleukin-6 (IL-6) were also measured, as was the improvement of lumbago and backache. We were not able to pool the data due to the variability of the tested Chinese herbal medicines and control interventions.

Based on the included trials, we created a 'Summary of findings' table for patient-important outcomes (fractures, quality of life, death, adverse effects) (see [Summary of findings 4](#)).

#### Fractures

Five trials reported the outcome fractures. One trial reported that eight new fractures occurred in the control group treated with placebo and calcium (0/70 versus 8/70; RR 0.06; 95% CI 0.00 to 1.00) ([Analysis 4.1](#)) ([Zhang RH 2004](#)). One trial reported one new fracture in the control group treated with placebo plus calcium and vitamin D (low-dose group: 0/60 versus 1/60; RR 0.33; 95% CI 0.01 to 8.02; high-dose group: 0/56 versus 1/60; RR 0.36; 95% CI 0.01 to 8.58) ([Analysis 4.1](#)) ([Zhu HM 2012](#)). One trial reported four new fractures in the herbal group (Bushen Zhuanggu granules plus calcium and vitamin D) and seven new fractures in the control group (placebo granules plus calcium and vitamin D) (4/88 versus 7/67; RR 0.44; 95% CI 0.13 to 1.43) ([Analysis 4.1](#)) ([Deng WM 2012](#)). One trial reported one new fracture in the control group (calcium and vitamin D) (0/45 versus 1/30; RR 0.22; 95% CI 0.01 to 5.34) ([Analysis 4.1](#)) ([Li ZP 2011](#)). One trial reported that no new fracture occurred in any group (Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule group, and calcitonin ampoule group) ([Analysis 4.1](#)) ([Zhang ZF 2011](#)).

#### Quality of life or symptoms including pain, muscle fatigue and limited mobility

Eight of 48 trials reported the improvement of lumbago and backache. Among them, four trials reported that Chinese herbal medicines were better than western medicines without reporting the number of cases with ache improvement in each group ([Liang DB 2012](#); [Wang XD 2011](#); [Xu H 2010](#); [Zhan HS 2009](#)). The other three trials reported as follows:

- 55/57 versus 48/57: RR 1.15; 95% CI 1.01 to 1.30 ([Analysis 4.5](#)) ([Chen XL 2010](#));
- 53/54 versus 51/53: RR 1.33; 95% CI 1.09 to 1.61 ([Analysis 4.5](#)) ([Dong Y 2010](#));
- 40/45 versus 18/30: RR 1.48; 95% CI 1.09 to 2.02 ([Analysis 4.5](#)) ([Li ZP 2011](#)).

In another trial, no significant difference was found between comparable groups (43/45 versus 35/37: RR 1.01; 95% CI 0.91 to 1.12) ([Analysis 4.5](#)) ([Zhang ZF 2011](#)).

Only one trial reported the outcome quality of life: the mean difference in quality of life score was 5.30 (95% CI 3.67 to 6.93) ([Analysis 4.4](#)) ([Liang DB 2012](#)).

#### Death

No trials reported this outcome.

#### Adverse effects

Eight trials out of 48 reported no remarkable adverse effects occurring in any groups ([Chen FS 2001](#); [Liang DB 2012](#); [Liu JM 2012](#); [Ruan XY 2006](#); [Tang ZA 2012](#); [Xie J 2004](#); [Zheng WK 2007](#); [Zou JJ 2005](#)). Fourteen trials reported some adverse symptoms:

- a few patients with nausea, vomiting, etc. after one month of treatment (Cao W 2010);
- three patients with constipation and canker sore symptoms (Chen YQ 2001);
- 21 (23.86%) and 21 (31.34%) adverse effects in the herbal group and control group, respectively, with the predominant effects being liver enzyme abnormality and gastrointestinal complaints (Deng WM 2012);
- a few patients with dizziness, rash, nausea, vomiting and cardiopalmus at the beginning of therapy, but no significant difference in comparison groups (Dong Y 2010);
- one patient with irregular vaginal bleeding and two with breast tenderness in the western medicine group (Fan HX 2004);
- two cases of abdominal distention, acid reflux, etc. in the Liuwei Dihuang pills group, three cases with similar gastrointestinal symptoms in the Liuwei Dihuang pills plus calcium and vitamin D group, and three with similar gastrointestinal symptoms in the calcium and vitamin D group (Ma C 2011);
- three patients with mild constipation in the herbal group (Wang XD 2011);
- four patients with adverse effects (gastrointestinal reaction, nervous system response, anaphylactic reaction, etc.) in the Jiangu granule group, five in the Gusongbao granule group and five in the western medicine group (Xiong YH 2008);
- six patients with nausea in the herbal group and three in the western medicine group (Xu H 2010);
- three patients with nausea in the herbal group and three in the western medicine group (Xu M 2009);
- three patients with constipation, one with dyesthesia, one with elevated ALT, six with abdominal discomfort and one with gum swelling in the Xuduanzhuanggu capsule group; one with dizziness, one with skin petechiae, one with abdominal discomfort and one with gum swelling in the Gusongbao granule group; one with constipation, one with abdominal discomfort, one with sore throat, one with gum swelling and one with electrocardiogram abnormality in the control group (Zhan HS 2009);
- five patients with dry mouth symptoms, dreaminess, dryness-heat in the experimental group, a few with a transient heightened blood calcium in the control group (Zhang RH 2004);
- five with flushed face, one with nausea and one with vomiting in 90 patients after using calcitonin (Zhang ZF 2011);
- 11 (18%), 12 (21%) and 11 (18%) adverse effects in the low-dose Xianlinggubao capsule group, high-dose Xianlinggubao capsule group and the control group, respectively, with the predominant effects being liver enzyme abnormality and gastrointestinal complaints (Zhu HM 2012).

The other 26 trials did not report adverse effects.

### **Bone mineral density (BMD)**

#### **BMD of the lumbar spine**

Twenty-one trials showed positive effects of Chinese herbal medicines plus western medicine treatments when compared to the same western medicine on the BMD of the lumbar spine:

- Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol after six months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.01 to 0.11) (Analysis 4.2) (Chen FS 2001);
- Shugan zishen huoxue tang plus Caltrate and alendronate sodium tablets versus Caltrate and alendronate sodium tablets after six months treatment (MD 0.12 g/cm<sup>3</sup>; 95% CI 0.08 to 0.16) (Analysis 4.2) (Han XL 2007);
- Shangke Yishen Zhuanggu pill, plus Caltrate and calcitonin, versus Caltrate and calcitonin after three months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.03 to 0.05) (Analysis 4.2) (Hu J 2012);
- Gukang tablet plus oyster shell calcium chewable tablets and vitamin A and D capsules versus oyster shell calcium chewable tablets and vitamin A and D capsules after three months treatment (MD 0.24 g/cm<sup>3</sup>; 95% CI 0.14 to 0.34) (Analysis 4.2) (Liu JM 2012);
- Ziyin Bushen Zhuanggu prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after eight months treatment (MD 0.14 g/cm<sup>3</sup>; 95% CI 0.08 to 0.20) (Analysis 4.2) (Li HW 2004);
- Liuwei Dihuang pills plus Caltrate versus Caltrate after six months treatment (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.02 to 0.08) (Analysis 4.2) (Ma C 2011);
- Xianlinggubao capsule plus Caltrate versus Caltrate after 12 months treatment (MD 0.30 g/cm<sup>3</sup>; 95% CI 0.25 to 0.35) (Analysis 4.2) (Wu W 2005);
- Migu tablet plus Caltrate versus Caltrate after 12 months treatment (MD 0.08 g/cm<sup>3</sup>; 95% CI 0.07 to 0.09) (Analysis 4.2) (Xie J 2004);
- Bushen Zhuanggutang plus Caltrate versus Caltrate after six months treatment (MD 0.14 g/cm<sup>3</sup>; 95% CI 0.06 to 0.22) (Analysis 4.2) (Ye AN 1998);
- Zishen prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after eight months treatment (MD 0.14 g/cm<sup>3</sup>; 95% CI 0.08 to 0.20) (Analysis 4.2) (Zhao G 2002);
- Guben Zhuanggu capsules plus Caltrate versus Caltrate after six months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI 0.01 to 0.05) (Analysis 4.2) (Zou JJ 2005);
- Qianggu capsule plus alendronate versus alendronate after six months treatment (MD 0.08 g/cm<sup>3</sup>; 95% CI 0.03 to 0.12) (Analysis 4.2) (Xu H 2010);
- Xianlinggubao capsule plus alendronate versus alendronate after six months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.03 to 0.09) (Analysis 4.2) (Xu M 2009);
- Xianlinggubao capsule plus Caltrate versus Caltrate after 12 months treatment (MD 0.31 g/cm<sup>3</sup>; 95% CI 0.28 to 0.34) (Analysis 4.2) (Qiu ZX 2010);
- Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.18 g/cm<sup>3</sup>; 95% CI 0.14 to 0.22), and Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.17 g/cm<sup>3</sup>; 95% CI 0.14 to 0.20) (Analysis 4.2) (Dai Y 2007);
- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.11 g/cm<sup>3</sup>; 95% CI 0.07 to 0.15) (Analysis 4.2) (Zheng WK 2007);
- Chinese medicine Bushenhuoxue recipe plus conventional western medicine (alfacalcidol soft capsules, bisphosphonate and salmon calcitonin, etc.) versus conventional western medicine after three months treatment (MD 0.16 g/cm<sup>3</sup>; 95% CI 0.09 to 0.22) (Analysis 4.2) (Cao GY 2010);

### **Chinese herbal medicines for treating osteoporosis (Review)**



- Shengsuiyin recipe plus Caltrate versus Caltrate after 12 months treatment (MD 0.31 g/cm<sup>3</sup>; 95% CI 0.28 to 0.34) ([Analysis 4.2](#)) ([Jian QQ 2010](#));
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.08 g/cm<sup>3</sup>; 95% CI 0.04 to 0.12) ([Analysis 4.2](#)) ([Zhang RH 2004](#));
- Chinese medicine (combination of 10 herbs) plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD 0.10 g/cm<sup>3</sup>; 95% CI 0.06 to 0.14) ([Analysis 4.2](#)) ([Cao W 2010](#));
- Huangqi plus calcium and vitamin D versus calcium and vitamin D after six months treatment (MD 0.06 g/cm<sup>3</sup>; 95% CI 0.01 to 0.11) ([Analysis 4.2](#)) ([Yang B 2007](#)).

No significant difference in the BMD of the lumbar spine was reported for any of the following comparisons of treatment groups:

- Jiarong tablet plus Caltrate versus Caltrate (MD 0.04 g/cm<sup>3</sup>; 95% CI -0.06 to 0.14) ([Analysis 4.2](#)) ([Chen YQ 2001](#));
- Bushen Kangsong pill plus calcium carbonate tablets versus calcium carbonate tablets (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.03 to 0.04) ([Analysis 4.2](#)) ([Guo JH 2008](#));
- Shugan zishen huoxue tang plus Caltrate and alendronate sodium tablets versus Caltrate and alendronate sodium tablets after three months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI -0.01 to 0.09) ([Analysis 4.2](#)) ([Han XL 2007](#));
- Bushen Yangxue tang plus Caltrate versus Caltrate (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.02 to 0.06) ([Analysis 4.2](#)) ([He XQ 2006](#));
- Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol versus calcium carbonate tablets and alfacalcidol (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.04 to 0.02) ([Analysis 4.2](#)) ([Liang DB 2012](#));
- Ziyin Bushen Zhuanggu prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after four months treatment (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.00 to 0.10) ([Analysis 4.2](#)) ([Li HW 2004](#));
- Zhuanggu capsule plus Caltrate versus Caltrate (MD 0.01 g/cm<sup>3</sup>; 95% CI 0.00 to 0.02) ([Analysis 4.2](#)) ([Li SL 2004](#));
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.01 to 0.05) ([Analysis 4.2](#)) ([Ma CZ 2011](#));
- Yishen Zhuanggu decoction plus calcitriol soft capsule versus calcitriol soft capsule (MD 0.02 g/cm<sup>3</sup>; 95% CI 0.00 to 0.05) ([Analysis 4.2](#)) ([Ma YJ 2011](#));
- Bushen Qianggu Huoxue therapy plus calcium and cod liver oil versus calcium and cod liver oil (MD 0.05 g/cm<sup>3</sup>; 95% CI -0.01 to 0.11) ([Analysis 4.2](#)) ([Tang ZA 2012](#));
- Antai capsule plus Caltrate versus Caltrate (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.00 to 0.08) ([Analysis 4.2](#)) ([Wang SW 2003](#));
- Hugu capsule plus Caltrate versus placebo capsule plus Caltrate (MD 0.03 g/cm<sup>3</sup>; 95% CI 0.00 to 0.06) ([Analysis 4.2](#)) ([Wang XD 2011](#));
- Xianlinggubao capsule plus Caltrate versus Caltrate after six months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.02 to 0.08) ([Analysis 4.2](#)) ([Wu W 2005](#));
- Zishen prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after four months treatment (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.00 to 0.10) ([Analysis 4.2](#)) ([Zhao G 2002](#));
- Guilu Erxiantang plus calcium carbonate tablet versus calcium carbonate tablet (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.03 to 0.09) ([Analysis 4.2](#)) ([Zhou XT 2001](#));
- Xianlinggubao capsule (low-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.04 to 0.04) and Xianlinggubao capsule (high-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.03 to 0.03) ([Analysis 4.2](#)) ([Zhu HM 2012](#));
- Bushen Kangsong pill plus calcium carbonate tablets versus calcium carbonate tablets after six months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.03 to 0.04) ([Analysis 4.2](#)) ([Guo JH 2008](#));
- Gusongbao granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.07 to 0.05) ([Analysis 4.2](#)) ([Xiong YH 2008](#));
- Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.03 to 0.09) ([Analysis 4.2](#)) ([Dong Y 2010](#));
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.03 to 0.06) ([Analysis 4.2](#)) ([Zhang XZ 2004](#));
- Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI -0.02 to 0.10) ([Analysis 4.2](#)) ([Xiong YH 2008](#));
- Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.01 to 0.05) and Gusongbao granule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.05 to 0.03) ([Analysis 4.2](#)) ([Zhan HS 2009](#));
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.04 to 0.06) ([Analysis 4.2](#)) ([Zhang ZF 2011](#));
- Huangqi plus calcium and vitamin D versus calcium and vitamin D after three months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.01 to 0.07) ([Analysis 4.2](#)) ([Yang B 2007](#)).
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.04 to 0.06) ([Analysis 4.2](#)) ([Zhang ZF 2011](#));
- Huangqi plus calcium and vitamin D versus calcium and vitamin D after three months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.01 to 0.07) ([Analysis 4.2](#)) ([Yang B 2007](#)).

#### BMD of the femoral neck

Seven trials showed positive effects of Chinese herbal medicines plus western medicine treatments when compared to the same western medicine on the BMD of the femoral neck:

- Jiarong tablet plus Caltrate versus Caltrate after six months treatment (MD 0.09 g/cm<sup>3</sup>; 95% CI 0.02 to 0.15) ([Analysis 4.2](#)) ([Chen YQ 2001](#));

- Xianlinggubao capsule plus Caltrate versus Caltrate after 12 months treatment (MD 0.30 g/cm<sup>3</sup>; 95% CI 0.25 to 0.35) ([Analysis 4.2](#)) ([Wu W 2005](#));
- Migu tablet plus Caltrate versus Caltrate (MD 0.09 g/cm<sup>3</sup>; 95% CI 0.08 to 0.10) ([Analysis 4.2](#)) ([Xie J 2004](#));
- Chinese medicine Bushenhuoxue recipe plus conventional western medicine (alfacalcidol soft capsules, bisphosphonate and salmon calcitonin, etc.) versus conventional western medicine after three months treatment (MD 0.17 g/cm<sup>3</sup>; 95% CI 0.12 to 0.23) ([Analysis 4.2](#)) ([Cao GY 2010](#));
- Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.26 g/cm<sup>3</sup>; 95% CI 0.22 to 0.30) and Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.24 g/cm<sup>3</sup>; 95% CI 0.21 to 0.27) ([Analysis 4.2](#)) ([Dai Y 2007](#));
- Huangqi plus calcium and vitamin D versus calcium and vitamin D after six months treatment (MD 0.07 g/cm<sup>3</sup>; 95% CI 0.03 to 0.11) ([Analysis 4.2](#)) ([Yang B 2007](#));
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.01 to 0.07) ([Analysis 4.2](#)) ([Zhang RH 2004](#)).

No significant difference in the BMD of the femoral neck was reported for any of the following comparisons of treatment groups:

- Qianggu capsules plus oestradiol valerate versus oestradiol valerate after six months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.01 to 0.07) ([Analysis 4.2](#)) ([Ruan XY 2006](#));
- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.02 to 0.04) ([Analysis 4.2](#)) ([Wang SW 2003](#));
- Xianlinggubao capsule plus Caltrate versus Caltrate after six months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI -0.02 to 0.08) ([Analysis 4.2](#)) ([Wu W 2005](#));
- Guben Zhuanggu capsules plus Caltrate versus Caltrate after six months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.01 to 0.02) ([Analysis 4.2](#)) ([Zou JJ 2005](#));
- Heche Dazao pill plus oyster shell calcium chewable tablets versus oyster shell calcium chewable tablets after three months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.00 to 0.07) ([Analysis 4.2](#)) ([Chen XL 2010](#));
- Gusongbao granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.03 to 0.05) and Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD -0.02 g/cm<sup>3</sup>; 95% CI -0.07 to 0.03) ([Analysis 4.2](#)) ([Xiong YH 2008](#));
- Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.01 to 0.03) and Gusongbao granule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.03 to 0.03) ([Analysis 4.2](#)) ([Zhan HS 2009](#));

- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after three months treatment (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.01 to 0.03) ([Analysis 4.2](#)) ([Ma CZ 2011](#));
- Bushen Qianggu Huoxue therapy plus calcium and cod liver oil versus calcium and cod liver oil after three months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.02 to 0.05) ([Analysis 4.2](#)) ([Tang ZA 2012](#));
- Xianlinggubao capsule (low-dose or high-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.05 to 0.03) ([Analysis 4.2](#)) ([Zhu HM 2012](#)).

#### BMD of Ward's triangle

Six trials showed positive effects of Chinese herbal medicines plus western medicine treatments when compared to the same western medicine on the BMD of Ward's triangle:

- Migu tablet plus Caltrate versus Caltrate (MD 0.09 g/cm<sup>3</sup>; 95% CI 0.08 to 0.10) ([Analysis 4.2](#)) ([Xie J 2004](#));
- Qianggu capsule plus alendronate versus alendronate after six months treatment (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.02 to 0.07) ([Analysis 4.2](#)) ([Xu H 2010](#));
- Xianlinggubao capsule plus alendronate versus alendronate after six months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.02 to 0.06) ([Analysis 4.2](#)) ([Xu M 2009](#));
- Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.23 g/cm<sup>3</sup>; 95% CI 0.19 to 0.27) and Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.28 g/cm<sup>3</sup>; 95% CI 0.24 to 0.32) ([Analysis 4.2](#)) ([Dai Y 2007](#));
- Bushen Qianggu Huoxue therapy plus calcium and cod liver oil versus calcium and cod liver oil after three months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.02 to 0.07) ([Analysis 4.2](#)) ([Tang ZA 2012](#));
- Hugu capsule plus Caltrate versus placebo capsule plus Caltrate after six months treatment (MD 0.05 g/cm<sup>3</sup>; 95% CI 0.02 to 0.08) ([Analysis 4.2](#)) ([Wang XD 2011](#)).

No significant difference in the BMD of Ward's triangle was reported for any of the following comparisons of treatment groups:

- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.03 to 0.03) ([Analysis 4.2](#)) ([Wang SW 2003](#));
- Gusongbao granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.06 to 0.04) and Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD -0.01 g/cm<sup>3</sup>; 95% CI -0.06 to 0.04) ([Analysis 4.2](#)) ([Xiong YH 2008](#));
- Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI 0.00 to 0.04) and Gusongbao granule plus calcium tablet versus placebo plus calcium tablet after six months treatment

(MD 0.01 g/cm<sup>3</sup>; 95% CI -0.02 to 0.04) (Analysis 4.2) (Zhan HS 2009);

- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.04 g/cm<sup>3</sup>; 95% CI 0.00 to 0.08) (Analysis 4.2) (Zhang RH 2004).

#### BMD of the trochanter

Three trials showed positive effects of Chinese herbal medicines plus western medicine treatments when compared to the same western medicine on the BMD of the trochanter:

- Migu tablet plus Caltrate versus Caltrate after six months treatment (MD 0.15 g/cm<sup>3</sup>; 95% CI 0.14 to 0.16) (Analysis 4.2) (Xie J 2004);
- Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.13 g/cm<sup>3</sup>; 95% CI 0.08 to 0.18) and Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.12 g/cm<sup>3</sup>; 95% CI 0.07 to 0.17) (Analysis 4.2) (Dai Y 2007);
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after six months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI 0.01 to 0.04) (Analysis 4.2) (Ma CZ 2011).

No significant difference in the BMD of the trochanter was reported for any of the following comparisons of treatment groups:

- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD 0.03 g/cm<sup>3</sup>; 95% CI 0.00 to 0.06) (Analysis 4.2) (Wang SW 2003);
- Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.02 to 0.02) and Gusongbao granule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.00 g/cm<sup>3</sup>; 95% CI -0.03 to 0.03) (Analysis 4.2) (Zhan HS 2009);
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.02 g/cm<sup>3</sup>; 95% CI -0.02 to 0.06) (Analysis 4.2) (Zhang RH 2004).

#### BMD of the hip bone

Compared with Calcium carbonate with vitamin D chewable tablets, Gushukang granule plus Calcium carbonate with vitamin D chewable tablets showed a statistically significantly better effect on the BMD of the hip bone after six months treatment (MD 0.15 g/cm<sup>3</sup>; 95% CI 0.11 to 0.19) (Analysis 4.2) (Chen ZX 2002). There was no significant difference in the comparison of Jinwugutong capsules plus calcium and placebo plus calcium regarding the BMD of the hip bone (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.02 to 0.04) (Analysis 4.2) (Zheng WK 2007).

#### BMD of the distal radius

There was no significant difference in the comparison of Gengnian Anyi tablet plus Caltrate and Caltrate regarding the BMD of the distal radius (MD 0.01 g/cm<sup>3</sup>; 95% CI -0.06 to 0.08) (Analysis 4.2) (Fan HX 2004). However, Bushen Zhuanggu granules plus calcium and vitamin D showed positive effects on the BMD of the distal radius when compared with placebo granules plus calcium and vitamin

D after five-year follow-up (MD 0.10 g/cm<sup>3</sup>; 95% CI 0.09 to 0.10) (Analysis 4.2) (Deng WM 2012).

#### T score in BMD measurement

One trial reported the T score in bone mineral density measurement: Erxian Yanggu decoction plus alendronate sodium tablets versus alendronate sodium tablets (MD of T score 0.91; 95% CI 0.57 to 1.25) (Analysis 4.3) (Huang JW 2008).

#### Biochemical indicators

The effects of the interventions on biochemical indicators are shown in Appendix 5.

#### Summary: Comparison 04

In summary, 37 trials out of 93 included trials evaluated Chinese herbal medicines plus conventional medicine compared with the same conventional medicine.

The results showed that the following Chinese herbal medicines appeared to increase the BMD of the lumbar spine: Gushen decoction, Shugan zishen huoxue tang, Erxian Yanggu decoction, Ziyin Bushen Zhuanggu prescription, Xianlinggubao capsules, Migu tablet, Bushen Zhuanggutang, Zishen prescription, Guben Zhuanggu capsules, Qianggu capsule, Jinwugutong capsule, Shengsuiyin recipe, Yigu capsule and Huangqi. However, the following did not: Jiarong tablet, Bushen Kangsong pill, Shugan zishen huoxue tang, Bushen Yangxue tang, Bushenhuoxue therapy, Ziyin Bushen Zhuanggu prescription, Zhuanggu capsule, Yiyuanjiangu decoction, Yishen Zhuanggu decoction, Bushen Qianggu Huoxue therapy, Antai capsule, Hugu capsule, Xianlinggubao capsule, Zishen prescription, Guilu Erxiantang, Bushen Kangsong pill, Gusongbao granule, Jiangu granule, Zhuangguqiangjin tablet and Shujinbogu tablet, Xuduanzhuanggu capsule and Huangqi.

The following Chinese herbal medicines appeared to increase the BMD of the femoral neck: Jiarong tablet, Xianlinggubao capsule, Migu tablet, Bushenhuoxue recipe, Huangqi and Yigu capsule. However, the following did not: Qianggu capsules, Antai capsule, Xianlinggubao capsule, Guben Zhuanggu capsules, Heche Dazao pill, Gusongbao granule, Jiangu granule, Xuduanzhuanggu capsule, Yiyuanjiangu decoction and Bushen Qianggu Huoxue therapy.

The following Chinese herbal medicines appeared to increase the BMD of Ward's triangle: Migu tablet, Qianggu capsule, Xianling Gubao capsule, Bushen Qianggu Huoxue therapy and Hugu capsule. However, the following did not: Antai capsule, Gusongbao granule, Xuduanzhuanggu capsule and Yigu capsule.

The following Chinese herbal medicines appeared to increase the BMD of the trochanter: Migu tablet, Yiyuanjiangu decoction and Xianlinggubao capsule. However, the following did not: Antai capsule, Xuduanzhuanggu capsule and Yigu capsule.

Gushukang granule seemed to increase the BMD of the hip bone, while Jinwugutong capsules did not.

Bushen Zhuanggu granules appeared to increase the BMD of the distal radius, while Gengnian Anyi tablet did not.

Erxian Yanggu decoction appeared to increase the T score of BMD.

## DISCUSSION

Due to poor study quality and limited data on the individual herbal interventions, no definitive conclusions can be drawn from this review on the effectiveness of any Chinese herbal medicine intervention tested to date.

### Summary of main results

One hundred and eight randomised trials were included in this review. Ninety-nine different Chinese herbal medicines were compared with placebo, no intervention, conventional pharmaceutical medicine or with the same co-intervention received by the Chinese herbal medicines group. In this review, many of the trials showed a symptomatic benefit of Chinese herbal medicines in patients with osteoporosis either when compared with placebo, no intervention or conventional western medicine. However, there was a lack of replicable evidence because no more than one trial ever compared the same Chinese herbal medicine and control treatment. Thus, the finding of a benefit of Chinese herbal medicine treatment may not be conclusive. Furthermore, the findings of this review should be interpreted with caution due to the small sample sizes and generally low methodological quality of the included studies.

Compared with placebo in three trials, Chinese herbal medicines had a statistically significant effect in increasing bone mineral density (BMD) in each trial. One reported some mild adverse effects (such as stomach/intestinal upset, headache and dizziness) from Chinese herbal medicines, but there were no significant differences between the Chinese herbal medicines and placebo groups.

Five randomised trials compared seven different Chinese herbal medicines with no intervention. Two trials showed Chinese herbal medicines to be significantly effective in increasing BMD, while three others showed no better effect. Four trials reported mild adverse effects (e.g. mild stomach discomfort, intestinal upset, etc.) of Chinese herbal medicines, but this did not affect the continuation of the treatment.

Sixty-one trials compared 58 different Chinese herbal medicines with western medicine. Twenty-three trials showed that Chinese herbal medicines were significantly effective in increasing BMD, while 38 showed no better effect. Twenty-three reported some adverse effects (e.g. dizziness, rash, nausea, vomiting, etc.) from Chinese herbal medicines, but most of them did not affect the continuation of the treatment. Six reported no occurrence of adverse effects and 38 did not report adverse effects.

Forty-eight trials compared 42 different Chinese herbal medicines plus western medicine with western medicine. Twenty-six showed better effects in increasing BMD, while 22 did not. Fourteen reported some adverse symptoms (e.g. nausea, vomiting, etc.) from Chinese herbal medicines, but there was no significant difference between comparison groups. Eight reported no remarkable adverse effects and the other 26 did not report adverse effects.

### Overall completeness and applicability of evidence

We performed this review to evaluate the benefit and harm of Chinese herbal medicines in patients with osteoporosis. Most of the Chinese herbal medicines evaluated were mixtures of different herbs and most of them were prescribed by the investigators without reporting of the quality standards for the preparations.

Interpretation of these findings should therefore be cautious considering that along with the other methodological limitations in the study designs, these studies cannot be replicated. There is a risk that statistically significant findings from a handful of studies at questionable risk of bias are given more prominence than the lack of data for relevant endpoints available from the vast majority of included studies in the review.

The Chinese herbal medicines evaluated generally appeared to be safe. However, we cannot conclude that using Chinese herbal medicines in osteoporosis patients is safe, because adverse effects were not sufficiently and adequately reported in all the included trials. In clinical trials beneficial and harmful effects should receive equal attention, and the recording and reporting of adverse effects must improve if we are to draw any conclusions about safety.

### Quality of the evidence

Due to the variations in the Chinese herbal medicines tested and the methodological limitations of the included trials, the evidence for Chinese herbal medicines for the treatment of osteoporosis is not conclusive. In general, Chinese herbal medicines might be a promising treatment. However, it is premature to recommend Chinese herbal medicines for routine use in osteoporosis considering the generally low quality of the evidence.

Most of the included trials suffered from insufficient reporting or inadequate methods of randomisation. The majority of the trials did not report how the random allocation was generated and concealed. Some trials had a significantly skewed distribution of participants among the groups compared which could not be explained if randomisation had been carried out properly. These trials were highly prone to selection bias.

Very few trials used a double-blinding method. The majority of treatment approaches in the included trials aimed to improve pain symptoms, which is a subjective indicator. If the outcome assessment is not blinded, then performance and detection bias may be a problem.

Most of the included trials were small. Although some data analyses did not demonstrate a statistically significant difference between the groups compared, the results were likely to have been underpowered to demonstrate equivalence. Therefore, the analyses from the small sample trials may not be able to establish with confidence that the two interventions had equivalent effects.

Overall the evidence is limited: potential bias may have occurred in the selection of participants, the administration of treatment and the assessment of outcomes in the included trials, which may obscure or exaggerate treatment effects. Methodologically less rigorous trials have been shown to have significantly larger intervention effects than trials conducted with more rigour (Egger 2003; Moher 1998; Schulz 1995). Therefore, the implications of our findings for clinical practice are very limited.

The trials identified in this review were mostly Chinese and all were conducted in Chinese participants: publication bias might therefore be an issue. An empirical study has shown that Chinese trials are significantly affected by publication bias (Vickers 1998). Furthermore, it is certainly an issue that so few of the included studies actually reported the right outcomes and we downgraded studies for selective reporting. Accordingly, publication bias should be taken into consideration when interpreting the present findings.

Moreover, most of the trials were of short duration and were not followed up long-term, thus they were unable to detect endpoint outcomes such as fracture or long-term adverse effects of the herbal treatments in patients with osteoporosis. Primary outcomes such as the occurrence of new fractures were reported in only a few trials, so we could not draw any conclusions about efficacy and safety.

### Potential biases in the review process

In this review, we comprehensively searched for studies from appropriate databases, and selected trials and extracted data in duplicate. However, we did not find any unpublished studies or studies published in languages other than Chinese or English. Secondly, due to our limited resources, including time, we were not able to contact the original authors to verify unclear information, such as the methods used for random allocation generation and concealment. Furthermore, almost all Chinese herbal medicines in the included trials were tested only once and on small samples. This made it impossible for us to pool data to draw a robust conclusion.

### Agreements and disagreements with other studies or reviews

We could not find any other reviews evaluating the benefits and harms of Chinese herbal medicines in patients with osteoporosis. Therefore, this review is the first time this has been reported. Many trials are not included in this review and are listed as excluded studies. Due to the variation among the Chinese herbal medicine interventions, it is not meaningful to compare the results from these excluded trials with those included in this review.

## AUTHORS' CONCLUSIONS

### Implications for practice

Based on this systematic review, some Chinese herbal medicines may have beneficial effects on the bone mineral density at anatomical sites in people with osteoporosis. However, a large number of the included studies have an uncertain risk of bias, there is a lack of relevant clinical endpoints in the available literature and the evidence is of low quality. Further rigorous studies are needed to demonstrate whether these effects are clinically meaningful and to detect other effects.

### Implications for research

The potential benefit of Chinese herbal medicines as a treatment for osteoporosis needs to be further investigated by conducting high-quality trials to produce convincing evidence. Trials comparing Chinese herbal medicines with conventional pharmaceutical medicine should be designed rigorously. It would also be interesting to verify the additional benefits of Chinese herbal medicines when combined with conventional medicine versus the same medicine by itself. There are a wide range of therapeutic strategies in Traditional Chinese Medicine that address osteoporosis and the related Chinese medicine diagnosis of kidney deficiency. It would be useful for those with expertise in Chinese herbal medicine to group the herbal formulae by therapeutic strategy, so that the Chinese herbal medicines can be tested with reference to the therapeutic framework from which they were derived.

Outcome measures should include both clinical and surrogate outcomes. Standardised monitoring and reporting should be used for assessment of adverse effects. The methodological quality of randomised trials of Chinese herbal medicines for osteoporosis needs to be improved. The following aspects should be addressed: (i) detailed reporting of the methods used to generate the allocation sequence and conceal allocation; (ii) sufficient application of double-blinding with the use of an adequate placebo; (iii) clear descriptions of withdrawals/drop-outs during the trial and use of intention-to-treat analysis; (iv) reporting of clinically important outcome measures from long-term follow-up; and (v) reporting of the trial according to the CONSORT Statement guidelines ([www.consort-statement.org](http://www.consort-statement.org)).

## ACKNOWLEDGEMENTS

The authors wish to acknowledge the helpful comments from Elizabeth Ghogomu, Lara Maxwell and the editorial group and their long-term support to make this review possible, and Christine Wade's contributions to the protocol and review.

This work is partially supported by the grant number 2011ZX09302-006(5) from the Ministry of Science and Technology of China. Jian Ping Liu was partially supported by grant number R24 AT001293 from the National Center for Complementary and Alternative Medicine of the US National Institutes of Health.

## REFERENCES

## References to studies included in this review

**An SJ 2000** {published data only}

An SJ, Li T, Li E. Effect of kidney-tonifying herbs on ovary function and bone mass in postmenopausal women. *Chinese Journal of Osteoporosis* 2000;**6**(2):55-9.

**Cao GY 2010** {published data only}

Cao GY, Zhang XM. Clinical observation of integrated traditional Chinese and western medicine in the treatment of osteoporosis. *Nei Mongol Journal of Traditional Chinese Medicine* 2010;**29**(2):18-9.

**Cao W 2010** {published data only}

Cao W, Li JW. Clinical research of the treatment of postmenopausal osteoporosis with integration of traditional and western medicine. *Journal of New Chinese Medicine* 2010;**42**(4):44-5.

**Chen FS 2001** {published data only}

Chen FS, Wei AS, Lang JM. Clinical observation on effect of 32 cases of postmenopausal osteoporosis treated with integrated traditional with western medicine. *New Journal of Traditional Chinese Medicine* 2001;**33**(11):42-3.

**Chen JP 1999** {published data only}

Chen JP, Shao M, Du Y, Huang HX, Zhu BH, Lin YF. Clinical observation of the therapeutic effect of 36 cases with postmenopausal osteoporosis treated with Gukang oral solution. *New Journal of Traditional Chinese Medicine* 1999;**31**(7):22-3.

**Chen NQ 2006** {published data only}

Chen NQ, An MH, Wu CL. Clinical study of Shenyao capsules on the treatment of 50 cases with primary osteoporosis. *Clinical Journal of Traditional Chinese Medicine* 2006;**18**(2):161-2.

**Chen X 2008** {published data only}

Chen X. Curative effect observation of Gukangfang on treatment of primary osteoporosis. *Zhejiang Journal of Integrative Traditional and Western Medicine* 2008;**18**(7):402-4.

**Chen XL 2010** {published data only}

Chen XL, Liang XH. Clinical observation of Heche Dazao pill on the treatment of 57 cases with primary osteoporosis. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 2010;**16**(8):40-1.

**Chen YQ 2001** {published data only}

Chen YQ, Huang YH. Clinical study of a Chinese medicine of replenishing kidney in treating postmenopausal osteoporosis. *China Contemporary Medicine* 2001;**7**(4):57-8.

**Chen ZX 2002** {published data only}

Chen ZX, Xu XJ, Huang G, Hu JM. Clinical study of the treatment of postmenopausal osteoporosis with Gushukang granule combined with calcium. *Chinese Journal of Clinical Rehabilitation* 2002;**6**(23):3541-2.

**Cui TH 1999** {published data only}

Cui TH, Yu JH, Ding S, Wang RP, Liu H, Shi QY, et al. A clinical study in 74 cases of type primary osteoporosis treated with Chinese medicine Strong bone capsule. *Suzhou University Journal of Medical Science* 1999;**19**(12):1291-4.

**Dai Y 2007** {published data only}

Dai Y, Shen L, Yang YP, Xie J, Zhou PQ. Effects of Migu tablet on bone mineral density, serum levels of osteoprotegerin and its ligand and bone metabolic markers in patients with postmenopausal osteoporosis. *Chinese Journal of Integrative Traditional and Western Medicine* 2007;**27**(8):696-9.

**Deng WM 2012** {published data only}

Deng WM, Zhang P, Huang H, Shen YG, Yang QH, Cui WL, et al. Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures. *Journal of Bone and Mineral Metabolism* 2012;**30**:517-24.

**Dong Y 2010** {published data only}

Dong Y, Lu Y, Hua LX. Efficacy of salmon calcitonin plus Xianlinggubao for osteoporosis and ostealgia in postmenopausal women: a clinical observation. *China Pharmacy* 2010;**21**(2):154-6.

**Dong YF 2004** {published data only}

Dong YF. Clinical observation of Herba epimedii prescription in treating osteoporosis. *Journal of Chinese Medicinal Materials* 2004;**27**(8):620-2.

**Fan HX 2004** {published data only}

Fan HX, Fan HY, Wang ZH. Clinical observation on the therapeutic effect of Gengnian Anyi tablet on postmenopausal osteoporosis. *Tianjin Journal of Traditional Chinese Medicine* 2004;**21**(1):20-1.

**Gang PH 2001** {published data only}

Gang PH, Jiang SY. Clinical observation of Gumiling on osteoporosis. The national academic seminar of osteoporosis and osteoarthritis in 2001. 2001:327-30.

**Gong L 2001** {published data only}

Gong L, Wang MY, Xia P, Cao JQ, Zhou JQ, Hu J. Clinical study of Yishen Zhuanggu mixture in treating 80 cases with primary osteoporosis. *Chinese Journal of Osteoporosis* 2001;**7**(2):149-51.

**Guo JH 2008** {published data only}

Guo JH, Zhang YW, Zhao ZM, Yao RB, Shang W, Zang XL, et al. Effects of Bushen Kangsong pellet on bone mineral density in postmenopausal osteoporosis. *Journal of Anhui Traditional Chinese Medicine College* 2008;**27**(5):14-5.

**Han XL 2007** {published data only}

Han XL, Lou ZJ, Shang FM, Lin HW. Clinical observation of Shugan zishen huoxue tang on 25 cases with postmenopausal osteoporosis. *Liaoning Journal of Traditional Chinese Medicine* 2007;**34**(9):1279-80.

**He MT 2007** {published data only}

He MT, Liang XM, Liang ZJ, Zhang BD. Clinical study of Bushen Huoxue recipe on the treatment of postmenopausal osteoporosis. *Shandong Journal of Traditional Chinese Medicine* 2007;**26**(7):447-9.

**He N 2006** {published data only}

He N. Treatment of postmenopausal osteoporosis by modified 'Zhaungyao Jianshen Tang': a therapeutic effect observation. *Journal of Traditional Chinese Orthopedics and Traumatology* 2006;**18**(11):10-1.

**He XQ 2006** {published data only}

He XQ. Clinical study of Bushen Yangxue tang on the treatment of postmenopausal osteoporosis and effect on BMD. *Journal of New Chinese Medicine* 2006;**38**(4):42-3.

**Huang JW 2008** {published data only}

Huang JW, Chen JC, Huang JH, Lin AJ, Lin XZ. The influence of bone mineral density and cell factors of Erxianyanggu decoction and alendronate sodium tablets for patients with osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 2008;**20**(3):12-3.

**Huang ZJ 2008** {published data only}

Huang ZJ, Chen JX, Bai YB. Clinical research of Zishengukang pill for osteoporosis. *Letters in Biotechnology* 2008;**19**(2):263-4.

**Hu J 2012** {published data only}

Hu J, Li C. Clinical observation of Bushenjianpi treatment of primary osteoporosis. *Hubei Journal of TCM* 2012;**34**(4):11-2.

**Jian QQ 2010** {published data only}

Jian QQ, Xu Y. Clinical observation on effect of integration of traditional and western medicine in treating postmenopausal osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 2010;**28**(9):82-3.

**Lan ZX 2006** {published data only}

Lan ZX, Li LZ, Zhang JT, Wang ZQ, Chen C, Liu JY. Clinical study of Guli on treating primary osteoporosis of deficiency in spleen and kidney. *Journal of Sichuan Traditional Chinese Medicine* 2006;**24**(6):75-7.

**Liang DB 2012** {published data only}

Liang DB, Zhuang H. Clinical observation of Bushenhuoxue therapy of osteoporosis. *Journal of New Chinese Medicine* 2012;**44**(5):53-5.

**Liao L 2004** {published data only}

Liao L, Li XS, Cai QH, Liang YS, Lai RB, Xiao WC, et al. Clinical research of the Bushen Shengsui principle treating postmenopausal osteoporosis. *Chinese Journal of Information on traditional Chinese medicine* 2004;**11**(4):287-90.

**Li BL 2007** {published data only}

Li BL, Huang CB, Tan JW, Li YF, Yang B. The Influence of bone metabolism using traditional Chinese medicine Jianshenfang granule in treating of postmenopausal osteoporosis patients. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2007;**15**(11):15-7.

**Li HW 2004** {published data only}

Li HW, Liu F. Clinical observation on effect of Ziyin Bushen Zhuanggu prescription in treating postmenopausal osteoporosis. *The Chinese Medicine Magazine of China* 2004;**2**(3):114-6.

**Ling JY 2008** {published data only}

Ling JY, Liu Q. Clinical study on treatment of postmenopausal osteoporosis by Bushenzhuanggu prescription. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(4):22-3.

**Lin W 2000** {published data only}

Lin W, Wu HF, Deng LP, Wei XY, Ye GC, Liu QS, et al. Clinical use of traditional Chinese medicine Migu decoction in treating postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 2000;**6**(3):71-2.

**Li SL 2004** {published data only}

Li SL, Fan GJ, Tang AH, Liu CH, Luo GB, Tang XY. Clinical study of the treatment of postmenopausal osteoporosis with Strong bone capsule. *Chinese Journal of Osteoporosis* 2004;**10**(3):330-2.

**Liu JM 2012** {published data only}

Liu JM, Xue L, Tian DX. Clinical research of primary osteoporosis treated with Gukang tablets. *World Journal of Integrated Traditional and Western Medicine* 2012;**7**(4):323-5, 354.

**Li YH 2008** {published data only}

Li YH, Liu HH, Yang HJ, Li Y, Zhang LF, Liu F, et al. Clinical research of Jingujian granule for old people with osteoporosis. *Beijing Journal of Traditional Chinese Medicine* 2008;**27**(10):758-61.

**Li YH 2010** {published data only}

Li YH, Xue L, Zhao FF, Zhu QQ, Li Y, Yang HJ. Effect of Jingujian granule on 129 primary osteoporosis cases. *Journal of Traditional Chinese Medicine* 2010;**51**(6):520-3.

**Li ZP 2011** {published data only}

Li ZP, Tong HT, Sun GH, Lao RP, Liu ZJ. The effects of Kanggusong soup plus Caltrate on ALP and IL-6 of postmenopausal osteoporosis. *Journal of Yunnan University of Traditional Chinese Medicine* 2011;**34**(4):37-8, 46.

**Li ZY 2006** {published data only}

Li ZY, Liu BG, Liu YM, Zhang JX. Clinical observation of Xianling Gubao capsules on postmenopausal osteoporosis. *Journal of Sichuan Traditional Chinese Medicine* 2006;**24**(1):83-4.

**Lv ZH 2002** {published data only}

Lv ZH, Wen ZJ, Wu SP, Qiu JM, Qiu JX. Clinical observation of Jianwei Bushen Zhuangjiintang on the treatment of primary osteoporosis. *China Journal of Orthopaedics and Traumatology* 2002;**15**(5):263-4.

**Ma C 2011** {published data only}

Ma C. Clinical analysis on Liuwei Dihuang pills plus calcium in treating postmenopausal osteoporosis. *China Medicine and Pharmacy* 2011;**1**(18):74-5.

**Ma CZ 2011** {published data only}

Ma CZ. Clinical observation on combined treatment of traditional Chinese medicine and western medicine in treating osteoporosis. *Journal of New Chinese Medicine* 2011;**43**(9):56-7.

**Mao YF 2011** {published data only}

Mao YF. Effect of Bushen Jianpi Jingu decoction on 75 postmenopausal osteoporosis. *Beijing Journal of Traditional Chinese Medicine* 2011;**30**(4):292-3.

**Ma YJ 2011** {published data only}

Ma YJ, Ma YJ, Ma YL. A clinical observation on treating senile osteoporosis with Yishen Zhuanggu decoction. *Chinese Journal of the Practical Chinese with Modern Medicine* 2011;**24**(5):18-9.

**Meng XD 2003** {published data only}

Meng XD, Xie YM, Huang YZ, Cui TH, Gao R, Tu RS, et al. Clinical study of Gujian capsule in treating primary osteoporosis with kidney-yang deficiency syndrome. *Chinese Journal of Clinical Rehabilitation* 2003;**7**(3):445-7, 457.

**Miu JQ 2008** {published data only}

Miu JQ. Clinical biochemical parameters observation of integrative Chinese and Western medicine for postmenopausal osteoporosis. *Chinese Journal of Applied Physiology* 2008;**24**(1):54-5.

**Mu G 2001** {published data only}

Mu G, Mu JJ, Wang P, Zhang K. Clinical observation of Bushen Qiangshen pill plus Caltrate on postmenopausal osteoporosis. *Chinese Journal of Integrated Traditional with Western Medicine* 2001;**21**(5):382-3.

**Mu G 2001a** {published data only}

Mu G, Wang P, Mu JJ. Clinical study of Bushen Qiangshen pill on postmenopausal osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2001;**9**(1):20-2.

**Ou L 2011** {published data only}

Ou L, Zeng XH, Zhao P. Clinical observation on Radix rehmanniae preparata and Radix astragali in treating postmenopausal osteoporosis. *Beijing Journal of Traditional Chinese Medicine* 2011;**30**(8):605-6.

**Peng T 2002** {published data only}

Peng T, Huang ML, Xiong W, Wang L, Yang YP, Qi K, et al. Clinical and experimental study of Qianggu soft extract in treatment of type postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 2002;**8**(4):337-41, 364.

**Qiu RB 2004** {published data only}

Qiu RB, Shen RZ, Zhang PQ. Treatment of postmenopausal osteoporosis with Yanghuo Sanzi tang--A report of 30 cases. *Journal of Traditional Chinese Medicine* 2004;**24**(2):102-4.

**Qiu RB 2008** {published data only}

Qiu RB, Shen RZ, Zhang PQ, Chen YL, Ye HP, Zhang Y. Clinical study about treatment of postmenopausal osteoporosis with Jiangu recipe. *Chinese Archives of Traditional Chinese Medicine* 2008;**26**(7):1529-30.

**Qiu ZX 2010** {published data only}

Qiu ZX. Observation of the effect of Xianlinggubao capsule on 67 senile osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2010;**18**(8):52.

**Qi ZX 1998** {published data only}

Qi ZX, Lin HY. Clinical observation on Bushen Qianggutang in treating primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 1998;**6**(6):41-2.

**Ruan XY 2006** {published data only}

Ruan XY, Qi JM, Liu YL, Ji Y, Chen BY. Effects of traditional Chinese medicine on bone mineral density and femoral neck strength in postmenopausal women. *Chinese Journal of Osteoporosis* 2006;**12**(2):181-4.

**Shao M 2003** {published data only}

Shao M, Huang HX, Zhao J. Clinical observation on effect of Gukang oral preparation in treating postmenopausal osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 2003;**15**(3):11-2.

**Shi CD 2012** {published data only}

Shi CD, Yuan PW, Yang XH. Observation of Kangshu Jiangu granule on postmenopausal osteoporosis, a report of 40 cases. *Shanxi Journal of Traditional Chinese Medicine* 2012;**28**(1):16-7.

**Song XW 2000** {published data only}

Song XW, Chen BX, Shen PZ. Clinical study on postmenopausal osteoporosis treated by kidney-nourishing herbs. *Shanghai Journal of Traditional Chinese Medicine* 2000;**34**(7):28-9.

**Tang ZA 2012** {published data only}

Tang ZA. Clinical observation on Bushen Qianggu Huoxue therapy in treating 42 primary osteoporosis. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 2012;**18**(4):50-1.

**Wang CC 2005** {published data only}

Wang CC, Shang LL, Liang JY. Clinical observation on the therapeutic effect of Gumikang capsule plus nuclear honey beans on postmenopausal osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 2005;**17**(8):15-6.

**Wang H 2007** {published data only}

Wang H. Clinical observation of Qianggu paste II for old people with osteoporosis. *Hubei Journal of Traditional Chinese Medicine* 2007;**29**(10):54-5.

**Wang J 2007** {published data only}

Wang J, Zhang WK, Wang ZH. Qianggu capsule for postmenopausal osteoporosis in 28 cases. *Herald of Medicine* 2007;**26**(11):1325-7.

**Wang JM 2008** {published data only}

Wang JM, Liu T. Clinical observation of Gukang on bone quality in postmenopausal osteoporosis patients. *Chinese Journal of Medical Traumatology & Orthopedics* 2008;**16**(11):8-9.



**Wang SW 2003** {published data only}

Wang SW, Zheng BR, Sun JY, Xie YH. Effects of Antai capsule on women with postmenopausal osteoporosis. *Journal of the Fourth Military Medical University* 2003;**24**(14):1324-7.

**Wang XD 2011** {published data only}

Wang XD, Deng WM, Hong MJ, Liu F, Wang Q, Sun P. Clinical study on Hugu capsule in treating postmenopausal osteoporosis. *Journal of Practical Medicine* 2011;**27**(9):1662-4.

**Wang XY 2000** {published data only}

Wang XY, Zhang CL, Mo LL, Qu YQ, Han LL. The effect of Bushen Jianpi herbs on bone metabolism and estrogen in perimenopausal woman. *Journal of Guangzhou University of Traditional Chinese Medicine* 2000;**17**(3):230-2.

**Wang YZ 2008** {published data only}

Wang YZ, Wang HC. Clinical research of Jiangu capsule for osteoporosis. *Chinese Journal of Guang Ming Chinese Medicine* 2008;**23**(8):1125-6.

**Wang ZK 2004** {published data only}

Wang ZK. The effects of Bushen Jianpi Migu prescription on pain and relevant biochemical indexes in patients with senile osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(27):5930, 5949.

**Wei RY 2011** {published data only}

Wei RY, Lao RP, Liu ZJ, Xu GR, Li ZP. Effect of anti-osteoporosis capsule on ostealgia and bone metabolism of postmenopausal osteoporosis patients. *Journal of New Chinese Medicine* 2011;**43**(1):61-3.

**Wu JZ 2010** {published data only}

Wu JZ, Zhou XM, Zheng CX. Clinical observation of Erxian soup for primary osteoporosis. *Journal of New Chinese Medicine* 2010;**42**(2):25-6.

**Wu MS 2001** {published data only}

Wu MS, Zhao SZ, Li E. Clinical study of Kanggusong granule in preventing and treating primary osteoporosis. *Traditional Chinese Medicine Research* 2001;**14**(1):26-8.

**Wu MS 2007** {published data only}

Wu MS, Li E, Zhao SZ, Bai X, Li AY. Channel tropism of the prescription for kidney tonifying by target-oriented administration for osteoporosis. *Journal of Clinical Rehabilitative Tissue Engineering Research* 2007;**11**(27):5336-40.

**Wu W 2005** {published data only}

Wu W, Li DF, Zhi XM, Han MQ. Preventive and therapeutic effects of Xianling Gubao capsule for postmenopausal osteoporosis. *Journal of Guangzhou University of Traditional Chinese Medicine* 2005;**22**(3):191-3.

**Xiao W 2008** {published data only}

Xiao W, Huang MQ. Therapeutic effect observation of selfmade Gusong recipe for postmenopausal osteoporosis. *Medicine Innovation Research* 2008;**5**(14):67-8.

**Xie J 2004** {published data only}

Xie J, Shen L, Yang YP, Zhou PQ, Gao L. Prevention action of Chinese herbs for tonifying kidney on bone loss in senile males: 1 year follow-up. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(24):5180-1.

**Xie YM 1997** {published data only}

Xie YM, Zhang FZ, Zhou WQ, Gao P, Fu RJ, Zhao TY, et al. Clinical study of Bugu Shengsui capsule in treating primary osteoporosis with kidney-yang deficiency syndrome. *Chinese Journal of Integrated Traditional and Western Medicine* 1997;**17**(9):526-30.

**Xiong YH 2008** {published data only}

Xiong YH, Teng WR, Liu T, Fu SC, Gu PF, Fu WY, et al. Jiangu granules in treatment of postmenopausal osteoporosis: a randomized, double-blind, double dummy, multicenter clinical trial. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(4):17-21.

**Xu H 2010** {published data only}

Xu H, Ren DH, Liang Z, Wang J. Clinical observation of Qiangu capsule plus alendronate on postmenopausal osteoporosis. *Journal of Zhejiang University of Traditional Chinese Medicine* 2010;**34**(4):503-4.

**Xu M 2009** {published data only}

Xu M, Liu BX, Huang CJ, Tang FY, Lou YM, Liang Z, et al. Clinical observation of Xianlinggubao plus alendronate on postmenopausal osteoporosis. *Journal of Liaoning University of Traditional Chinese Medicine* 2009;**11**(1):94-5.

**Xu W 2005** {published data only}

Xu W, Chen YC, Zhang JF. Clinical observation on effect of Yishen Yanggan mixture in treating liver-kidney deficiency postmenopausal osteoporosis. *Chinese Traditional and Herbal Drugs* 2005;**36**(6):898-9.

**Xu YL 2007** {published data only}

Xu YL, Jin JJ, Xu DY, Zheng Y. Effects of acupoint sticking of Migudan on bone Gla protein and hydroxyproline in the patients of primary osteoporosis. *Chinese Journal of Information on Traditional Chinese Medicine* 2007;**14**(6):17-9.

**Yang B 2007** {published data only}

Yang B, Yang J. Clinical research of Huangqi for patients with postmenopausal osteoporosis. *Sichuan Medical Journal* 2007;**28**(3):291-3.

**Ye AN 1998** {published data only}

Ye AN. Clinical observation of Bushen Zhuanggutang in treating 60 cases with senile osteoporosis. *New Journal of Traditional Chinese Medicine* 1998;**30**(7):52-3.

**Yuan YN 2000** {published data only}

Yuan YN, Liu Y, Han P. Treatment of 30 cases of primary osteoporosis with Shanke Jiegu tables. *Hunan Guiding Journal of Traditional Chinese Medicine and Pharmacology* 2000;**6**(9):31-2.

**Zhang DS 2011** {published data only}

Zhang DS, Cao W, Chen H, Zhang FK. Treatment of integration of traditional and western medicine on 60 cases with postmenopausal osteoporosis. *Traditional Chinese Medicinal Research* 2011;**24**(3):34-6.

**Zhang J 2003** {published data only}

Zhang J, Yin SL, Yin HQ, Ling HW, Li W, Li XQ. Clinical observation on effect of Liuwei Dihuang pills in treating postmenopausal osteoporosis. *Journal of Clinical Internal Medicine* 2003;**20**(10):558.

**Zhang RH 2004** {published data only}

Zhang RH, Chen KJ, Lu DX, Zhu XF, Ma XC. Clinical study on treatment of postmenopausal osteoporosis by Yiigu capsule. *Chinese Journal of Integrated Traditional with Western Medicine* 2004;**24**(8):680-4.

**Zhang XG 2011** {published data only}

Zhang XG. Effect of Zhuangguayin on 100 cases with primary osteoporosis. *Acta Chinese Medicine and Pharmacology* 2011;**39**(1):109-11.

**Zhang XJ 2008** {published data only}

Zhang XJ, He BR, Nie J. Clinical study on effect of Bushenhuoxue capsules for treatment of osteoporosis in aged males. *Chinese Archives of Traditional Chinese Medicine* 2008;**26**(2):307-11.

**Zhang XZ 2004** {published data only}

Zhang XZ, Han JF, Qian GF, He M, Li Y, Gu L. Effects of Xianlinggubao capsule on bone mineral density and cytokines in postmenopausal osteoporotic patients. *Chinese Journal of Osteoporosis* 2004;**10**(1):90-3.

**Zhang YL 1996** {published data only}

Zhang YL, Wu SL. Clinical observation of herbal medicine in treating 120 senile male cases with primary osteoporosis. *New Journal of Traditional Chinese Medicine* 1996;**28**(2):58-60.

**Zhang YP 2007** {published data only}

Zhang YP, Cui YH, Kang HY, Zhang B. Therapeutic effect observation and influence of bone formation and damage indexes of Shigu yin for patients with postmenopausal osteoporosis. *Journal of New Chinese Medicine* 2007;**39**(1):30-1.

**Zhang YS 2003** {published data only}

Zhang YS, Zhai MY, Guo L, Liu N, Han MX, Bai XM. Clinical and experimental study of the treatment of primary osteoporosis with Huoluo Gukang pills. *Journal of Traditional Chinese Orthopedics and Traumatology* 2003;**15**(7):9-11.

**Zhang ZF 2011** {published data only}

Zhang ZF, Ye WH. Effect of Zhuangguqiangjin tablet on cases with liver and kidney deficiency osteoporosis. *Journal of New Chinese Medicine* 2011;**43**(5):70-2.

**Zhan HS 2009** {published data only}

Zhan HS, Shi YY, Zhao YF, Hu XY, He ZY, Lou XF, et al. Phase clinical investigation of Xuduanzhuanggu capsules to the primary osteoporotic patient. *Chinese Journal of Osteoporosis* 2009;**15**(3):197-200.

**Zhan ML 2007** {published data only}

Zhan ML, Yang YF, Zhang J, Li JP. Therapeutic effect observation of Bushenyangxue decoction for postmenopausal osteoporosis. *Gansu Journal of Traditional Chinese Medicine* 2007;**20**(2):37-8.

**Zhao G 2002** {published data only}

Zhao G, Cai DF, Dong SF, Fan Y. Clinical study in 25 cases of postmenopausal osteoporosis treated with Zishen prescription. *Journal of Traditional Chinese Medicine* 2002;**43**(6):444-5.

**Zhao HX 2001** {published data only}

Zhao HX. Clinical efficacy of Kanggusong capsule in treating postmenopausal osteoporosis. *Chinese Journal of Traditional Chinese Medicine and Pharmacy* 2001;**16**(2):31-3.

**Zhao LN 2003** {published data only}

Zhao LN. Preventive and therapeutic effects of Yinyanghuo for osteoporosis. *Modern Journal of Integrated Traditional Chinese and Western Medicine* 2003;**12**(9):922-3.

**Zheng WK 2007** {published data only}

Zheng WK, Liu CY, Han CY, Zhou YJ. Clinical study on treatment of postmenopausal osteoporosis by Jinwugutong capsule. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2007;**15**(3):30-2.

**Zhong RQ 2007** {published data only}

Zhong RQ, Pan GM, Deng WM, Zhang GC. Clinical study of Gushenyijingtang on the treatment of primary osteoporosis of deficiency in kidney yang. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2007;**15**(9):16-8.

**Zhou LZ 2001** {published data only}

Zhou LZ, Ma Y. Clinical observation of traditional Chinese medicine on primary osteoporosis. The National Academic Seminar of Osteoporosis and Osteoarthritis in 2001. 2001:134-9.

**Zhou XT 2001** {published data only}

Zhou XT. Clinical research of 45 cases with osteoporosis treated by Guilu Erxiantang. *Jiangsu Journal of Traditional Chinese Medicine* 2001;**22**(6):28.

**Zhou ZK 2006** {published data only}

Zhou ZK, Zeng HB, Qin JJ, Chen C. Clinical observation of Huangqi Sanxian tang on 30 cases with postmenopausal osteoporosis. *Journal of New Chinese Medicine* 2006;**38**(6):40-1.

**Zhu HJ 2011** {published data only}

Zhu HJ, Duan ZZ, Liao KH, Tan N, Huang SG. Clinical observation on Bushen Tianjing Huoxue therapy in treating primary osteoporosis. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 2011;**17**(12):30-2.

**Zhu HM 2012** {published data only}

Zhu HM, Qin L, Garner P, Genant HK, Zhang G, Dai K, et al. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis. *Osteoporosis International* 2012;**23**:1317-27.

**Zou JJ 2005** {published data only}

Zou JJ, Liu ZM, Zheng JY, Zhao WM, Liu Y, Shi YQ. Clinical investigation of Gu Ben Jian Gu capsules to the primary osteoporotic patient. *Journal of Practical Training of Medicine* 2005;**33**(2):96-8.

**References to studies excluded from this review**
**Ai SC 2003** {published data only}

Ai SC, Yang L, Liao FZ, Chen XL. Influence of herbal application at Shenque (CV 8) on BGP in primary osteoporosis. *Shanghai Journal of Acupuncture and Moxibustion* 2003;**22**(3):39-40.

**Ai SC 2003a** {published data only}

Ai SC, Wong M, Liao FZ, Chen XL. Influence of herbal application at Shenque on interleukin-6 in primary osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 2003;**21**(2):13-5.

**Bo LY 2003** {published data only}

Bo LY, Wu CS, Wang XX. Clinical observation on the use of Gushukang in treating of osteoporotic compression fracture of the spine. *Chinese Journal of Bone Tumor and Bone Disease* 2003;**2**(5):298-300.

**Chen AP 2005** {published data only}

Chen AP, Chen YZ. Clinical observation on effect of Liuwei Dihuang pills in treating senile osteoporosis. *Journal of Chinese Modern Medicine* 2005;**2**(5):456-7.

**Chen JJ 2010** {published data only}

Chen JJ, Lou Q, Ning JC. Analysis of CT bone mineral density of senile osteoporosis cases treated by integration of traditional Chinese and western medicine. *International Medicine & Health Guidance News* 2010;**16**(12):1488-90.

**Chen XF 2003** {published data only}

Chen XF, Jiang YX. Effect of Xianling Gubao plus vitamin D3 and calcium amino acid chelate on bone mineral density and pain in osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2003;**7**(27):3769.

**Chen XF 2007** {published data only}

Chen XF, Lan TF. Therapeutic effect observation of Bushen Jianpi Huoxue method for patients with senile osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 2007;**25**(10):60-1.

**Dai Y 2007a** {published data only}

Dai Y, Shen L. Effects of Migu tablet on bone mineral density, serum matrix metalloproteinase-2 level and bone metabolic markers in postmenopausal osteoporosis. *China Journal of Chinese Materia Medica* 2007;**32**(22):2409-12.

**Deng WM 1997** {published data only}

Deng WM, He YS, Feng YJ. Clinical study on postmenopausal osteoporosis syndrome treated with tonifying kidney to strength bone decoction. *Chinese Journal of Traditional Medical Science and Technology* 1997;**4**(2):70-2.

**Deng WM 1997a** {published data only}

Deng WM, He YS, Feng YJ. Clinical effect of kidney-tonifying herbs on postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 1997;**3**(1):64-6.

**Deng WM 2001** {published data only}

Deng WM, Shen YG, He YS, Wei S. Influences of Bushen Zhuanggu granule on contents of sexual hormones and metabolism of calcium and phosphorous in early menopausal woman. *Journal of Guangzhou University of Traditional Chinese Medicine* 2001;**18**(4):301-3.

**Deng WM 2002** {published data only}

Deng WM, Cui WL, Shen YG, Yang QH, He YS, Wei S. Effects of a 2-year treatment with Bushen Zhuanggu granule for postmenopausal osteoporosis. *Journal of Guangzhou University of Traditional Chinese Medicine* 2002;**19**(4):275-8.

**Ding GZ 1995** {published data only}

Ding GZ, Zhang ZL, Zhou Y, Li R. Clinical study on effect of Bushen Jiangu capsule on postmenopausal osteoporosis. *Chinese Journal of Integrated Traditional and Western Medicine* 1995;**15**(7):392-4.

**Dong YL 2004** {published data only}

Dong YL. Clinical observation of Liuwei Dihuang pills combined with west medicine in treating 60 senile patients with deficiency of kidney-YIN osteoporosis. *Clinical Journal of Traditional Chinese Medicine* 2004;**16**(2):135-6.

**Fan GF 2008** {published data only}

Fan GF, Qi ZJ, Chen RX, Dong SL, Wang FG, Zhou CJ. Therapeutic effect observation of Qiangjin Zhuanggu pill for patients with primary osteoporotic lumbago and backache. *Journal of Traditional Chinese Orthopedics and Traumatology* 2008;**20**(2):13-4.

**Fan ZY 1995** {published data only}

Fan ZY. Clinical observation on effect of Yugu pill in treating osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 1995;**13**(1):43-4.

**Ge L 2005** {published data only}

Ge L, Dai FF, Cai X. Clinical observation of treating primary osteoporosis of female patients with Jiangu pills. *Jiangsu Journal of Traditional Chinese Medicine* 2005;**26**(3):24-5.

**Gong L 2000** {published data only}

Gong L, Wang MY, Cao JQ, Xu F, Zhou PQ, Hu J. Clinical study of Yishen Zhuanggu mixture in treating 17 cases with osteoporosis. *Journal of Traditional Chinese Medicine* 2000;**41**(10):606-7.

**Gong ZF 2011** {published data only}

Gong ZF. Effect of Bushenshujing soup and Celecoxib on primary osteoporosis with low back pain. *Chinese Journal of Clinical Research* 2011;**24**(2):155-6.

**Gu M 2004** {published data only}

Gu M, Guo JN. Clinical study of the treatment of primary osteoporosis with Fortune's drynaria rhizome. *Chinese Journal of Rehabilitation* 2004;**19**(5):297.

**Guo F 2003** {published data only}

Guo F. Clinical observation on Yishen Yanggan decoction treating 30 cases of osteoporosis. *Modern Diagnosis & Treatment* 2003;**14**(5):268-9.

**Guo HN 1998** {published data only}

Guo HN, Wang WZ, Tian WM. Clinical observation of herbal medicine in treating 120 primary osteoporosis. *Journal of Hebei Traditional Chinese Medicine and Pharmacology* 1998;**13**(3):4-6.

**Gu T 2011** {published data only}

Gu T, Jin W. Integration of traditional and western medicine on 26 primary osteoporosis. *Yunnan Journal of Traditional Chinese Medicine and Materia Medica* 2011;**32**(4):32.

**He YC 2008** {published data only}

He YC, Liao KX, Huang YR, Jiang TB. Curative effect of Xianlinggubao capsule on thoracolumbar burst fracture in senile patients with osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**163**(312-13):12-3.

**Hu XD 2011** {published data only}

Hu XD. Clinical discussion on treating 164 cases of patients with senile osteoporosis in TCM. *Clinical Journal of Chinese Medicine* 2011;**3**(3):94-5.

**Jia JH 2010** {published data only}

Jia JH, Chen XF, Zhang Z, Wang XP. Shugukang decoction in the treatment of primary osteoporosis: a clinical observation of 60 cases. *Journal of Anhui Traditional Chinese Medical College* 2010;**29**(1):28-31.

**Jiang SY 1995** {published data only}

Jiang SY, Shang YP, Wu LS, Liu BY, Zhang L, Guo RY, et al. Clinical observation of Gushukang granule on osteoporosis. *Chinese Journal of Osteoporosis* 1995;**1**(2):158, 167-9.

**Ke Q 2005** {published data only}

Ke Q, Liu HQ, Niu W. Effect of kidney-tonifying herbs on bone mineral density, serum calcium and serum alkaline phosphatase in postmenopausal osteoporosis patients. *Chinese Journal of Clinical Rehabilitation* 2005;**9**(31):186, 189.

**Ke Q 2005a** {published data only}

Ke Q, Liu HQ, Chen XC, Wu DF. Clinical observation of kidney-tonifying herbs in treating 95 senile male cases with renal deficiency primary osteoporosis. *Information on Traditional Chinese Medicine* 2005;**22**(6):26-7.

**Li BL 2007a** {published data only}

Li BL, Li YF, Tan JW, Geng WZ, Zhan Q. Effect of bone metabolism index of Jianshen prescription for patients with postmenopausal osteoporotic vertebral fracture. *Journal of Traditional Chinese Orthopedics and Traumatology* 2007;**19**(9):4-5.

**Li CX 2005** {published data only}

Li CX. Effect of movement therapy plus herbal medicine on bone mineral density in senile osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2005;**9**(7):95, 97.

**Li JF 2008** {published data only}

Li JF, Xiao YH. Therapeutic effect observation of Bushen Qianggu tang for primary osteoporosis. *Practical Clinical Medicine* 2008;**9**(5):66-7.

**Lin HY 1998** {published data only}

Lin HY, Qi ZX. Clinical observation of Yishen Jiangu tang in treating osteoporosis. *Fujian Journal of Traditional Chinese Medicine* 1998;**29**(2):9-10.

**Liu HB 2005** {published data only}

Liu HB, Ai SC, Wu LD. Clinical observation of medicine-separated sticking on Shenque on sex hormone in primary osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 2005;**23**(9):74-5.

**Liu HQ 2010** {published data only}

Liu HQ, Qin JJ. Effect of Gukang granule in treating postmenopausal osteoporosis with kidney yang deficiency. *Journal of Shandong University of TCM* 2010;**34**(1):48-9.

**Liu TS 2008** {published data only}

Liu TS. Therapeutic effect of integrative Chinese and Western medicine for patients with osteoporosis in 62 cases. *Journal of Shanxi College of Traditional Chinese Medicine* 2008;**9**(6):34-5.

**Liu YS 2011** {published data only}

Liu YS. Treatment of 49 cases of postmenopausal osteoporosis with Jiaweiexian soup. *Guangming Journal of Chinese Medicine* 2011;**26**(4):698-9.

**Liu YX 1998** {published data only}

Liu YX. Clinical study of Fuguning granule on postmenopausal osteoporosis. *Liaoning Journal of Traditional Chinese Medicine* 1998;**25**(6):284-5.

**Li YM 2005** {published data only}

Li YM. Treatment of 60 cases of postmenopausal osteoporosis with Bushen Huoxue preparation. *Journal of Nanjing University of Traditional Chinese Medicine* 2005;**21**(1):56-7.

**Luo QY 2011** {published data only}

Luo QY, Wen DH. Treatment of 24 cases of senile osteoporosis with Huoluoxiaoling pill. *Journal of Practical Traditional Chinese Medicine* 2011;**27**(4):245.

**Lu W 2004** {published data only}

Lu W, Chu XG, Peng TP. Clinical study of the treatment of primary osteoporosis with Bushen Jiangu tang. *Jiangxi Journal of Traditional Chinese Medicine* 2004;**35**(259):27.

**Lu ZD 2004** {published data only}

Lu ZD, Wang YS. Clinical observation of Gushukang in treating 80 primary osteoporosis patients. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(18):3652.

**Pan X 2004** {published data only}

Pan X, Wang DY. Treatment of 34 cases of primary osteoporosis with Huangqi injection to acupoint. *Shanxi Journal of Traditional Chinese Medicine* 2004;**25**(12):1133-4.

**Peng T 2003** {published data only}

Peng T, Chu ZR, Lu Y, Qi K, Liu JQ, Huang JH. Clinical observation of Qianggu extracts in treating postmenopausal osteoporosis. *Acta Universitatis Traditionis Medicinalis Sinensis Pharmacologiae Shanghai* 2003;**17**(3):25-7.

**Qi ZX 2000** {published data only}

Qi ZX, Lin HY. The clinical research of Shengsuuiyin on the primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2000;**8**(5):21-2.

**Ren JH 2011** {published data only}

Ren JH. Effect of Jinwugutong and alendronate sodium on postmenopausal osteoporosis patients with pain. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 2011;**17**(1):60-1.

**Shang YM 2007** {published data only}

Shang YM, Liu YY, Li HP. Clinical observation of Xianlinggubao capsule on postmenopausal osteoporosis. *Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care* 2007;**14**(1):55.

**Shi B 2010** {published data only}

Shi B. Clinical observation of traditional Chinese Medicine for senile osteoporosis. *Chinese Journal of Ethnomedicine and Ethnopharmacy* 2010;**19**(12):39-40.

**Shou ZX 2008** {published data only}

Shou ZX, Shen L, Fan H, Xie J, Yang YP, Zhou PQ, et al. Clinical observation on Qianggu Huoli pills in the treatment of primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(10):1-2.

**Shuai B 2008** {published data only}

Shuai B, Shen L, Yang YP, Xie J, Zhou PQ, Gao L, et al. Clinical study (phase III) on the effects of Jiangu granula in primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(3):27-30.

**Shu J 2005** {published data only}

Shu J. Clinical observation of Bushen Yijing prescription in treating 50 osteoporosis patients. *Journal of Occupational Health and Damage* 2005;**20**(2):143-4.

**Song HX 2003** {published data only}

Song HX. Treatment of 84 cases of osteoporosis with Bushen Yijing method. *Shanxi Journal of Traditional Chinese Medicine* 2003;**24**(12):1075-7.

**Song XW 1997** {published data only}

Song XW, Song ZJ, Shen PZ. Clinical observation of Bushen herbal medicine in treating postmenopausal osteoporosis. *The Practical Journal of Integrating Chinese with Modern Medicine* 1997;**10**(9):892.

**Song XW 2001** {published data only}

Song XW, Shen PZ, Chen BX. Clinical study of Bushenhuoxue recipe on postmenopausal osteoporosis. *China Journal of Orthopaedics and Traumatology* 2001;**14**(8):476.

**Su CH 2004** {published data only}

Su CH, Cui TH, Sang SB, Wu YW, Ding S, Jiang YM, et al. Comparison of strong bone capsule and calcium carbonate combined with vitamin D in the treatment of senile osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(29):6429-31.

**Su CH 2005** {published data only}

Su CH, Cui TH, Sang SB, Wu YW, Wang DL, Jiang JW, et al. Clinical study of 105 patients with postmenopausal osteoporosis treated by TCM strong bone capsule and Caltrate. *Liaoning Journal of Traditional Chinese Medicine* 2005;**32**(7):701-3.

**Sun JM 2002** {published data only}

Sun JM, Fu GM, Zhang HL. Analysis of the therapeutic effect of Yiqi Tiansui mixture on osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2002;**6**(9):1309.

**Sun X 2002** {published data only}

Sun X. Clinical observation of the therapeutic effect of Jiawei Zuogui pill on osteoporosis with back pain. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2002;**10**(5):36-7.

**Sun YM 2008** {published data only}

Sun YM, Wang PM, Zha W, Zhao HQ, Xia JL, Liu XQ, et al. Research on the influence of the manifestations in the primary osteoporosis patients by Ge Gen (Radix Puerariae). *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(4):14-6.

**Su YB 2008** {published data only}

Su YB, Li MX, Lin YF, Zheng YM, Wu ZB, Rao HC, et al. Clinical observation of Qianggu Huoxue tang for primary osteoporosis combined with distal radius fracture. *Journal of Traditional Chinese Orthopedics and Traumatology* 2008;**20**(7):17-8.

**Su ZW 2010** {published data only}

Su ZW, Zheng ZY, Jin J. Clinical observation of Bushenzhuanggu soup for primary osteoporosis. *Journal of Hebei Traditional Chinese Medicine and Pharmacology* 2010;**25**(1):17-8.

**Tang JM 1999** {published data only}

Tang JM, Liu KJ, Wang GX. Effect of Jiangu powder on bone mineral density in three type of renal deficiency of osteoporosis. *Chinese Journal of Information on Traditional Chinese Medicine* 1999;**6**(10):51.

**Tan X 2010** {published data only}

Tan X, Huang H, Liu Z, Liu HY, Shao Y, Ceng D, et al. Clinical study of the effect of Bushen Zhuanggu powder on bone transformation in aged males with osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2010;**18**(7):17-20.

**Tu PS 2008** {published data only}

Tu PS, Deng WQ, Li MJ, Wu XY, Lv ZY, Zhou HJ. Clinical observation of Shuanggu decoction for patients with postmenopausal osteoporosis in 30 cases. *Chinese Journal of Traditional Medical Science and Technology* 2008;**15**(6):471-2.

**Wang CH 2003** {published data only}

Wang CH, Tian LM, Jiang YP, Li JC, Chen XF, Li F, et al. Clinical effects of Gusongkang capsule on senile osteoporosis. *Journal of the Fourth Military Medical University* 2003;**24**(11):1029-31.

**Wang GH 2011** {published data only}

Wang GH, Wei XX. Clinical observation on primary osteoporosis treated by Zhuanggutongluobao. *China Journal of Chinese Medicine* 2011;**26**(8):999-1000.

**Wang HM 1998** {published data only}

Wang HM, Ge JR, Li N. Clinical observation of treating osteoporosis of old people with Bugu capsule. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 1998;**6**(4):13-4.

**Wang J 2008** {published data only}

Wang J, Li WJ, Wang HY, Yang JY, Lin XS, Li A. Therapeutic effect observation of Ganshen Tongzhi method in treating postmenopausal osteoporosis in 38 cases. *Journal of New Chinese Medicine* 2008;**40**(6):54-5.

**Wang JH 2001** {published data only}

Wang JH, Li ZG. The investigation on the treatment effect with osteoporosis by Qianggu pill. *Hunan Guiding Journal of Traditional Chinese Medicine and Pharmacology* 2001;**7**(5):243-4.

**Wang LM 2004** {published data only}

Wang LM, Guo HS, Guo MX. Clinical observation on effect of Jiangu tang in treating 69 cases with senile osteoporosis. *Chinese Journal of Clinical Practical Medicine* 2004;**5**(11):103-4.

**Weng M 2003** {published data only}

Weng M, Ai SC. Influence of medicine-separated sticking on Shenque (RN8) on calcitonin in primary osteoporosis. *Tianjin Journal of Traditional Chinese Medicine* 2003;**20**(5):48-9.

**Wu CM 2004** {published data only}

Wu CM, Zhang SQ, Zhang ZM. Clinical observation on effect of Bushen Zhuanggu capsule in treating osteoporosis. *Journal of Sichuan Traditional Chinese Medicine* 2004;**22**(2):76-7.

**Wu D 2008** {published data only}

Wu D, Chen RH, Fang JL. Bushen Tiaogan method for patients with senile osteoporosis in 31 cases. *Journal of Shandong University of Traditional Chinese Medicine* 2008;**32**(2):126-7.

**Wu XG 2008** {published data only}

Wu XG, Wu DH. Effects of Xianlinggubao, compound calcium amino acid chelate capsules and salcalcitonin in treating osteoporosis fracture. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(4):20-1.

**Xia WF 2006** {published data only}

Xia WF, Chen LL. Comparison of traditional Chinese medicine (Qianggu capsule) and risedronate sodium in management of postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 2006;**12**(4):393-6.

**Xie J 2001** {published data only}

Xie J, Shen L, Yang YP, Zhou PQ, Gao L. The effect of Chinese traditional medicine of kidney invigoration on bone mass after Colles' fracture. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2001;**9**(2):1-3.

**Xie J 2003** {published data only}

Xie J, Shen L, Yang YP, Zhou PQ, Gao L. Clinical study on bone loss preventive effect of Chinese drugs for kidney-tonifying in aged males. *Chinese Journal of Integrated Traditional and Western Medicine* 2003;**23**(1):4-6.

**Xu CY 2004** {published data only}

Xu CY, Li BS, Xin BZ. Effect of the self-made Bushen Jianpi Tongluo decoction on pain and bone mineral density of patients with osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(30):6698-9.

**Xu LZ 2001** {published data only}

Xu LZ, Hou BX, Shi Q, Xie KY. Analysis of the therapeutic effect of Yishen Zhuanggu granules on osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 2001;**13**(9):9-10.

**Xu PH 2001** {published data only}

Xu PH, Huang ZJ, Xiong FL, Zhang HM, Yu DK. Clinical study of Bushen Jiangu capsule in treating liver-kidney deficiency osteoporosis. *Traditional Chinese Drug Research & Clinical Pharmacology* 2001;**12**(4):245-7, 307.

**Yang JP 2007** {published data only}

Yang JP, Wang JB, Ding CG, Huo ST. Effect of Gushibao capsule on bone density and bone metabolism of osteoporosis. *Hebei Journal of Traditional Chinese Medicine* 2007;**29**(5):399-400.

**Yang WH 2010** {published data only}

Yang WH, Shi X. Clinical study on Bushen Tongluo decoction plus western medicine in treating primary osteoporosis of kidney deficiency and blood-stasis. *Shanghai Journal of Traditional Chinese Medicine* 2010;**44**(7):36-7, 46.

**Yan XP 2007** {published data only}

Yan XP, Zhu JL, Yan Y, Kong WP, Lu P, Tao QW. Clinical study of Bushen Qiangdu recipe on 102 cases with ankylosing spondylitis, osteoporosis or osteopenia. *China Journal of Traditional Chinese Medicine and Pharmacy* 2007;**22**(8):571-3.

**Yu YH 2011** {published data only}

Yu YH, Chen JY, Wang J. Effect of Erzhi pill on postmenopausal osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2011;**19**(4):42-3.

**Zhang GM 2001** {published data only}

Zhang GM, Guan SY, Wang WZ. Clinical study in postmenopausal osteoporosis treated with Xianguning powder. *Acta Chinese Medicine and Pharmacology* 2001;**29**(2):31-2.

**Zhang H 1999** {published data only}

Zhang H, Wei ZY, Dong JW, Cui DZ, Cheng YC. Clinical observation on effect of Gubao capsule in treating primary

osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 1999;**11**(11):3-4, 63.

**Zhang WY 2005** {published data only}

Zhang WY. Report of treating 45 cases of senile osteoporosis with Bupi Yishen Huoxue prescription. *Gansu Journal of Traditional Chinese Medicine* 2005;**18**(12):22-3.

**Zhao G 2004** {published data only}

Zhao G, Xu ZL, Shao QX, Feng JL, Xue JP, Wang XG, et al. Comparison of tibolone tablets and kidney-invigorating traditional Chinese medicine in prevention and treatment of postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 2004;**10**(3):337-9.

**Zhao Z 2010** {published data only}

Zhao Z, Xiang K, Sun L. Clinical observation of 30 cases of primary osteoporosis in elderly people treated with Yanghe capsule. *World Journal of Integrated Traditional and Western Medicine* 2010;**5**(8):698-700.

**Zheng NX 2011** {published data only}

Zheng NX, Zhang XH, Guo HM, Wang PC, Du HF, Guo HY, et al. Clinical observation of Duhuoji shengtang on osteoporosis. *Hebei Medicine* 2011;**17**(2):225-7.

**Zheng XH 2004** {published data only}

Zheng XH, Huang L. The clinical research of Gukangye on the primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2004;**12**(3):20-1.

**Zheng ZW 2010** {published data only}

Zheng ZW, Wang Z. Clinical observation of Bushenzhuanggu soup on primary osteoporosis. *Family Medicine (Medical Tribune)* 2010;**2**(7):516-8. [DOI: [10.3969/j.issn.1671-4954.2010.07.030](https://doi.org/10.3969/j.issn.1671-4954.2010.07.030)]

**Zhong J 2010** {published data only}

Zhong J, Tan SS, Xie LS. Zhuanggubushen decoction and acupuncture treat osteoporosis. *Journal of Zhejiang University of Traditional Chinese Medicine* 2010;**34**(3):408, 410.

**Zhong RQ 2007a** {published data only}

Zhong RQ, Pan GM, Deng WM, Zhang GC. Clinical observation on effects of Gushenyijingtang in treating hip osteoporotic fractures. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2007;**15**(7):50-2.

**Zhong RQ 2007b** {published data only}

Zhong RQ, Pan GM, Deng WM, Zhang GC. Clinical observation of Gushenyijing tang on treatment of thoracic vertebral compression osteoporotic fracture. *Journal of South Medical University* 2007;**27**(11):1724-5.

**Zhou PQ 1997** {published data only}

Zhou PQ, Shen L, Yang YP, Xie J. Clinical study on effect of Migu tablet on postmenopausal osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 1997;**15**(1):20-2.

**Zhu LP 2008** {published data only}

Zhu LP. Effect of Bushen Jianpi decoction on osteoporosis during climacteric. *Zhejiang Journal of Integrated Traditional Chinese and Western Medicine* 2008;**18**(3):139-41.

## Additional references

**Altman 2003**

Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;**326**(7382):219.

**Bengner 1988**

Bengner U, Johnell O, Redlund-Johnell I. Changes in incidence and prevalence of vertebral fractures during 30 years. *Calcified Tissue International* 1988;**42**(5):293-6.

**Cameron 2013**

Cameron M, Chrubasik S. Topical herbal therapies for treating osteoarthritis. *Cochrane Database of Systematic Reviews* 2013, Issue 5. [DOI: [10.1002/14651858.CD010538](https://doi.org/10.1002/14651858.CD010538)]

**Chen 2012**

Chen J, Yao Y, Chen H, Kwong JSW, Chen J. Shengmai (a traditional Chinese herbal medicine) for heart failure. *Cochrane Database of Systematic Reviews* 2012, Issue 11. [DOI: [10.1002/14651858.CD005052.pub4](https://doi.org/10.1002/14651858.CD005052.pub4)]

**Chen 2013**

Chen Y, Gong Z, Chen X, Tang L, Zhao X, Yuan Q, et al. Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome. *Cochrane Database of Systematic Reviews* 2013, Issue 8. [DOI: [10.1002/14651858.CD008568.pub2](https://doi.org/10.1002/14651858.CD008568.pub2)]

**Cole 2008**

Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. *Current Rheumatology Reports* 2008;**10**(2):92-6.

**Confavreux 2012**

Confavreux CB, Canoui-Poitaine F, Schott AM, Ambrosi V, Tainturier V, Chapurlat R. Persistence at 1 year of oral anti-osteoporotic drugs: a prospective study in a comprehensive health insurance database. *European Journal of Endocrinology* 2012;**166**(4):735-41.

**Cumming 1997**

Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. *Epidemiologic Reviews* 1997;**19**(2):244-57.

**Diez 2002**

Diez F. Guidelines for the diagnosis of osteoporosis by densitometric methods. *Journal of Manipulative and Physiological Therapeutics* 2002;**25**(6):403-15.

**Egger 2003**

Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. *Health Technology Assessment* 2003;**7**(1):1-76.

**Feng 2013**

Feng M, Yuan W, Zhang R, Fu P, Wu T. Chinese herbal medicine Huangqi type formulations for nephrotic syndrome. *Cochrane Database of Systematic Reviews* 2013, Issue 6. [DOI: [10.1002/14651858.CD006335.pub3](https://doi.org/10.1002/14651858.CD006335.pub3)]

**Flower 2012**

Flower A, Liu JP, Lewith G, Little P, Li Q. Chinese herbal medicine for endometriosis. *Cochrane Database of Systematic Reviews* 2012, Issue 5. [DOI: [10.1002/14651858.CD006568.pub3](https://doi.org/10.1002/14651858.CD006568.pub3)]

**Gan 2013**

Gan T, Chen J, Jin SJ, Wang Y. Chinese medicinal herbs for cholelithiasis. *Cochrane Database of Systematic Reviews* 2013, Issue 6. [DOI: [10.1002/14651858.CD004547.pub2](https://doi.org/10.1002/14651858.CD004547.pub2)]

**Genant 1999**

Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. *Osteoporosis International* 1999;**10**(4):259-64.

**Gu 2013**

Gu S, Yang AWH, Xue CCL, Li CG, Pang C, Zhang W, et al. Chinese herbal medicine for atopic eczema. *Cochrane Database of Systematic Reviews* 2013, Issue 9. [DOI: [10.1002/14651858.CD008642.pub2](https://doi.org/10.1002/14651858.CD008642.pub2)]

**Guo 2003a**

Guo SHF. Advances in treatment of osteoporosis (I). *Modern Diagnosis & Treatment* 2003;**14**(5):257-62.

**Guo 2003b**

Guo SHF. Advances in treatment of osteoporosis (II). *Modern Diagnosis & Treatment* 2003;**14**(6):321-6.

**Guo 2012**

Guo Z, Jia X, Liu JP, Liao J, Yang Y. Herbal medicines for advanced colorectal cancer. *Cochrane Database of Systematic Reviews* 2012, Issue 9. [DOI: [10.1002/14651858.CD004653.pub3](https://doi.org/10.1002/14651858.CD004653.pub3)]

**Haguenauer 2005**

Haguenauer D, Welch V, Shea B, Tugwell P, Wells G. Fluoride for treating postmenopausal osteoporosis. *Cochrane Database of Systematic Reviews* 2005, Issue 1. [DOI: [10.1002/14651858.CD002825](https://doi.org/10.1002/14651858.CD002825)]

**Higgins 2011**

Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org). The Cochrane Collaboration.

**Holroyd 2008**

Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. *Best Practice & Research Clinical Endocrinology & Metabolism* 2008;**22**(5):671-85.

**Horst-Sikorska 2011**

Horst-Sikorska W, Wawrzyniak A. The role of hormonal therapy in osteoporosis. *Endokrynologia Polska* 2011;**62**(1):61-4.

**Howe 2011**

Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. *Cochrane Database of Systematic Reviews* 2011, Issue 7. [DOI: [10.1002/14651858.CD000333](https://doi.org/10.1002/14651858.CD000333)]

**ICH GCP 1997**

International Conference on Harmonisation Expert Working Group. Code of Federal Regulations & International Conference on Harmonisation Guidelines. 1. Vol. **1**, Pennsylvania: Parexel/Barnett, 1997.

**IOF 2014**

International Osteoporosis Foundation. What is Osteoporosis?. <http://www.iofbonehealth.org/what-is-osteoporosis>.

**Kushner 1998**

Kushner P. Osteoporosis: unmasking the silent epidemic. *Hospital Medicine* 1998;**34**:25-39.

**Leong 2002**

Leong KH. Medical treatment of osteoporosis--increasing options. *Annals of the Academy of Medicine, Singapore* 2002;**31**(1):43-7.

**Meng 2003**

Meng XD, Xie YM, Huang YZH, Cui TH, Gao R, Tu RSH, et al. Clinical study of Gu-Jian capsule in treating primary osteoporosis with kidney-yang deficiency syndrome. *Chinese Journal of Clinical Rehabilitation* 2003;**7**(3):445-7, 457.

**Moher 1998**

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. *Lancet* 1998;**352**(9128):609-13.

**Nguyen 2000**

Nguyen TV, Center JR, Eisman JA. Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology Study. *Maturitas* 2000;**36**(1):27-34.

**NOF 2014**

National Osteoporosis Foundation. What is Osteoporosis?. <http://nof.org/articles/7>.

**Osteoporosis 1999**

Osteoporosis diagnostic criteria subject group in China. The Chinese diagnostic criteria of primary osteoporosis. *Chinese Journal of Osteoporosis* 1999;**5**(1):1-3.

**Qiu 2001**

Qiu GX. Osteoporosis and fracture. The First Countrywide Osteoporosis Academic Conference of China Medical Association. 2001:12-9.

**Raisz 2005**

Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. *Journal of Clinical Investigation* 2005;**115**(12):3318-25.



**Rates 2001**

Rates SMK. Plants as source of drugs. *Toxicon* 2001;**39**(5):603-13.

**RevMan 2012 [Computer program]**

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.

**Rizzoli 2012**

Rizzoli R. Bisphosphonates treatment in patients with osteoporosis. *Therapeutische Umschau. Revue Thérapeutique* 2012;**69**(3):173-81.

**Sambrook 2000**

Sambrook P, O'Neill S, Diamond T, Flicker L, MacLennan A. Postmenopausal osteoporosis treatment guidelines. *Australian Family Physician* 2000;**29**(8):756-8.

**Schulz 1995**

Schulz KF, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**(5):408-12.

**Silverman 2012**

Silverman S, Christiansen C. Individualizing osteoporosis therapy. *Osteoporosis International* 2012;**23**(3):797-809.

**Vickers 1998**

Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. *Controlled Clinical Trials* 1998;**19**(2):159-66.

**Wells 2008a**

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: [10.1002/14651858.CD001155.pub2](https://doi.org/10.1002/14651858.CD001155.pub2)]

**Wells 2008b**

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: [10.1002/14651858.CD003376.pub3](https://doi.org/10.1002/14651858.CD003376.pub3)]

**Wells 2008c**

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: [10.1002/14651858.CD004523.pub3](https://doi.org/10.1002/14651858.CD004523.pub3)]

**CHARACTERISTICS OF STUDIES**
**Characteristics of included studies [ordered by study ID]**
**An SJ 2000**

Methods

Country: China

**WHO 1994**

World Health Organization. Assessment of fracture risk and its application to screening postmenopausal osteoporosis. Report of a WHO Study Group. WHO Technical Report Series 843, 1994:1-129.

**Winsloe 2009**

Winsloe C, Earl S, Dennison EM, Cooper C, Harvey NC. Early life factors in the pathogenesis of osteoporosis. *Current Osteoporosis Reports* 2009;**7**(4):140-4.

**Woolf 2003**

Woolf AD, Pflieger B. Burden of major musculoskeletal conditions. *Bulletin of the World Health Organization* 2003;**81**(9):646-56.

**Wylie 2010**

Wylie CD. Setting a standard for a "silent" disease: defining osteoporosis in the 1980s and 1990s. *Studies in History and Philosophy of Biological and Biomedical Sciences* 2010;**41**(4):376-85.

**Xia 2001**

Xia YX. Medicated diets therapy for osteoporosis. The First Countrywide Osteoporosis Academic Conference of China Medical Association. 2001:171-2.

**Xue 2000**

Xue Y. The retrospect and prospect of osteoporosis. New Century Seminar of Osteoporosis and Arthrosis Prospect and Constructing Convention of Osteoporosis and Osteoarthritis of China Health Care Scientific and Technological College. 2000:1.

**Yang 2013**

Yang J, Zhu L, Wu Z, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. *Cochrane Database of Systematic Reviews* 2013, Issue 4. [DOI: [10.1002/14651858.CD005096.pub4](https://doi.org/10.1002/14651858.CD005096.pub4)]

**Zhang 2012**

Zhang H, Huang QR, Gu JM, Hu WW, Liu YJ, Hu YQ, et al. Comparison of the effects of cholecalciferol and calcitriol on calcium metabolism and bone turnover in Chinese postmenopausal women with vitamin D insufficiency. *Acta Pharmacologica Sinica* 2012;**33**:490-5.

**Zhou 2001b**

Zhou LZH, Ma Y. Clinical examining of purgation-tonifying therapy of Chinese traditional medicine on primary osteoporosis. Academic Seminar of Countrywide Osteoporosis and Osteoarthritis. 2001:134-9.

**An SJ 2000** (Continued)

Setting: hospital based

Aim: to observe the therapeutic effect and mechanism of kidney-tonifying herbs on postmenopausal osteoporosis

Study design: double-blind, randomised controlled trial

Analysis: T-test

Loss to follow-up: not reported

**Participants**

Ethnicity: Chinese

111 postmenopausal osteoporosis patients enrolled: 31 in Kanggusong granule group, 40 in ipriflavone group, 40 in Caltrate group

Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels recommended by WHO; BMD detected by DXA

Exclusion criteria: secondary osteoporosis

**Interventions**

Experimental: Kanggusong granule, 12 g, twice daily, for 9 months

Control 1: ipriflavone (200 mg, 3 times a day) and Caltrate (1 tablet per day), for 9 months

Control 2: Caltrate (1 tablet per day), for 9 months

**Outcomes**

BMD, E2, Ca, P, ALP, fractures

**Notes**

No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	It was described as double-blind but did not describe who was blinded
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Cao GY 2010**

**Methods**

Country: China

Setting: hospital based

Aim: to observe the therapeutic effect of integrated traditional Chinese and western medicine on primary osteoporosis

**Cao GY 2010** (Continued)

Study design: randomised controlled trial

Analysis: T-test

Loss to follow-up: not reported

Participants	Ethnicity: Chinese 57 primary osteoporosis patients enrolled: 30 in trial group, 27 in control group  Inclusion criteria: WHO diagnostic criteria for osteoporosis based on bone density levels  Exclusion criteria: secondary osteoporosis
Interventions	Experimental: Chinese medicine Bushenhuoxue recipe (1 dose per day, water fried) and conventional western medicine (alfacalcidol soft capsules, bisphosphonate and salmon calcitonin, etc.) based on the patient's condition, for 3 months  Control: conventional western medicine based on the patient's condition, for 3 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No detailed description and P value for the baseline comparison not stated

**Cao W 2010**

Methods	Country: China  Setting: hospital based  Aim: to observe the therapeutic effect of integrated traditional Chinese and western medicine on post-menopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese

**Chinese herbal medicines for treating osteoporosis (Review)**

**Cao W 2010** (Continued)

120 postmenopausal osteoporosis patients enrolled: 60 in trial group, 60 in control group

Inclusion criteria: WHO diagnostic criteria for osteoporosis based on bone density levels

Exclusion criteria: serious women's illnesses, malignant tumour, diabetes, etc.

Interventions	<p>Experimental: Chinese medicine (combinations of herbs) (1 dose per day, water fried 300 ml, twice a day), tamoxifen (20 mg per day) and Caltrate (600 mg, 1 to 2 tablets per day), for 3 months</p> <p>Control: tamoxifen (20 mg per day) and Caltrate (600 mg, 1 to 2 tablets per day), for 3 months</p>
Outcomes	BMD, Ca, ALP, adverse events
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'.
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Chen FS 2001**

Methods	<p>Country: China</p> <p>Setting: outpatients and inpatients</p> <p>Aim: to observe the therapeutic effect of integrated traditional Chinese and western medicine on postmenopausal osteoporosis</p> <p>Study design: randomised controlled trial</p> <p>Analysis: T-test</p> <p>Loss to follow-up: not reported</p>
Participants	<p>Ethnicity: Chinese</p> <p>64 postmenopausal osteoporosis patients enrolled: 32 in trial group, 32 in control group</p> <p>Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA</p> <p>Exclusion criteria: not mentioned</p>

**Chen FS 2001** (Continued)

Interventions	Experimental: Gushen decoction (1 dose per day), Caltrate (600 mg per day) and Alfacalcidol (0.25 µg per day), for 24 weeks  Control: Caltrate (600 mg per day) and Alfacalcidol (0.25 µg per day), for 24 weeks
Outcomes	BMD, E2, Ca, P, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Chen JP 1999**

Methods	Country: China  Setting: outpatients  Aim: to observe the therapeutic effect of Gukang oral liquid on postmenopausal osteoporosis  Study design: single-blind, randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese 61 postmenopausal osteoporosis patients enrolled: 36 in trial group, 25 in control group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by single photon absorptiometry (SPA)  Exclusion criteria: secondary osteoporosis, etc.
Interventions	Experimental: Gukang oral liquid (a basic herbal compound), 10 ml, 3 times a day, for 6 months  Control: Tridin, 1 tablet, 3 times a day, for 6 months
Outcomes	BMD

**Chen JP 1999** (Continued)

Notes No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind but did not describe who was blinded
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Chen NQ 2006**

Methods	Country: China Setting: outpatients Aim: to observe the therapeutic effect of Shenyao capsules on primary osteoporosis Study design: single-blind, randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 100 primary osteoporosis patients enrolled: 50 in trial group, 50 in control group Inclusion criteria: WHO diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: secondary osteoporosis, endocrine disease
Interventions	Experimental: Shenyao capsules (2 capsules, 3 times a day) for 6 months Control: Caltrate (600 mg, once a day), for 6 months
Outcomes	BMD, Ca, P, ALP, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported
<b>Risk of bias</b>	
Bias	Authors' judgement Support for judgement

**Chen NQ 2006** (Continued)

Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind but did not describe who was blinded
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No detailed description and P value for baseline comparison not stated

**Chen X 2008**

Methods	Country: China Setting: hospital based Aim: to observe the therapeutic effect of Gukang decoction on primary osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi <sup>2</sup> test Loss to follow-up: not reported
Participants	Ethnicity: China 83 primary osteoporosis patients enrolled: 42 in trial group, 41 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: not mentioned
Interventions	Experimental: Gukang decoction, 1 dose per day, for 4 months Control: alendronate sodium tablets, 10 mg, once a day, for 4 months
Outcomes	BMD, E2, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	High risk	Sequence generated by some rule based on clinic time
Allocation concealment	High risk	Allocation based on clinic time
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Chinese herbal medicines for treating osteoporosis (Review)**

**Chen X 2008** (Continued)

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Chen XL 2010**

Methods	Country: China Setting: outpatients Aim: to observe the therapeutic effect of Heche Dazao pill on primary osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 114 primary osteoporosis patients enrolled: 57 in trial group, 57 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis Exclusion criteria: liver or kidney disease, endocrine diseases, etc.
Interventions	Experimental: Heche Dazao pill (1 dose per day, water fried twice, twice a day) and Gaitianli (300 mg, 3 times a day), for 3 months Control: Gaitianli (300 mg, 3 times a day), for 3 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported



**Chen XL 2010** (Continued)

Free of other bias	Low risk	The study appears to be free of other sources of bias
--------------------	----------	---

**Chen YQ 2001**

Methods	Country: China Setting: outpatients Aim: to observe the therapeutic effect of Jiarong tablet on postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 61 postmenopausal osteoporosis patients enrolled: 20 in trial group, 20 in Livial group, 21 in Caltrate group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: not mentioned
Interventions	Experimental: Jiarong tablet (5 g, 3 times a day) and Caltrate (1 tablet per day), for 6 months Control: Livial (2.5 mg, every other day) and Caltrate (1 tablet per day), or Caltrate (1 tablet per day), for 6 months
Outcomes	BMD, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

**Chen ZX 2002**

Methods	Country: China  Setting: hospital based  Aim: to observe the therapeutic effect of Gushukang granule on postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese 62 postmenopausal osteoporosis patients enrolled: 23 in Gushukang granule and Calcium carbonate with vitamin D chewable tablets group, 20 in Gushukang granule group, 19 in Calcium carbonate with vitamin D chewable tablets group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels recommended by WHO, BMD detected by DXA  Exclusion criteria: secondary osteoporosis
Interventions	Experimental: Gushukang granule (10 g, twice a day) and Calcium carbonate with vitamin D chewable tablets (1 tablet, twice a day), or Gushukang granule (10 g, twice a day), for 6 months  Control: Calcium carbonate with vitamin D chewable tablets, 1 tablet, twice a day, for 6 months
Outcomes	BMD, Ca, P, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers table
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Cui TH 1999**

Methods	Country: China  Setting: hospital based  Aim: to observe the therapeutic effect of Strong Bone capsule on postmenopausal osteoporosis
---------	---

**Cui TH 1999** (Continued)

Study design: randomised controlled trial

Analysis: T-test

Loss to follow-up: not reported

Participants	Ethnicity: Chinese  105 postmenopausal osteoporosis patients enrolled: 74 in trial group, 31 in control group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels recommended by WHO; BMD detected by DXA  Exclusion criteria: not mentioned
Interventions	Experimental: Strong Bone capsule (a basic herbal compound), 5 capsules, 3 times a day, for 3 months  Control: Caltrate, 1 tablet per day, for 3 months
Outcomes	BMD, E2, Ca, P, ALP, BGP, CT, adverse effects
Notes	The study was supported by administration of traditional Chinese medicine scientific research funds in Jiangsu Province, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

**Dai Y 2007**

Methods	Country: China  Setting: hospital based  Aim: to observe the therapeutic effect of Migu tablet on BMD, OPG, etc. in patients with postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: analysis of variance (F-test)  Loss to follow-up: not reported
---------	--

**Dai Y 2007** (Continued)

Participants	<p>Ethnicity: Chinese</p> <p>160 postmenopausal osteoporosis patients enrolled: 54 in Migu tablet trial group, 53 in Xianlinggubao group, 53 in compound calcium amino acid chelate capsules group</p> <p>Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA</p> <p>Exclusion criteria: disease-affected bone metabolism, endocrine diseases, etc</p>
Interventions	<p>Experimental: Migu tablet group: Migu tablet, 1 tablet, 3 times a day and compound calcium amino acid chelate capsule, 1 g, once a day; for 24 weeks</p> <p>Xianlinggubao group: Xianlinggubao capsule, 0.5, g 3 times a day and compound calcium amino acid chelate capsule, 1 g, once a day, for 24 weeks</p> <p>Control: compound calcium amino acid chelate capsule, 1 g, once a day, for 24 weeks</p>
Outcomes	BMD
Notes	The study was supported by a health department funded project in Hubei Province, but no declarations of interest for the primary researchers was reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

**Deng WM 2012**

Methods	<p>Country: China</p> <p>Setting: hospital based</p> <p>Aim: to observe the kidney-tonifying herbal Fufangs with phytoestrogenic Epimedium for prevention of postmenopausal osteoporosis with both BMD and fracture as study endpoints</p> <p>Study design: a multicentre, double-blind, randomised controlled trial</p> <p>Analysis: F-test, Chi<sup>2</sup> test based on the intention-to-treat (ITT) principle</p> <p>Loss to follow-up: 5-year follow-up. At the end of 5 years, 155 participants had completed the study (13 drop-outs in the treatment group, 26 drop-outs in the control group); the difference in drop-out rate was statistically significant between the 2 groups (P &lt; 0.05)</p>
---------	---

**Deng WM 2012** (Continued)

Participants	Ethnicity: Chinese  194 postmenopausal osteoporosis patients enrolled: 101 in experimental group, 93 in placebo group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis  Exclusion criteria: those who used any kind of anti-osteoporosis drugs or had been under HRT during the past year; current medical disease(s) associated with potential development of metabolic bone diseases, including Paget disease, osteomalacia, bone marrow disease, hereditary disorders of calcium or mineral metabolism, adrenal disorders, poorly controlled diabetes mellitus, severe connective tissue disorders, gastrointestinal diseases and current or past history of clinically significant haematological, endocrinological, cardiovascular, renal, hepatic, gastrointestinal, psychiatric or neurological diseases
Interventions	Experimental: Bushen Zhuanggu granules (10 g per day, twice per day), plus calcium (600 mg) and vitamin D (400 IU)  Control: placebo granules (10 g per day, twice per day), plus calcium (600 mg) and vitamin D (400 IU)
Outcomes	BMD, fracture, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

**Dong Y 2010**

Methods	Country: China  Setting: outpatients  Aim: to evaluate the efficacy and safety of salmon calcitonin plus Xianlinggubao for osteoporosis and ostealgia in postmenopausal women  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese

**Chinese herbal medicines for treating osteoporosis (Review)**

**Dong Y 2010** (Continued)

160 postmenopausal osteoporosis patients enrolled: 54 in Xianlinggubao plus salmon calcitonin group, 53 in Xianlinggubao group, 53 in salmon calcitonin control group

Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA

Exclusion criteria: disease-affected bone metabolism, endocrine diseases, secondary osteoporosis, liver or kidney disease, etc.

Interventions	<p>Experimental: Xianlinggubao plus salmon calcitonin group: Xianlinggubao (1.5 g, twice a day), salmon calcitonin (500 IU, once a day) and Caltrate (1 tablet per day), for 3 months</p> <p>Xianlinggubao group: Xianlinggubao (1.5 g, twice a day) and Caltrate (1 tablet per day), for 3 months</p> <p>Control: salmon calcitonin (500 IU, once a day) and Caltrate (1 tablet per day), for 3 months</p>
Outcomes	BMD, ALP, BGP, Ca, P, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Dong YF 2004**

Methods	<p>Country: China</p> <p>Setting: outpatients</p> <p>Aim: to observe the therapeutic effect of traditional Chinese herbs on primary osteoporosis</p> <p>Study design: randomised controlled trial</p> <p>Analysis: T-test, Chi<sup>2</sup> test</p> <p>Loss to follow-up: not reported</p>
Participants	<p>Ethnicity: Chinese</p> <p>80 senile osteoporosis patients enrolled: 40 in trial group, 40 in control group</p> <p>Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA</p>

**Dong YF 2004** (Continued)

Exclusion criteria: endocrine diseases, secondary osteoporosis, etc.

Interventions	Experimental: traditional Chinese herbs (Longspur Epimedium, etc.), 1 dose per day, for 6 months Control: vitamin D (10000 U, once a day), Caltrate (600 mg, once a day), for 6 months
---------------	---

Outcomes	BMD
----------	-----

Notes	No funding sources or declarations of interest for the primary researchers reported
-------	---

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Fan HX 2004**

Methods	Country: China Setting: outpatients Aim: to observe the therapeutic effect of Gengnian Anyi tablet on postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 60 postmenopausal osteoporosis patients enrolled: 22 in herb trial group, 18 in nilestriol control group, 20 in Caltrate group Inclusion criteria: international diagnostic criteria for osteoporosis, BMD detected by SPA Exclusion criteria: endocrine diseases, etc.
Interventions	Experimental: Gengnian Anyi tablet (6 tablets, 3 times a day) and Caltrate (1 tablet per day), for 6 months Control: nilestriol (2 mg, once a half month) and Caltrate (1 tablet per day), or Caltrate (1 tablet per day), for 6 months

**Fan HX 2004** (Continued)

Outcomes	BMD, adverse effects	
Notes	No funding sources or declarations of interest for the primary researchers reported	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

**Gang PH 2001**

Methods	Country: China Setting: outpatients Aim: to observe the therapeutic effect of Gumiling granule on primary osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported	
Participants	Ethnicity: Chinese 25 primary osteoporosis patients enrolled: 15 in herb trial group, 10 in control group Inclusion criteria: BMD, detected by DXA Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.	
Interventions	Experimental: Gumiling granule (10 g, 3 times a day), for 6 months Control: bicarbonate calcium chewable(1 g, twice a day), for 6 months	
Outcomes	BMD, adverse effects	
Notes	No funding sources or declarations of interest for the primary researchers reported	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>

**Chinese herbal medicines for treating osteoporosis (Review)**



**Gang PH 2001** (Continued)

Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

**Gong L 2001**

Methods	Country: China  Setting: outpatients  Aim: to observe the therapeutic effect of Yishen Zhuanggu mixture on primary osteoporosis  Study design: randomised controlled trial  Analysis: T-test, F-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  80 primary osteoporosis patients enrolled: 46 in herb trial group, 17 in herb control group, 17 in blank control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: endocrine diseases, etc.
Interventions	Experimental: Yishen Zhuanggu mixture (25 ml, twice a day) in herb trial group, Shengu capsule (2 capsules, 3 times a day) in herb control group, for 6 months  Control: blank
Outcomes	BMD, BGP, adverse effects
Notes	The study was supported by a Science and Technology Commission funded project in Beijing, but no declarations of interest of the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided

**Gong L 2001** *(Continued)*

Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Guo JH 2008**

Methods	Country: China  Setting: outpatients  Aim: to explore the effect of Bushen Kangsong pill on BMD in postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  84 postmenopausal osteoporosis patients enrolled: 42 in trial group, 42 in control group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: disease-affected bone metabolism, liver or kidney disease, etc.
Interventions	Experimental: Bushen Kangsong pill, 3 g, 3 times a day, calcium carbonate, 4 tablets, 3 times a day, for 6 months  Control: calcium carbonate, 4 tablets, 3 times a day, for 6 months
Outcomes	BMD
Notes	The study was supported by the Science Foundation for Post-doctoral Scientists of Jiangsu Province, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Chinese herbal medicines for treating osteoporosis (Review)**

**Guo JH 2008** (Continued)

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Han XL 2007**

Methods	Country: China Setting: outpatients and inpatients Aim: to explore the effect of Shugan Zishen Huoxue tang on postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi <sup>2</sup> test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 42 postmenopausal osteoporosis patients enrolled: 25 in herb trial group, 17 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: endocrine diseases, etc.
Interventions	Experimental: Shugan Zishen Huoxue tang (100 ml, twice a day), Caltrate (1.2 g, twice a day) and alendronate sodium (10 mg, once a day), for 6 months Control: Caltrate (1.2 g, twice a day) and alendronate sodium tablets (10 mg, once a day), for 6 months
Outcomes	BMD, E2
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported

**Han XL 2007** *(Continued)*

Free of other bias	Low risk	The study appears to be free of other sources of bias
--------------------	----------	---

**He MT 2007**

Methods	Country: China Setting: outpatients Aim: to explore the effect of Bushen Jianpi Huoxue recipe on postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 160 postmenopausal patients enrolled: 80 in herb trial group, 80 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: endocrine diseases, fractures, metabolic disease, etc.
Interventions	Experimental: Bushen Jianpi Huoxue recipe (1 dose per day), for 6 months Control: alendronate sodium tablets (70 mg per week), for 6 months
Outcomes	BMD, IL-6, BGP, ALP, E2
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**He N 2006**

Methods	Country: China
---------	----------------

**Chinese herbal medicines for treating osteoporosis (Review)**

**He N 2006** (Continued)

Setting: hospital based

Aim: to explore the effect of Jiawei Zhuangyao Jianshen tang on postmenopausal osteoporosis

Study design: randomised controlled trial

Analysis: T-test

Loss to follow-up: not reported

Participants	Ethnicity: Chinese  58 postmenopausal osteoporosis patients enrolled: 29 in trial group, 29 in control group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: not mentioned
Interventions	Experimental: Jiawei Zhuangyao Jianshen tang (1 dose per day) for 3 months  Control: compound calcium amino acid chelate capsules (1 g, once a day), for 3 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**He XQ 2006**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to explore the effect of Bushen Yangxue tang on postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test
---------	--

**He XQ 2006** (Continued)

Loss to follow-up: not reported

Participants	Ethnicity: Chinese  60 postmenopausal osteoporosis patients enrolled: 32 in trial group, 28 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: endocrine disease, liver or kidney disease
Interventions	Experimental: Bushen Yangxue tang (1 dose per day) and Caltrate (once a day), for 6 months  Control: Caltrate (once a day), for 6 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Hu J 2012**

Methods	Country: China  Setting: inpatients  Aim: to explore the effect of Shangke Yishen Zhuanggu pill on primary osteoporosis  Study design: randomised controlled trial  Analysis: T-test, F-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  300 primary osteoporosis patients enrolled: 155 in trial group, 145 in control group  Inclusion criteria: WHO diagnostic criteria for osteoporosis

**Hu J 2012** (Continued)

Exclusion criteria: not mentioned

Interventions	Experimental: Shangke Yishen Zhuanggu pill (6 g, 3 times a day), Caltrate (1.2 g, twice a day), and miacalcic ampoule (50 U, 3 times a day, intramuscular injection), for 3 months  Control: Caltrate (1.2 g, twice a day), and miacalcic ampoule (50 U, 3 times a day, intramuscular injection), for 3 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Huang JW 2008**

Methods	Country: China  Setting: hospital based  Aim: to explore the effect of Erxian Yanggu decoction on postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  67 postmenopausal osteoporosis patients enrolled: 34 in trial group, 33 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: endocrine diseases, secondary osteoporosis, patients with uterine/breast disease
Interventions	Experimental: Erxian Yanggu decoction, 1 dose per day, alendronate sodium tablets, 70 mg per week, for 6 months

**Huang JW 2008** (Continued)

Control: alendronate sodium tablets, 70 mg per week, for 6 months

Outcomes	IL-6
Notes	The study was supported by administration of traditional Chinese medicine scientific research funds in Zhejiang Province, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Huang ZJ 2008**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Zishen Gukang pill in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  60 postmenopausal osteoporosis patients enrolled: 30 in trial group, 30 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA, DPA, SPA, etc.  Exclusion criteria: disease-affected bone metabolism, etc.
Interventions	Experimental: Zishen Gukang pill (6 g, 3 times a day)  Control: Caltrate (2 pills, once a day), for 3 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported



**Huang ZJ 2008** (Continued)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	High risk	Sequence generated by some rule based on clinic time
Allocation concealment	High risk	Allocation based on clinic time
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Jian QQ 2010**

Methods	Country: China Setting: inpatients Aim: to study the effects of Shengsuuiyin recipe in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 144 postmenopausal osteoporosis patients enrolled: 73 in trial group, 71 in control group Inclusion criteria: diagnostic criteria for osteoporosis on Obstetrics and Gynecology in Chinese Medicine Exclusion criteria: not mentioned
Interventions	Experimental: Shengsuuiyin recipe (1 dose per day, water fried) and Caltrate (750 mg, once a day), for 12 months Control: Caltrate, 750 mg, once a day, for 12 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported
<b>Risk of bias</b>	
Bias	Authors' judgement    Support for judgement

**Jian QQ 2010** (Continued)

Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Lan ZX 2006**

Methods	Country: China Setting: hospital based Aim: to study the effects of Guli powder in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 60 primary osteoporosis patients enrolled: 30 in trial group, 30 in control group Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: disease-affected bone metabolism
Interventions	Experimental: Guli powder (10 g, 3 times a day), for 3 months Control: Caltrate (once a day), for 3 months
Outcomes	BMD, Ca, P, ALP
Notes	The study was supported by administration of traditional Chinese medicine scientific research funds in Sichuan Province, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Chinese herbal medicines for treating osteoporosis (Review)**

**Lan ZX 2006** (Continued)

All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Li BL 2007**

Methods	Country: China  Setting: hospital based  Aim: to observe the mechanism of Jianshen decoction in treating patients with postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  60 postmenopausal osteoporosis patients enrolled: 30 in trial group, 30 in control group  Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: endocrine diseases, disease-affected bone metabolism
Interventions	Experimental: Jianshen decoction, 1 dose per day, for 6 months  Control: alendronate sodium tablets, 10 mg, once a day, for 6 months
Outcomes	BMD, ALP, BGP, E2, IL-6
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported

**Chinese herbal medicines for treating osteoporosis (Review)**

**Li BL 2007** (Continued)

Free of other bias      Unclear risk      P value for the baseline comparison not stated

**Li HW 2004**

**Methods**      Country: China  
 Setting: hospital based  
 Aim: to study the effects of Ziyin Bushen Zhuanggu prescription in the treatment of postmenopausal osteoporosis  
 Study design: randomised controlled trial  
 Analysis: T-test, Chi<sup>2</sup> test  
 Loss to follow-up: not reported

**Participants**      Ethnicity: Chinese  
 45 postmenopausal osteoporosis patients enrolled: 25 in trial group, 20 in control group  
 Inclusion criteria: international diagnostic criteria for osteoporosis, BMD detected by DXA  
 Exclusion criteria: endocrine diseases, etc

**Interventions**      Experimental: Ziyin Bushen Zhuanggu prescription (1 dose per day), Caltrate (1.2 g, twice a day) and micalcin (50 IU, injection, twice per week), for 8 months  
 Control: Caltrate (1.2 g, twice a day) and micalcin (50 IU, injection, twice a week), for 8 months

**Outcomes**      BMD, E2

**Notes**      No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Li SL 2004**

Methods	<p>Country: China</p> <p>Setting: hospital based</p> <p>Aim: to study the effects of Zhuanggu capsule in the treatment of postmenopausal osteoporosis</p> <p>Study design: randomised controlled trial</p> <p>Analysis: T-test</p> <p>Loss to follow-up: not reported</p>
Participants	<p>Ethnicity: Chinese</p> <p>60 postmenopausal osteoporosis patients enrolled: 30 in trial group, 30 in control group</p> <p>Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA</p> <p>Exclusion criteria: endocrine diseases, etc</p>
Interventions	<p>Experimental: Zhuanggu capsule (4 capsules, 3 times a day) and Caltrate (600 mg, once a day), for 6 months</p> <p>Control: Caltrate (600 mg, once a day), for 6 months</p>
Outcomes	BMD, E2, Ca, P, ALP, BGP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Li YH 2008**

Methods	<p>Country: China</p> <p>Setting: outpatients and inpatients</p> <p>Aim: to study the effects of Jingujian granule in the treatment of senile osteoporosis</p> <p>Study design: randomised controlled trial</p>
---------	---

**Li YH 2008** (Continued)

 Analysis: T-test, Chi<sup>2</sup> test

Loss to follow-up: not reported

Participants	Ethnicity: Chinese  120 senile osteoporosis patients enrolled: 80 in trial group, 40 in control group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels recommended by WHO  Exclusion criteria: secondary osteoporosis, liver or kidney disease
Interventions	Experimental: Jingujian granule, 8 g, twice a day, for 3 months  Control: Caltrate, 600 mg, once a day, for 3 months
Outcomes	BMD, ALP, BGP, adverse effects
Notes	The study was supported by a China academy of traditional Chinese medicine advantage diseases research project, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Li YH 2010**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to study the effects of Jingujian granule 1, 2 or 3 in the treatment of primary osteoporosis based on epigastralgia traditional Chinese medicine  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: 30 drop-outs (11 in trial group, 19 in control group) were not included in the analysis
Participants	Ethnicity: Chinese

**Li YH 2010** (Continued)

210 primary osteoporosis patients enrolled: 140 in trial group (11 drop-outs), 70 in control group (19 drop-outs)

Inclusion criteria: Chinese diagnostic criteria for osteoporosis and guiding principles for clinical research on new drugs in traditional Chinese medicine, BMD detected by DXA

Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.

Interventions	<p>Experimental: Jingujian granule 1, 2 or 3 based on epigastralgia traditional Chinese medicine (kidney deficiency; spleen and kidney deficiency; spleen and kidney deficiency, and blood stasis), 8 g, twice a day, for 3 months</p> <p>Control: Caltrate, 600 mg, once a day, for 3 months</p>
Outcomes	BMD, ALP, E2, CT, BGP, adverse events
Notes	The study was supported by a China academy of traditional Chinese medicine advantage diseases research project, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Li ZP 2011**

Methods	<p>Country: China</p> <p>Setting: hospital based</p> <p>Aim: to study the effects of Kanggusong soup in the treatment of postmenopausal osteoporosis</p> <p>Study design: randomised controlled trial</p> <p>Analysis: T-test, Chi<sup>2</sup> test</p> <p>Loss to follow-up: not reported</p>
Participants	<p>Ethnicity: Chinese</p> <p>75 postmenopausal osteoporosis patients enrolled: 45 in trial group, 30 in control group</p> <p>Inclusion criteria: Chinese diagnostic criteria for osteoporosis</p>

**Li ZP 2011** (Continued)

Exclusion criteria: secondary osteoporosis, endocrine disease, liver or kidney disease, etc.

Interventions	Experimental: Kanggusong soup (1 dose per day, twice a day) and Caltrate (1 tablet per night), for 3 months  Control: Caltrate (1 tablet per night), for 3 months
Outcomes	ALP, IL-6, fractures
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Li ZY 2006**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Xianling Gusong capsules in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test, Ridit test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  43 postmenopausal osteoporosis patients enrolled: 21 in trial group, 22 in control group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: secondary osteoporosis, liver or kidney disease
Interventions	Experimental: Xianling Gusong capsules (4 capsules, 3 times a day), for 6 months  Control: Caltrate (1 pill, twice a day), for 6 months



**Li ZY 2006** (Continued)

Outcomes	BMD	
Notes	No funding sources or declarations of interest for the primary researchers reported	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Liang DB 2012**

Methods	Country: China Setting: hospital based Aim: to study the effects of Bushenhuoxue therapy in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi <sup>2</sup> test, Ridit test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 80 primary osteoporosis patients enrolled: 40 in trial group, 40 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.
Interventions	Experimental: Bushenhuoxue therapy (1 dose, per day), calcium carbonate tablets (1 tablet (0.5 g), twice a day), and alfacalcidol (1 tablet (0.5 µg) per day), for 3 months Control: calcium carbonate tablets (1 tablet (0.5 g), twice a day), and alfacalcidol (1 tablet (0.5 µg) per day), for 3 months
Outcomes	BMD, quality of life, adverse events
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**
**Chinese herbal medicines for treating osteoporosis (Review)**

**Liang DB 2012** (Continued)

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	No information provided
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Liao L 2004**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Bushen Shengsui principle in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  100 postmenopausal osteoporosis patients enrolled: 32 in herb trial group, 39 in control group, 29 in blank group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: endocrine diseases, etc.
Interventions	Experimental: Bushen Shengsui principle, 1 dose per day, for 6 months  Control: Premarin (1 tablet per day) and medroxyprogesterone (2.5 mg per day), or blank, for 6 months
Outcomes	BMD, E2, adverse effects
Notes	The study was supported by a science and technology planning project Zhongshan, Guangdong Province, but no declarations of interest for the primary researchers reported

**Risk of bias**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Unclear risk	No information provided

**Liao L 2004** (Continued)

Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Lin W 2000**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Migu decoction in the treatment of postmenopausal osteoporosis  Study design: double-blind, randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  20 postmenopausal osteoporosis patients enrolled: 13 in trial group, 7 in control group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: endocrine diseases
Interventions	Experimental: Migu decoction, for 4 months  Control: placebo, for 4 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed	Low risk	No missing outcome data

**Lin W 2000** (Continued)

All outcomes

Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Ling JY 2008**

Methods	Country: China Setting: outpatients Aim: to study the effects of Bushen Zhuanggu decoction in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test, Ridit test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 60 primary osteoporosis patients enrolled: 30 in trial group, 30 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: endocrine diseases, liver or kidney disease, etc
Interventions	Experimental: Bushen Zhuanggu decoction, 1 dose per day, for 3 months Control: alendronate sodium tablets, 10 mg, once a day, for 3 months
Outcomes	BMD, E2, ALP, P
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

### Liu JM 2012

Methods	<p>Country: China</p> <p>Setting: outpatients</p> <p>Aim: to study the effects of Gukang tablet in the treatment of primary osteoporosis</p> <p>Study design: randomised controlled trial</p> <p>Analysis: T-test, Chi<sup>2</sup> test, Ridit test</p> <p>Loss to follow-up: not reported</p>
Participants	<p>Ethnicity: Chinese</p> <p>80 primary osteoporosis patients enrolled: 40 in trial group, 40 in control group</p> <p>Inclusion criteria: Chinese diagnostic criteria for osteoporosis</p> <p>Exclusion criteria: endocrine diseases, liver or kidney disease, etc.</p>
Interventions	<p>Experimental: Gukang tablet (0.5 g per tablet, 6, 3 times a day), Gaitianli tablets (50 mg per tablet, 2 tablets, 3 times a day) and vitamin A and D capsules (1 pill, twice a day), for 3 months</p> <p>Control: Gaitianli tablets (50 mg per tablet, 2 tablets, 3 times a day), and vitamin A and D capsules (1 pill, twice a day), for 3 months</p>
Outcomes	BMD, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

### Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

### Lv ZH 2002

Methods	<p>Country: China</p> <p>Setting: hospital based</p> <p>Aim: to study the effects of Jiawei Bushen Zhuangjintang in the treatment of primary osteoporosis</p>
---------	---

**Lv ZH 2002** (Continued)

	Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  90 primary osteoporosis patients enrolled: 48 in trial group, 42 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: not mentioned
Interventions	Experimental: Jiawei Bushen Zhuangjintang, 1 dose per day, for 3 months  Control: calcium granule, 5 g, 3 times a day, for 3 months
Outcomes	BMD
Notes	The study was supported by administration of traditional Chinese medicine scientific research funds in Guangdong Province, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Ma C 2011**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to study the effects of Liuwei Dihuang pills in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: F-test, Chi <sup>2</sup> test  Loss to follow-up: 1 drop-out in Liuwei Dihuang pills group was not included in the analysis
Participants	Ethnicity: Chinese

**Chinese herbal medicines for treating osteoporosis (Review)**

**Ma C 2011** (Continued)

108 postmenopausal osteoporosis patients enrolled: 36 in Liuwei Dihuang pills group, 36 in Caltrate group, 36 in Liuwei Dihuang pills plus Caltrate group

Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA

Exclusion criteria: endocrine diseases, etc.

Interventions	<p>Liuwei Dihuang pills group: Liuwei Dihuang pills, 8 pills, 3 times a day, for 6 months</p> <p>Caltrate group: Caltrate, 1 tablet, 3 times a day, for 6 months</p> <p>Liuwei Dihuang pills plus Caltrate group: Liuwei Dihuang pills (8 pills, 3 times a day) and Caltrate (1 tablet, 3 times a day), for 6 months</p>
Outcomes	BMD, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Ma CZ 2011**

Methods	<p>Country: China</p> <p>Setting: outpatients and inpatients</p> <p>Aim: to study the effects of Yiyuanjiangu decoction in the treatment of primary osteoporosis</p> <p>Study design: randomised controlled trial</p> <p>Analysis: T-test, Chi<sup>2</sup> test</p> <p>Loss to follow-up: not reported</p>
Participants	<p>Ethnicity: Chinese</p> <p>120 primary osteoporosis patients enrolled: 60 in trial group, 60 in control group</p> <p>Inclusion criteria: Chinese diagnostic criteria for osteoporosis</p> <p>Exclusion criteria: endocrine diseases, liver or kidney disease, etc.</p>

**Ma CZ 2011** (Continued)

Interventions	Experimental: Yiyuanjiangu decoction (1 dose per day), Miacalcin ampoule (50 U, once a day, intramuscular), and calcium carbonate tablet (1 tablet (0.75 g), twice a day), for 3 months  Control: Miacalcin ampoule (50 U, once a day, intramuscular) and calcium carbonate tablet (1 tablet (0.75 g), twice a day), for 3 months
Outcomes	BMD, ALP, Ca, P
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Ma YJ 2011**

Methods	Country: China  Setting: outpatients  Aim: to study the effects of Yishen Zhuanggu decoction in the treatment of senile osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Ridit test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  100 senile osteoporosis enrolled: 50 in trial group, 50 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis  Exclusion criteria: secondary osteoporosis, endocrine diseases, liver or kidney disease, etc.
Interventions	Experimental: Yishen Zhuanggu decoction (1 dose per day) and calcitriol soft capsule (0.25 mg, twice a day), for 3 months  Control: calcitriol soft capsule (0.25 mg, twice a day), for 3 months
Outcomes	BMD



**Ma YJ 2011** (Continued)

Notes No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Mao YF 2011**

Methods	Country: China  Setting: outpatients  Aim: to study the effects of Bushen Jianpi Jingu decoction in the treatment of postmenopausal osteoporosis  Study design: single-blind, randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  75 postmenopausal osteoporosis patients enrolled: 39 in trial group, 36 in control group  Inclusion criteria: diagnostic criteria for osteoporosis recommend by WHO, BMD detected by DXA  Exclusion criteria: liver or kidney disease, disease-affected bone metabolism, etc.
Interventions	Experimental: Bushen Jianpi Jingu decoction, 1 dose per day, for 3 months  Control: Miacalcin ampoule (50 U), for 3 months
Outcomes	BGP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

**Mao YF 2011** (Continued)

Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Single-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Unclear risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Meng XD 2003**

Methods	Country: China Setting: hospital based Aim: to study the effects of Gujian capsule in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi <sup>2</sup> test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 68 primary osteoporosis patients enrolled: 35 in trial group (1 drop-out), 33 in control group (2 drop-out) Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.
Interventions	Experimental: Gujian capsule (2 capsules, 3 times a day), for 6 months Control: alfacalcidol (0.5 µg, twice a day), for 6 months
Outcomes	BMD, PTH, CT, E2, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Meng XD 2003** (Continued)

## All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Miu JQ 2008**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to study the effects of a traditional Chinese medicine capsule in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  90 postmenopausal osteoporosis patients enrolled: 60 in trial group, 30 in control group  Inclusion criteria: diagnostic criteria for osteoporosis recommend by WHO, BMD detected by DXA  Exclusion criteria: secondary osteoporosis, liver or kidney disease
Interventions	Experimental: traditional Chinese medicine capsule (300 mg per pill, 5 pills per day), calcium gluconate, 2 g, 3 times a day, for 9 months  Control: calcium gluconate, 2 g, 3 times a day, for 9 months
Outcomes	BGP, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data

**Miu JQ 2008** (Continued)

Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Mu G 2001**

Methods	Country: China  Setting: outpatients  Aim: to study the effects of Bushen Qiangshen pill in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test, Ridit test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  40 postmenopausal osteoporosis patients enrolled: 20 in trial group, 20 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by CUBA ultrasound absorptiometry  Exclusion criteria: endocrine diseases, secondary osteoporosis
Interventions	Experimental: Bushen Qiangshen pill (1 pill, twice a day) and Caltrate (1 tablet, twice a day), for 12 weeks  Control: Caltrate, 1 tablet, twice a day, for 12 weeks
Outcomes	E2, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Mu G 2001a**

Methods	Country: China  Setting: outpatients  Aim: to study the effects of Bushen Qiangshen pill in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test, Ridit test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  30 postmenopausal osteoporosis patients enrolled: 15 in trial group, 15 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by CUBA ultrasound absorptiometry  Exclusion criteria: endocrine diseases, secondary osteoporosis
Interventions	Experimental: Bushen Qiangshen pill, 1 pill, twice a day, for 12 weeks  Control: Caltrate, 1 tablet, twice a day, for 12 weeks
Outcomes	E2, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Ou L 2011**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Radix rehmanniae preparata, Radix astragali, etc. in the treatment of postmenopausal osteoporosis
---------	---

**Ou L 2011** (Continued)

Study design: randomised controlled trial

Analysis: T-test

Loss to follow-up: not reported

Participants	Ethnicity: Chinese  64 postmenopausal osteoporosis patients enrolled: 32 in trial group, 32 in control group  Inclusion criteria: Chinese and WHO diagnostic criteria for osteoporosis  Exclusion criteria: not mentioned
Interventions	Experimental: Radix rehmanniae preparata, Radix astragali, etc. (1 dose per day), for 6 months  Control: calcium carbonate tablets (600 mg per day, once a day), for 6 months
Outcomes	BMD, E2, ALP, Ca, P, PTH, CT
Notes	The study was supported by Shanxi Provincial Department of Education project, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Peng T 2002**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Qianggu soft extract in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese

**Peng T 2002** (Continued)

118 postmenopausal osteoporosis patients enrolled: 78 in trial group, 21 in calcium gluconate oral group, 19 in blank control group

Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA

Exclusion criteria: endocrine diseases

Interventions	Experimental: Qianggu soft extract, 20 ml, 3 times a day, for 6 months Control: calcium gluconate (500 mg, 3 times a day), or blank, for 6 months
Outcomes	BMD, E2, Ca, ALP, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Qi ZX 1998**

Methods	Country: China Setting: hospital based Aim: to study the effects of Bushen Qianggutang in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 40 primary osteoporosis patients enrolled: 20 in trial group, 20 in control group Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: secondary osteoporosis

**Qi ZX 1998** (Continued)

Interventions	Experimental: Bushen Qianggutang, 1 dose per day, fried, for 3 months Control: Caltrate, 600 mg, twice a day, for 3 months	
Outcomes	BMD	
Notes	No funding sources or declarations of interest for the primary researchers reported	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Qiu RB 2004**

Methods	Country: China Setting: hospital based Aim: to study the effects of Yanghuo Sanzi tang in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi <sup>2</sup> test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 60 postmenopausal osteoporosis patients enrolled: 30 in trial group, 30 in control group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: not mentioned
Interventions	Experimental: Yanghuo Sanzi tang, 150 ml, twice a day, for 6 months Control: Caltrate, 2 tablets per day, for 6 months
Outcomes	BMD, E2, BGP, IL-6
Notes	No funding sources or declarations of interest for the primary researchers reported



**Qiu RB 2004** (Continued)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Qiu RB 2008**

Methods	Country: China  Setting: outpatients  Aim: to study the effects of Jiangu prescription in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  120 postmenopausal osteoporosis enrolled: 60 in trial group, 60 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: endocrine disease, liver or kidney disease, disease-affected bone metabolism, etc.
Interventions	Experimental: Jiangu prescription, 1 dose per day, for 6 months  Control: alendronate sodium tablets, 10 mg, once a day, for 6 months
Outcomes	BMD, BGP, E2, IL-6
Notes	The study was supported by a Shenzhen science and technology planning project, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

**Qiu RB 2008** (Continued)

Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Qiu ZX 2010**

Methods	Country: China Setting: inpatients Aim: to study the effects of Xianlinggubao capsule in the treatment of senile osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 136 senile osteoporosis patients enrolled: 67 in trial group, 69 in control group Inclusion criteria: BMD Exclusion criteria: other diseases
Interventions	Experimental: Xianlinggubao capsule (1 g, 3 times a day) and Caltrate (1 tablet, twice a day), for 12 months Control: Caltrate, 1 tablet, twice a day, for 12 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Qiu ZX 2010** (Continued)

All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No detailed description of diagnostic standard and P value for the baseline comparison not stated

**Ruan XY 2006**

Methods	Country: China  Setting: outpatients  Aim: to study the effects of Qianggu capsules in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  150 postmenopausal osteoporosis or osteopenia patients enrolled: 50 in herbal trial and hormone group, 50 in herbal group, 50 in hormone group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: endocrine disease, digestion disease, mental disorder, etc.
Interventions	Experimental: Qianggu capsules (1 capsule, 3 times a day) and oestradiol valerate (0.5 to 1.5 mg, once a day), for 24 weeks; Qianggu capsules (1 capsule, 3 times a day), for 24 weeks  Control: oestradiol valerate (0.5 to 1.5 mg, once a day), for 24 weeks
Outcomes	BMD, adverse effects
Notes	The study was supported by Beijing administration of traditional Chinese medicine scientific research funds and Capital Foundation of Medical Developments Project, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Ruan XY 2006** (Continued)

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Shao M 2003**

Methods	Country: China Setting: hospital based Aim: to study the effects of Gukang oral liquid in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 60 postmenopausal osteoporosis patients enrolled: 30 in trial group, 30 in control group Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: secondary osteoporosis, etc.
Interventions	Experimental: Gukang oral liquid, 10 ml, 3 times a day, for 6 months Control: alendronate, 1 tablet per day, for 6 months
Outcomes	BMD, E2, ALP, BGP, IL-6
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported

**Shao M 2003** (Continued)

Free of other bias	Unclear risk	P value for the baseline comparison not stated
--------------------	--------------	--

**Shi CD 2012**

Methods	Country: China Setting: outpatients Aim: to study the effects of Kangshu Jiangu granule in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi <sup>2</sup> test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 76 postmenopausal osteoporosis patients enrolled: 40 in trial group, 36 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis Exclusion criteria: liver or kidney disease, endocrine disease, etc.
Interventions	Experimental: Kangshu Jiangu granule, 4 g, 3 times a day, for 6 months Control: Caltrate, 1 tablet, once a day, for 6 months
Outcomes	BMD
Notes	The study was supported by Shanxi Provincial Department of traditional Chinese medicine (TCM) modernisation research plan, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Song XW 2000**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of kidney-tonifying herbs in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  68 postmenopausal osteoporosis patients enrolled: 23 in herb group, 23 in nilestriol group, 22 in control group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: secondary osteoporosis
Interventions	Experimental: kidney-tonifying herbs, twice a day, for 6 months  Control: nilestriol, 0.2 mg, twice per month; or calcium, 400 mg/d, for 6 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Tang ZA 2012**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to study the effects of Bushen Qianggu Huoxue therapy in the treatment of postmenopausal osteoporosis
---------	---

**Tang ZA 2012** (Continued)

Study design: randomised controlled trial

Analysis: T-test

Loss to follow-up: not reported

Participants	Ethnicity: Chinese  82 postmenopausal osteoporosis patients enrolled: 42 in trial group, 40 in control group  Inclusion criteria: WHO diagnostic criteria for osteoporosis  Exclusion criteria: liver or kidney disease, endocrine disease, metabolic disease, etc.
Interventions	Experimental: Bushen Qianggu Huoxue therapy (1 dose per day), calcium (1000 mg per day) and cod liver oil (1 pill per day), for 3 months  Control: calcium (1000 mg per day) and cod liver oil (1 pill per day), for 3 months
Outcomes	BMD, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Wang CC 2005**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Gumikang capsule in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese

**Wang CC 2005** (Continued)

60 postmenopausal osteoporosis patients enrolled: 32 in trial group, 28 in control group

Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA

Exclusion criteria: metabolic disease, endocrine disease

Interventions	Experimental: Gumikang capsule, 5 capsules, twice a day, for 6 months Control: calcium gluconate, 500 mg, 3 times a day, for 6 months
Outcomes	BMD, E2, Ca, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Wang H 2007**

Methods	Country: China Setting: hospital based Aim: to study the effects of Qianggu paste II in the treatment of senile osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 123 senile osteoporosis patients enrolled: 75 in trial group, 48 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: disease-affected bone metabolism
Interventions	Experimental: Qianggu paste II (3.0 g, 3 times a day, for 6 months)



**Wang H 2007** (Continued)

Control: calcium gluconate (500 mg, 3 times a day, for 6 months)

Outcomes	BMD, E2, ALP, Ca, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Wang J 2007**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Qianggu capsule in the treatment of senile osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Ridit test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  54 postmenopausal osteoporosis patients enrolled: 28 in trial group, 26 in control group  Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: disease-affected bone metabolism
Interventions	Experimental: Qianggu capsule, 0.25 g, 3 times a day, for 6 months  Control: alfa calcidol capsule, 0.5 µg, twice a day, for 6 months
Outcomes	BMD, Ca, P, ALP, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

**Wang J 2007** (Continued)

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Wang JM 2008**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to study the effects of Gukang oral liquid in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Ridit test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  70 postmenopausal osteoporosis patients enrolled: 32 in trial group, 34 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: disease-affected bone metabolism, secondary osteoporosis
Interventions	Experimental: Gukang oral liquid, 10 ml, 3 times a day, for 6 months  Control: alendronate sodium tablets, 10 mg, once a day, for 6 months
Outcomes	ALP, Ca, E2
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Chinese herbal medicines for treating osteoporosis (Review)**

**Wang JM 2008** (Continued)

All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Wang SW 2003**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Antai capsule in the treatment of postmenopausal osteoporosis  Study design: double-blind, randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  168 postmenopausal osteoporosis patients enrolled: 65 in herbal group, 60 in ipriflavone group, 63 in Caltrate group Inclusion criteria: WHO diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: endocrine disease
Interventions	Experimental: Antai capsule (3 capsules, 3 times a day) and Caltrate (1 tablet per day), for 6 months  Control: ipriflavone (200 mg, 3 times a day) and Caltrate (1 tablet per day), or Caltrate (1 tablet per day), for 6 months
Outcomes	BMD, E2, Ca, P, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported

**Wang SW 2003** (Continued)

Free of other bias	Unclear risk	P value for the baseline comparison not stated
--------------------	--------------	--

**Wang XD 2011**

Methods	Country: China Setting: hospital based Aim: to study the effects of Hugu capsule in the treatment of postmenopausal osteoporosis Study design: double-blind, placebo-controlled, randomised controlled trial Analysis: T-test Loss to follow-up: not reported
---------	--

Participants	Ethnicity: Chinese 122 postmenopausal osteoporosis patients enrolled: 61 in trial group, 61 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis Exclusion criteria: bone metabolic disease, endocrine disease, etc.
--------------	--

Interventions	Experimental: Hugu capsule (4 capsules, 3 times a day) and Caltrate (1 tablet per day), for 6 months Control: placebo capsule (4 capsules, 3 times a day) and Caltrate (1 tablet per day), for 6 months
---------------	--

Outcomes	BMD, adverse effects
----------	----------------------

Notes	No funding sources or declarations of interest for the primary researchers reported
-------	---

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Wang XY 2000**

Methods	Country: China Setting: hospital based
---------	---

**Chinese herbal medicines for treating osteoporosis (Review)**

**Wang XY 2000** (Continued)

Aim: to study the effects of Bushen Yigu soft extract in the treatment of osteoporosis

Study design: single-blind, placebo-controlled, randomised controlled trial

Analysis: F-test, T-test

Loss to follow-up: not reported

Participants	<p>Ethnicity: Chinese</p> <p>96 osteoporosis patients enrolled: 37 in herbal group, 37 in Alfacalcidol group, 22 in placebo group</p> <p>Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by SPA</p> <p>Exclusion criteria: endocrine disease</p>
Interventions	<p>Experimental: Bushen Yigu soft extract, 20 ml, twice a day, for 3 months</p> <p>Control: Alfacalcidol, 0.25 mg per day, or placebo, for 3 months</p>
Outcomes	BMD, E2
Notes	The study was supported by a national department of traditional Chinese medicine (TCM) modernisation research project, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Wang YZ 2008**

Methods	<p>Country: China</p> <p>Setting: outpatients</p> <p>Aim: to study the effects of Jiangu capsule in the treatment of primary osteoporosis</p> <p>Study design: randomised controlled trial</p> <p>Analysis: T-test</p> <p>Loss to follow-up: not reported</p>
---------	---

**Wang YZ 2008** (Continued)

Participants	Ethnicity: Chinese  125 primary osteoporosis patients enrolled: 63 in trial group, 62 in control group  Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: secondary osteoporosis, metabolic disease, etc.
Interventions	Experimental: Jiangu capsule, 9 g, 3 times a day, for 12 months  Control: Caltrate, 1 tablet per day, for 12 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Wang ZK 2004**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Bushen Jianpi Migu prescription in the treatment of senile osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  150 senile osteoporosis patients enrolled: 83 in trial group, 67 in control group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: endocrine disease, secondary osteoporosis

**Wang ZK 2004** (Continued)

Interventions	Experimental: Bushen Jianpi Migu prescription, 1 dose per day, for 3 months Control: Caltrate, 1 tablet, twice a day, for 3 months	
Outcomes	BMD, Ca, P, ALP, BMC	
Notes	No funding sources or declarations of interest for the primary researchers reported	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Low risk	Drawing of lots
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Wei RY 2011**

Methods	Country: China Setting: hospital based Aim: to study the effects of Kanggusong capsule in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi <sup>2</sup> test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 80 postmenopausal osteoporosis patients enrolled: 48 in trial group, 32 in control group Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, the Chinese diagnostic criteria for primary osteoporosis Exclusion criteria: secondary osteoporosis
Interventions	Experimental: Kanggusong capsule, 3, 3 times a day, for 6 months Control: Caltrate, 1 tablet each night, for 6 months
Outcomes	BMD

**Wei RY 2011** (Continued)

Notes No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Wu JZ 2010**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to study the effects of Erxian soup in the treatment of primary osteoporosis  Study design: randomised controlled trial  Analysis: F-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  58 primary osteoporosis patients with deficiency of liver and kidney enrolled: 30 in trial group, 28 in control group  Inclusion criteria: the Chinese diagnostic criteria for primary osteoporosis and guiding principles for clinical research on new drugs in traditional Chinese medicine  Exclusion criteria: bone metabolic disease, endocrine disease, etc.
Interventions	Experimental: Erxian soup, 1 pack per day, for 6 months  Control: Caltrate, 1 tablet per day, for 6 months
Outcomes	BMD, ALP, Ca, P
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------



**Wu JZ 2010** (Continued)

Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Wu MS 2001**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to study the effects of Kanggusong granule in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: F-test, T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  90 postmenopausal osteoporosis patients enrolled: 30 in Kanggusong granule Tiejie group, 30 in Kanggusong granule group, 30 in ipriflavone group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: endocrine diseases, etc.
Interventions	Experimental: Kanggusong granule, 12 g, twice a day, for 3 months  Control: ipriflavone, 1 tablet, 3 times a day, for 3 months
Outcomes	E2, Ca, P, ALP, PTH
Notes	The study was supported by the National Natural Science Foundation, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided

**Wu MS 2001** (Continued)

Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Wu MS 2007**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to study the effects of prescription for tonifying kidney in the treatment of osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Ridit test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  180 osteoporosis patients enrolled: 30 in prescription for tonifying kidney group, 30 in kidney meridian sticking group, 30 in urinary bladder meridian sticking group, 30 in ipriflavone group, 30 in Gushukang group, 30 in non-meridian or acupoint sticking group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: secondary osteoporosis, patients with fractures, etc.
Interventions	Experimental: prescription for tonifying kidney, 10 pills, 3 times a day; Kanggusong Tiejie (kidney meridian sticking or urinary bladder meridian sticking), once per 2 days; for 6 months  Control: ipriflavone, 200 mg, 3 times a day, for 6 months
Outcomes	BMD, Ca, P, E2, PTH, CT, adverse effects
Notes	The study was supported by the National Natural Science Foundation, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Wu MS 2007** (Continued)

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Wu W 2005**

Methods	Country: China Setting: outpatients and inpatients Aim: to study the effects of Xianling Gubao capsules in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 68 postmenopausal osteoporosis patients enrolled: 34 in trial group, 34 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: secondary osteoporosis
Interventions	Experimental: Xianling Gubao capsules (1 g, 3 times a day) and Caltrate (1 tablet per day), for 12 months Control: Caltrate, 1 tablet per day, for 12 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported

**Wu W 2005** (Continued)

Free of other bias	Low risk	The study appears to be free of other sources of bias
--------------------	----------	---

**Xiao W 2008**

Methods	Country: China Setting: hospital based Aim: to study the effects of Gusong decoction in the treatment of osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 40 osteoporosis patients enrolled: 20 in trial group, 20 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels Exclusion criteria: secondary osteoporosis
Interventions	Experimental: Gusong decoction (15 ml, 3 times a day) and alendronate sodium tablet (1 tablet per day), for 5 months Control: alendronate sodium tablet, 1 tablet per day, for 5 months
Outcomes	BMD, E2, ALP, IL-6, BGP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Xie J 2004**

Methods	Country: China
---------	----------------

**Chinese herbal medicines for treating osteoporosis (Review)**

**Xie J 2004** (Continued)

Setting: hospital based

Aim: to study the effects of Migu tablet in the treatment of senile osteoporosis

Study design: randomised controlled trial

Analysis: T-test

Loss to follow-up: 21 drop-outs were not included in the analysis

Participants	Ethnicity: Chinese  65 senile osteoporosis males enrolled (21 drop-out): 24 in trial group, 20 in control group  Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: metabolic disease, etc.
Interventions	Experimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year  Control: Caltrate, 600 mg per day, for 1 year
Outcomes	BMD, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	High risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Xie YM 1997**

Methods

Country: China

Setting: outpatients and inpatients

Aim: to study the effects of Bugu Shengsui capsule in the treatment of primary osteoporosis

Study design: single-blind, randomised controlled trial

Analysis: T-test, Chi<sup>2</sup> test, Ridit test

Loss to follow-up: not reported

**Xie YM 1997** (Continued)

Participants	Ethnicity: Chinese  80 primary osteoporosis patients with kidney-yang deficiency enrolled: 50 in trial group, 30 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by SPA and DXA  Exclusion criteria: secondary osteoporosis, endocrine disease, etc.
Interventions	Experimental: Bugu Shengsui capsule, 3 capsules, 3 times a day, for 6 months  Control: vitamin D2 (10,000 U per day) and calcium tablet (500 mg, 3 times a day), for 6 months
Outcomes	BMD, Ca, ALP, PTH, CT, adverse effects
Notes	The study was supported by the state administration of traditional Chinese medicine youth fund, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Xiong YH 2008**

Methods	Country: China  Setting: hospital based  Aim: to study the effects of Gusongbao granule in the treatment of postmenopausal osteoporosis  Study design: double-blind, placebo-controlled, randomised controlled trial  Analysis: T-test  Loss to follow-up: 36 drop-outs (12 in Gusongbao granule group, 13 in placebo group, 11 in Jiangu granule group) were not included in the analysis
Participants	Ethnicity: Chinese  144 postmenopausal osteoporosis patients enrolled: 48 (12 drop-outs) in Gusongbao granule group, 48 (13 drop-outs) in placebo group, 48 (11 drop-outs) in Jiangu granule group

**Xiong YH 2008** (Continued)

Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA

Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.

Interventions	<p>Gusongbao granule group: Gusongbao granule, 1 dose, twice a day, Osteoform calcium amino acid chelate compound capsule, 1 pill, twice a day, for 6 months</p> <p>Jiangu granule group: 1 dose, twice a day, Osteoform calcium amino acid chelate compound capsule, 1 pill, twice a day, for 6 months</p> <p>Placebo group: 1 dose, twice a day, Osteoform calcium amino acid chelate compound capsule, 1 pill, twice a day</p>
Outcomes	BMD, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Xu H 2010**

Methods	<p>Country: China</p> <p>Setting: outpatients and inpatients</p> <p>Aim: to study the effects of Qianggu capsule in the treatment of postmenopausal osteoporosis</p> <p>Study design: randomised controlled trial</p> <p>Analysis: T-test</p> <p>Loss to follow-up: not reported</p>
Participants	<p>Ethnicity: Chinese</p> <p>120 postmenopausal osteoporosis patients enrolled: 40 in trial group, 40 in control A group, 40 in control B group</p> <p>Inclusion criteria: Chinese diagnostic criteria for osteoporosis</p>

**Xu H 2010** (Continued)

	Exclusion criteria: not mentioned
Interventions	Experimental: Qianggu capsule (1 capsule, 3 times a day) and alendronate sodium (70 mg per week) Control A: alendronate sodium (70 mg per week) Control B: Qianggu capsule (1 capsule, 3 times a day)
Outcomes	BMD, adverse events
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Random numbers table
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Xu M 2009**

Methods	Country: China Setting: outpatients and inpatients Aim: to study the effects of Xianlinggubao capsule in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 156 postmenopausal osteoporosis patients enrolled: 52 in trial group, 52 in control A group, 52 in control B group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: secondary osteoporosis, disease-affected bone metabolism, endocrine disease, etc.
Interventions	Experimental: Xianlinggubao capsule (3 capsules, 3 times a day) and alendronate sodium (70 mg per week)



**Xu M 2009** (Continued)

Control A: alendronate sodium (70 mg per week)

Control B: Xianlinggubao capsule (3 capsules, 3 times a day)

Outcomes	BMD, adverse events
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Random numbers table
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Xu W 2005**

Methods	Country: China Setting: outpatients Aim: to study the effects of Yishen Yanggan mixture in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi <sup>2</sup> test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 110 postmenopausal osteoporosis patients with liver-kidney deficiency enrolled: 60 in trial group, 50 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: not mentioned
Interventions	Experimental: Yishen Yanggan mixture, 50 ml, twice a day, for 6 months Control: calcium gluconate, 4 tablets, 3 times a day, for 6 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Xu W 2005** (Continued)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Xu YL 2007**

Methods	Country: China  Setting: outpatients  Aim: to study the effects of acupoint sticking of Migudan in the treatment of primary osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  96 primary osteoporosis patients enrolled: 48 in trial group, 48 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: secondary osteoporosis, endocrine disease
Interventions	Experimental: acupoint sticking of Migudan (3 times a week), for 3 months  Control: Gaitianli (3 tablets, 3 times a day), for 3 months
Outcomes	BGP, Hyp, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers

**Xu YL 2007** (Continued)

Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Yang B 2007**

Methods	Country: China  Setting: inpatients  Aim: to study the effects of Huangqi in the treatment of osteoporosis  Study design: randomised controlled trial  Analysis: F-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  58 osteoporosis patients enrolled: 20 in trial group of Huangqi, 20 in control group of Liweiai, 18 in control group of blank Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: endocrine disease, liver or kidney disease, etc.
Interventions	Experimental: Huangqi, 1 dose per day, for 6 months  Control: Liweiai, 2.5 mg, once a day, for 6 months  Blank group: no drug
Outcomes	BMD, ALP, P, Ca
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed	Low risk	No missing outcome data

**Yang B 2007** (Continued)

All outcomes

Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Ye AN 1998**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to observe the effects of Bushen Zhuanggutang in the treatment of senile osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  60 senile osteoporosis patients enrolled: 31 in trial group, 29 in control group  Inclusion criteria: WHO diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: secondary osteoporosis
Interventions	Experimental: Bushen Zhuanggutang (1 dose per day, fried) and Caltrate (1 tablet per day), for 6 months  Control: Caltrate (1 tablet per day), for 6 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Yuan YN 2000**

Methods	Country: China Setting: hospital based Aim: to observe the effects of Shangke Jiegu tablet in the treatment of primary osteoporosis Study design: single-blinded, randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 60 primary osteoporosis patients enrolled: 30 in trial group, 30 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by SPA Exclusion criteria: endocrine disease, etc.
Interventions	Experimental: Shangke Jiegu tablet, 4 tablets, 3 times a day, for 6 months Control: vitamin D2 (10,000 U per day) and calcium tablet (500 mg, 3 times a day), for 6 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Zhan HS 2009**

Methods	Country: China Setting: hospital based Aim: to observe the effects of Xuduanzhuanggu capsule in the treatment of primary osteoporosis
---------	---

**Zhan HS 2009** (Continued)

Study design: double-blinded, placebo and positive-controlled, randomised controlled trial

Analysis: T-test

Loss to follow-up: 67 drop-outs (37 in herb trial group, 18 in positive control group, 21 in placebo group) were not included in the analysis

Participants	Ethnicity: Chinese  600 primary osteoporosis patients enrolled: 360 in herb trial group (37 drop-outs), 120 in positive control group (18 drop-outs), 120 in placebo group (21 drop-outs)  Inclusion criteria: Chinese diagnostic criteria for osteoporosis  Exclusion criteria: secondary osteoporosis, disease-affected bone metabolism, metabolic disease, liver or kidney disease, etc.
Interventions	Experimental: Xuduanzhuanggu capsule (2 capsules, 3 times a day), Gusongbao granule placebo (1 packet, 3 times a day) and calcium tablet (1 tablet, once a day), for 6 months  Control: Xuduanzhuanggu capsule placebo (2 capsules, 3 times a day), Gusongbao granule (1 packet, 3 times a day) and calcium tablet (1 tablet, once a day), for 6 months  Placebo: Xuduanzhuanggu capsule placebo (2 capsules, 3 times a day), Gusongbao granule placebo (1 packet, 3 times a day) and calcium tablet (1 tablet, once a day), for 6 months
Outcomes	BMD, adverse events
Notes	The study was supported by a National High Technology Research and Development Program, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Insufficient information about the sequence generation process
Allocation concealment	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Unclear risk	Insufficient information about drop-outs
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhan ML 2007**

Methods	Country: China  Setting: hospital based  Aim: to observe the effects of Bushen Yangxue decoction in the treatment of postmenopausal osteoporosis
---------	--

**Zhan ML 2007** (Continued)

Study design: randomised controlled trial

Analysis: T-test

Loss to follow-up: not reported

Participants	Ethnicity: Chinese  40 postmenopausal osteoporosis patients enrolled: 20 in trial group, 20 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: not mentioned
Interventions	Experimental: Bushen Yangxue decoction, 1 dose per day, for 6 months  Control: calcium gluconate, 4 tablets, 3 times a day, for 6 months
Outcomes	Ca, P
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhang DS 2011**

Methods	Country: China  Setting: outpatients  Aim: to observe the effects of Bushenyiqihuoxue soup in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese

**Zhang DS 2011** (Continued)

120 postmenopausal osteoporosis patients enrolled: 60 in trial group, 60 in control group

Inclusion criteria: guiding principles for clinical research on new drugs in traditional Chinese medicine

Exclusion criteria: metabolic disease, etc.

Interventions	Experimental: Bushenyiqihuoxue soup (1 dose per day, water fried 600 ml, twice a day), tamoxifen (20 mg, once a day) and Caltrate (1 tablet, twice a day), for 3 months  Control: tamoxifen (20 mg, once a day) and Caltrate (1 tablet, twice a day), for 3 months
Outcomes	ALP, Ca
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No detailed description of the detection of BMD and biochemical indicators

**Zhang J 2003**

Methods	Country: China  Setting: hospital based  Aim: to observe the effects of Liuwei Dihuang pills in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  42 postmenopausal osteoporosis patients enrolled: 24 in trial group, 18 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: not mentioned
Interventions	Experimental: Liuwei Dihuang pills, 8 pills, 3 times a day, for 12 months



**Zhang J 2003** (Continued)

Control: calcium, 500 mg per day, for 12 months

Outcomes	BMD, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Zhang RH 2004**

Methods	Country: China  Setting: hospital based  Aim: to observe the effects of Yigu capsule in the treatment of postmenopausal osteoporosis  Study design: double-blinded, randomised controlled trial  Analysis: F-test, Chi <sup>2</sup> test  Loss to follow-up: 10 drop-outs were not included in the analysis
Participants	Ethnicity: Chinese  210 postmenopausal osteoporosis patients enrolled: 70 (3 drop-outs) in herbal trial group, 70 (4 drop-outs) in control group, 70 (3 drop-outs) in placebo group  Inclusion criteria: WHO diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: metabolic disease, etc.
Interventions	Experimental: Yigu capsule (4 capsules, 3 times a day) and calcium (510 mg), for 6 months  Control: Alfacalcidol (1 capsule per day) and calcium (510 mg), or placebo and calcium (510 mg), for 6 months
Outcomes	BMD, E2, Ca, P, ALP, BGP, fractures

**Zhang RH 2004** (Continued)

Notes The study was supported by the National Science Foundation and China Postdoctoral Science Foundation, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers generated by computer
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blinded
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhang XG 2011**

Methods	Country: China Setting: outpatients Aim: to observe the effects of Bushenjianpi Zhuangguyin in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 100 primary osteoporosis patients enrolled: 50 in trial group, 50 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: secondary osteoporosis, disease-affected bone metabolism, etc.
Interventions	Experimental: Bushenjianpi Zhuangguyin, 1 dose per day, water fried, twice a day, for 12 weeks Control: Caltrate, 600 mg, twice a day, and Miacalcin ampoule 50 IU, once a day, for 12 weeks
Outcomes	BMD, Ca, P, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

**Zhang XG 2011** (Continued)

Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

**Zhang XJ 2008**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to observe the effects of Bushenhuoxue capsule in the treatment of senile osteoporosis  Study design: randomised controlled trial  Analysis: T-test, F-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  60 senile osteoporosis patients enrolled: 30 in trial group, 30 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: secondary osteoporosis, liver or kidney disease, disease-affected bone metabolism
Interventions	Experimental: Bushenhuoxue capsule, 4 pills, 3 times a day, for 12 months  Control: Caltrate, 600 mg, once a day and Rocaltrol, 0.5 mg, once a day, for 12 months
Outcomes	BMD, E2, IL-6, BGP
Notes	The study was supported by the Zhejiang Provincial Department of traditional Chinese medicine (TCM) modernisation research project, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Chinese herbal medicines for treating osteoporosis (Review)**

**Zhang XJ 2008** (Continued)

All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Zhang XZ 2004**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to observe the effects of Xianlinggubao capsule in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  178 postmenopausal osteoporosis patients enrolled: 62 in trial group (Xianlinggubao capsule), 66 in control group 1 (tibolone), 50 in control group 2 (Osteoform)  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: liver or kidney disease, disease-affected bone metabolism, etc.
Interventions	Experimental: Xianlinggubao capsule and Osteoform, 1.0 g, 3 times a day, for 48 weeks  Control 1: tibolone tablets and Osteoform, 1.25 mg, once a day  control 2: Osteoform, 1 g, once a day
Outcomes	BMD, E2, ALP, BGP, IL-6
Notes	The study was supported by National Natural Science Foundation, but no declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Random numbers table
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed	Low risk	No missing outcome data

**Zhang XZ 2004** (Continued)

All outcomes

Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Zhang YL 1996**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to observe the effects of TPF capsule in the treatment of senile osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  120 senile osteoporosis patients enrolled: 60 in trial group, 60 in control group  Inclusion criteria: WHO diagnostic criteria for osteoporosis based on bone density levels, BMD detected by SPA  Exclusion criteria: not mentioned
Interventions	Experimental: TPF capsule, 3 to 4 capsules, 3 times a day, for 6 months  Control: calcium granule, 10 g, twice a day, for 6 months
Outcomes	BMD, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

### Zhang YP 2007

Methods	Country: China Setting: hospital based Aim: to observe the effects of Shigu yin in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test, F-test, Chi <sup>2</sup> test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 120 postmenopausal osteoporosis patients enrolled: 40 in Shigu yin group, 40 in Caltrate group, 40 in blank group Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: disease-affected bone metabolism, metabolic disease, etc.
Interventions	Experimental: Shigu yin, 200 ml, twice a day, for 6 months Control: Caltrate, 600 mg, twice a day, for 6 months blank: no treatment
Outcomes	BMD, BGP, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

#### **Risk of bias**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

### Zhang YS 2003

Methods	Country: China Setting: outpatients
---------	--

**Zhang YS 2003** (Continued)

Aim: to observe the effects of Huoluo Gukang pills in the treatment of primary osteoporosis

Study design: randomised controlled trial

Analysis: T-test, Chi<sup>2</sup> test

Loss to follow-up: not reported

Participants	Ethnicity: Chinese  210 primary osteoporosis patients enrolled: 81 in herbal trial group, 74 in herbal control group, 55 in blank group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: secondary osteoporosis, etc.
Interventions	Experimental: Huoluo Gukang pills, 6.0 g, 3 times a day, for 6 months; Gushukang granule, 10.0 g, twice a day, for 6 months  Control: blank (no drug)
Outcomes	E2, BGP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhang ZF 2011**

Methods	Country: China  Setting: hospital based  Aim: to observe the effects of Zhuangguqiangjin tablet in the treatment of primary osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test
---------	--

**Zhang ZF 2011** (Continued)

Loss to follow-up: 8 drop-outs (3 in trial group, 5 in control group) were not included in the analysis

Participants	Ethnicity: Chinese  90 primary osteoporosis patients with deficiency of kidney and liver enrolled: 48 in trial group (3 drop-outs), 42 in control group (5 drop-outs)  Inclusion criteria: Chinese diagnostic criteria for primary osteoporosis, BMD detected by DXA  Exclusion criteria: diseases which can affect bone conversion biochemical index, etc.
Interventions	Experimental: Zhuangguqiangjin tablet (5, 3 times a day for 3 months, then twice a day for 1 year), Shu-jinbogu tablet (5 tablets, 3 times a day, for 2 to 4 weeks), Miacalcin ampoule (50 IU, injection, once every other day for 10 days; once every 2 days for 10 days; once every 5 days for 10 days. In the 3rd, 6th, 9th and 12th month repeated again)  Control: Miacalcin ampoule (50 IU, injection, once every other day for 10 days; once every 2 days for 10 days; once every 5 days for 10 days. In the 3rd, 6th, 9th and 12th month repeated again)
Outcomes	BMD, Ca, P, ALP, adverse effects, fracture
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhao G 2002**

Methods	Country: China  Setting: outpatients  Aim: to observe the effects of Zishen prescription in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese



**Zhao G 2002** (Continued)

45 postmenopausal osteoporosis patients enrolled: 25 in trial group, 20 in control group

Inclusion criteria: international diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA

Exclusion criteria: diseases which can affect therapeutic effect

Interventions	Experimental: Zishen prescription (25 ml, twice a day), Caltrate (1.2 g, twice a day) and Miacalcin (50 IU, injection, twice weekly), for 8 months  Control: Caltrate (1.2 g, twice a day) and Miacalcin (50 IU, injection, twice weekly), for 8 months
Outcomes	BMD, E2
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhao HX 2001**

Methods	Country: China  Setting: hospital based  Aim: to observe the effects of Kanggusong capsule in the treatment of postmenopausal osteoporosis  Study design: double-blinded, placebo-controlled, randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: 35 drop-outs (11 in trial group, 16 in control group, 8 in opening experimental group) were not included in the analysis
Participants	Ethnicity: Chinese  198 postmenopausal osteoporosis patients enrolled: 70 (11 drop-outs) in trial group, 70 (16 drop-outs) in control group, 58 (8 drop-outs) in opening experimental group  Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA

**Zhao HX 2001** (Continued)

	Exclusion criteria: diseases which can affect biochemical markers of bone turnover
Interventions	Experimental: Kanggusong capsule, 3 capsules, 3 times a day, for 1 year Control: placebo, 3 capsules, 3 times a day, for 1 year
Outcomes	BMD, fractures
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Computer QBASIC procedure
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Unclear risk	No reasons for missing data provided
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhao LN 2003**

Methods	Country: China Setting: hospital based Aim: to observe the effects of Yinyanghuo in the treatment of postmenopausal osteoporosis Study design: double-blinded, randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 25 postmenopausal osteoporosis patients enrolled: 15 in trial group, 10 in control group Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: not mentioned
Interventions	Experimental: Yinyanghuo, fried, 200 g per day, 3 times a day, for 3 to 6 months Control: Premarin, 0.625 mg per day, for 3 to 6 months
Outcomes	BMD, Ca, P, ALP

**Zhao LN 2003** (Continued)

Notes No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

**Zheng WK 2007**

Methods	Country: China Setting: hospital based Aim: to observe the effects of Jinwugutong capsules in the treatment of postmenopausal osteoporosis Study design: double-blinded, placebo-controlled, randomised controlled trial Analysis: T-test, F-test, Chi <sup>2</sup> test Loss to follow-up: 11 drop-outs (5 in trial group, 6 in control group) were not included in the analysis
Participants	Ethnicity: Chinese 120 postmenopausal osteoporosis patients enrolled: 60 in trial group, 60 in control group Inclusion criteria: WHO diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: disease-affected bone metabolism, used medicines that affected bone metabolism
Interventions	Experimental: Jinwugutong capsules (3 capsules, 3 times a day) plus calcium (510 mg per day), for 6 months Control: placebo capsules (3 capsules, 3 times a day) plus calcium (510 mg per day), for 6 months
Outcomes	BMD, BGP, ALP, Ca, P, adverse effect
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

**Zheng WK 2007** (Continued)

Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhong RQ 2007**

Methods	Country: China Setting: outpatients Aim: to observe the effects of Gushen Yijing tang in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi <sup>2</sup> test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 80 primary osteoporosis patients enrolled: 39 in trial group, 41 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: endocrine disease, liver or kidney disease
Interventions	Experimental: Gushen Yijing tang (1 dose and 2 times a day), for 6 months Control: Caltrate (600 mg, twice a day) for 6 months
Outcomes	BMD, Ca, P, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'

**Zhong RQ 2007** (Continued)

All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhou LZ 2001**

Methods	Country: China  Setting: hospital based  Aim: to observe the effects of Tongbu Qianggutang in the treatment of primary osteoporosis  Study design: randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  40 primary osteoporosis patients enrolled: 30 in trial group, 10 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA  Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.
Interventions	Experimental: Tongbu Qianggutang (400 ml per day), for 3 months  Control: calcium (1.5 g, 3 times a day) plus vitamin D3 (0.25 µg per day), for 3 months
Outcomes	ALP, CT, BGP, Ca, P, E2, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported

**Zhou LZ 2001** (Continued)

Free of other bias	Low risk	The study appears to be free of other sources of bias
--------------------	----------	---

**Zhou XT 2001**

Methods	Country: China Setting: outpatients Aim: to observe the effects of Guilu Erxiantang in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported
Participants	Ethnicity: Chinese 85 primary osteoporosis patients enrolled: 45 in trial group, 40 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: secondary osteoporosis
Interventions	Experimental: Guilu Erxiantang (1 dose per day) and calcium carbonate tablet (300 mg per day), for 6 months Control: calcium carbonate tablet (300 mg per day), for 6 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhou ZK 2006**

Methods	Country: China  Setting: outpatients and inpatients  Aim: to observe the effects of Huangqi Sanxian tang in the treatment of postmenopausal osteoporosis  Study design: randomised controlled trial  Analysis: T-test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  50 postmenopausal osteoporosis patients enrolled: 30 in trial group, 20 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA  Exclusion criteria: bone metabolic disease induced by diabetes mellitus, liver or kidney disease
Interventions	Experimental: Huangqi Sanxian tang (1 dose per day), for 3 months  Control: nilestriol (2 mg, twice per month), for 3 months
Outcomes	BMD, E2, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhu HJ 2011**

Methods	Country: China  Setting: inpatients  Aim: to observe the effects of Bushen Tianjing Huoxue therapy in the treatment of primary osteoporosis  Study design: randomised controlled trial
---------	--

**Zhu HJ 2011** (Continued)

Analysis: T-test  
 Loss to follow-up: not reported

Participants	Ethnicity: Chinese  61 primary osteoporosis patients enrolled: 31 in trial group, 30 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis  Exclusion criteria: secondary osteoporosis, endocrine disease, liver or kidney disease, etc.
Interventions	Experimental: Bushen Tianjing Huoxue therapy (1 dose per day, twice a day), for 6 months  Control: Caltrate (600 mg, once a day) and calcitriol soft capsule (0.25 µg, once a day), for 6 months
Outcomes	BMD
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zhu HM 2012**

Methods	Country: China  Setting: hospital based  Aim: to observe the effects of Bushen Tianjing Huoxue therapy in the treatment of primary osteoporosis  Study design: a multicentre, double-blinded, placebo-controlled, randomised controlled trial  Analysis: F-test, based on the intention-to-treat (ITT) principle  Loss to follow-up: 42 drop-outs (15 in low-dose Xianlinggubao group, 14 in high-dose Xianlinggubao group, 13 in placebo group)
Participants	Ethnicity: Chinese



**Zhu HM 2012** (Continued)

180 postmenopausal osteoporosis patients enrolled: 61 in low-dose Xianlinggubao group, 58 in high-dose Xianlinggubao group, 61 in placebo group

Inclusion criteria: BMD criteria for osteoporosis

Exclusion criteria: previous exposure to toremifene, tamoxifen, droloxifene, lasofoxifene or other investigational selective oestrogen receptor modulators; use of bisphosphonates during the past 24 months; history of advanced scoliosis, osteoarthritis or other clinical spinal deformity which would interfere with BMD measurement etc.

Interventions	Experimental: Xianlinggubao capsule, 3 g (6 capsules) per day in low-dose group, or 6 g (12 capsules) per day in high-dose group, plus calcium (500 mg) and vitamin D (200 IU), for 12 months  Control: placebo capsule (12 capsules per day), plus calcium (500 mg) and vitamin D (200 IU), for 12 months
Outcomes	BMD, fracture, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind
Incomplete outcome data addressed All outcomes	Unclear risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

**Zou JJ 2005**

Methods	Country: China  Setting: outpatients  Aim: to observe the effects of Guben Zhuanggu capsules in the treatment of primary osteoporosis  Study design: single-blinded, randomised controlled trial  Analysis: T-test, Chi <sup>2</sup> test  Loss to follow-up: not reported
Participants	Ethnicity: Chinese  60 primary osteoporosis patients enrolled: 30 in trial group, 30 in control group  Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA

**Zou JJ 2005** (Continued)

Exclusion criteria: secondary osteoporosis, endocrine disease

Interventions	Experimental: Guben Zhuanggu capsules (2 capsules, 3 times a day) and Caltrate (600 mg, once a day), for 6 months  Control: Guben Zhuanggu capsules simulated (2 capsule, 3 times a day) and Caltrate (600 mg, once a day), for 6 months
Outcomes	BMD, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

ALP: alkaline phosphatase  
 BGP: bone Gla protein  
 BMC: bone mineral content  
 BMD: bone mineral density  
 Ca: serum calcium  
 CT: computed tomography  
 DPA: dual photon absorptiometry  
 DXA: dual energy X-ray absorptiometry  
 E2: oestradiol  
 HRT: hormone replacement therapy  
 Hyp: hydroxyproline  
 IL-6: interleukin-6  
 OPG: osteoprotegerin  
 P: phosphorus  
 PTH: parathyroid hormone  
 SPA: single photon absorptiometry  
 WHO: World Health Organization

**Characteristics of excluded studies** [ordered by study ID]

Study	Reason for exclusion
<a href="#">Ai SC 2003</a>	Randomised controlled trial comparing herbal application Shenque (CV 8) with sodium etidronate in 70 primary osteoporosis patients. However, the herbal intervention was acupoint patch and did not meet the inclusion criteria

Study	Reason for exclusion
Ai SC 2003a	Non-randomised study comparing herbal application Shenque with sodium etidronate in 70 patients with osteoporosis
Bo LY 2003	Randomised controlled trial comparing Gushukang particles with calcium carbonate plus vitamin D in 94 cases with osteoporotic compression fracture of the spine. However, the outcome measure was general therapeutic effect based on different evaluated standards and did not meet the inclusion criteria
Chen AP 2005	Randomised controlled trial comparing Liuwei Dihuang pills with Caltrate in 40 senile osteoporosis patients. However, the diagnosis of osteoporosis was not based on a BMD test
Chen JJ 2010	Randomised controlled trial comparing Zini Bushenjiangu soup and routine western medicine treatment with routine western medicine treatment in 43 senile osteoporosis patients. However, the treatment duration was less than 3 months
Chen XF 2003	Randomised controlled trial comparing Xianlinggubao plus vitamin D3 and calcium amino acid chelate with calcium gluconate in 150 osteoporosis patients. The trial intervention did not meet the inclusion criteria
Chen XF 2007	Randomised controlled trial comparing Bushen Jianpi mixture with Caltrate in 64 senile primary osteoporosis patients. However, it did not report the part of BMD measured
Dai Y 2007a	Randomised controlled trial comparing Migupian (68) and Xianlinggubao (50) with Caltrate (42) in 160 postmenopausal osteoporosis patients. However, the trial was published repeatedly
Deng WM 1997	Randomised controlled trial comparing tonifying kidney to strength bone decoction with calcitonin in 135 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
Deng WM 1997a	Randomised controlled trial comparing kidney-tonifying herbs with calcitonin in 77 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
Deng WM 2001	The participants were not osteoporosis patients
Deng WM 2002	Randomised controlled trial comparing Bushen Zhuanggu granule with calcitonin in 175 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
Ding GZ 1995	Randomised controlled trial comparing Bushen Jiangu capsule with calcium in 34 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
Dong YL 2004	Randomised controlled trial comparing Liuwei Dihuang pills plus calcium tablet and vitamin C with calcium tablet plus vitamin C in 60 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and did not meet the inclusion criteria
Fan GF 2008	Randomised controlled trial comparing Qiangjin Zhuanggu pill with oyster shell calcium chewable tablets in 248 primary osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Fan ZY 1995	Randomised controlled trial comparing Yugu pill with nilestriol in 90 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test
Ge L 2005	Randomised controlled trial comparing Jiangu pills with Caltrate in 40 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test

Study	Reason for exclusion
Gong L 2000	Randomised controlled trial comparing traditional medicine (Yishen Zhuanggu mixture or Shengu capsule) with no treatment in 80 primary osteoporosis patients. However, it was a duplicate publication
Gong ZF 2011	Randomised controlled trial comparing Bushenshujin soup and celecoxib capsules with celecoxib capsules in 90 primary osteoporosis patients. However, the treatment duration was 4 to 12 weeks
Gu M 2004	Randomised controlled trial comparing Fortune's drynariae rhizome with calcium gluconate in 82 primary osteoporosis patients. However, it did not report the part of BMD measured
Gu T 2011	Randomised controlled trial comparing Gushu recipes, calcium carbonate D3 and elcatonin injection with calcium carbonate D3 and elcatonin injection in 43 primary osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Guo F 2003	Randomised controlled trial comparing Yishen Yanggan decoction with calcium gluconate in 60 osteoporosis patients. However, it did not report the part of BMD measured
Guo HN 1998	Randomised controlled trial comparing Tiankui tang with gonadal hormone in 120 primary osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
He YC 2008	Randomised controlled trial comparing Xianlinggubao capsule with salmon calcitonin in 88 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Hu XD 2011	Randomised controlled trial comparing Chinese Traditional Medicine recipe with high calcium tablets and Caltrate in 164 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Jia JH 2010	The type of interventions did not meet the inclusion criteria
Jiang SY 1995	Randomised controlled trial comparing Gushukang granule with calcium tablet and vitamin D in 400 primary osteoporosis patients. However, it did not report the BMD of the ulna and radius respectively
Ke Q 2005	Randomised controlled trial comparing Jiangu recipe preparation with alendronate sodium tablet in 70 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
Ke Q 2005a	Randomised controlled trial comparing Jiangu recipe preparation with alendronate sodium tablet in 95 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test
Li BL 2007a	Randomised controlled trial comparing Jianshen prescription with alendronate sodium in 60 postmenopausal osteoporosis patients. However, it was a duplicate publication
Li CX 2005	Randomised controlled trial comparing movement therapy plus Bushen Tongluo tang with Caltrate in 87 senile osteoporosis patients. The therapy intervention did not meet the inclusion criteria
Li JF 2008	Randomised controlled trial comparing Bushen Qianggu tang plus calcium with calcium in 120 primary osteoporosis patients. However, the treatment duration was less than 3 months
Li YM 2005	Non-randomised study comparing Bushen Huoxue preparation with Caltrate in 60 patients with postmenopausal osteoporosis

Study	Reason for exclusion
<a href="#">Lin HY 1998</a>	Randomised controlled trial comparing Yishen Jiangu tang with Caltrate in 40 primary osteoporosis patients. However, it was published repeatedly
<a href="#">Liu HB 2005</a>	Non-randomised study comparing medicine-separated sticking on Shenqu with sodium etidronate in 130 patients with primary osteoporosis
<a href="#">Liu HQ 2010</a>	The type of interventions did not meet the inclusion criteria
<a href="#">Liu TS 2008</a>	Randomised controlled trial comparing Traditional Chinese Medicine plus alfacalcidol soft capsule with alfacalcidol soft capsule in 124 primary osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
<a href="#">Liu YS 2011</a>	Without control group
<a href="#">Liu YX 1998</a>	Randomised controlled trial comparing Fuguning granule with calcium tablet in 100 postmenopausal osteoporosis patients. However, it did not report the BMD of the ulna and radius respectively
<a href="#">Lu W 2004</a>	Randomised controlled trial comparing Bushen Jiangu tang with tibolone tablets in 80 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test
<a href="#">Lu ZD 2004</a>	Randomised controlled trial comparing Gushukang with nilestriol in 40 postmenopausal osteoporosis patients. However, it did not report the part of BMD measured
<a href="#">Luo QY 2011</a>	Without control group
<a href="#">Pan X 2004</a>	Non-randomised study comparing Huangqi injection to acupoint plus Caltrate with Caltrate in 64 patients with primary osteoporosis
<a href="#">Peng T 2003</a>	Non-randomised study comparing Qianggu extracts with calcium gluconate in 102 patients with postmenopausal osteoporosis
<a href="#">Qi ZX 2000</a>	Randomised controlled trial comparing Shengsuiyin with Caltrate in 40 primary osteoporosis patients. However, it was published repeatedly
<a href="#">Ren JH 2011</a>	Randomised controlled trial comparing Jinwugutong capsule and alendronate with alendronate in 90 postmenopausal osteoporosis patients. However, the outcome measure was general therapeutic effect about pain degree based on visual analogue scale (VAS) and it did not meet the inclusion criteria
<a href="#">Shang YM 2007</a>	Randomised controlled trial comparing Xianlinggubao capsule with conjugated oestrogens or calcium, or both, in 90 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
<a href="#">Shi B 2010</a>	Randomised controlled trial comparing Traditional Chinese Medicine differentiation with calcium and vitamin D in 110 senile osteoporosis patients. However, it did not report the part of BMD measured
<a href="#">Shou ZX 2008</a>	Randomised controlled trial comparing Qianggu Huoli tablet plus Caltrate with Caltrate in 227 primary osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
<a href="#">Shu J 2005</a>	Randomised controlled trial comparing Bushen Yijing prescription with calcium tablet in 50 cases of osteoporosis. The interventions in both arms were used for 7 weeks (less than 3 months)

Study	Reason for exclusion
Shuai B 2008	Randomised controlled trial comparing Jiangu granule with Gusongbao granule in 96 primary osteoporosis patients. However, the control treatment did not meet the inclusion criteria
Song HX 2003	Randomised controlled trial comparing Bushen Zhuanggu pill with calcium in 84 osteoporosis patients. However, it did not report the part of BMD measured
Song XW 1997	Randomised controlled trial comparing Bushen herbal medicine with calcium in 55 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
Song XW 2001	Randomised controlled trial comparing Bushenhuoxue recipe with nilestriol or calcium in 68 postmenopausal osteoporosis patients. However, it was published repeatedly
Su CH 2004	Randomised controlled trial comparing strong bone capsule with calcium carbonate plus vitamin D in 250 senile osteoporosis patients. However, the diagnostic method was not based on a BMD test
Su CH 2005	Randomised controlled trial comparing strong bone capsule with Caltrate in 105 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
Su YB 2008	Randomised controlled trial comparing Qianggu Huoxue pill with Caltrate in 61 primary osteoporosis patients. However, the treatment duration was less than 3 months
Su ZW 2010	Randomised controlled trial comparing Bushenzhuanggu soup, calcitriol capsule, calcium supplement with vitamin D chewable tablets, calcitonin injection and bone peptide injection with calcitriol capsule, calcium supplement with vitamin D chewable tablets, calcitonin injection and bone peptide injection in 110 primary osteoporosis patients. However, the treatment duration was less than 3 months
Sun JM 2002	Randomised controlled trial comparing Yiqi Tiansui mixture plus Caltrate with Caltrate in 40 patients. However, this trial had the same data as the trial conducted by Mu G 2001
Sun X 2002	Randomised controlled trial comparing Jiawei Zuogui pill with calcium in 90 patients. However, this trial had the same data as the trial conducted by Lv ZH
Sun YM 2008	Randomised controlled trial comparing Gegen with alfacalcidol in 44 primary osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Tan X 2010	The type of interventions did not meet the inclusion criteria
Tang JM 1999	Randomised controlled trial comparing Jiangu powder with activated calcium powder in 98 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test
Tu PS 2008	Randomised controlled trial comparing Bushen prescription with no treatment in 60 osteoporosis patients. However, the treatment duration was less than 3 months
Wang CH 2003	Non-randomised study comparing Gusongkang capsule with calcium lactate in 100 patients with senile osteoporosis
Wang GH 2011	Randomised controlled trial comparing Zhuanggutongluobao with vitamin D2 plus calcium tablet in 65 patients with primary osteoporosis. However, the comparability between groups was bad
Wang HM 1998	Non-randomised study comparing Bugu capsule with activated calcium powder in 60 patients with senile osteoporosis
Wang J 2008	Randomised controlled trial comparing Bugan Yishen tang with alfacalcidol in 65 postmenopausal osteoporosis patients. However, the treatment duration was less than 3 months

Study	Reason for exclusion
Wang JH 2001	Randomised controlled trial comparing Qianggu pill with calcium lactate plus vitamin D in 120 osteoporosis patients. However, it was not clear that all were primary osteoporosis patients
Wang LM 2004	Randomised controlled trial comparing Jiangu tang with Suplical in 99 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Weng M 2003	Randomised controlled trial comparing medicine-separated sticking on Shenque (RN8) with sodium etidronate in 70 primary osteoporosis patients. However, the herbal intervention was an acupuncture patch and it did not meet the inclusion criteria
Wu CM 2004	Randomised controlled trial comparing Bushen Zhuanggu capsule with diethylstilbestrol in 71 osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Wu D 2008	Randomised controlled trial comparing Xiaoyao san plus Caltrate with Caltrate in 60 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Wu XG 2008	Randomised controlled trial comparing Xianlinggubao capsule with no treatment in 87 osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Xia WF 2006	Unavailable data
Xie J 2001	The participants were not patients with osteoporosis
Xie J 2003	The participants were not patients with osteoporosis
Xu CY 2004	Randomised controlled trial comparing Bushen Jianpi Tongluo decoction plus Yishen Jiangu tablet and Caltrate with Yishen Jiangu tablet and Caltrate in 125 primary osteoporosis patients. The interventions in both arms were used for 60 days (less than 3 months)
Xu LZ 2001	Randomised controlled trial comparing Bupi Yishen Huoxue prescription with calcium or analgesic discontinuously in 130 osteoporosis patients. However, it was not clear that all were primary osteoporosis patients
Xu PH 2001	Non-randomised study comparing Bushen Jiangu capsule with Gusongbao particles in 330 patients with osteoporosis
Yan XP 2007	Without control group
Yang JP 2007	Randomised controlled trial comparing Gushibao capsule with calcium tablet plus vitamin D in 105 osteoporosis patients. However, it was not clear that all were primary osteoporosis patients
Yang WH 2010	The type of interventions did not meet the inclusion criteria
Yu YH 2011	Randomised controlled trial comparing Erzhi pill with alendronate sodium tablets, Erzhi pill and alendronate sodium tablets with alendronate sodium tablets, in 60 postmenopausal osteoporosis patients. However, it did not report the part of BMD measured
Zhang GM 2001	Randomised controlled trial comparing Xianguning powder with nilestriol in 80 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test

Study	Reason for exclusion
Zhang H 1999	Randomised controlled trial comparing Gubao capsule with Vita-D3 or Longmu Zhuanggu powder in 140 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test
Zhang WY 2005	Randomised controlled trial comparing Bupi Yishen Huoxue prescription with oestradiol or testosterone in 45 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Zhao G 2004	Randomised controlled trial comparing Qianggu capsule with tibolone tablets in 69 postmenopausal osteoporosis patients. However, the diagnostic method was not reported definitively
Zhao Z 2010	Randomised controlled trial comparing Yanghe capsule with Caltrate in 60 primary osteoporosis patients. However, it did not report the part of BMD measured
Zheng NX 2011	The type of interventions did not meet the inclusion criteria
Zheng XH 2004	Randomised controlled trial comparing Gukangye with calcium tablet in 150 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test
Zheng ZW 2010	Randomised controlled trial comparing Bushenzhuanggu soup plus western medicines (ossification alcohol capsule, calcium supplement with vitamin D chewable tablets, calcitonin and salmon calcitonin injection) with the same western medicines in 110 primary osteoporosis patients. However, the treatment duration was less than 3 months
Zhong J 2010	Randomised controlled trial comparing Zhuanggubushen decoction plus carp calcitonin injection J with carp calcitonin injection in 50 osteoporosis patients. However, the treatment duration was less than 3 months and the participants did not meet the inclusion criteria
Zhong RQ 2007a	Randomised controlled trial comparing Gushen Yijing tang with Caltrate in 79 osteoporotic fracture patients. However, the participants did not meet the inclusion criteria
Zhong RQ 2007b	Randomised controlled trial comparing Gushen Yijing tang with Caltrate in 124 osteoporotic fracture patients. However, the participants did not meet the inclusion criteria
Zhou PQ 1997	Non-randomised study comparing Migu tablet with nilestriol in 50 patients with postmenopausal osteoporosis
Zhu LP 2008	Randomised controlled trial comparing Bushen Jianpi tang plus oyster shell calcium chewable tablets with oyster shell calcium chewable tablets in 80 postmenopausal osteoporosis patients. However, the treatment duration was less than 3 months

BMD: bone mineral density

## DATA AND ANALYSES


### Comparison 1. Chinese herbal medicines versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 New fractures	1	104	Risk Ratio (M-H, Fixed, 95% CI)	0.05 [0.00, 0.85]




Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Kanggusong capsule versus placebo (12 months)	1	104	Risk Ratio (M-H, Fixed, 95% CI)	0.05 [0.00, 0.85]
<b>2 Bone mineral density (BMD)</b>	<b>3</b>		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 Migu decoction versus placebo (BMD of lumbar spine, 4 months)	1	20	Mean Difference (IV, Fixed, 95% CI)	0.16 [0.06, 0.26]
2.2 Kanggusong capsule versus placebo (BMD of lumbar spine, 12 months)	1	140	Mean Difference (IV, Fixed, 95% CI)	0.06 [0.02, 0.10]
2.3 Bushen Yigu soft extract versus placebo (BMD of radius, 3 months)	1	59	Mean Difference (IV, Fixed, 95% CI)	0.06 [0.03, 0.09]
2.4 Bushen Yigu soft extract versus placebo (BMD of ulna, 3 months)	1	59	Mean Difference (IV, Fixed, 95% CI)	0.06 [0.02, 0.10]
<b>3 Oestradiol (E2)</b>	<b>1</b>		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 Bushen Yigu soft extract versus placebo (3 months)	1	59	Mean Difference (IV, Random, 95% CI)	122.89 [92.97, 152.81]
<b>4 Symptoms including pain, muscle fatigue and limited mobility</b>	<b>1</b>	<b>104</b>	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [1.05, 1.37]
4.1 Kanggusong capsule versus placebo (Bone pain at lumbar spine, 12 months)	1	104	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [1.05, 1.37]


**Analysis 1.1. Comparison 1 Chinese herbal medicines versus placebo, Outcome 1 New fractures.**




**Analysis 1.2. Comparison 1 Chinese herbal medicines versus placebo, Outcome 2 Bone mineral density (BMD).**




**Analysis 1.3. Comparison 1 Chinese herbal medicines versus placebo, Outcome 3 Oestradiol (E2).**



**Analysis 1.4. Comparison 1 Chinese herbal medicines versus placebo, Outcome 4 Symptoms including pain, muscle fatigue and limited mobility.**







### Comparison 2. Chinese herbal medicines versus no intervention

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
<b>1 Bone mineral density (BMD)</b>	4		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 Bushen Shengsui principle versus no intervention (BMD of lumbar spine, 6 months)	1	61	Mean Difference (IV, Fixed, 95% CI)	0.07 [-0.06, 0.20]
1.2 Bushen Shengsui principle versus no intervention (BMD of femoral neck, 6 months)	1	61	Mean Difference (IV, Fixed, 95% CI)	0.10 [-0.00, 0.20]
1.3 Qianggu soft extract versus no intervention (BMD of femoral neck, 6 months)	1	97	Mean Difference (IV, Fixed, 95% CI)	0.09 [0.03, 0.15]
1.4 Shigu yin versus no treatment (BMD of Femoral neck, 6 months)	1	80	Mean Difference (IV, Fixed, 95% CI)	0.08 [0.03, 0.13]
1.5 Yishen Zhuanggu mixture versus no intervention (BMD of femoral neck, 6months)	1	63	Mean Difference (IV, Fixed, 95% CI)	0.05 [-0.01, 0.11]
1.6 Shengu capsule versus no intervention (BMD of femoral neck, 6 months)	1	34	Mean Difference (IV, Fixed, 95% CI)	0.02 [-0.06, 0.09]
<b>2 Oestradiol (E2)</b>	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 Bushen Shengsui principle versus no intervention (6 months)	1	61	Mean Difference (IV, Fixed, 95% CI)	4.40 [-4.61, 13.41]
2.2 Yishen Zhuanggu mixture versus no treatment (6 months)	1	22	Mean Difference (IV, Fixed, 95% CI)	2.10 [-6.22, 10.42]
2.3 Huoluo Gukang pills versus no intervention (6 months)	1	136	Mean Difference (IV, Fixed, 95% CI)	2.40 [-1.22, 6.02]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.4 Gushukang granule versus no intervention (6 months)	1	129	Mean Difference (IV, Fixed, 95% CI)	2.10 [-1.69, 5.89]
<b>3 Bone Gla protein (BGP)</b>	<b>3</b>		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 Yishen Zhuanggu mixture versus no treatment (6 months)	1	63	Mean Difference (IV, Random, 95% CI)	-1.0 [-6.15, 4.15]
3.2 Shenggu capsule versus no treatment (6 months)	1	34	Mean Difference (IV, Random, 95% CI)	-5.10 [-10.63, 0.43]
3.3 Huoluo Gukang pills versus no treatment (6 months)	1	136	Mean Difference (IV, Random, 95% CI)	2.70 [1.23, 4.17]
3.4 Gushukang granule versus no treatment (6 months)	1	129	Mean Difference (IV, Random, 95% CI)	3.5 [1.92, 5.08]
3.5 Shigu yin versus no treatment (6 months)	1	80	Mean Difference (IV, Random, 95% CI)	1.2 [0.17, 2.23]

**Analysis 2.1. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 1 Bone mineral density (BMD).**






**Analysis 2.2. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 2 Oestradiol (E2).**



**Analysis 2.3. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 3 Bone Gla protein (BGP).**



**Comparison 3. Chinese herbal medicines versus western medicine**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
<b>1 New fractures</b>	1	142	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.1 Kanggusong granule versus Caltrate (9 months)	1	71	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>2 Bone mineral density (BMD)</b>	51		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Kanggusong granule versus ipriflavone plus Caltrate (BMD of lumbar spine, 9 months)	1	71	Mean Difference (IV, Random, 95% CI)	0.0 [-0.05, 0.05]
2.2 Kanggusong granule versus Caltrate (BMD of lumbar spine, 9 months)	1	71	Mean Difference (IV, Random, 95% CI)	0.04 [-0.02, 0.10]
2.3 Kanggusong capsule versus Caltrate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.06 [0.02, 0.11]
2.4 Strong Bone capsule versus Caltrate (BMD of lumbar spine, 3 months)	1	105	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.08, 0.06]
2.5 Qianggu capsule versus active vitamin D3 (BMD of lumbar spine, 6 months)	1	54	Mean Difference (IV, Random, 95% CI)	0.04 [-0.01, 0.09]
2.6 Qianggu capsule versus alendronate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.01 [-0.04, 0.05]
2.7 Herba epimedii prescription versus vitamin D plus Caltrate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.03 [-0.00, 0.06]
2.8 Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone (BMD of lumbar spine, 6 months)	1	66	Mean Difference (IV, Random, 95% CI)	0.0 [-0.12, 0.12]
2.9 Bushen Qianggutang versus Caltrate (BMD of lumbar spine, 3 months)	1	40	Mean Difference (IV, Random, 95% CI)	0.09 [0.01, 0.17]
2.10 Bushen Jianpi Migu prescription versus Caltrate (BMD of lumbar spine, 3 months)	1	150	Mean Difference (IV, Random, 95% CI)	0.06 [0.03, 0.09]
2.11 Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (BMD of lumbar spine, 6 months)	1	141	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.05]
2.12 Bushen Huoxue capsules versus Caltrate and Rocalirol (BMD of lumbar spine, 12 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.02 [-0.05, 0.09]
2.13 Bushen Zhuanggu tang versus alendronate sodium tablets (BMD of lumbar spine, 3 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.04 [0.01, 0.07]
2.14 Bushenjianpi Zhuanggu yin versus Caltrate and calcitonin (BMD of lumbar spine, 12 weeks)	1	100	Mean Difference (IV, Random, 95% CI)	0.16 [0.10, 0.22]
2.15 Jiawei Bushen Zhuangjintang versus calcium granule (BMD of lumbar spine, 3 months)	1	90	Mean Difference (IV, Random, 95% CI)	0.10 [0.05, 0.15]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.16 Gukang oral liquid versus alendronate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.05]
2.17 Kidney-tonifying herbs versus nilestriol (BMD of lumbar spine, 6 months)	1	46	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.09, 0.05]
2.18 Kidney-tonifying herbs versus calcium (BMD of lumbar spine, 6 months)	1	46	Mean Difference (IV, Random, 95% CI)	0.02 [-0.04, 0.08]
2.19 Yishen Yanggan mixture versus calcium gluconate (BMD of lumbar spine, 6 months)	1	110	Mean Difference (IV, Random, 95% CI)	0.04 [0.01, 0.07]
2.20 Yinyanghuo versus conjugated oestrogens (BMD of lumbar spine, 3 to 6 months)	1	25	Mean Difference (IV, Random, 95% CI)	0.03 [-0.04, 0.10]
2.21 Shenyao capsules versus Caltrate (BMD of lumbar spine, 6 months)	1	100	Mean Difference (IV, Random, 95% CI)	0.0 [-0.05, 0.05]
2.22 Guli powder versus Caltrate (BMD of lumbar spine, 3 months, male)	1	30	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.05]
2.23 Guli powder versus Caltrate (BMD of lumbar spine, 3 months, female)	1	30	Mean Difference (IV, Random, 95% CI)	0.04 [-0.07, 0.15]
2.24 Gushen Yijing tang versus Caltrate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.06 [-0.02, 0.14]
2.25 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (BMD of lumbar spine, 6 months)	1	30	Mean Difference (IV, Random, 95% CI)	0.12 [-0.01, 0.26]
2.26 Huangqi Sanxian tang versus nilestriol (BMD of lumbar spine, 3 months)	1	50	Mean Difference (IV, Random, 95% CI)	0.00 [-0.03, 0.04]
2.27 Zishen Gukang pill versus Caltrate plus vitamin D (BMD of lumbar spine, 3 months)	1	60	Mean Difference (IV, Random, 95% CI)	-0.00 [-0.05, 0.04]
2.28 Xianling Gusong capsules versus Caltrate (BMD of lumbar spine, 6 months)	1	43	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.08, 0.02]
2.29 Jianshenfang granule versus alendronate sodium (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.09 [-0.03, 0.21]
2.30 Jiangu recipe versus alendronate sodium tablets (BMD of lumbar spine, 12 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.02 [-0.00, 0.04]
2.31 Gukang decoction versus alendronate sodium tablets (BMD of lumbar spine, 4 months)	1	83	Mean Difference (IV, Random, 95% CI)	-0.00 [-0.03, 0.03]



Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.32 Gumiling granule versus bicarbonate calcium chewable (BMD of lumbar spine, 6 months)	1	25	Mean Difference (IV, Random, 95% CI)	0.04 [-0.02, 0.09]
2.33 Gujian capsule versus alfacalcidol (BMD of lumbar spine, 6 months)	1	65	Mean Difference (IV, Random, 95% CI)	0.14 [0.03, 0.26]
2.34 Xianlinggubao capsule versus alendronate (BMD of lumbar spine, 6 months)	1	104	Mean Difference (IV, Random, 95% CI)	0.0 [-0.02, 0.02]
2.35 Erxian soup versus Caltrate (BMD of lumbar spine, 6 months)	1	58	Mean Difference (IV, Random, 95% CI)	0.06 [0.02, 0.11]
2.36 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of lumbar spine, 6 months)	1	30	Mean Difference (IV, Random, 95% CI)	0.25 [0.11, 0.39]
2.37 Gukang oral liquid versus calcium gluconate (BMD of radius, 6 months)	1	61	Mean Difference (IV, Random, 95% CI)	0.02 [0.01, 0.04]
2.38 Herba epimedii prescription versus vitamin D plus Caltrate (BMD of radius, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.07 [0.04, 0.11]
2.39 Bushen Yigu soft extract versus Alfacalcidol (BMD of radius, 3 months)	1	74	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
2.40 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (BMD of radius, 6 months)	1	50	Mean Difference (IV, Random, 95% CI)	0.08 [-0.12, 0.28]
2.41 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of radius, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.04 [-0.02, 0.11]
2.42 Liuwei Dihuang pills versus calcium (BMD of radius, 12 months)	1	42	Mean Difference (IV, Random, 95% CI)	0.04 [0.03, 0.05]
2.43 Gukang oral liquid versus calcium gluconate (BMD of ulna, 6 months)	1	61	Mean Difference (IV, Random, 95% CI)	0.0 [-0.02, 0.02]
2.44 Bushen Yigu soft extract versus Alfacalcidol (BMD of ulna, 3 months)	1	74	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.05]
2.45 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (BMD of ulna, 6 months)	1	50	Mean Difference (IV, Random, 95% CI)	0.06 [-0.01, 0.13]
2.46 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of ulna, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.05 [-0.00, 0.11]
2.47 Liuwei Dihuang pills versus calcium (BMD of ulna, 12 months)	1	42	Mean Difference (IV, Random, 95% CI)	0.02 [0.01, 0.03]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.48 Kanggusong granule versus ipriflavone plus Caltrate (BMD of femoral neck, 9 months)	1	71	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.04, 0.02]
2.49 Kanggusong granule versus Caltrate (BMD of femoral neck, 9 months)	1	71	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.05]
2.50 Herba epimedii prescription versus vitamin D plus Caltrate (BMD of femoral neck, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.06 [0.02, 0.10]
2.51 Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone (BMD of femoral neck, 6 months)	1	66	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.11, 0.09]
2.52 Kidney-tonifying herbs versus nilestriol (BMD of femoral neck, 6 months)	1	46	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.06]
2.53 Kidney-tonifying herbs versus calcium (BMD of femoral neck, 6 months)	1	46	Mean Difference (IV, Random, 95% CI)	0.05 [0.01, 0.09]
2.54 Gumikang capsule versus calcium gluconate (BMD of femoral neck, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.02 [-0.04, 0.08]
2.55 Yanghuo Sanzi tang versus Caltrate (BMD of femoral neck, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.05 [0.02, 0.08]
2.56 Qianggu soft extract versus calcium gluconate (BMD of femoral neck, 6 months)	1	99	Mean Difference (IV, Random, 95% CI)	0.07 [0.02, 0.12]
2.57 Qianggu capsules versus oestradiol valerate (BMD of femoral neck, 6 months)	1	90	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.06]
2.58 Qianggu paste versus calcium gluconate tablets (BMD of femoral neck, 6 months)	1	123	Mean Difference (IV, Random, 95% CI)	0.07 [0.03, 0.11]
2.59 Qianggu capsule versus active vitamin D3 (BMD of femoral neck, 6 months)	1	54	Mean Difference (IV, Random, 95% CI)	0.03 [-0.01, 0.07]
2.60 Shigu yin versus Caltrate (BMD of femoral neck, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.03 [-0.01, 0.07]
2.61 Jiangu capsule versus Caltrate (BMD of femoral neck, 12 months)	1	125	Mean Difference (IV, Random, 95% CI)	0.04 [0.03, 0.06]
2.62 Gujian capsule versus alfacalcidol (BMD of femoral neck, 6 months)	1	65	Mean Difference (IV, Random, 95% CI)	0.08 [0.03, 0.14]
2.63 Bushenhuoxue capsules versus Caltrate and Rocalirol (BMD of femoral neck, 12 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.02 [-0.06, 0.10]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.64 Bushenjianpi Zhuangguycin versus Caltrate and calcitonin (BMD of femoral neck, 12 weeks)	1	100	Mean Difference (IV, Random, 95% CI)	0.06 [0.00, 0.12]
2.65 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (BMD of femoral neck, 6 months)	1	30	Mean Difference (IV, Random, 95% CI)	0.09 [-0.05, 0.23]
2.66 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of femoral neck, 6 months)	1	30	Mean Difference (IV, Random, 95% CI)	0.07 [-0.06, 0.20]
2.67 Kanggusong granule versus ipriflavone plus Caltrate (BMD of Ward's, 9 months)	1	71	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.07, 0.01]
2.68 Kanggusong granule versus Caltrate (BMD of Ward's, 9 months)	1	71	Mean Difference (IV, Random, 95% CI)	0.0 [-0.04, 0.04]
2.69 Kidney-tonifying herbs versus nilestriol (BMD of Ward's, 6 months)	1	46	Mean Difference (IV, Random, 95% CI)	0.06 [0.02, 0.10]
2.70 Kidney-tonifying herbs versus calcium (BMD of Ward's, 6 months)	1	46	Mean Difference (IV, Random, 95% CI)	0.10 [0.06, 0.14]
2.71 Gujian capsule versus alfacalcidol (BMD of Ward's, 6 months)	1	65	Mean Difference (IV, Random, 95% CI)	0.08 [0.01, 0.15]
2.72 Qianggu capsule versus alendronate (BMD of Ward's, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.03]
2.73 Xianlinggubao capsule versus alendronate (BMD of Ward's, 6 months)	1	104	Mean Difference (IV, Random, 95% CI)	-0.00 [-0.02, 0.02]
2.74 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (BMD of Ward's, 6 months)	1	30	Mean Difference (IV, Random, 95% CI)	0.07 [-0.05, 0.19]
2.75 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of Ward's, 6 months)	1	30	Mean Difference (IV, Random, 95% CI)	0.10 [-0.01, 0.22]
2.76 Kanggusong granule versus ipriflavone plus Caltrate (BMD of trochanter, 9 months)	1	71	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
2.77 Kanggusong granule versus Caltrate (BMD of trochanter, 9 months)	1	71	Mean Difference (IV, Random, 95% CI)	0.03 [-0.00, 0.06]
2.78 Gujian capsule versus alfacalcidol (BMD of trochanter, 6 months)	1	65	Mean Difference (IV, Random, 95% CI)	0.14 [0.07, 0.20]
2.79 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (BMD of trochanter, 6 months)	1	30	Mean Difference (IV, Random, 95% CI)	0.11 [-0.04, 0.27]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.80 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of trochanter, 6 months)	1	30	Mean Difference (IV, Random, 95% CI)	0.19 [0.04, 0.33]
2.81 Gushukang granule versus Calcium carbonate with vitamin D chewable tablets (BMD of hip bone, 6 months)	1	39	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.06]
2.82 Guli powder versus Caltrate (BMD of hip bone, 3 months, male)	1	30	Mean Difference (IV, Random, 95% CI)	0.0 [-0.04, 0.04]
2.83 Guli powder versus Caltrate (BMD of hip bone, 3 months, female)	1	30	Mean Difference (IV, Random, 95% CI)	0.03 [-0.05, 0.11]
2.84 TPF capsule versus calcium granule (BMD of distal radius, 6 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.20 [0.17, 0.23]
2.85 Jiawei Zhuangyao Jianshen tang versus compound calcium amino acid chelate capsules (BMD of calcaneus, 3 months)	1	58	Mean Difference (IV, Random, 95% CI)	0.06 [0.01, 0.11]
2.86 Liuwei Dihuang pills versus Caltrate (BMD of lumbar spine, 6 months)	1	71	Mean Difference (IV, Random, 95% CI)	0.05 [0.03, 0.07]
2.87 Bushen Jianpi Jingu decoction versus calcitonin (BMD of lumbar spine, 3 months)	1	75	Mean Difference (IV, Random, 95% CI)	0.02 [-0.09, 0.13]
2.88 Bushen Jianpi Jingu decoction versus calcitonin (BMD of femoral neck, 3 months)	1	75	Mean Difference (IV, Random, 95% CI)	0.05 [-0.02, 0.12]
2.89 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (BMD of lumbar spine, 6 months)	1	64	Mean Difference (IV, Random, 95% CI)	0.05 [0.03, 0.07]
2.90 Kangshu Jiangu granule versus Caltrate (BMD of femoral neck, 6 months)	1	76	Mean Difference (IV, Random, 95% CI)	0.08 [0.01, 0.15]
2.91 Kangshu Jiangu granule versus Caltrate (BMD of lumbar spine, 6 months)	1	76	Mean Difference (IV, Random, 95% CI)	0.11 [0.01, 0.21]
2.92 Bushen Tianjing Huoxue therapy versus Caltrate and calcitriol soft capsule (BMD of lumbar spine, 6 months)	1	61	Mean Difference (IV, Random, 95% CI)	0.04 [-0.00, 0.07]
<b>3 T score in BMD measurement</b>	<b>2</b>	<b>330</b>	Std. Mean Difference (IV, Random, 95% CI)	<b>0.11 [-0.12, 0.34]</b>
3.1 Jingujian granule versus Caltrate (T score, 3 months)	1	120	Std. Mean Difference (IV, Random, 95% CI)	0.03 [-0.35, 0.41]
3.2 Jingujian granule versus Caltrate (T score, 3 months)	1	210	Std. Mean Difference (IV, Random, 95% CI)	0.16 [-0.12, 0.45]
<b>4 Symptoms including pain, muscle fatigue and limited mobility</b>	<b>12</b>		Risk Ratio (M-H, Fixed, 95% CI)	<b>Subtotals only</b>

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 Jiawei Bushen Zhuangjintang versus calcium granule (3 months)	1	90	Risk Ratio (M-H, Fixed, 95% CI)	1.68 [1.28, 2.19]
4.2 Qiangu soft extract versus calcium gluconate (6 months)	1	99	Risk Ratio (M-H, Fixed, 95% CI)	1.86 [1.24, 2.80]
4.3 Kanggusong granule versus ipriflavone (3 months)	1	60	Risk Ratio (M-H, Fixed, 95% CI)	1.6 [1.07, 2.39]
4.4 Yishen Yanggan mixture versus calcium gluconate (6 months)	1	110	Risk Ratio (M-H, Fixed, 95% CI)	1.70 [1.28, 2.25]
4.5 Yinyanghuo versus conjugated oestrogens (3 to 6 months)	1	25	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.72, 1.28]
4.6 Gumiling granule versus bicarbonate calcium chewable (6 months)	1	25	Risk Ratio (M-H, Fixed, 95% CI)	4.26 [1.43, 12.72]
4.7 Jiawei Zhuangyao Jianshen tang versus compound calcium amino acid chelate capsules (3 months)	1	58	Risk Ratio (M-H, Fixed, 95% CI)	1.25 [0.94, 1.66]
4.8 Zishen Gukang pill versus Caltrate plus vitamin D (3 months)	1	60	Risk Ratio (M-H, Fixed, 95% CI)	1.27 [1.01, 1.61]
4.9 Xianling Gusong capsules versus Caltrate (3 months)	1	43	Risk Ratio (M-H, Fixed, 95% CI)	1.57 [1.03, 2.39]
4.10 Kanggusong capsule versus Caltrate (6 months)	1	80	Risk Ratio (M-H, Fixed, 95% CI)	1.51 [1.12, 2.04]
4.11 Jiangu recipe versus alendronate sodium tablets (12 months)	1	120	Risk Ratio (M-H, Fixed, 95% CI)	1.65 [1.31, 2.08]
4.12 Jingujian granule versus Caltrate (3 months)	1	100	Risk Ratio (M-H, Fixed, 95% CI)	3.15 [1.89, 5.26]
<b>5 Oestradiol (E2)</b>	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Mean Difference (IV, Random, 95% CI)	12.17 [8.27, 16.07]
5.2 Kanggusong granule versus Caltrate (9 months)	1	71	Mean Difference (IV, Random, 95% CI)	11.0 [6.97, 15.03]
5.3 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Random, 95% CI)	10.46 [4.29, 16.63]
5.4 Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone (6 months)	1	66	Mean Difference (IV, Random, 95% CI)	4.0 [-3.92, 11.92]
5.5 Bushen Qiangshen pill versus Caltrate (3 months)	1	30	Mean Difference (IV, Random, 95% CI)	6.71 [-2.28, 15.70]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.6 Qianggu soft extract versus calcium gluconate (6 months)	1	99	Mean Difference (IV, Random, 95% CI)	4.20 [0.89, 7.51]
5.7 Gukang oral liquid versus alendronate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	3.90 [-6.64, 14.44]
5.8 Gumikang capsule versus calcium gluconate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	3.5 [1.14, 5.86]
5.9 Bushen Yigu soft extract versus Alfacalcidol (3 months)	1	74	Mean Difference (IV, Random, 95% CI)	76.29 [31.19, 121.39]
5.10 Kanggusong granule versus ipriflavone (3 months)	1	60	Mean Difference (IV, Random, 95% CI)	4.18 [-13.85, 22.21]
5.11 Yanghuo Sanzi tang versus Caltrate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	23.07 [17.83, 28.31]
5.12 Gusong recipe versus alendronate sodium tablets (5 months)	1	40	Mean Difference (IV, Random, 95% CI)	3.90 [-9.01, 16.81]
5.13 Gushukang granule versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	13.98 [3.90, 24.06]
5.14 Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (6 months)	1	141	Mean Difference (IV, Random, 95% CI)	3.15 [0.28, 6.02]
5.15 Prescription for tonifying kidney versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	14.00 [3.68, 24.32]
5.16 Kidney meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	11.99 [1.15, 22.83]
5.17 Urinary bladder meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	17.99 [7.65, 28.33]
5.18 Huangqi Sanxian tang versus nilestriol (3 months)	1	50	Mean Difference (IV, Random, 95% CI)	-32.97 [-39.42, -26.52]
5.19 Gukang oral liquid versus alendronate sodium tablets (6 months)	1	70	Mean Difference (IV, Random, 95% CI)	5.09 [2.81, 7.37]
5.20 Gukang decoction versus alendronate sodium tablets (4 months)	1	83	Mean Difference (IV, Random, 95% CI)	-0.65 [-9.04, 7.74]
5.21 Jianshenfang granule versus alendronate sodium (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	5.83 [4.21, 7.45]
5.22 Jiangu recipe versus alendronate sodium tablets (6 months)	1	120	Mean Difference (IV, Random, 95% CI)	5.82 [3.69, 7.95]
5.23 Jiangu recipe versus alendronate sodium tablets (12 months)	1	120	Mean Difference (IV, Random, 95% CI)	10.75 [8.55, 12.95]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.24 Bushen Zhuanggu tang versus alendronate sodium tablets (3 months)	1	60	Mean Difference (IV, Random, 95% CI)	5.37 [2.07, 8.67]
5.25 Bushen Huoxue capsule versus Caltrate and Rocalirol (12 months)	1	59	Mean Difference (IV, Random, 95% CI)	2.13 [0.42, 3.84]
5.26 Jingujian granule versus Caltrate (3 months)	1	210	Mean Difference (IV, Random, 95% CI)	4.85 [4.56, 5.14]
5.27 Qianggu paste versus calcium gluconate tablets (6 months)	1	123	Mean Difference (IV, Random, 95% CI)	4.20 [1.79, 6.61]
5.28 Tongbu Qianggutang versus calcium plus vitamin D3 (female, 3 months)	1	18	Mean Difference (IV, Random, 95% CI)	5.03 [-8.01, 18.07]
5.29 Tongbu Qianggutang versus calcium plus vitamin D3 (male, 3 months)	1	22	Mean Difference (IV, Random, 95% CI)	1.89 [-17.98, 21.77]
5.30 Gujian capsule versus alfacalcidol (6 months)	1	58	Mean Difference (IV, Random, 95% CI)	22.35 [-10.51, 55.21]
5.31 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Random, 95% CI)	8.78 [0.92, 16.64]
<b>6 Serum calcium (Ca)</b>	<b>22</b>		Mean Difference (IV, Random, 95% CI)	Subtotals only
6.1 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.17, -0.01]
6.2 Kanggusong granule versus Caltrate (9 months)	1	71	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.11, 0.05]
6.3 Gushukang granule versus Calcium carbonate with vitamin D chewable tablets (6 months)	1	39	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.10, 0.06]
6.4 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Random, 95% CI)	-0.13 [-0.22, -0.04]
6.5 Qianggu soft extract versus calcium gluconate (6 months)	1	99	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.05, -0.01]
6.6 Gumikang capsule versus calcium gluconate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	1.40 [1.39, 1.41]
6.7 Bushen Jianpi Migu prescription versus Caltrate (3 months)	1	150	Mean Difference (IV, Random, 95% CI)	0.01 [-0.05, 0.07]
6.8 Kanggusong granule versus ipriflavone (3 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.10 [0.03, 0.17]
6.9 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (6 months)	1	44	Mean Difference (IV, Random, 95% CI)	0.10 [-0.05, 0.25]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.10 Yinyanghuo versus conjugated oestrogens (3 to 6 months)	1	25	Mean Difference (IV, Random, 95% CI)	0.54 [0.23, 0.85]
6.11 Gushukang granule versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.07, 0.03]
6.12 Shenyao capsules versus Caltrate (6 months)	1	100	Mean Difference (IV, Random, 95% CI)	0.02 [-0.08, 0.12]
6.13 Guli powder versus Caltrate (3 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.09 [0.02, 0.16]
6.14 Prescription for tonifying kidney versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.0 [-0.05, 0.05]
6.15 Kidney meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.06, 0.04]
6.16 Urinary bladder meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.06, 0.04]
6.17 Gushen Yijing tang versus Caltrate (6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.23 [0.11, 0.35]
6.18 Gukang oral liquid versus alendronate sodium tablets (6 months)	1	70	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.06, 0.02]
6.19 Qianggu capsule versus active vitamin D3 (6 months)	1	54	Mean Difference (IV, Random, 95% CI)	0.01 [-0.06, 0.08]
6.20 Jiangu capsule versus Caltrate (12 months)	1	125	Mean Difference (IV, Random, 95% CI)	-0.06 [-0.11, -0.01]
6.21 Bushen Yangxue tang versus calcium gluconate (6 months)	1	40	Mean Difference (IV, Random, 95% CI)	0.13 [-0.00, 0.26]
6.22 Bushenjianpi Zhuangguysin versus Caltrate and calcitonin (12 weeks)	1	100	Mean Difference (IV, Random, 95% CI)	0.74 [0.66, 0.82]
6.23 Erxian soup versus Caltrate (6 months)	1	58	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.25, 0.21]
6.24 Qianggu paste versus calcium gluconate tablets (6 months)	1	123	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.06, -0.00]
6.25 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.10, 0.06]
6.26 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
<b>7 Phosphorus (P)</b>	<b>17</b>		Mean Difference (IV, Fixed, 95% CI)	Subtotals only



Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.1 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Mean Difference (IV, Fixed, 95% CI)	0.06 [-0.03, 0.15]
7.2 Kanggusong granule versus Caltrate (9 months)	1	71	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.29, 0.27]
7.3 Gushukang granule versus Calcium carbonate with vitamin D chewable tablets (6 months)	1	39	Mean Difference (IV, Fixed, 95% CI)	0.01 [-0.09, 0.11]
7.4 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Fixed, 95% CI)	-0.12 [-0.21, -0.03]
7.5 Bushen Jianpi Migu prescription versus Caltrate (3 months)	1	150	Mean Difference (IV, Fixed, 95% CI)	0.03 [-0.02, 0.08]
7.6 Kanggusong granule versus ipriflavone (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.07 [-0.20, 0.06]
7.7 Yinyanghuo versus conjugated oestrogens (3 to 6 months)	1	25	Mean Difference (IV, Fixed, 95% CI)	0.13 [-0.13, 0.39]
7.8 Shenyao capsules versus Caltrate (6 months)	1	100	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.08, 0.06]
7.9 Gushukang granule versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.13, 0.11]
7.10 Guli powder versus Caltrate (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.05 [-0.13, 0.03]
7.11 Prescription for tonifying kidney versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.04 [-0.15, 0.07]
7.12 Kidney meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.13, 0.11]
7.13 Urinary bladder meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.13, 0.11]
7.14 Gushen Yijing tang versus Caltrate (6 months)	1	80	Mean Difference (IV, Fixed, 95% CI)	0.04 [-0.09, 0.17]
7.15 Qianggu capsule versus active vitamin D3 (6 months)	1	54	Mean Difference (IV, Fixed, 95% CI)	0.02 [-0.05, 0.09]
7.16 Jiangu capsule versus Caltrate (12 months)	1	125	Mean Difference (IV, Fixed, 95% CI)	0.09 [-0.20, 0.38]
7.17 Bushenzhuanggu decoction versus alendronate sodium tablets (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.24 [0.10, 0.38]
7.18 Bushenjianpi Zhuangguyin versus Caltrate and calcitonin (12 weeks)	1	100	Mean Difference (IV, Fixed, 95% CI)	-0.37 [-0.48, -0.26]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.19 Erxian soup versus Caltrate (6 months)	1	58	Mean Difference (IV, Fixed, 95% CI)	-0.03 [-0.20, 0.14]
7.20 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.12, 0.10]
7.21 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Fixed, 95% CI)	0.0 [-0.15, 0.15]
<b>8 Alkaline phosphatase (ALP)</b>	<b>32</b>		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Mean Difference (IV, Fixed, 95% CI)	1.69 [0.79, 2.59]
8.2 Kanggusong granule versus Caltrate (9 months)	1	71	Mean Difference (IV, Fixed, 95% CI)	1.28 [0.30, 2.26]
8.3 Gushukang granule versus Calcium carbonate with vitamin D chewable tablets (6 months)	1	39	Mean Difference (IV, Fixed, 95% CI)	-0.5 [-1.70, 0.70]
8.4 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Fixed, 95% CI)	-0.07 [-0.25, 0.11]
8.5 Bushen Qiangshen pill versus Caltrate (3 months)	1	30	Mean Difference (IV, Fixed, 95% CI)	0.27 [-1.27, 1.81]
8.6 Qianggu soft extract versus calcium gluconate (6 months)	1	99	Mean Difference (IV, Fixed, 95% CI)	3.60 [2.62, 4.58]
8.7 Gukang oral liquid versus alendronate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-1.06 [-2.54, 0.42]
8.8 Gumikang capsule versus calcium gluconate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	3.41 [2.84, 3.98]
8.9 Bushen Jianpi Migu prescription versus Caltrate (3 months)	1	150	Mean Difference (IV, Fixed, 95% CI)	0.10 [0.01, 0.19]
8.10 Kanggusong granule versus ipriflavone (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.13 [-0.07, 0.33]
8.11 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (6 months)	1	44	Mean Difference (IV, Fixed, 95% CI)	-0.29 [-1.67, 1.09]
8.12 Liuwei Dihuang pills versus calcium (12 months)	1	42	Mean Difference (IV, Fixed, 95% CI)	0.55 [-0.12, 1.22]
8.13 TPF capsule versus calcium granule (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	3.84 [2.53, 5.15]
8.14 Yinyanghuo versus conjugated oestrogens (3 to 6 months)	1	25	Mean Difference (IV, Fixed, 95% CI)	-7.0 [-11.17, -2.83]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.15 Gusong recipe versus alendronate sodium tablets (5 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	-1.05 [-2.86, 0.76]
8.16 Shenyao capsules versus Caltrate (6 months)	1	100	Mean Difference (IV, Fixed, 95% CI)	-2.40 [-3.58, -1.22]
8.17 Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (6 months)	1	141	Mean Difference (IV, Fixed, 95% CI)	-2.94 [-4.34, -1.54]
8.18 Guli powder versus Caltrate (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.30 [-2.97, 3.57]
8.19 Huangqi Sanxian tang versus nilestriol (3 months)	1	50	Mean Difference (IV, Fixed, 95% CI)	-0.03 [-1.14, 1.08]
8.20 Gushen Yijing tang versus Caltrate (6 months)	1	80	Mean Difference (IV, Fixed, 95% CI)	2.17 [0.73, 3.61]
8.21 Gukang oral liquid versus alendronate sodium Tablets	1	70	Mean Difference (IV, Fixed, 95% CI)	0.48 [-0.34, 1.30]
8.22 Qianggu capsule versus active vitamin D3 (6 months)	1	54	Mean Difference (IV, Fixed, 95% CI)	0.71 [-1.17, 2.59]
8.23 Jiangu capsule versus Caltrate (12 months)	1	125	Mean Difference (IV, Fixed, 95% CI)	2.04 [1.32, 2.76]
8.24 Jianshenfang granule versus alendronate sodium tablets (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.33 [-2.79, 3.45]
8.25 Jingujian granule versus Caltrate (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	0.53 [-0.69, 1.75]
8.26 Jianshenfang granule versus alendronate sodium tablets (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.33 [-2.78, 3.44]
8.27 Bushen Zhuanggu tang versus alendronate sodium tablets (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.11 [-0.99, 0.77]
8.28 Bushenjianpi Zhuanggu yin versus Caltrate and calcitonin (12 weeks)	1	100	Mean Difference (IV, Fixed, 95% CI)	-0.82 [-2.83, 1.19]
8.29 Jingujian granule versus Caltrate (3 months)	1	210	Mean Difference (IV, Fixed, 95% CI)	2.40 [2.21, 2.59]
8.30 Erxian soup versus Caltrate (6 months)	1	58	Mean Difference (IV, Fixed, 95% CI)	0.0 [-0.87, 0.87]
8.31 Qianggu paste versus calcium gluconate tablets (6 months)	1	123	Mean Difference (IV, Fixed, 95% CI)	3.60 [2.86, 4.34]
8.32 Bushen Yangxue tang versus calcium gluconate (6 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	2.62 [0.84, 4.40]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.33 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	0.18 [-1.08, 1.44]
8.34 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Fixed, 95% CI)	0.91 [0.15, 1.67]
<b>9 Bone Gla protein (BGP)</b>	<b>14</b>		Mean Difference (IV, Random, 95% CI)	Subtotals only
9.1 Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (6 months)	1	141	Mean Difference (IV, Random, 95% CI)	-2.13 [-2.74, -1.52]
9.2 Acupoint sticking of Migudan versus oyster shell calcium chewable tablets (3 months)	1	96	Mean Difference (IV, Random, 95% CI)	1.55 [1.24, 1.86]
9.3 Gukang oral liquid versus alendronate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.93, 0.73]
9.4 Gusong recipe versus alendronate sodium tablets (5 months)	1	40	Mean Difference (IV, Random, 95% CI)	-0.10 [-1.11, 0.91]
9.5 Yanghuo Sanzi tang versus Caltrate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	2.71 [-0.30, 5.72]
9.6 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Random, 95% CI)	-0.49 [-2.17, 1.19]
9.7 Shigu yin versus Caltrate (6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.80 [-0.34, 1.94]
9.8 Jingujian granule versus Caltrate (3 months)	1	120	Mean Difference (IV, Random, 95% CI)	2.53 [-0.38, 5.44]
9.9 Jianshenfang granule versus alendronate sodium (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.49 [-1.59, 2.57]
9.10 Jiangu recipe versus alendronate sodium tablets (12 months)	1	120	Mean Difference (IV, Random, 95% CI)	1.81 [-0.31, 3.93]
9.11 Bushen Huoxue capsules versus Caltrate and Rocalirol (12 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.93 [0.35, 1.51]
9.12 Kanggusong capsule versus Caltrate (6 months)	1	80	Mean Difference (IV, Random, 95% CI)	1.78 [0.40, 3.16]
9.13 Liuwei Dihuang pills versus calcium (12 months)	1	42	Mean Difference (IV, Random, 95% CI)	17.9 [12.43, 23.37]
9.14 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Random, 95% CI)	-1.50 [-5.07, 2.08]
<b>10 Interleukin-6 (IL-6)</b>	<b>7</b>		Mean Difference (IV, Fixed, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.1 Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (6 months)	1	141	Mean Difference (IV, Fixed, 95% CI)	-5.72 [-14.05, 2.61]
10.2 Gukang oral liquid versus alendronate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-3.5 [-15.93, 8.93]
10.3 Yanghuo Sanzi tang versus Caltrate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-20.29 [-35.67, -4.91]
10.4 Jianshenfang granule versus alendronate sodium (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-12.56 [-29.26, 4.14]
10.5 Jiangu recipe versus alendronate sodium tablets (12 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	-19.99 [-30.92, -9.06]
10.6 Bushen Huoxue capsules versus Caltrate and Rocalirol (12 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-18.70 [-34.16, -3.24]
10.7 Gusong recipe versus alendronate sodium tablets (5 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	-3.5 [-18.72, 11.72]
<b>11 Parathyroid hormone (PTH)</b>	<b>6</b>		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
11.1 Prescription for tonifying kidney versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-13.0 [-41.67, 15.67]
11.2 Kidney meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-13.01 [-41.95, 15.93]
11.3 Urinary bladder meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-3.01 [-31.44, 25.42]
11.4 Kanggusong granule versus ipriflavone (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	11.81 [-14.64, 38.26]
11.5 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (6 months)	1	44	Mean Difference (IV, Fixed, 95% CI)	-10.63 [-140.92, 119.66]
11.6 TPF capsule versus calcium granule (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	-254.0 [-399.06, -108.94]
11.7 Gujian capsule versus alfacalcidol (6 months)	1	48	Mean Difference (IV, Fixed, 95% CI)	-22.57 [-60.92, 15.78]
11.8 Gushukang granule versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-3.02 [-30.91, 24.87]
11.9 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Fixed, 95% CI)	-2.06 [-6.74, 2.62]
<b>12 Computed tomography (CT)</b>	<b>8</b>		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
12.1 Prescription for tonifying kidney versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.96 [-3.71, 5.63]
12.2 Kidney meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	-1.01 [-5.44, 3.42]
12.3 Urinary bladder meridian sticking versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	-0.01 [-4.68, 4.66]
12.4 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (6 months)	1	44	Mean Difference (IV, Random, 95% CI)	15.93 [-24.16, 56.02]
12.5 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Random, 95% CI)	16.25 [10.43, 22.07]
12.6 Jingujian granule versus Caltrate (3 months)	1	210	Mean Difference (IV, Random, 95% CI)	21.98 [17.01, 26.95]
12.7 TPF capsule versus Calcium granule (6 months)	1	120	Mean Difference (IV, Random, 95% CI)	17.71 [11.53, 23.89]
12.8 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Random, 95% CI)	-6.18 [-12.89, 0.52]
12.9 Gujian capsule versus alfacalcidol (6 months)	1	57	Mean Difference (IV, Random, 95% CI)	-12.77 [-70.92, 45.38]
12.10 Gushukang granule versus ipriflavone (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	-0.01 [-4.44, 4.42]
12.11 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Random, 95% CI)	0.11 [-0.04, 0.26]

**Analysis 3.1. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 1 New fractures.**


Study or subgroup	Herbal drugs n/N	West medicine n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
<b>3.1.1 Kanggusong granule versus Caltrate (9 months)</b>					
An SJ 2000	0/31	0/40			Not estimable
<b>Subtotal (95% CI)</b>	<b>31</b>	<b>40</b>			<b>Not estimable</b>
Total events: 0 (Herbal drugs), 0 (West medicine)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
<b>3.1.2 Kanggusong granule versus ipriflavone plus Caltrate (9 months)</b>					
An SJ 2000	0/31	0/40			Not estimable
<b>Subtotal (95% CI)</b>	<b>31</b>	<b>40</b>			<b>Not estimable</b>
Total events: 0 (Herbal drugs), 0 (West medicine)					
Heterogeneity: Not applicable					

Favours treatment    0.001    0.1    1    10    1000    Favours control


Study or subgroup	Herbal drugs n/N	West medicine n/N	Risk Ratio		Weight	Risk Ratio M-H, Fixed, 95% CI
			M-H, Fixed, 95% CI			
Test for overall effect: Not applicable						
<b>Total (95% CI)</b>	<b>62</b>	<b>80</b>				<b>Not estimable</b>
Total events: 0 (Herbal drugs), 0 (West medicine)						
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
Test for subgroup differences: Not applicable						


**Analysis 3.2. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 2 Bone mineral density (BMD).**


Study or subgroup	Herbal drugs		West medicine		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
<b>3.2.1 Kanggusong granule versus ipriflavone plus Caltrate (BMD of lumbar spine, 9 months)</b>							
An SJ 2000	31	1 (0.1)	40	1 (0.1)		100%	0[-0.05,0.05]
<b>Subtotal ***</b>	<b>31</b>		<b>40</b>			<b>100%</b>	<b>0[-0.05,0.05]</b>
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
<b>3.2.2 Kanggusong granule versus Caltrate (BMD of lumbar spine, 9 months)</b>							
An SJ 2000	31	1 (0.1)	40	0.9 (0.1)		100%	0.04[-0.02,0.1]
<b>Subtotal ***</b>	<b>31</b>		<b>40</b>			<b>100%</b>	<b>0.04[-0.02,0.1]</b>
Heterogeneity: Not applicable							
Test for overall effect: Z=1.4(P=0.16)							
<b>3.2.3 Kanggusong capsule versus Caltrate (BMD of lumbar spine, 6 months)</b>							
Wei RY 2011	48	0.7 (0.1)	32	0.7 (0.1)		100%	0.06[0.02,0.11]
<b>Subtotal ***</b>	<b>48</b>		<b>32</b>			<b>100%</b>	<b>0.06[0.02,0.11]</b>
Heterogeneity: Not applicable							
Test for overall effect: Z=2.64(P=0.01)							
<b>3.2.4 Strong Bone capsule versus Caltrate (BMD of lumbar spine, 3 months)</b>							
Cui TH 1999	74	0.8 (0.2)	31	0.8 (0.2)		100%	-0.01[-0.08,0.06]
<b>Subtotal ***</b>	<b>74</b>		<b>31</b>			<b>100%</b>	<b>-0.01[-0.08,0.06]</b>
Heterogeneity: Not applicable							
Test for overall effect: Z=0.29(P=0.77)							
<b>3.2.5 Qianggu capsule versus active vitamin D3 (BMD of lumbar spine, 6 months)</b>							
Wang J 2007	28	0.8 (0.1)	26	0.8 (0.1)		100%	0.04[-0.01,0.09]
<b>Subtotal ***</b>	<b>28</b>		<b>26</b>			<b>100%</b>	<b>0.04[-0.01,0.09]</b>
Heterogeneity: Not applicable							
Test for overall effect: Z=1.54(P=0.12)							
<b>3.2.6 Qianggu capsule versus alendronate (BMD of lumbar spine, 6 months)</b>							
Xu H 2010	40	0.7 (0.1)	40	0.7 (0.1)		100%	0.01[-0.04,0.05]
<b>Subtotal ***</b>	<b>40</b>		<b>40</b>			<b>100%</b>	<b>0.01[-0.04,0.05]</b>
Heterogeneity: Not applicable							






































**Analysis 3.3. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 3 T score in BMD measurement.**





**Analysis 3.4. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 4 Symptoms including pain, muscle fatigue and limited mobility.**








Study or subgroup	Herbal drugs		West medicine		Risk Ratio		Weight	Risk Ratio		
	n/N	n/N	n/N	n/N	M-H, Fixed, 95% CI			M-H, Fixed, 95% CI		
Test for overall effect: $Z=4.39(P<0.0001)$										
Test for subgroup differences: $\text{Chi}^2=27.44, \text{df}=1 (P=0), I^2=59.91\%$										
					0.01	0.1	1	10	100	
					Favours treatment			Favours control		

**Analysis 3.5. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 5 Oestradiol (E2).**

Study or subgroup	Herbal drugs		West medicine		Mean Difference	Weight	Mean Difference			
	N	Mean(SD)	N	Mean(SD)				Random, 95% CI	Random, 95% CI	
<b>3.5.1 Kanggusong granule versus ipriflavone plus Caltrate (9 months)</b>										
An SJ 2000	31	32.5 (10.3)	40	20.4 (4.6)		100%	12.17[8.27,16.07]			
<b>Subtotal ***</b>	<b>31</b>		<b>40</b>			<b>100%</b>	<b>12.17[8.27,16.07]</b>			
Heterogeneity: Not applicable										
Test for overall effect: $Z=6.12(P<0.0001)$										
<b>3.5.2 Kanggusong granule versus Caltrate (9 months)</b>										
An SJ 2000	31	32.5 (10.3)	40	21.5 (5.6)		100%	11[6.97,15.03]			
<b>Subtotal ***</b>	<b>31</b>		<b>40</b>			<b>100%</b>	<b>11[6.97,15.03]</b>			
Heterogeneity: Not applicable										
Test for overall effect: $Z=5.36(P<0.0001)$										
<b>3.5.3 Strong Bone capsule versus Caltrate (3 months)</b>										
Cui TH 1999	74	44.2 (19.4)	31	33.7 (12.2)		100%	10.46[4.29,16.63]			
<b>Subtotal ***</b>	<b>74</b>		<b>31</b>			<b>100%</b>	<b>10.46[4.29,16.63]</b>			
Heterogeneity: Not applicable										
Test for overall effect: $Z=3.32(P=0)$										
<b>3.5.4 Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone (6 months)</b>										
Liao L 2004	32	25.2 (19.3)	34	21.2 (12.6)		100%	4[-3.92,11.92]			
<b>Subtotal ***</b>	<b>32</b>		<b>34</b>			<b>100%</b>	<b>4[-3.92,11.92]</b>			
Heterogeneity: Not applicable										
Test for overall effect: $Z=0.99(P=0.32)$										
<b>3.5.5 Bushen Qiangshen pill versus Caltrate (3 months)</b>										
Mu G 2001a	15	21.9 (13.2)	15	15.2 (11.9)		100%	6.71[-2.28,15.7]			
<b>Subtotal ***</b>	<b>15</b>		<b>15</b>			<b>100%</b>	<b>6.71[-2.28,15.7]</b>			
Heterogeneity: Not applicable										
Test for overall effect: $Z=1.46(P=0.14)$										
<b>3.5.6 Qianggu soft extract versus calcium gluconate (6 months)</b>										
Peng T 2002	78	21.1 (5.9)	21	16.9 (7.1)		100%	4.2[0.89,7.51]			
<b>Subtotal ***</b>	<b>78</b>		<b>21</b>			<b>100%</b>	<b>4.2[0.89,7.51]</b>			
Heterogeneity: Not applicable										
Test for overall effect: $Z=2.49(P=0.01)$										
<b>3.5.7 Gukang oral liquid versus alendronate (6 months)</b>										
Shao M 2003	30	64 (19.9)	30	60.1 (21.8)		100%	3.9[-6.64,14.44]			
<b>Subtotal ***</b>	<b>30</b>		<b>30</b>			<b>100%</b>	<b>3.9[-6.64,14.44]</b>			
Heterogeneity: Not applicable										
					-20	-10	0	10	20	
					Favours control			Favours treatment		













**Analysis 3.6. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 6 Serum calcium (Ca).**













**Analysis 3.7. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 7 Phosphorus (P).**










**Analysis 3.8. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 8 Alkaline phosphatase (ALP).**


















**Analysis 3.9. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 9 Bone Gla protein (BGP).**







**Analysis 3.10. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 10 Interleukin-6 (IL-6).**






**Analysis 3.11. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 11 Parathyroid hormone (PTH).**





**Analysis 3.12. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 12 Computed tomography (CT).**





**Comparison 4. Chinese herbal medicines plus western medicine versus western medicine**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
<b>1 New fractures</b>	5		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Risk Ratio (M-H, Fixed, 95% CI)	0.06 [0.00, 1.00]
1.2 Xianlinggubao capsule (low-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (12 months)	1	120	Risk Ratio (M-H, Fixed, 95% CI)	0.33 [0.01, 8.02]
1.3 Xianlinggubao capsule (high-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (12 months)	1	116	Risk Ratio (M-H, Fixed, 95% CI)	0.36 [0.01, 8.58]
1.4 Bushen Zhuanggu granules plus calcium and vitamin D versus placebo granules plus calcium and vitamin D (5 years)	1	155	Risk Ratio (M-H, Fixed, 95% CI)	0.44 [0.13, 1.43]
1.5 Kanggusong soup plus Caltrate versus Caltrate (3 months)	1	75	Risk Ratio (M-H, Fixed, 95% CI)	0.22 [0.01, 5.34]
1.6 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	90	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>2 Bone mineral density (BMD)</b>	43		Mean Difference (IV, Random, 95% CI)	Subtotals only



Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol (BMD of lumbar spine, 6 months)	1	64	Mean Difference (IV, Random, 95% CI)	0.06 [0.01, 0.11]
2.2 Jiarong tablet plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	41	Mean Difference (IV, Random, 95% CI)	0.04 [-0.05, 0.14]
2.3 Ziyin Bushen Zhuanggu prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin (BMD of lumbar spine, 8 months)	1	45	Mean Difference (IV, Random, 95% CI)	0.14 [0.08, 0.20]
2.4 Zhuanggu capsule plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.01 [0.00, 0.02]
2.5 Antai capsule plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	128	Mean Difference (IV, Random, 95% CI)	0.04 [-0.00, 0.08]
2.6 Bushen Zhuanggutang plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.14 [0.06, 0.22]
2.7 Zishen prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin (BMD of lumbar spine, 8 months)	1	45	Mean Difference (IV, Random, 95% CI)	0.14 [0.08, 0.20]
2.8 Guilu Erxiantang plus calcium carbonate tablet versus calcium carbonate tablet (BMD of lumbar spine, 6 months)	1	85	Mean Difference (IV, Random, 95% CI)	0.03 [-0.03, 0.09]
2.9 Guben Zhuanggu capsules plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.03 [0.01, 0.05]
2.10 Migu tablet plus Caltrate versus Caltrate (BMD of Lumbar spine, 12 months)	1	44	Mean Difference (IV, Random, 95% CI)	0.08 [0.07, 0.09]
2.11 Shugan zishen huoxue tang plus Caltrate and alendronate sodium versus Caltrate plus alendronate sodium (BMD of lumbar spine, 6 months)	1	42	Mean Difference (IV, Random, 95% CI)	0.12 [0.08, 0.16]
2.12 Bushen Yangxue tang plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.06]
2.13 Bushen Kangsong pill plus calcium carbonate tablets versus calcium carbonate tablets (BMD of lumbar spine, 6 months)	1	84	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.04]
2.14 Gusongbao granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule (BMD of lumbar spine, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.07, 0.05]
2.15 Qianggu capsule plus alendronate versus alendronate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.08 [0.03, 0.12]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.16 Xianlinggubao capsule plus Caltrate versus Caltrate (BMD of lumbar spine, 12 months)	1	68	Mean Difference (IV, Random, 95% CI)	0.30 [0.25, 0.35]
2.17 Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate (BMD of lumbar spine, 3 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.03 [-0.03, 0.09]
2.18 Xianlinggubao capsule plus alendronate versus alendronate (BMD of lumbar spine, 6 months)	1	104	Mean Difference (IV, Random, 95% CI)	0.06 [0.03, 0.09]
2.19 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate (BMD of lumbar spine, 48 weeks)	1	112	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.06]
2.20 Xianlinggubao capsule plus Caltrate versus Caltrate (BMD of lumbar spine, 12 months)	1	136	Mean Difference (IV, Random, 95% CI)	0.31 [0.28, 0.34]
2.21 Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule (BMD of lumbar spine, 6 months)	1	106	Mean Difference (IV, Random, 95% CI)	0.18 [0.14, 0.22]
2.22 Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule (BMD of lumbar spine, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	0.04 [-0.02, 0.10]
2.23 Jinwugutong capsules plus calcium versus placebo plus calcium (BMD of lumbar spine, 6 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.11 [0.07, 0.15]
2.24 Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet (BMD of lumbar spine, 6 months)	1	480	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.05]
2.25 Chinese medicine Bushenhuoxue recipe plus conventional western medicine versus conventional western medicine (BMD of lumbar spine, 3 months)	1	57	Mean Difference (IV, Random, 95% CI)	0.16 [0.09, 0.22]
2.26 Gusongbao granule plus calcium tablet versus placebo plus calcium tablet (BMD of lumbar spine, 6 months)	1	240	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
2.27 Shengsuiyin recipe plus Caltrate versus Caltrate (BMD of Lumbar spine, 12 months)	1	144	Mean Difference (IV, Random, 95% CI)	0.31 [0.28, 0.34]
2.28 Yigu capsule plus calcium versus placebo plus calcium (BMD of lumbar spine, 6 months)	1	140	Mean Difference (IV, Random, 95% CI)	0.08 [0.04, 0.12]
2.29 Chinese medicine (combination of 10 herbs) plus tamoxifen and Caltrate versus ta-	1	120	Mean Difference (IV, Random, 95% CI)	0.10 [0.06, 0.14]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
moxifen and Caltrate (BMD of lumbar spine, 3 months)				
2.30 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (BMD of lumbar spine, 12 months)	1	90	Mean Difference (IV, Random, 95% CI)	0.01 [-0.04, 0.06]
2.31 Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule (BMD of lumbar spine, 6 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.17 [0.14, 0.20]
2.32 Huangqi plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	36	Mean Difference (IV, Random, 95% CI)	0.06 [0.01, 0.11]
2.33 Jiarong tablet plus Caltrate versus Caltrate (BMD of femoral neck, 6 months)	1	41	Mean Difference (IV, Random, 95% CI)	0.09 [0.02, 0.15]
2.34 Antai capsule plus Caltrate versus Caltrate (BMD of femoral neck, 6 months)	1	128	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
2.35 Xianlinggubao capsule plus Caltrate versus Caltrate (BMD of femoral neck, 12 months)	1	68	Mean Difference (IV, Random, 95% CI)	0.3 [0.25, 0.35]
2.36 Guben Zhuanggu capsules plus Caltrate versus Caltrate (BMD of femoral neck, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.02]
2.37 Migu tablet plus Caltrate versus Caltrate (BMD of femoral neck, 12 months)	1	44	Mean Difference (IV, Random, 95% CI)	0.09 [0.08, 0.10]
2.38 Qianggu capsules plus oestradiol valerate versus oestradiol valerate (BMD of femoral neck, 6 months)	1	88	Mean Difference (IV, Random, 95% CI)	0.03 [-0.01, 0.07]
2.39 Chinese medicine Bushenhuoxue recipe plus conventional western medicine versus conventional western medicine (BMD of femoral neck, 3 months)	1	57	Mean Difference (IV, Random, 95% CI)	0.17 [0.12, 0.23]
2.40 Heche Dazao pill plus oyster shell calcium chewable tablets versus oyster shell calcium chewable tablets (BMD of femoral neck, 3 months)	1	114	Mean Difference (IV, Random, 95% CI)	0.04 [0.00, 0.07]
2.41 Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule (BMD of femoral neck, 6 months)	1	106	Mean Difference (IV, Random, 95% CI)	0.26 [0.22, 0.30]
2.42 Huangqi plus Caltrate versus Caltrate (BMD of femoral neck, 6 months)	1	36	Mean Difference (IV, Random, 95% CI)	0.07 [0.03, 0.11]
2.43 Gusongbao granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino	1	96	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.05]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
acid chelate capsule (BMD of femoral neck, 6 months)				
2.44 Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule (BMD of femoral neck, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.07, 0.03]
2.45 Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet (BMD of femoral neck, 6 months)	1	480	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
2.46 Gusongbao granule plus calcium tablet versus placebo plus calcium tablet (BMD of femoral neck, 6 months)	1	240	Mean Difference (IV, Random, 95% CI)	0.0 [-0.03, 0.03]
2.47 Yigu capsule plus calcium versus placebo plus calcium (BMD of femoral neck, 6 months)	1	140	Mean Difference (IV, Random, 95% CI)	0.04 [0.01, 0.07]
2.48 Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule (BMD of femoral neck, 6 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.24 [0.21, 0.27]
2.49 Antai capsule plus Caltrate versus Caltrate (BMD of Ward's, 6 months)	1	128	Mean Difference (IV, Random, 95% CI)	0.0 [-0.03, 0.03]
2.50 Migu tablet plus Caltrate versus Caltrate (BMD of Ward's, 12 months)	1	44	Mean Difference (IV, Random, 95% CI)	0.09 [0.08, 0.10]
2.51 Qianggu capsule plus alendronate versus alendronate (BMD of Ward's, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.05 [0.02, 0.07]
2.52 Xianlinggubao capsule plus alendronate versus alendronate (BMD of Ward's, 6 months)	1	104	Mean Difference (IV, Random, 95% CI)	0.04 [0.02, 0.06]
2.53 Gusongbao granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule (BMD of Ward's, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.06, 0.04]
2.54 Xianlinggubao capsule plus compound calcium amino acid chelate capsules versus compound calcium amino acid chelate capsules (BMD of Ward's, 6 months)	1	106	Mean Difference (IV, Random, 95% CI)	0.23 [0.19, 0.27]
2.55 Migu tablet plus compound calcium amino acid chelate capsules versus compound calcium amino acid chelate capsules (BMD of Ward's, 6 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.28 [0.24, 0.32]
2.56 Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule (BMD of Ward's, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.06, 0.04]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.57 Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet (BMD of Ward's, 6 months)	1	480	Mean Difference (IV, Random, 95% CI)	0.02 [-0.00, 0.04]
2.58 Gusongbao granule plus calcium tablet versus placebo plus calcium tablet (BMD of Ward's, 6 months)	1	240	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
2.59 Yigu capsule plus calcium versus placebo plus calcium (BMD of Ward's, 6 months)	1	140	Mean Difference (IV, Random, 95% CI)	0.04 [0.00, 0.08]
2.60 Antai capsule plus Caltrate versus Caltrate (BMD of trochanter, 6 months)	1	128	Mean Difference (IV, Random, 95% CI)	0.03 [0.00, 0.06]
2.61 Migu tablet plus Caltrate versus Caltrate (BMD of trochanter, 12 months)	1	44	Mean Difference (IV, Random, 95% CI)	0.15 [0.14, 0.16]
2.62 Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet (BMD of trochanter, 6 months)	1	480	Mean Difference (IV, Random, 95% CI)	0.0 [-0.02, 0.02]
2.63 Migu tablet plus compound calcium amino acid chelate capsules versus compound calcium amino acid chelate capsules (BMD of trochanter, 6 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.12 [0.07, 0.17]
2.64 Xianlinggubao capsule plus compound calcium amino acid chelate capsules versus compound calcium amino acid chelate capsules (BMD of trochanter, 6 months)	1	106	Mean Difference (IV, Random, 95% CI)	0.13 [0.08, 0.18]
2.65 Gusongbao granule plus calcium tablet versus placebo plus calcium tablet (BMD of trochanter, 6 months)	1	240	Mean Difference (IV, Random, 95% CI)	0.0 [-0.03, 0.03]
2.66 Yigu capsule plus calcium versus placebo plus calcium (BMD of trochanter, 6 months)	1	140	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.06]
2.67 Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets (BMD of hip bone, 6 months)	1	42	Mean Difference (IV, Random, 95% CI)	0.15 [0.11, 0.19]
2.68 Jinwugutong capsules plus calcium versus placebo plus calcium (BMD of hip bone, 6 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
2.69 Gengnian Anyi tablet plus Caltrate versus Caltrate (BMD of distal radius, 6 months)	1	42	Mean Difference (IV, Random, 95% CI)	0.01 [-0.06, 0.08]
2.70 Shangke Yishen Zhuanggu pill plus Caltrate and calcitonin versus Caltrate and calcitonin (BMD of lumbar spine, 3 months)	1	300	Mean Difference (IV, Random, 95% CI)	0.04 [0.03, 0.05]
2.71 Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol versus calci-	1	80	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.04, 0.02]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
um carbonate tablets and alfacalcidol (BMD of lumbar spine, 3 months)				
2.72 Gukang tablet plus oyster shell calcium chewable tablets and vitamin A and D capsules versus oyster shell calcium chewable tablets and vitamin A and D capsules (BMD of lumbar spine, for 3 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.24 [0.14, 0.34]
2.73 Liuwei Dihuang pills plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	72	Mean Difference (IV, Random, 95% CI)	0.05 [0.02, 0.08]
2.74 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (BMD of lumbar spine, 3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.05]
2.75 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (BMD of femoral neck, 3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
2.76 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (BMD of trochanter, 3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.02 [0.01, 0.04]
2.77 Yishen Zhuanggu decoction plus calcitriol soft capsule versus calcitriol soft capsule (BMD of lumbar spine, 3 months)	1	100	Mean Difference (IV, Random, 95% CI)	0.02 [-0.00, 0.05]
2.78 Hugu capsule plus Caltrate versus placebo capsule plus Caltrate (BMD of lumbar spine, 6 months)	1	122	Mean Difference (IV, Random, 95% CI)	0.03 [-0.00, 0.06]
2.79 Hugu capsule plus Caltrate versus placebo capsule plus Caltrate (BMD of Ward's, 6 months)	1	122	Mean Difference (IV, Random, 95% CI)	0.05 [0.02, 0.08]
2.80 Bushen Qianggu Huoxue therapy plus calcium and cod liver oil versus calcium and cod liver oil (BMD of lumbar spine, 3 months)	1	84	Mean Difference (IV, Random, 95% CI)	0.05 [-0.01, 0.11]
2.81 Bushen Qianggu Huoxue therapy plus calcium and cod liver oil versus calcium and cod liver oil (BMD of femoral neck, 3 months)	1	84	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.05]
2.82 Bushen Qianggu Huoxue therapy plus calcium and cod liver oil versus calcium and cod liver oil (BMD of Ward's, 3 months)	1	84	Mean Difference (IV, Random, 95% CI)	0.04 [0.02, 0.07]
2.83 Xianlinggubao capsule (low-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (BMD of lumbar spine, 12 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.0 [-0.04, 0.04]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.84 Xianlinggubao capsule (high-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (BMD of lumbar spine, 12 months)	1	116	Mean Difference (IV, Random, 95% CI)	0.0 [-0.03, 0.03]
2.85 Xianlinggubao capsule (low-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (BMD of femoral neck, 12 months)	1	120	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
2.86 Xianlinggubao capsule (high-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (BMD of femoral neck, 12 months)	1	116	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
2.87 Bushen Zhuanggu granules plus calcium and vitamin D versus placebo granules plus calcium and vitamin D (BMD of distal radius, 5 years)	1	155	Mean Difference (IV, Random, 95% CI)	0.10 [0.09, 0.10]
<b>3 T score in BMD measurement</b>	1	67	Mean Difference (IV, Fixed, 95% CI)	0.91 [0.57, 1.25]
3.1 Erxian Yanggu decoction plus alendronate sodium tablets versus alendronate sodium tablets (T score, 6 months)	1	67	Mean Difference (IV, Fixed, 95% CI)	0.91 [0.57, 1.25]
<b>4 Quality of life</b>	1	80	Mean Difference (IV, Fixed, 95% CI)	5.30 [3.67, 6.93]
4.1 Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol versus calcium carbonate tablets and alfacalcidol (3 months)	1	80	Mean Difference (IV, Fixed, 95% CI)	5.30 [3.67, 6.93]
<b>5 Symptoms including pain, muscle fatigue and limited mobility</b>	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
5.1 Heche Dazao pill plus oyster shell calcium chewable tablets versus oyster shell calcium chewable tablets (3 months)	1	114	Risk Ratio (M-H, Fixed, 95% CI)	1.15 [1.01, 1.30]
5.2 Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Risk Ratio (M-H, Fixed, 95% CI)	1.33 [1.09, 1.61]
5.3 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	82	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.91, 1.12]
5.4 Kanggusong soup plus Caltrate versus Caltrate (3 months)	1	75	Risk Ratio (M-H, Fixed, 95% CI)	1.48 [1.09, 2.02]
<b>6 Oestradiol (E2)</b>	9		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1 Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol (6 months)	1	64	Mean Difference (IV, Random, 95% CI)	4.54 [0.47, 8.61]
6.2 Ziyin Bushen Zhuanggu prescription plus Caltrate and Calcitonin versus Caltrate plus Calcitonin (8 months)	1	45	Mean Difference (IV, Random, 95% CI)	23.21 [14.46, 31.96]
6.3 Zhuanggu capsule plus Caltrate versus Caltrate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	4.06 [2.56, 5.56]
6.4 Bushen Qiangshen pill plus Caltrate versus Caltrate (3 months)	1	40	Mean Difference (IV, Random, 95% CI)	7.60 [-0.51, 15.71]
6.5 Antai capsule plus Caltrate versus Caltrate (6 months)	1	128	Mean Difference (IV, Random, 95% CI)	11.0 [8.14, 13.86]
6.6 Zishen prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin (8 months)	1	45	Mean Difference (IV, Random, 95% CI)	23.21 [14.46, 31.96]
6.7 Shugan zishen huoxue tang plus Caltrate and alendronate sodium tablets versus Caltrate plus alendronate sodium tablets (6 months)	1	42	Mean Difference (IV, Random, 95% CI)	26.99 [18.44, 35.54]
6.8 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate (48 weeks)	1	112	Mean Difference (IV, Random, 95% CI)	6.04 [4.61, 7.47]
6.9 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Random, 95% CI)	40.85 [33.61, 48.09]
<b>7 Serum calcium (Ca)</b>	<b>12</b>		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol (6 months)	1	64	Mean Difference (IV, Random, 95% CI)	0.05 [-0.02, 0.12]
7.2 Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets (6 months)	1	42	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.09, 0.07]
7.3 Zhuanggu capsule plus Caltrate versus Caltrate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.01 [-0.07, 0.09]
7.4 Antai capsule plus Caltrate versus Caltrate (6 months)	1	128	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.09, 0.03]
7.5 Jinwugutong capsules plus calcium versus placebo plus calcium (6 months)	1	120	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.11, 0.01]




Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.6 Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.03 [-0.09, 0.15]
7.7 Bushenyiqihuoxue soup plus tamoxifen and Caltrate versus tamoxifen and Caltrate (3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.37 [0.32, 0.42]
7.8 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.13, -0.01]
7.9 Chinese medicine (combination of 10 herbs) plus tamoxifen and Caltrate versus tamoxifen and Caltrate (3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.37 [0.32, 0.42]
7.10 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	90	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.10, 0.06]
7.11 Huangqi plus Caltrate versus Caltrate (6 months)	1	36	Mean Difference (IV, Random, 95% CI)	0.28 [0.11, 0.45]
7.12 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (3 months)	1	120	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.06, 0.02]
<b>8 Phosphorus (P)</b>	10		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol (6 months)	1	64	Mean Difference (IV, Fixed, 95% CI)	-0.13 [-0.27, 0.01]
8.2 Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets (6 months)	1	42	Mean Difference (IV, Fixed, 95% CI)	-0.02 [-0.11, 0.07]
8.3 Zhuanggu capsule plus Caltrate versus Caltrate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.01 [-0.06, 0.08]
8.4 Antai capsule plus Caltrate versus Caltrate (6 months)	1	128	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.23, 0.21]
8.5 Jinwugutong capsules plus calcium versus placebo plus calcium (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	-0.02 [-0.09, 0.05]
8.6 Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Mean Difference (IV, Fixed, 95% CI)	0.01 [-0.12, 0.14]
8.7 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Fixed, 95% CI)	-0.03 [-0.08, 0.02]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.8 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	90	Mean Difference (IV, Fixed, 95% CI)	-0.02 [-0.08, 0.04]
8.9 Huangqi plus Caltrate versus Caltrate (6 months)	1	36	Mean Difference (IV, Fixed, 95% CI)	0.31 [0.14, 0.48]
8.10 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	0.06 [-0.22, 0.34]
<b>9 Alkaline phosphatase (ALP)</b>	<b>15</b>		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
9.1 Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets (6 months)	1	39	Mean Difference (IV, Fixed, 95% CI)	-0.5 [-1.70, 0.70]
9.2 Zhuanggu capsule plus Caltrate versus Caltrate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.0 [-1.55, 1.55]
9.3 Bushen Qiangshen pill plus Caltrate versus Caltrate (3 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	-0.31 [-1.72, 1.10]
9.4 Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Mean Difference (IV, Fixed, 95% CI)	-0.99 [-1.52, -0.46]
9.5 Antai capsule plus Caltrate versus Caltrate (6 months)	1	128	Mean Difference (IV, Fixed, 95% CI)	1.28 [0.55, 2.01]
9.6 Traditional Chinese capsule plus calcium gluconate versus calcium gluconate (9 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	1.77 [1.20, 2.34]
9.7 Jinwugutong capsules plus calcium versus placebo plus calcium (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	1.01 [-0.04, 2.06]
9.8 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Fixed, 95% CI)	1.73 [0.71, 2.75]
9.9 Chinese medicine (combination of 10 herbs) plus tamoxifen and Caltrate versus tamoxifen and Caltrate (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	-0.26 [-1.64, 1.12]
9.10 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	90	Mean Difference (IV, Fixed, 95% CI)	0.08 [-0.54, 0.70]
9.11 Bushenyiqihuoxue soup plus tamoxifen and Caltrate versus tamoxifen and Caltrate (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	3.54 [1.68, 5.40]
9.12 Huangqi plus Caltrate versus Caltrate (6 months)	1	36	Mean Difference (IV, Fixed, 95% CI)	0.82 [0.63, 1.01]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
9.13 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate (48 weeks)	1	112	Mean Difference (IV, Fixed, 95% CI)	10.48 [9.81, 11.15]
9.14 Kanggusong soup plus Caltrate versus Caltrate (3 months)	1	75	Mean Difference (IV, Fixed, 95% CI)	-1.61 [-3.17, -0.05]
9.15 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	0.31 [-0.48, 1.10]
<b>10 Bone Gla protein (BGP)</b>	<b>8</b>		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
10.1 Zhuanggu capsule plus Caltrate versus Caltrate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-2.3 [-4.07, -0.53]
10.2 Traditional Chinese capsule plus calcium gluconate versus calcium gluconate (9 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	1.23 [0.88, 1.58]
10.3 Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Mean Difference (IV, Fixed, 95% CI)	0.56 [-0.30, 1.42]
10.4 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Fixed, 95% CI)	2.60 [1.66, 3.54]
10.5 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate (48 weeks)	1	112	Mean Difference (IV, Fixed, 95% CI)	6.24 [5.69, 6.79]
10.6 Xianlinggubao capsule plus Caltrate versus Caltrate (12 months)	1	68	Mean Difference (IV, Fixed, 95% CI)	1.85 [0.87, 2.83]
10.7 Jinwugutong capsules plus calcium versus placebo plus calcium (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	2.47 [1.44, 3.50]
10.8 Huangqi plus Caltrate versus Caltrate (6 months)	1	36	Mean Difference (IV, Fixed, 95% CI)	0.63 [0.50, 0.76]
<b>11 Interleukin-6 (IL-6)</b>	<b>3</b>		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
11.1 Erxian Yanggu decoction plus alendronate sodium tablets versus alendronate sodium tablets (6 months)	1	67	Mean Difference (IV, Fixed, 95% CI)	-16.18 [-19.62, -12.74]
11.2 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate (48 weeks)	1	112	Mean Difference (IV, Fixed, 95% CI)	-133.3 [-139.94, -126.66]
11.3 Kanggusong soup plus Caltrate versus Caltrate (3 months)	1	75	Mean Difference (IV, Fixed, 95% CI)	-16.32 [-31.60, -1.04]


**Analysis 4.1. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 1 New fractures.**




**Analysis 4.2. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 2 Bone mineral density (BMD).**





































**Analysis 4.3. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 3 T score in BMD measurement.**







**Analysis 4.4. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 4 Quality of life.**




**Analysis 4.5. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 5 Symptoms including pain, muscle fatigue and limited mobility.**





**Analysis 4.6. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 6 Oestradiol (E2).**







**Analysis 4.7. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 7 Serum calcium (Ca).**







**Analysis 4.8. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 8 Phosphorus (P).**







**Analysis 4.9. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 9 Alkaline phosphatase (ALP).**









**Analysis 4.10. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 10 Bone Gla protein (BGP).**








**Analysis 4.11. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 11 Interleukin-6 (IL-6).**





## ADDITIONAL TABLES

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials**

Name of herbs	Preparation	English names (Latin names) of the composition	Study ID
Kanggusong granule	Granule	Chinese herbal medicine manufactured by Hebei Handan pharmaceutical factory, which is composed of prepared rhizome of adhesive rehmannia ( <i>Radix rehmanniae preparata</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), <i>Cuscuta</i> seed ( <i>Semen cuscutae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), etc.	An SJ 2000; Wu MS 2001
Bushenhuoxue recipe	Decoction	Herbal mixture composed of deer horn glue ( <i>Colla cornus cervi</i> ), prepared rhizome of adhesive rehmannia ( <i>Radix rehmanniae preparata</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Cuscuta</i> seed ( <i>Semen cuscutae</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ), membranous milk vetch root ( <i>Radix astragali</i> ), <i>Danshen</i> root ( <i>Radix salviae miltiorrhizae</i> ), <i>Rhizoma corydalis</i> ( <i>Rhizoma corydalis</i> ), <i>Fortune's drynaria</i> rhizome ( <i>Rhizoma drynariae</i> ), <i>Liquorice</i> root ( <i>Radix glycyrrhizae</i> ), <i>Frankincense</i> ( <i>olibanum</i> ), <i>Myrrh</i> ( <i>Commiphora molmol</i> ), <i>Dragon's bones</i> ( <i>Os Draconis</i> ) and oyster shell ( <i>Concha ostreae</i> )	Cao GY 2010
Chinese medicine (combinations of 10 herbs)	Decoction	Herbal mixture composed of <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Fortune's drynaria</i> rhizome ( <i>Rhizoma drynariae</i> ), <i>Glossy privet</i> fruit ( <i>Fructus ligustri lucidi</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>liquorice</i> root ( <i>Radix glycyrrhizae</i> ), <i>Szechuan lovage</i> rhizome ( <i>Rhizoma chuanxiong</i> ), <i>Chinese angelica</i> ( <i>Radix angelicae sinensis</i> ), <i>Himalayan teasel</i> root ( <i>Radix dipsaci</i> ), <i>Ground beetle</i> ( <i>Eupolyphaga seu steleophaga</i> ) and <i>liquorice</i> root ( <i>Radix glycyrrhizae</i> )	Cao W 2010
Gushen decoction	Decoction	Herbal mixture composed of 6 herbs: <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>King Solomon's seal</i> rhizome ( <i>Rhizoma polygonati</i> ), <i>Barbary wolfberry</i> fruit ( <i>Fructus lycii</i> ), <i>human placenta</i> ( <i>Placenta hominis</i> ), <i>Rehmanniae radix preparata</i> and <i>clematis</i> root ( <i>Radix clematidis</i> )	Chen FS 2001
Gukang oral liquid	Oral liquid	Herbal mixture manufactured by affiliated orthopedics hospital of Guangzhou University of Traditional Chinese Medicine. It is a combined medicine composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>desert-living cistanche</i> ( <i>Herba cistanches</i> ), <i>liquorice</i> root ( <i>Radix glycyrrhizae</i> ), <i>Danshen</i> root ( <i>Radix salviae miltiorrhizae</i> ), etc.	Chen JP 1999; Shao M 2003; Wang JM 2008
Shenyao capsules	Capsule	Chinese patent herbal medicine composed of <i>Red leaves to kidney</i> ( <i>Trachelospermum jasminoides</i> Lem. Var. <i>heterophyllum</i> Tsiang), <i>White leaves to kidney</i> ( <i>euonymus fortunei</i> Hand. Mazz), <i>Cotton kidney</i> ( <i>Urena procumbens</i> L), <i>Litchi kidney</i> ( <i>Agri-monia pilosa</i> Ledeb Var <i>japonica</i> Nakai), <i>Dragon buds kidney</i>	Chen NQ 2006

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

 (Salvia substolonifera Stib), Fagopyrum esculentum kidney  
(Fagopyrum cymosum Meisn), etc.

Gukang dection	Decoction	Herbal mixture composed of Epimedium (Herba epimedii), Psoralea corylifolia (Fructus psoraleae), Rehmanniae radix preparata, Danshen root (Radix salviae miltiorrhizae), desert-living cistanche (Herba cistanches), liquorice root (Radix glycyrrhizae), Chinese angelica (Radix angelicae sinensis), white peony root (Radix paeoniae alba), Cuscuta seed (Semen cuscutae), Chinese date (Fructus jujubae), etc.	Chen X 2008
Heche Dazao pill	Decoction	Herbal mixture composed of human placenta (Placenta hominis), Rehmanniae radix preparata, Radix asparagi, Radix ophiopogonis (Radix ophiopogonis), Eucommia bark (Cortex eucommiae), two-tooth achyranthes root (Radix achyranthis bidentatae), Amur cork tree bark (Cortex phellodendri), tortoise shell (Carapax et plastrum testudinis), liquorice root (Radix glycyrrhizae), Psoralea corylifolia (Fructus psoraleae), Dioscorea batatas (Rhizoma dioscoreae) and Wolfiporia cocos (Poria)	Chen XL 2010
Jiarong tablet	Tablet	Chinese patent herbal medicine manufactured by Xi'an Boai Medicine limited company	Chen YQ 2001
Gushukang granule	Granule	Chinese patent herbal medicine composed of Epimedium (Herba epimedii), Rehmanniae radix preparata, liquorice root (Radix glycyrrhizae), Danshen root (Radix salviae miltiorrhizae), Fortune's drynaria rhizome (Rhizoma drynariae), etc.	Chen ZX 2002; Wu MS 2007; Zhang YS 2003
Strong Bone capsule	Capsule	Herbal mixture composed of deer horn glue (Colla cornus cervi), desert-living cistanche (Herba cistanches), prepared rhizome of rehmannia (Radix rehmanniae preparata), tortoise shell (Carapax et plastrum testudinis), Eucommia bark (Cortex eucommiae), bitter orange (Fructus aurantii), Suberect spatholobus stem (Caulis spatholobi), etc.	Cui TH 1999
Xianlinggubao capsule	Capsule	Chinese patent herbal medicine composed of Epimedium (Herba epimedii), Himalayan teasel root (Radix dipsaci), Psoralea corylifolia (Fructus psoraleae), etc.	Dai Y 2007; Dong Y 2010; Qiu ZX 2010; Wu W 2005; Xu M 2009; Zhang XZ 2004; Zhu HM 2012
Migu tablet	Tablet	The medicine was developed by Union Hospital of Tongji Medical College and composed of Epimedium (Herba epimedii), Eucommia bark (Cortex eucommiae), Psoralea corylifolia (Fructus psoraleae), etc.	Dai Y 2007; Xie J 2004
Herba epimedii prescription	Decoction	Herbal mixture composed of Epimedium (Herba epimedii), Psoralea corylifolia (Fructus psoraleae), Eucommia bark (Cortex eucommiae), oyster shell (Concha ostreae), common monkshood mother root, processed radix aconiti (Radix aconiti preparata), Kusnezoff monkshood root (Radix aconiti kusnezoffii), Chinese angelica (Radix angelicae sinensis) and Szechuan lovage rhizome (Rhizoma chuanxiong)	Dong YF 2004
Gengnian Anyi tablet	Tablet	Chinese patent herbal medicine manufactured by Hubei traditional Chinese medicine company. The main composition was Rehmanniae radix preparata, Dioscorea batatas (Rhizoma dioscoreae), Eucommia bark (Cortex eucommiae), desert-living cistanche (Herba cistanches), etc.	Fan HX 2004

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

Gumiling granule	Granule	Self developed herbal mixture (no details on composition)	Gang PH 2001
Shengu capsule	Capsule	Chinese patent medicine manufactured by Beijing Tianjiu Medicine limited company. The main composition was oyster shell ( <i>Concha ostreae</i> )	Gong L 2001
Yishen Zhuanggu mixture	Decoction	Chinese patented medicine manufactured by Beijing Xuanwu hospital. It is a combined medicine composed of <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Radix codonopsis pilosulae</i> ( <i>Radix codonopsis</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), <i>Rehmanniae radix preparata</i> , liquorice root ( <i>Radix glycyrrhizae</i> ), etc.	Gong L 2001
Bushen Kangsong pill	Pill	Chinese patent medicine manufactured by the People's Liberation Army General Hospital of Nanjing Military Region. It is composed of <i>Rehmanniae radix preparata</i> , Chinese taxillus twig ( <i>Herba taxilli</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), common macrocarpium fruit ( <i>Fructus corni</i> ), Barbary wolfberry fruit ( <i>Fructus lycii</i> ), hairy antler ( <i>Cornu Cervi Pantotrichum</i> ), Himalayan teasel root ( <i>Radix dipsaci</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Eucommia bark</i> ( <i>Cortex eucommiae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), desert-living cistanche ( <i>Herba cistanches</i> ), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), <i>Cuscuta seed</i> ( <i>Semen cuscutae</i> ), cassia bark ( <i>Cortex cinnamomi</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), Dragon's bones ( <i>Os Draconis</i> ), oyster shell ( <i>Concha ostreae</i> ), hawthorn fruit ( <i>Fructus crataegi</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), etc.	Guo JH 2008
Shugan zishen huoxue tang	Decoction	Herbal mixture composed of Chinese thorowax root ( <i>Radix bupleuri</i> ), white peony root ( <i>Radix paeoniae alba</i> ), Nutgrass galin-gale rhizome ( <i>Rhizoma cyperi</i> ), bitter orange ( <i>Fructus aurantii</i> ), <i>Pinellia tuber</i> ( <i>Rhizoma pinelliae</i> ), <i>Wolfiporia cocos</i> ( <i>Poria</i> ), prepared rhizome of adhesive rehmannia ( <i>Radix rehmanniae preparata</i> ), common macrocarpium fruit ( <i>Fructus corni</i> ), tortoise shell ( <i>Carapax et plastrum testudinis</i> ), East Asian tree fern rhizome ( <i>Rhizoma cibotii</i> ), <i>Fructus chaenomelis</i> ( <i>Chaenomeles speciosa Nakai</i> ), prepared frankincense ( <i>olibanum</i> ), Myrrh prepared ( <i>Commiphora molmol</i> ) and Szechuan lovage rhizome ( <i>Rhizoma chuanxiong</i> )	Han XL 2007
Bushen Jianpi Huoxue recipe	Decoction	Herbal mixture composed of <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), desert-living cistanche ( <i>Herba cistanches</i> ), <i>Rehmanniae radix preparata</i> , white peony root ( <i>Radix paeoniae alba</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), <i>Cuscuta seed</i> ( <i>Semen cuscutae</i> ), Danshen root ( <i>Radix salviae miltiorrhizae</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ) and Chinese date ( <i>Fructus jujubae</i> )	He MT 2007
Jiawei Zhuangyao Jianshen tang	Decoction	Herbal mixture composed of East Asian tree fern rhizome ( <i>Rhizoma cibotii</i> ), Cherokee rose fruit ( <i>Fructus rosae laevigatae</i> ), Chinese taxillus twig ( <i>Herba taxilli</i> ), suberect spatholobus stem ( <i>Caulis spatholobi</i> ), Philippine flemingia root ( <i>Moghania philippinensis li.</i> ), beautiful millettia root ( <i>Millettia speciosa champ</i> ), <i>Cuscuta seed</i> ( <i>Semen cuscutae</i> ), glossy privet fruit ( <i>Fructus ligustri lucidi</i> ), <i>Rhizoma corydalis</i> ( <i>Rhizoma corydalis</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), red peony root ( <i>Radix paeoniae rubra</i> ) and largehead <i>atractylodes rhizome</i> ( <i>Rhizoma atractylodis macrocephalae</i> )	He N 2006

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

Bushen Yangxue tang	Decoction	Herbal mixture composed of medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> ), Epimedium ( <i>Herba epimedii</i> ), Cherokee rose fruit ( <i>Fructus rosae laevigatae</i> ), Barbary wolfberry fruit ( <i>Fructus lycii</i> ), Chinese date ( <i>Fructus jujubae</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), white peony root ( <i>Radix paeoniae alba</i> ) and tuber fleece flower root ( <i>Radix polygoni multiflori</i> ), etc.	He XQ 2006; Zhan ML 2007
Shangke Yishen Zhuanggu pill	Pill	Herbal mixture composed of <i>Rehmanniae radix preparata</i> , Chinese angelica ( <i>Radix angelicae sinensis</i> ), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), Sanqi ( <i>Radix notoginseng</i> ), Wolfiporia cocos ( <i>Poria</i> ), Danshen root ( <i>Radix salviae miltiorrhizae</i> ), common macrocarpium fruit ( <i>Fructus corni</i> ), Szechuan lovage rhizome ( <i>Rhizoma chuanxiong</i> ), membranous milk vetch root ( <i>Radix astragali</i> ), etc.	Hu J 2012
Erxian Yanggu tang	Decoction	Herbal mixture composed of medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> ), common curculigo rhizome ( <i>Rhizoma curculiginis</i> ), Epimedium ( <i>Herba epimedii</i> ), Barbary wolfberry fruit ( <i>Fructus lycii</i> ), Eucommia bark ( <i>Cortex eucommiae</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), Amur cork tree bark ( <i>Cortex phellodendri</i> ), common anemarrhena rhizome ( <i>Rhizoma anemarrhenae</i> ), deer horn glue ( <i>Colla cornus cervi</i> ), tortoise shell glue ( <i>Colla carapacis et plastris testudinis</i> ), paniculate swallow wort root ( <i>Radix Cynanchi Paniculati</i> ), white peony root ( <i>Radix paeoniae alba</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), <i>Radix astragali preparata</i> and bitter orange ( <i>Fructus aurantii</i> )	Huang JW 2008
Zishen Gukang pill	Pill	Chinese patent medicine manufactured by the Traditional Chinese Medicine Hospital of Henan province pharmacy. It is composed of Epimedium ( <i>Herba epimedii</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), prepared rhizome of adhesive rehmannia ( <i>Radix rehmanniae preparata</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), common macrocarpium fruit ( <i>Fructus corni</i> ), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), etc.	Huang ZJ 2008
Shengsuiyin	Decoction	Herbal mixture composed of medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> ), Chinese taxillus twig ( <i>Herba taxilli</i> ), Cuscuta seed ( <i>Semen cuscutae</i> ), tortoise shell glue ( <i>Colla carapacis et plastris testudinis</i> ), Epimedium ( <i>Herba epimedii</i> ), common macrocarpium fruit ( <i>Fructus corni</i> ), <i>Radix codonopsis pilosulae</i> ( <i>Radix codonopsis</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), Wolfiporia cocos ( <i>Poria</i> ) and glossy privet fruit ( <i>Fructus ligustri lucidi</i> )	Jian QQ 2010
Guli powder	Powder	Chinese patent medicine manufactured by drug manufactory of the research institute of traditional Chinese medicine of Sichuan province. It is composed of <i>Radix codonopsis pilosulae</i> ( <i>Radix codonopsis</i> ), large head atractylodes rhizome ( <i>Rhizoma atractylodis macrocephalae</i> ), Wolfiporia cocos ( <i>Poria</i> ), <i>Radix angelicae</i> ( <i>Radix angelicae dahuricae</i> ), Epimedium ( <i>Herba epimedii</i> ), common cnidium fruit ( <i>Fructus cnidii</i> ), <i>Psoralea</i> fruits ( <i>Fructus psoraleae</i> ), <i>Rehmanniae radix preparata</i> , two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), etc.	Lan ZX 2006
Jianshenfang granule	Granule	Chinese patent medicine manufactured by Guangzhou Yuexiu District Orthopedic Hospital. It is composed of Himalayan teasel root ( <i>Radix dipsaci</i> ), clematis root ( <i>Radix clematidis</i> ),	Li BL 2007

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

		Cherokee rose fruit ( <i>Fructus rosae laevigatae</i> ), East Asian tree fern rhizome ( <i>Rhizoma cibotii</i> ), Philippine flemingia root ( <i>Moghania philippinensis</i> li.), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), etc.	
Ziyin Bushen Zhuanggu prescription	Decoction	Investigator-prescribed herbal mixture composed of <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ), <i>Rehmanniae radix preparata</i> , deer horn glue ( <i>Colla cornus cervi</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), <i>Rhizoma corydalis</i> ( <i>Rhizoma corydalis</i> ), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), Danshen root ( <i>Radix salviae miltiorrhizae</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Wolfiporia cocos</i> ( <i>Poria</i> ), etc.	Li HW 2004
Zhuanggu capsule	Capsule	Herbal mixture composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), common cnidium fruit ( <i>Fructus cnidii</i> ), human placenta ( <i>Placenta hominis</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), Sanqi ( <i>Radix notoginseng</i> ), etc.	Li SL 2004
Jingujian granule	Granule	Chinese patent medicine manufactured by Xiyuan Hospital of Chinese Academy of Traditional Chinese Medicine pharmacy. It is composed of Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ), Szechuan lovage rhizome ( <i>Rhizoma chuanxiong</i> ), large head <i>atractylodes</i> rhizome ( <i>Rhizoma atractylodis macrocephalae</i> ), Manchurian wild ginger ( <i>Herba asari</i> ), etc.	Li YH 2008
Jingujian granule (1,2,3)	Granule	Jingujian granule 1: <i>Rehmanniae radix preparata</i> , common macrocarpium fruit ( <i>Fructus corni</i> ), <i>Cuscuta</i> seed ( <i>Semen cuscutae</i> ), tortoise shell ( <i>Carapax et plastrum testudinis</i> ), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ), etc. Jingujian granule 2: <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), <i>Radix codonopsis pilosulae</i> ( <i>Radix codonopsis</i> ), large-head <i>atractylodes</i> rhizome ( <i>Rhizoma atractylodis macrocephalae</i> ), etc. Jingujian granule 3: <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), medicinal cyathula root ( <i>Radix cyathulae</i> ), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), Manchurian wild ginger ( <i>Herba asari</i> ), large-head <i>atractylodes</i> rhizome ( <i>Rhizoma atractylodis macrocephalae</i> ), Szechuan lovage rhizome ( <i>Rhizoma chuanxiong</i> )	Li YH 2010
Kanggusong soup	Decoction	Herbal mixture composed of <i>Rehmanniae radix preparata</i> 18 g, Barbary wolfberry fruit ( <i>Fructus lycii</i> ) 9 g, <i>Epimedium</i> ( <i>Herba epimedii</i> ) 18 g, Himalayan teasel root ( <i>Radix dipsaci</i> ) 9 g, membranous milk vetch root ( <i>Radix astragali</i> ) 9 g, <i>Wolfiporia cocos</i> ( <i>Poria</i> ) 9 g, Danshen root ( <i>Radix salviae miltiorrhizae</i> ) 18 g, <i>Radix puerariae</i> ( <i>Radix puerariae</i> ) 9 g, suberect <i>spatholobus</i> stem ( <i>Caulis spatholobi</i> ) 18 g, etc.	Li ZP 2011
Xianling Gusong capsule	Capsule	The capsule included <i>Epimedium</i> ( <i>Herba epimedii</i> ), common curculigo rhizome ( <i>Rhizoma curculiginis</i> ), medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> ), ginseng ( <i>Radix ginseng</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), human placenta ( <i>Placenta hominis</i> ) and common <i>anemarrhena</i> rhizome ( <i>Rhizoma anemarrhenae</i> ).	Li ZY 2006

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

Bushenhuoxue therapy	Decoction	Herbal mixture composed of Rehmanniae radix preparata 24 g, Epimedium (Herba epimedii) 18 g, membranous milk vetch root (Radix astragali) 15 g, common macrocarpium fruit (Fructus corni) 12 g, Dioscorea batatas (Rhizoma dioscoreae) 12 g, Eucommia bark (Cortex eucommiae) 12g, Danshen root (Radix salviae miltiorrhizae) 12 g, tree peony bark (Cortex moutan) 9 g, Wolfiporia cocos (Poria) 9 g, oriental water plantain rhizome (Rhizoma alismatis) 9 g, safflower (Flos carthami) 9 g, Sanqi (Radix notoginseng) 3 g	Liang DB 2012
Bushen Shengsui principle	Decoction	Investigator-prescribed herbal mixture composed of Psoralea corylifolia (Fructus psoraleae), Epimedium (Herba epimedii), Eucommia bark (Cortex eucommiae) and glossy privet fruit (Fructus ligustri lucidi)	Liao L 2004
Migu decoction	Decoction	Self developed herbal mixture (no details on composition)	Lin W 2000
Bushen Zhuanggu tang	Decoction	Herbal mixture composed of East Asian tree fern rhizome (Rhizoma cibotii), Himalayan teasel root (Radix dipsaci), medicinal Indian mulberry root (Radix morindae officinalis), Epimedium (Herba epimedii), Psoralea corylifolia (Fructus psoraleae), liquorice root (Radix glycyrrhizae), white peony root (Radix paeoniae alba), Chinese angelica (Radix angelicae sinensis), Szechuan lovage rhizome (Rhizoma chuanxiong), safflower (Flos carthami) and two-tooth achyranthes root (Radix achyranthis bidentatae)	Ling JY 2008
Gukang tablet	Tablet	Chinese patent medicine manufactured by Laiyang biological chemical pharmaceutical factory. It is composed of Rehmanniae radix preparata, Epimedium (Herba epimedii), suberect spatholobus stem (Caulis spatholobi), Chinese Pyrola Herb (Herba Pyrolae), Eucommia bark (Cortex eucommiae), medicinal Indian mulberry root (Radix morindae officinalis), common curculigo rhizome (Rhizoma curculiginis), desert-living cistanche (Herba cistanches), two-tooth achyranthes root (Radix achyranthis bidentatae), Chinese angelica (Radix angelicae sinensis), safflower (Flos carthami), etc.	Liu JM 2012
Jiawei Bushen Zhuangjintang	Decoction	Investigator-prescribed herbal formulation composed of Rehmanniae radix preparata, Chinese angelica (Radix angelicae sinensis), two-tooth achyranthes root (Radix achyranthis bidentatae), Asiatic cornelian cherry fruit (Fructus corni), Wolfiporia cocos (Poria), Himalayan teasel root (Radix dipsaci), Eucommia bark (Cortex eucommiae), white peony root (Radix paeoniae alba), green tangerine peel (Pericarpium citri reticulatae viride), Slenderstyle acanthopanax bark (Cortex acanthopanax), hairy antler (Corn Cervi Pantotrichum), etc.	Lv ZH 2002
Yiyuanjiangu decoction	Decoction	Herbal mixture composed of Rehmanniae radix preparata 15 g, Psoralea corylifolia (Fructus psoraleae) 15 g, Epimedium (Herba epimedii) 10 g, Radix angelicae pubescentis 10 g, Barbary wolfberry fruit (Fructus lycii) 10 g, East Asian tree fern rhizome (Rhizoma cibotii) 10 g, Chinese angelica (Radix angelicae sinensis) 10 g, membranous milk vetch root (Radix astragali) 20 g, two-tooth achyranthes root (Radix achyranthis bidentatae) 20 g, Chinese taxillus twig (Herba taxilli) 20 g, Himalayan teasel root (Radix dipsaci) 12 g, etc.	Ma CZ 2011

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

Yishen Zhuanggu decoction	Decoction	Herbal mixture composed of Rehmanniae radix preparata 24 g, Fortune's drynaria rhizome (Rhizoma drynariae) 20g, Himalayan teasel root (Radix dipsaci) 20 g, Epimedium (Herba epimedii) 30 g, Chinese angelica (Radix angelicae sinensis) 15 g, white peony root (Radix paeoniae alba) 10 g, Eucommia bark (Cortex eucommiae) 20 g, Chinese taxillus twig (Herba taxilli) 30g, membranous milk vetch root (Radix astragali) 30g, Dioscorea batatas (Rhizoma dioscoreae) 2 0g, tuber fleece flower root (Radix polygoni multiflori) 20 g and Cuscuta seed (Semen cuscutae) 15 g	Ma YJ 2011
Bushen Jianpi Jingu decoction	Decoction	Herbal mixture composed of Rehmanniae radix preparata 20 g, Dioscorea batatas (Rhizoma dioscoreae) 15 g, common macrocarpium fruit (Fructus corni) 12 g, Barbary wolfberry fruit (Fructus lycii) 12 g, Eucommia bark (Cortex eucommiae) 15 g, Psoralea corylifolia (Fructus psoraleae) 15 g, Fortune's drynaria rhizome (Rhizoma drynariae) 15 g, Radix codonopsis pilosulae (Radix codonopsis) 20 g, membranous milk vetch root (Radix astragali) 20 g, large-head atractylodes rhizome (Rhizoma atractylodis macrocephalae) 10 g, Wolfiporia cocos (Poria) 10 g and liquorice root (Radix glycyrrhizae) 10 g	Mao YF 2011
Gujian capsule	Capsule	Developed by Xiyuan hospital of China academy of TCM (no details on composition)	Meng XD 2003
Traditional Chinese capsule	Capsule	The capsule included Epimedium (Herba epimedii), Fortune's drynaria rhizome (Rhizoma drynariae), liquorice root (Radix glycyrrhizae), King Solomon's seal rhizome (Rhizoma polygonati), Radix puerariae (Radix puerariae), Rhizoma corydalis (Rhizoma corydalis), etc.	Miu JQ 2008
Bushen Qiangshen pill	Pill	Chinese patented medicine composed of ginseng (Radix ginseng), hairy antler (Cornu cervi pantotrichum), desert-living cistanche (Herba cistanches), liquorice root (Radix glycyrrhizae), Barbary wolfberry fruit (Fructus lycii), etc.	Mu G 2001; Mu G 2001a
Radix rehmanniae preparata and Radix astragali	Decoction	Herbal mixture composed of Rehmanniae radix preparata 30 g, membranous milk vetch root (Radix astragali) 30 g, etc.	Ou L 2011
Qianggu soft extract	Slurry	Herbal mixture composed of medicinal Indian mulberry root (Radix morindae officinalis), Cuscuta seed (Semen cuscutae), liquorice root (Radix glycyrrhizae), Chinese angelica (Radix angelicae sinensis), etc.	Peng T 2002
Bushen Qianggutang	Decoction	Investigator-prescribed formula composed of Himalayan teasel root (Radix dipsaci), Cuscuta seed (Semen cuscutae), Psoralea corylifolia (Fructus psoraleae), Fortune's drynaria rhizome (Rhizoma drynariae), common macrocarpium fruit (Fructus corni), Barbary wolfberry fruit (Fructus lycii), glossy privet fruit (Fructus ligustri lucidi), Dioscorea batatas (Rhizoma dioscoreae), Wolfiporia cocos (Poria), etc.	Qi ZX 1998
Yanghuo Sanzi tang	Decoction	Herbal mixture composed of Epimedium (Herba epimedii), Fructus Schisandrae (Fructus schisandrae chinensis), common macrocarpium fruit (Fructus corni), Psoralea corylifolia (Fructus psoraleae), mulberry fruit (Fructus mori), Barbary wolfberry fruit (Fructus lycii), oyster shell (Concha ostreae), prepared	Qiu RB 2004



**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

		fleece flower root ( <i>Radix polygoni multiflori preparata</i> ) and red ginseng ( <i>Radix ginseng rubra</i> )	
Jiangu recipe	Decoction	Herbal mixture composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> ), common cnidium fruit ( <i>Fructus cnidii</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), deer horn glue ( <i>Colla cornus cervi</i> ), hawthorn fruit ( <i>Fructus crataegi</i> ), common macrocarpium fruit ( <i>Fructus corni</i> ) and <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> )	Qiu RB 2008
Qianggu capsule	Capsule	Chinese patent medicine manufactured by Beijing Qihuang Pharmaceutical Limited Company; the main composition was Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> )	Ruan XY 2006; Wang J 2007; Xu H 2010
Kangshu Jiangu granule	Granule	Chinese patent medicine manufactured by Shanxi college of traditional Chinese medicine pharmaceutical factory. It is composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ) 20 g, <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ) 15 g, two-tooth <i>Achyranthes</i> root ( <i>Radix achyranthis bidentatae</i> ) 15 g, Danshen root ( <i>Radix salviae miltiorrhizae</i> ) 15 g, large-head <i>Atractylodes</i> rhizome ( <i>Rhizoma atractylodis macrocephalae</i> ) 12 g, etc.	Shi CD 2012
Kidney-tonifying herbs	Granule	Herbal mixture composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), desert-living <i>Cistanche</i> ( <i>Herba cistanches</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), tuber fleece flower root ( <i>Radix polygoni multiflori</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), safflower ( <i>Flos carthami</i> ), common <i>Aucklandia</i> root ( <i>Radix aucklandiae</i> ), etc.	Song XW 2000
Bushen Qianggu Huoxue therapy	Decoction	Herbal mixture composed of <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ) 15 g, Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ) 10 g, <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ) 15 g, <i>Epimedium</i> ( <i>Herba epimedii</i> ) 10 g, Barbary wolfberry fruit ( <i>Fructus lycii</i> ) 15 g, <i>Rehmannia</i> radix <i>preparata</i> 15 g, desert-living <i>Cistanche</i> ( <i>Herba cistanches</i> ) 10 g, deer horn glue ( <i>Colla cornus cervi</i> ) 10 g, medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> ) 10 g, <i>Cuscuta</i> seed ( <i>Semen cuscutae</i> ) 15 g, East Asian tree fern rhizome ( <i>Rhizoma cibotii</i> ) 10 g, Himalayan teasel root ( <i>Radix dipsaci</i> ) 10 g, Sanqi ( <i>Radix notoginseng</i> ) 10 g, Danshen root ( <i>Radix salviae miltiorrhizae</i> ) 10 g, suberect <i>Spatholobus</i> stem ( <i>Caulis spatholobi</i> ) 15 g, etc.	Tang ZA 2012
Gumikang capsule	Capsule	Herbal mixture composed of human placenta ( <i>Placenta hominis</i> ), hairy antler ( <i>Cornu cervi pantotrichum</i> ), etc.	Wang CC 2005
Qianggu paste	Paste	Chinese patent medicine manufactured by Affiliated Hospital of Wuhan University of Technology pharmacy, composed of flat stem milk vetch seed ( <i>Semen astragali complanati</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), etc.	Wang H 2007
Antai capsule	Capsule	Chinese herbal medicine manufactured by the medicine research institute of Fourth Military Medical University.	Wang SW 2003
Hugu capsule	Capsule	Chinese patent medicine manufactured by Dongguan Super Success Pharmaceutical Co., Ltd. It is composed of tuber fleece	Wang XD 2011

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

		flower root ( <i>Radix polygoni multiflori</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Rehmanniae radix preparata</i> , etc.	
Bushen Yigu soft extract	Oral liquid	Herbal mixture composed of prepared rhizome of adhesive rehmannia ( <i>Radix rehmanniae preparata</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), large-head atractylodes rhizome ( <i>Rhizoma atractylodis macrocephalae</i> ), oriental water plantain rhizome ( <i>Rhizoma alismatis</i> ), etc.	Wang XY 2000
Jiangu capsule	Capsule	Chinese patent medicine manufactured by Affiliated Hospital of Luohe Medical College pharmacy, composed of liquorice root ( <i>Radix glycyrrhizae</i> ), Danshen root ( <i>Radix salviae miltiorrhizae</i> ), Szechuan lovage rhizome ( <i>Rhizoma chuanxiong</i> ), <i>Cuscuta</i> seed ( <i>Semen cuscutae</i> ), Asiatic cornelian cherry fruit ( <i>Fructus corni</i> ), Dragon's bones ( <i>Os Draconis</i> ), oyster shell ( <i>Concha ostreae</i> ) and medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> )	Wang YZ 2008
Bushen Jianpi Migu prescription	Decoction	Investigator-prescribed herbal formulation composed of liquorice root ( <i>Radix glycyrrhizae</i> ), <i>Cuscuta</i> seed ( <i>Semen cuscutae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), Asiatic cornelian cherry fruit ( <i>Fructus corni</i> ), Dragon's bones ( <i>Os Draconis</i> ), oyster shell ( <i>Concha ostreae</i> ), deer horn glue ( <i>Colla cornus cervi</i> ), <i>Rehmanniae radix preparata</i> , desert-living cistanche ( <i>Herba cistanches</i> ), <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ), suberect spatholobus stem ( <i>Caulis spatholobi</i> ), medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> ), Szechuan lovage rhizome ( <i>Rhizoma chuanxiong</i> ), liquorice root ( <i>Radix glycyrrhizae</i> )	Wang ZK 2004
Kanggusong capsule (self developed)	Capsule	Manufactured by the First Attached Hospital of Hebei Northern Institute, composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), Himalayan teasel root ( <i>Radix dipsaci</i> ), <i>Rehmanniae radix preparata</i> , Barbary wolfberry fruit ( <i>Fructus lycii</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), <i>Wolfiporia cocos</i> ( <i>Poria</i> ), Danshen root ( <i>Radix salviae miltiorrhizae</i> ), <i>Radix puerariae</i> ( <i>Radix puerariae</i> ) and suberect spatholobus stem ( <i>Caulis spatholobi</i> )	Wei RY 2011
Erxian soup	Liquid	Herbal mixture composed of common curculigo rhizome ( <i>Rhizoma curculiginis</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), common anemarrhena rhizome ( <i>Rhizoma anemarrhenae</i> ), Amur cork tree bark ( <i>Cortex phellodendri</i> )	Wu JZ 2010
Urinary bladder meridian sticking	Patch	Herbal mixture composed of <i>Rehmannia</i> root ( <i>Radix rehmanniae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), Danshen root ( <i>Radix salviae miltiorrhizae</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), <i>Radix angelicae pubescentis</i> , etc.	Wu MS 2007
Kidney meridian sticking	Patch	Herbal mixture composed of <i>Rehmannia</i> root ( <i>Radix rehmanniae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), Danshen root ( <i>Radix salviae miltiorrhizae</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), <i>Radix angelicae pubescentis</i> , etc.	Wu MS 2007
Prescription for tonifying kidney	Pill	Herbal mixture composed of <i>Rehmannia</i> root ( <i>Radix rehmanniae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), Danshen root ( <i>Radix salviae miltiorrhizae</i> ), For-	Wu MS 2007

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

		tune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), <i>Radix angelicae pubescentis</i> , etc.	
Gusong fang	Decoction	Herbal mixture composed of nutmeg, Chinese angelica ( <i>Radix angelicae sinensis</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), desert-living cistanche ( <i>Herba cistanches</i> ), etc.	Xiao W 2008
Bugu Shengsui capsule	Capsule	Herbal mixture composed of <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), East Asian tree fern rhizome ( <i>Rhizoma cibotii</i> ), Sanqi ( <i>Radix notoginseng</i> ), ginseng ( <i>Radix ginseng</i> ), etc.	Xie YM 1997
Jiangu granule	Granule	Chinese patent medicine manufactured by Ruijin hospital pharmacy, composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Radix codonopsis pilosulae</i> ( <i>Radix codonopsis</i> ), large-head <i>atractylodes</i> rhizome ( <i>Rhizoma atractylodis macrocephalae</i> ), glossy privet fruit ( <i>Fructus ligustri lucidi</i> ), etc.	Xiong YH 2008
Gusongbao granule	Granule	Chinese patent medicine composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Rehmanniae radix preparata</i> , oyster shell ( <i>Concha ostreae</i> ), etc.	Xiong YH 2008; Zhan HS 2009
Yishen Yanggan mixture	Oral liquid	Herbal mixture composed of liquorice root ( <i>Radix glycyrrhizae</i> ), common macrocarpium fruit ( <i>Fructus corni</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), desert-living cistanche ( <i>Herba cistanches</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), etc.	Xu W 2005
Acupoint sticking of Migudan	Patch	Herbal mixture composed of <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), Himalayan teasel root ( <i>Radix dipsaci</i> ), Szechuan lovage rhizome ( <i>Rhizoma chuanxiong</i> ), processed <i>radix aconiti</i> ( <i>Radix aconiti preparata</i> ), tuberculate <i>Speranskia</i> herb ( <i>Garden balsam stem</i> ), two-tooth <i>achyranthes</i> root ( <i>Radix achyranthis bidentatae</i> ), Manchurian wild ginger ( <i>Herba asari</i> ), etc.	Xu YL 2007
Huangqi	Decoction	Single herb of liquorice root ( <i>Radix glycyrrhizae</i> )	Yang B 2007
Bushen Zhuanggutang	Decoction	Investigator-prescribed formula composed of <i>Eucommia</i> bark ( <i>Cortex eucommiae</i> ), <i>Rehmanniae radix preparata</i> , Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), Barbary wolfberry fruit ( <i>Fructus lycii</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Radix codonopsis pilosulae</i> ( <i>Radix codonopsis</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), common macrocarpium fruit ( <i>Fructus corni</i> ) and Sanqi ( <i>Radix notoginseng</i> )	Ye AN 1998
Shangke Jiegu tablet	Tablet	Chinese patent herbal medicine composed of Sanqi ( <i>Radix notoginseng</i> ), safflower ( <i>Flos carthami</i> ), frankincense ( <i>olibanum</i> ), myrrh ( <i>Commiphora molmol</i> ), ground beetle ( <i>Eupolyphaga seu steleophaga</i> ), etc.	Yuan YN 2000
Xuduanzhuanggu capsule	Capsule	Chinese patent medicine manufactured by Zhejiang Di'er medicine limited company	Zhan HS 2009
Bushenyiqihuoxue soup	Decoction	Herbal mixture composed of <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), glossy privet fruit ( <i>Fructus ligustri lucidi</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), white peony root ( <i>Radix paeoniae alba</i> ), Chinese angelica ( <i>Radix angelicae</i> )	Zhang DS 2011

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

		sinensis), Himalayan teasel root ( <i>Radix dipsaci</i> ), ground beetle ( <i>Eupolyphaga seu steleophaga</i> ) and liquorice root ( <i>Radix glycyrrhizae</i> )	
Liawei Dihuang pill	Pill	Chinese patent medicine	Ma C 2011; Zhang J 2003
Yigu capsule	Capsule	Herbal mixture composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Barbary wolfberry fruit</i> ( <i>Fructus lycii</i> ), <i>Chinese angelica</i> ( <i>Radix angelicae sinensis</i> ), <i>two-tooth achyranthes root</i> ( <i>Radix achyranthis bidentatae</i> ), etc.	Zhang RH 2004
Bushenjianpi Zhuangguyin	Decoction	Herbal mixture composed of human placenta ( <i>Placenta hominis</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), <i>red peony root</i> ( <i>Radix paeoniae rubra</i> ), <i>white peony root</i> ( <i>Radix paeoniae alba</i> ), <i>Chinese angelica</i> ( <i>Radix angelicae sinensis</i> ), <i>Radix codonopsis pilosulae</i> ( <i>Radix codonopsis</i> ), <i>liquorice root</i> ( <i>Radix glycyrrhizae</i> ), <i>large-head atractylodes rhizome</i> ( <i>Rhizoma atractylodis macrocephalae</i> ), <i>common macrocarpium fruit</i> ( <i>Fructus corni</i> ), <i>common cnidium fruit</i> ( <i>Fructus cnidii</i> ), <i>Chinese thorowax root</i> ( <i>Radix bupleuri</i> ), <i>Eucommia bark</i> ( <i>Cortex eucommiae</i> ), <i>two-tooth achyranthes root</i> ( <i>Radix achyranthis bidentatae</i> ), <i>Amur cork tree bark</i> ( <i>Cortex phellodendri</i> ), <i>tortoise shell</i> ( <i>Carapax et plastrum testudinis</i> ), <i>liquorice root</i> ( <i>Radix glycyrrhizae</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Wolfiporia cocos</i> ( <i>Poria</i> ), <i>scorpion</i> , <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Sanqi</i> ( <i>Radix notoginseng</i> ), <i>leech</i> ( <i>Hirudo</i> ), etc.	Zhang XG 2011
Bushen Huoxue capsule	Capsule	Herbal mixture composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Eucommia bark</i> ( <i>Cortex eucommiae</i> ), <i>Himalayan teasel root</i> ( <i>Radix dipsaci</i> ), <i>deer horn glue</i> ( <i>Colla cornus cervi</i> ), <i>common macrocarpium fruit</i> ( <i>Fructus corni</i> ), <i>liquorice root</i> ( <i>Radix glycyrrhizae</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), <i>Chinese angelica</i> ( <i>Radix angelicae sinensis</i> ), <i>Safflower</i> ( <i>Flos carthami</i> ), etc.	Zhang XJ 2008
TPF capsule	Capsule	Chinese herbal medicine composed of <i>cake uterine</i> , <i>Colla corii asini</i> , <i>Corium stomachium galli</i>	Zhang YL 1996
Shigu yin	Liquid	Chinese patent medicine manufactured by Third Affiliated Hospital of Luohe Medical College pharmacy, composed of <i>Rehmanniae radix preparata</i> , <i>East Asian tree fern rhizome</i> ( <i>Rhizoma cibotii</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>oyster shell</i> ( <i>Concha ostreae</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), etc.	Zhang YP 2007
Huoluo Gukang pill	Pill	Condensed pill composed of <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), <i>Fortune's drynaria rhizome</i> ( <i>Rhizoma drynariae</i> ), <i>liquorice root</i> ( <i>Radix glycyrrhizae</i> ), <i>safflower</i> ( <i>Flos carthami</i> ), <i>Zedoary</i> ( <i>Rhizoma curcuma</i> ), <i>deer horn glue</i> ( <i>Colla cornus cervi</i> ), <i>Lumbricus</i> ( <i>Pheretima</i> ), etc.	Zhang YS 2003
Zhuangguqiangjin tablet	Tablet	Manufactured by Dongwan Hospital of Traditional Chinese Medicine, composed of <i>Slenderstyle acanthopanax bark</i> ( <i>Cortex acanthopanax</i> ), <i>deer horn glue</i> ( <i>Colla cornus cervi</i> ), <i>desert-living cistanche</i> ( <i>Herba cistanche</i> ), <i>Philippine flemingia root</i> ( <i>Moghania philippinensis</i> li.), <i>Eucommia bark</i> ( <i>Cortex eucommiae</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), <i>two-tooth achyranthes root</i> ( <i>Radix achyranthis bidentatae</i> ), <i>Radix codonopsis pilosulae</i> ( <i>Radix codonopsis</i> ), <i>Chinese angelica</i> ( <i>Radix angelicae</i>	Zhang ZF 2011

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

		sinensis), tortoise shell ( <i>Carapax et plastrum testudinis</i> ), tuber fleece flower root ( <i>Radix polygoni multiflori</i> ), Amur cork tree bark ( <i>Cortex phellodendri</i> ), <i>Cortex lycii radialis</i> ( <i>Cortex lycii</i> ), incised notopterygium rhizome ( <i>Rhizoma et radix notopterygii</i> ) and <i>Radix angelicae pubescentis</i>	
Shujinbogu tablet	Tablet	Manufactured by Dongwan Hospital of Traditional Chinese Medicine, composed of tree peony bark ( <i>Cortex moutan</i> ), rhubarb ( <i>Radix et rhizoma rhei</i> ), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), tuberculate <i>Speranskia</i> herb ( <i>Garden balsam stem</i> ), Szechuan lovage rhizome ( <i>Rhizoma chuanxiong</i> ), Chinese angelica ( <i>Radix angelicae sinensis</i> ), Rehmannia root ( <i>Radix rehmanniae</i> ), mulberry twig ( <i>Ramulus mori</i> ), ground beetle ( <i>Eupolyphaga seu steleophaga</i> ), common cnidium fruit ( <i>Fructus cnidii</i> ), common aucklandia root ( <i>Radix aucklandiae</i> ), Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ) and <i>Flos caryophyllata</i> ( <i>Flos caryophylli</i> )	Zhang ZF 2011
Zishen prescription	Decoction	Investigator-prescribed formula composed of <i>Rehmanniae radix preparata</i> , common macrocarpium fruit ( <i>Fructus corni</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), <i>Wolfiporia cocos</i> ( <i>Poria</i> ), Barbary wolfberry fruit ( <i>Fructus lycii</i> ), tortoise shell glue ( <i>Colla carapacis et platri testudinis</i> ), crude Dragon's bones ( <i>Os Draconis</i> ) and crude oyster shell ( <i>Concha ostreae</i> )	Zhao G 2002
Kanggusong capsule	Capsule	Chinese patent medicine manufactured by Shenzhen Sanjiu medicine limited company, composed of hairy antler ( <i>Corn Cervi Pantotrichum</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), desert-living cistanche ( <i>Herba cistanches</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), common cnidium fruit ( <i>Fructus cnidii</i> ), etc.	Zhao HX 2001
Yinyanghuo	Decoction	Single herb of <i>Epimedium</i> ( <i>Herba epimedii</i> )	Zhao LN 2003
Jinwugutong capsule	Capsule	Chinese patent medicine manufactured by Guizhou Shenqi Pharmaceutical limited company, composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), two-tooth achyranthes root ( <i>Radix achyranthis bidentatae</i> ), <i>Cibotium barometz</i> ( <i>Rhizoma cibotii</i> ), <i>Zaocys dhumnade</i> ( <i>Zaocys</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), etc.	Zheng WK 2007
Gushen Yijing tang	Decoction	Herbal mixture composed of Fortune's drynaria rhizome ( <i>Rhizoma drynariae</i> ), <i>Psoralea corylifolia</i> ( <i>Fructus psoraleae</i> ), Barbary wolfberry fruit ( <i>Fructus lycii</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), prepared rhizome of adhesive rehmannia ( <i>Radix rehmanniae preparata</i> ), white peony root ( <i>Radix paeoniae alba</i> ), glossy privet fruit ( <i>Fructus ligustri lucidi</i> ), <i>Dioscorea batatas</i> ( <i>Rhizoma dioscoreae</i> ), <i>Wolfiporia cocos</i> ( <i>Poria</i> ), Chinese date ( <i>Fructus jujubae</i> ), etc.	Zhong RQ 2007
Tongbu Qianggutang	Decoction	Herbal mixture composed of <i>Epimedium</i> ( <i>Herba epimedii</i> ), glossy privet fruit ( <i>Fructus ligustri lucidi</i> ), liquorice root ( <i>Radix glycyrrhizae</i> ), Sanqi ( <i>Radix notoginseng</i> ), wine rhubarb ( <i>Radix et rhizoma rhei</i> ), etc.	Zhou LZ 2001
Guilu Erxiantang	Decoction	Herbal mixture composed of tortoise shell ( <i>Carapax et plastrum testudinis</i> ), hairy antler ( <i>Corn Cervi Pantotrichum</i> ), <i>Epimedium</i> ( <i>Herba epimedii</i> ), clematis root ( <i>Radix clematidis</i> ), prepared rhizome of adhesive rehmannia ( <i>Radix rehmanniae preparata</i> ), desert-living cistanche ( <i>Herba cistanches</i> ), medicinal Indian mulberry root ( <i>Radix morindae officinalis</i> ), liquorice root ( <i>Radix</i>	Zhou XT 2001

**Table 1. The preparation and composition of the Chinese herbal medicines in the included trials** (Continued)

		glycyrrhizae), Radix codonopsis pilosulae (Radix codonopsis), Chinese angelica (Radix angelicae sinensis) and safflower (Flos carthami)	
Huangqi Sanxian tang	Decoction	Herbal mixture composed of common curculigo rhizome (Rhizoma curculiginis), Epimedium (Herba epimedii), liquorice root (Radix glycyrrhizae), Sanqi (Radix notoginseng), etc.	Zhou ZK 2006
Bushen Tianjing Huoxue therapy	Decoction	Herbal mixture composed of Eucommia bark (Cortex eucommiae) 15 g, Himalayan teasel root (Radix dipsaci) 15 g, Chinese taxillus twig (Herba taxilli) 10 g, Epimedium (Herba epimedii) 15 g, Psoralea corylifolia (Fructus psoraleae) 15 g, common macrocarpium fruit (Fructus corni) 10 g, Danshen root (Radix salviae miltiorrhizae) 10g, suberect spatholobus stem (Caulis spatholobi) 30 g, Fortune's drynaria rhizome (Rhizoma drynariae) 30 g, two-tooth achyranthes root (Radix achyranthis bidentatae) 30 g, membranous milk vetch root (Radix astragali) 30 g, large-head atractylodes rhizome (Rhizoma atractylodis macrocephalae) 10 g, Wolfiporia cocos (Poria) 20 g and liquorice root (Radix glycyrrhizae) 5 g	Zhu HJ 2011
Guben Zhuanggu capsule	Capsule	Chinese patent medicine manufactured by Zhejiang Di'er medicine limited company	Zou JJ 2005
Bushen Zhuanggu granules	Granule	Chinese patent medicine manufactured by Yifan Pharmacy Company of Guangdong Province, with the following seven herbal compounds: Epimedium (Herba epimedii), Rehmannia (Rehmannia), Dioscorea batatas (Rhizoma dioscoreae), Cornus officinalis (Fructus corni), Cinnamomum cassia (Cortex cinnamomi), Drynaria fortunei (Rhizoma drynariae) and Morinda officinalis (Radix morindae officinalis)	Deng WM 2012

## APPENDICES

### Appendix 1. MEDLINE search strategy

Database	Time span	Search strategy
MEDLINE	1966 to 2013	1. exp bone diseases, metabolic/ 2. osteoporos#s.tw. 3. bone density/ 4. bone densit\$.tw. 5. bone mineral densit\$.tw. 6. exp bone/ and bones.mp. [mp=title, original title, abstract, name of substance word, subject heading word] 7. bone loss\$.tw. 8. osteomalacia.tw. 9. osteodystrophy.tw. 10. exp bone demineralization, pathologic/ 11. (bone adj demineralization).tw. 12. osteopenia.tw. 13. bone mass.tw. 14. exp densitometry/ 15. densitometry.tw.

(Continued)

16. dexa.tw.
17. exp fractures/
18. fracture\$.tw.
19. or/1-18
20. exp Medicine, Herbal/
21. exp Plants, Medicinal/
22. exp Medicine, Traditional/
23. exp Drugs, Chinese Herbal/
24. herb\$.tw.
25. plant.mp. or plants.tw. [mp=title, original title, abstract, name of substance word, subject heading word]
26. phytomedicine.tw.
27. botanical.tw.
28. weed\$.tw.
29. algae.tw.
30. (fungi or fungus).tw.
31. ((traditional or chinese or herbal) adj medicine).tw.
32. ((oriental or chinese) adj tradition\$.tw.
33. or/20-32
34. 19 and 33

## Appendix 2. EMBASE search strategy

Database	Time span	Search strategy
EMBASE	1998 to 2013	<ol style="list-style-type: none"> <li>1. exp OSTEOPOROSIS/</li> <li>2. exp Metabolic Bone Disease/</li> <li>3. osteoporo\$.tw.</li> <li>4. exp Bone Density/</li> <li>5. (bone adj2 densit\$.tw.</li> <li>6. exp BONE/</li> <li>7. bone loss.tw.</li> <li>8. osteomalacia.tw.</li> <li>9. osteodystrophy.tw.</li> <li>10. exp Bone Demineralization/</li> <li>11. (bone adj deminerali#ation).tw.</li> <li>12. osteopenia.tw.</li> <li>13. bone mass.tw.</li> <li>14. exp bone densitometry/</li> <li>15. densitometry.tw.</li> <li>16. dexa.tw.</li> <li>17. exp Fracture/</li> <li>18. fracture\$.tw.</li> <li>19. or/1-18</li> <li>20. exp Herbal Medicine/</li> <li>21. exp Medicinal Plant/</li> <li>22. exp Traditional Medicine/</li> <li>23. exp Chinese Medicine/</li> <li>24. herb\$.tw.</li> <li>25. (plant or plants).tw.</li> <li>26. phytomedicine.tw.</li> <li>27. botanical.tw.</li> <li>28. weed\$.tw.</li> <li>29. algae.tw.</li> <li>30. (fungi or fungus).tw.</li> <li>31. ((traditional or chinese or herbal) adj medicine).tw.</li> </ol>

(Continued)

32. ((oriental or chinese) adj tradition\$.tw.
33. or/20-32
34. 19 and 33
35. random\$.ti,ab.
36. factorial\$.ti,ab.
37. (crossover\$ or cross over\$ or cross-over\$).ti,ab.
38. placebo\$.ti,ab.
39. (doubl\$ adj blind\$).ti,ab.
40. (singl\$ adj blind\$).ti,ab.
41. assign\$.ti,ab.
42. allocat\$.ti,ab.
43. volunteer\$.ti,ab.
44. crossover procedure.sh.
45. double blind procedure.sh.
46. randomized controlled trial.sh.
47. single blind procedure.sh.
48. or/35-47
49. exp animal/ or nonhuman/ or exp animal experiment/
50. exp human/
51. 49 and 50
52. 49 not 51
53. 48 not 52
54. 34 and 53

### Appendix 3. CENTRAL search strategy

Database	Time span	Search strategy
CENTRAL in <i>The Cochrane Library</i>	Issue 12, 2012	#1 MeSH descriptor Osteoporosis explode all trees in MeSH products #2 MeSH descriptor Bone Diseases, Metabolic explode all trees in MeSH products #3 osteopor* in All Fields in all products #4 MeSH descriptor Bone Density explode all trees in MeSH products #5 bone near/j2 densit* in All Fields in all products #6 MeSH descriptor Bone and Bones explode all trees in MeSH products #7 bone loss in All Fields in all products #8 osteomalacia in All Fields in all products #9 osteodystrophy in All Fields in all products #10 MeSH descriptor Bone Demineralization, Pathologic explode all trees in MeSH products #11 bone next deminerali* in All Fields in all products #12 osteopenia in All Fields in all products #13 bone mass in All Fields in all products #14 MeSH descriptor Densitometry explode all trees in MeSH products #15 densitometry in All Fields in all products #16 dexa in All Fields in all products #17 MeSH descriptor Fractures, Bone explode all trees in MeSH products #18 fractur* in All Fields in all products #19 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18) #20 MeSH descriptor Medicine, Herbal explode all trees in MeSH products #21 MeSH descriptor Plants, Medicinal explode all trees in MeSH products #22 MeSH descriptor Medicine, Traditional explode all trees in MeSH products #23 MeSH descriptor Drugs, Chinese Herbal explode all trees in MeSH products #24 herb* in All Fields in all products #25 plant or plants in All Fields in all products



(Continued)

#26 phytomedicine in All Fields in all products  
 #27 botanical in All Fields in all products  
 #28 weed\* in All Fields in all products  
 #29 algae in All Fields in all products  
 #30 fungi or fungus in All Fields in all products  
 #31 (traditional or chinese or herbal) next medicine in All Fields in all products  
 #32 (oriental or chinese) next tradition\* in All Fields in all products  
 #33 (#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32)  
 #34 (#19 AND #33)

#### Appendix 4. CBM search strategy

Database	Time span	Search strategy
CBM	1979 to 2013	1 explode "osteoporosis"/cure of Chinese traditional medicine, the combination of Western and traditional medicine 2 osteoporosis/tw 3 Chinese herbal medicine/tw 4 Chinese traditional medicine/tw 5 2 and (3 or 4) 6 1 or 5

#### Appendix 5. Effects of interventions on biochemical indicators

##### Chinese herbal medicines versus placebo (Comparison 01)

###### *Oestradiol (E2) levels*

Compared with the placebo group, those treated with Bushen Yigu soft extract after three months treatment had statistically significantly increased serum levels of oestradiol (mean difference (MD) 122.89 pg/ml; 95% confidence interval (CI) 92.97 to 152.81) ([Analysis 1.3](#)) ([Wang XY 2000](#)).

##### Chinese herbal medicines versus no intervention (Comparison 02)

###### *Oestradiol (E2) levels*

There was no significant difference in levels of serum or urinary oestradiol between Chinese herbal medicines (Bushen Shengsui principle ([Analysis 2.2](#)) ([Liao L 2004](#)), Yishen Zhuanggu mixture ([Analysis 2.2](#)) ([Gong L 2001](#)), Huoluo Gukang pills or Gushukang granule ([Analysis 2.2](#)) ([Zhang YS 2003](#))) and no intervention after six months treatment.

###### *Bone Gla protein (BGP) levels*

Compared with the no intervention group, in those treated with Yishen Zhuanggu mixture or Shengu capsule there were no statistically significant effects on BGP after six months treatment (MD -1.00 µg/L; 95% CI -6.15 to 4.15 and MD -5.10 µg/L; 95% CI -10.63 to 0.43, respectively) ([Analysis 2.3](#)) ([Gong L 2001](#)). Those treated with Huoluo Gukang pills or Gushukang granule had statistically significant increases in BGP after six months treatment (MD 2.70 µg/L; 95% CI 1.23 to 4.17 and MD 3.50 µg/L; 95% CI 1.92 to 5.08, respectively) ([Analysis 2.3](#)) ([Zhang YS 2003](#)). Treatment with Shigu yin also increased BGP after six months treatment (MD 1.20 µg/L; 95% CI 0.17 to 2.23) ([Analysis 2.3](#)) ([Zhang YP 2007](#)).

##### Chinese herbal medicines versus western medicine (Comparison 03)

###### *Oestradiol (E2) levels*

Nine trials showed positive effects of herbal treatments on serum or urinary measures of oestradiol when compared to calcium supplementation, or calcium combined with vitamin D supplementation, or calcium combined with synthesised isoflavone (ipriflavone):

- Kanggusong granule versus Caltrate after nine months treatment (MD 11.00 pg/ml; 95% CI 6.97 to 15.03), Kanggusong granule versus ipriflavone plus Caltrate after nine months treatment (MD 12.17 pg/ml; 95% CI 8.27 to 16.07) ([Analysis 3.5](#)) ([An SJ 2000](#));

- Strong Bone capsule versus Caltrate after three months treatment (MD 10.46 pg/ml; 95% CI 4.29 to 16.63) ([Analysis 3.5](#)) ([Cui TH 1999](#));
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 8.78 pg/ml; 95% CI 0.92 to 16.64) ([Analysis 3.5](#)) ([Ou L 2011](#));
- Qianggu soft extract versus calcium gluconate after six months treatment (MD 4.20 pg/ml; 95% CI 0.89 to 7.51) ([Analysis 3.5](#)) ([Peng T 2002](#));
- Gumikang capsule versus calcium gluconate after six months treatment (MD 3.50 pg/ml; 95% CI 1.14 to 5.86) ([Analysis 3.5](#)) ([Wang CC 2005](#));
- Yanghuo Sanzi tang versus Caltrate after six months treatment (MD 23.06 pg/ml; 95% CI 17.82 to 28.30) ([Analysis 3.5](#)) ([Qiu RB 2004](#));
- Jingujian granule versus Caltrate after three months treatment (MD 4.85 pg/ml; 95% CI 4.56 to 5.14) ([Analysis 3.5](#)) ([Li YH 2010](#));
- Qianggu paste versus calcium gluconate tablets after six months treatment (MD 4.20 pg/ml; 95% CI 1.79 to 6.61) ([Analysis 3.5](#)) ([Wang H 2007](#));
- Bushen Huoxue capsule versus Caltrate plus Rocalirol after 12 months treatment (MD 2.13 pg/ml; 95% CI 0.42 to 3.84) ([Analysis 3.5](#)) ([Zhang XJ 2008](#)).

However, in the following two trials, Chinese herbal medicines did not show a significant effect:

- Bushen Qiangshen pill versus Caltrate (MD 6.71 pg/ml; 95% CI -2.28 to 15.70) ([Analysis 3.5](#)) ([Mu G 2001a](#));
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (female MD 5.03 pg/ml; 95% CI -8.01 to 18.07; male MD 1.89 pg/ml; 95% CI -17.98 to 21.77) ([Analysis 3.5](#)) ([Zhou LZ 2001](#)).

Seven trials showed a better effect of Chinese herbal medicines when compared with western medicine:

- Bushen Jianpi Huoxue recipe versus alendronate sodium tablets after six months treatment (MD 3.15 pg/ml; 95% CI 0.28 to 6.02) ([Analysis 3.5](#)) ([He MT 2007](#));
- prescription for tonifying kidney versus ipriflavone (MD 14.00 pg/ml; 95% CI 3.68 to 24.32), kidney meridian sticking versus ipriflavone (MD 11.99 pg/ml; 95% CI 1.15 to 22.83), urinary bladder meridian sticking versus ipriflavone (MD 17.99 pg/ml; 95% CI 7.65 to 28.33), Gushukang granule versus ipriflavone (MD 13.98 pg/ml; 95% CI 3.90 to 24.06) after six months treatment ([Analysis 3.5](#)) ([Wu MS 2007](#));
- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD 5.09 pg/ml; 95% CI 2.81 to 7.37) ([Analysis 3.5](#)) ([Wang JM 2008](#));
- Jianshenfang granule versus alendronate sodium tablets after six months treatment (MD 5.83 pg/ml; 95% CI 4.21 to 7.45) ([Analysis 3.5](#)) ([Li BL 2007](#));
- Jiangu recipe versus alendronate sodium tablets after 12 months treatment (MD 10.75 pg/ml; 95% CI 8.55 to 12.95) ([Analysis 3.5](#)) ([Qiu RB 2008](#));
- Bushen Zhuanggu tang versus alendronate sodium tablets after three months treatment (MD 5.37 pg/ml; 95% CI 2.07 to 8.67) ([Analysis 3.5](#)) ([Ling JY 2008](#));
- Bushen Yigu soft extract versus Alfacalcidol after three months treatment (MD 76.29 nmol/L; 95% CI 31.19 to 121.39) ([Analysis 3.5](#)) ([Wang XY 2000](#)).

However, another five trials found no significant difference between groups in levels of oestradiol:

- Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone after six months treatment (MD 4.00 pg/ml; 95% CI -3.92 to 11.92) ([Analysis 3.5](#)) ([Liao L 2004](#));
- Gukang oral liquid versus alendronate after six months treatment (MD 3.90 pg/ml; 95% CI -6.64 to 14.44) ([Analysis 3.5](#)) ([Shao M 2003](#));
- Kanggusong granule versus ipriflavone after three months treatment (MD 4.18 pg/ml; 95% CI -13.85 to 22.21) ([Analysis 3.5](#)) ([Wu MS 2001](#));
- Gukang decoction versus alendronate sodium tablets after four months treatment (MD -0.65 pg/ml; 95% CI -9.04 to 7.74) ([Analysis 3.5](#)) ([Chen X 2008](#));
- Gujian capsule versus alfacalcidol after six months treatment (MD 22.35 pg/ml; 95% CI -10.51 to 55.21) ([Analysis 3.5](#)) ([Meng XD 2003](#)).

One trial showed a worse effect of Chinese herbal medicine: Huangqi Sanxian tang versus nilestriol after three months treatment (MD -32.97 pg/ml; 95% CI -39.42 to -26.52) ([Analysis 3.5](#)) ([Zhou ZK 2006](#)).

### Serum calcium (Ca) levels

In 12 trials comparing herbal treatments to calcium and vitamin D and, in one case, isoflavone, there were no significant differences between groups in changes in serum calcium:

- Kanggusong granule versus Caltrate after nine months treatment (MD -0.03 mmol/L; 95% CI -0.11 to 0.05) ([Analysis 3.6](#)) ([An SJ 2000](#));
- Gushukang granule versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.02 mmol/L; 95% CI -0.10 to 0.06) ([Analysis 3.6](#)) ([Chen ZX 2002](#));

- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD -0.01 mmol/L; 95% CI -0.05 to 0.03) ([Analysis 3.6](#)) ([Ou L 2011](#));
- Bushen Jianpi Migu prescription versus Caltrate after three months treatment (MD 0.01 mmol/L; 95% CI -0.05 to 0.07) ([Analysis 3.6](#)) ([Wang ZK 2004](#));
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD 0.10 mmol/L; 95% CI -0.05 to 0.25) ([Analysis 3.6](#)) ([Xie YM 1997](#));
- Shenyao capsules versus Caltrate after six months treatment (MD 0.02 mmol/L; 95% CI -0.08 to 0.12) ([Analysis 3.6](#)) ([Chen NQ 2006](#));
- prescription for tonifying kidney versus ipriflavone (MD 0.00 mmol/L; 95% CI -0.05 to 0.05), kidney meridian sticking versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.06 to 0.04), urinary bladder meridian sticking versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.06 to 0.04), Gushukang granule versus ipriflavone (MD -0.02 mmol/L; 95% CI -0.07 to 0.03) after six months treatment ([Analysis 3.6](#)) ([Wu MS 2007](#));
- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD -0.02 mmol/L; 95% CI -0.06 to 0.02) ([Analysis 3.6](#)) ([Wang JM 2008](#));
- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.01 mmol/L; 95% CI -0.06 to 0.08) ([Analysis 3.6](#)) ([Wang J 2007](#));
- Bushen Yangxue tang versus calcium gluconate after six months treatment (MD 0.13 mmol/L; 95% CI -0.00 to 0.26) ([Analysis 3.6](#)) ([Zhan ML 2007](#));
- Erxian soup versus Caltrate after six months treatment (MD -0.02 mmol/L; 95% CI -0.25 to 0.21) ([Analysis 3.6](#)) ([Wu JZ 2010](#));
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD -0.02 mmol/L; 95% CI -0.10 to 0.06) ([Analysis 3.6](#)) ([Zhou LZ 2001](#)).

Patients treated with herbal formulae for three to six months showed significantly higher levels of serum calcium in six trials comparing herbal treatment with calcium supplementation, isoflavone supplementation or conjugated hormones:

- Gumikang capsule versus calcium gluconate after six months treatment (MD 1.40 mmol/L; 95% CI 1.39 to 1.41) ([Analysis 3.6](#)) ([Wang CC 2005](#));
- Kanggusong granule versus ipriflavone after three months treatment (MD 0.10 mmol/L; 95% CI 0.03 to 0.17) ([Analysis 3.6](#)) ([Wu MS 2001](#));
- Yinyanghuo versus conjugated oestrogens after three to six months treatment (MD 0.54 mmol/L; 95% CI 0.23 to 0.85) ([Analysis 3.6](#)) ([Zhao LN 2003](#));
- Guli powder versus Caltrate after three months treatment (MD 0.09 mmol/L; 95% CI 0.02 to 0.16) ([Analysis 3.6](#)) ([Lan ZX 2006](#));
- Gushen Yijing tang versus Caltrate after six months treatment (MD 0.23 mmol/L; 95% CI 0.11 to 0.35) ([Analysis 3.6](#)) ([Zhong RQ 2007](#));
- Bushenjianpi Zhuangguayin versus Caltrate and calcitonin ampoule after 12 weeks (MD 0.74 mmol/L; 95% CI 0.66 to 0.82) ([Analysis 3.6](#)) ([Zhang XG 2011](#)).

Five trials reported statistically significantly lower levels of serum calcium in the group treated with Chinese herbal medicines compared to supplementation with calcium or calcium and vitamin D and, in one case, isoflavone plus Caltrate:

- Kanggusong granule versus ipriflavone plus Caltrate after nine months treatment (MD -0.09 mmol/L; 95% CI -0.17 to -0.01) ([Analysis 3.6](#)) ([An SJ 2000](#));
- Strong Bone capsule versus Caltrate after three months treatment (MD -0.13 mmol/L; 95% CI -0.22 to -0.04) ([Analysis 3.6](#)) ([Cui TH 1999](#));
- Qianggu soft extract versus calcium gluconate (MD -0.03 mmol/L; 95% CI -0.05 to -0.01) ([Analysis 3.6](#)) ([Peng T 2002](#));
- Qianggu paste versus calcium gluconate tablets after six months treatment (MD -0.03 mmol/L; 95% CI -0.06 to -0.00) ([Analysis 3.6](#)) ([Wang H 2007](#));
- Jiangu capsule versus Caltrate after 12 months treatment (MD -0.06 mmol/L; 95% CI -0.11 to -0.01) ([Analysis 3.6](#)) ([Wang YZ 2008](#)).

### Phosphorus (P) levels

Eleven trials showed no significant effects of herbal treatments on phosphorus when compared to calcium supplementation, or calcium combined with vitamin D supplementation, or calcium combined with synthesised isoflavone (ipriflavone):

- Kanggusong granule versus ipriflavone plus Caltrate (MD 0.06 mmol/L; 95% CI -0.03 to 0.15), Kanggusong granule versus Caltrate (MD -0.01 mmol/L; 95% CI -0.29 to 0.27) after nine months treatment ([Analysis 3.7](#)) ([An SJ 2000](#));
- Gushukang granule versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD 0.01 mmol/L; 95% CI -0.09 to 0.11) ([Analysis 3.7](#)) ([Chen ZX 2002](#));
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 0.00 mmol/L; 95% CI -0.15 to 0.15) ([Analysis 3.7](#)) ([Ou L 2011](#));
- Bushen Jianpi Migu prescription versus Caltrate after three months treatment (MD 0.03 mmol/L; 95% CI -0.02 to 0.08) ([Analysis 3.7](#)) ([Wang ZK 2004](#));
- Shenyao capsules versus Caltrate after six months treatment (MD -0.01 mmol/L; 95% CI -0.08 to 0.06) ([Analysis 3.7](#)) ([Chen NQ 2006](#));
- Guli powder versus Caltrate after three months treatment (MD -0.05 mmol/L; 95% CI -0.13 to 0.03) ([Analysis 3.7](#)) ([Lan ZX 2006](#));
- Gushen Yijing tang versus Caltrate after six months treatment (MD 0.04 mmol/L; 95% CI -0.09 to 0.17) ([Analysis 3.7](#)) ([Zhong RQ 2007](#));

- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.02 mmol/L; 95% CI -0.05 to 0.09) ([Analysis 3.7](#)) ([Wang J 2007](#));
- Jiangu capsule versus Caltrate after 12 months treatment (MD 0.09 mmol/L; 95% CI -0.20 to 0.38) ([Analysis 3.7](#)) ([Wang YZ 2008](#));
- Erxian soup versus Caltrate after six months treatment (MD -0.03 mmol/L; 95% CI -0.20 to 0.14) ([Analysis 3.7](#)) ([Wu JZ 2010](#));
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD -0.01 mmol/L; 95% CI -0.12 to 0.10) ([Analysis 3.7](#)) ([Zhou LZ 2001](#)).

Three trials found no significant differences between groups for phosphorus when comparing herbal formulae to conventional western medicines:

- Kanggusong granule versus ipriflavone after three months treatment (MD -0.07 mmol/L; 95% CI -0.20 to 0.06) ([Analysis 3.7](#)) ([Wu MS 2001](#));
- Yinyanghuo versus conjugated oestrogens after three to six months treatment (MD 0.13 mmol/L; 95% CI -0.13 to 0.39) ([Analysis 3.7](#)) ([Zhao LN 2003](#));
- prescription for tonifying kidney versus ipriflavone (MD -0.04 mmol/L; 95% CI -0.15 to 0.07), kidney meridian sticking versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.13 to 0.11), urinary bladder meridian sticking versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.13 to 0.11), Gushukang granule versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.13 to 0.11) after six months treatment ([Analysis 3.7](#)) ([Wu MS 2007](#)).

One trial showed better effects of Bushen Zhuanggu tang compared to alendronate sodium tablets after three months treatment (MD 0.24 mmol/L; 95% CI 0.10 to 0.38) ([Analysis 3.7](#)) ([Ling JY 2008](#)).

Two other trials showed worse effects of Chinese herbal medicines:

- Strong Bone capsule compared with Caltrate after three months treatment (MD -0.12 mmol/L; 95% CI -0.21 to -0.03) ([Analysis 3.7](#)) ([Cui TH 1999](#));
- Bushenjianpi Zhuanggu yin versus Caltrate and calcitonin ampoule after 12 weeks treatment (MD -0.37 mmol/L; 95% CI -0.48 to -0.26) ([Analysis 3.7](#)) ([Zhang XG 2011](#)).

#### **Alkaline phosphatase (ALP) levels**

Eleven trials showed no significant effects of herbal treatments on alkaline phosphatase when compared to calcium supplementation, or calcium combined with vitamin D supplementation, or calcium combined with synthesised isoflavone (ipriflavone):

- Gushukang granule versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.50  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.70 to 0.70) ([Analysis 3.8](#)) ([Chen ZX 2002](#));
- Strong Bone capsule versus Caltrate after three months treatment (MD -0.07  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.25 to 0.11) ([Analysis 3.8](#)) ([Cui TH 1999](#));
- Bushen Qiangshen pill versus Caltrate after three months treatment (MD 0.27  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.27 to 1.81) ([Analysis 3.8](#)) ([Mu G 2001a](#));
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD -0.29  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.67 to 1.09) ([Analysis 3.8](#)) ([Xie YM 1997](#));
- Liuwei Dihuang pills versus calcium after 12 months treatment (MD 0.55  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.12 to 1.22) ([Analysis 3.8](#)) ([Zhang J 2003](#));
- Guli powder versus Caltrate after three months treatment (MD 0.30  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -2.97 to 3.57) ([Analysis 3.8](#)) ([Lan ZX 2006](#));
- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.71  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.17 to 2.59) ([Analysis 3.8](#)) ([Wang J 2007](#));
- Jingujian granule versus Caltrate after three months treatment (MD 0.53  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.69 to 1.75) ([Analysis 3.8](#)) ([Li YH 2008](#));
- Bushenjianpi Zhuanggu yin versus Caltrate and calcitonin ampoule after 12 weeks treatment (MD -0.82  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -2.83 to 1.19) ([Analysis 3.8](#)) ([Zhang XG 2011](#));
- Erxian soup versus Caltrate after six months treatment (MD 0.00  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.87 to 0.87) ([Analysis 3.8](#)) ([Wu JZ 2010](#));
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD 0.18  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.08 to 1.44) ([Analysis 3.8](#)) ([Zhou LZ 2001](#)).

Twelve trials showed better effects of herbal treatments on alkaline phosphatase when compared to calcium supplementation, or calcium combined with vitamin D supplementation, or calcium combined with synthesised isoflavone (ipriflavone):

- Kanggusong granule versus ipriflavone plus Caltrate (MD 1.69  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.79 to 2.59), Kanggusong granule versus Caltrate (MD 1.28  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.30 to 2.26) after nine months treatment ([Analysis 3.8](#)) ([An SJ 2000](#));
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 0.91  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.15 to 1.67) ([Analysis 3.8](#)) ([Ou L 2011](#));
- Qianggu soft extract versus calcium gluconate after six months treatment (MD 3.60  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 2.62 to 4.58) ([Analysis 3.8](#)) ([Peng T 2002](#));
- Gumikang capsule versus calcium gluconate after six months treatment (MD 3.41  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 2.84 to 3.98) ([Analysis 3.8](#)) ([Wang CC 2005](#));

- Bushen Jianpi Migu prescription versus Caltrate after three months treatment (MD 0.10  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.01 to 0.19) ([Analysis 3.8](#)) ([Wang ZK 2004](#));
- Liuwei Dihuang pills versus calcium after six months treatment (MD 0.43  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.11 to 0.75) ([Analysis 3.8](#)) ([Zhang J 2003](#));
- TPF capsule versus calcium granule after six months treatment (MD 3.84  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 2.53 to 5.15) ([Analysis 3.8](#)) ([Zhang YL 1996](#));
- Gushen Yijing tang versus Caltrate after six months treatment (MD 2.17  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.73 to 3.61) ([Analysis 3.8](#)) ([Zhong RQ 2007](#));
- Jiangu capsule versus Caltrate after 12 months treatment (MD 2.04  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 1.32 to 2.76) ([Analysis 3.8](#)) ([Wang YZ 2008](#));
- Jingujian granule versus Caltrate after three months treatment (MD 2.40  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 2.21 to 2.59) ([Analysis 3.8](#)) ([Li YH 2010](#));
- Qianggu paste versus calcium gluconate tablets after six months treatment (MD 3.60  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 2.86 to 4.34) ([Analysis 3.8](#)) ([Wang H 2007](#));
- Bushen Yangxue tang versus calcium gluconate after six months treatment (MD 2.62  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.84 to 4.40) ([Analysis 3.8](#)) ([Zhan ML 2007](#)).

Seven trials showed no significant effects of herbal treatments on alkaline phosphatase when compared to conventional western medicines:

- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD -1.06  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -2.54 to 0.42) ([Analysis 3.8](#)) ([Shao M 2003](#));
- Kanggusong granule versus ipriflavone after three months treatment (MD 0.13  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.07 to 0.33) ([Analysis 3.8](#)) ([Wu MS 2001](#));
- Huangqi Sanxian tang versus nilestriol after three months treatment (MD -0.03  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.14 to 1.08) ([Analysis 3.8](#)) ([Zhou ZK 2006](#));
- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD 0.48  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.34 to 1.30) ([Analysis 3.8](#)) ([Wang JM 2008](#));
- Jianshenfang granule versus alendronate sodium tablets after six months treatment (MD 0.33  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -2.78 to 3.44) ([Analysis 3.8](#)) ([Li BL 2007](#));
- Bushen Zhuanggu tang versus alendronate sodium tablets after three months treatment (MD -0.11  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.99 to 0.77) ([Analysis 3.8](#)) ([Ling JY 2008](#));
- Gusong recipe versus alendronate sodium tablets after five months treatment (MD -1.05  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -2.86 to 0.76) ([Analysis 3.8](#)) ([Xiao W 2008](#)).

Another three trials showed a worse effect of herbal treatments when compared to calcium supplementation, hormones or alendronate sodium tablets:

- Shenyao capsules versus Caltrate after six months treatment (MD -2.40  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -3.58 to -1.22) ([Analysis 3.8](#)) ([Chen NQ 2006](#));
- Yinyanghuo versus conjugated oestrogens after three to six months treatment (MD -7.00  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -11.17 to -2.83) ([Analysis 3.8](#)) ([Zhao LN 2003](#));
- Bushen Jianpi Huoxue recipe versus alendronate sodium tablets after six months treatment (MD -2.94  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -4.34 to 1.54) ([Analysis 3.8](#)) ([He MT 2007](#)).

### **Bone Gla protein (BGP) levels**

One trial found that there was a significant difference in BGP between Chinese herbal and western medicines:

- Acupoint sticking of Migudan versus oyster shell calcium chewable tablets after three months treatment (MD 1.55  $\mu\text{g}/\text{L}$ ; 95% CI 1.24 to 1.86) ([Analysis 3.9](#)) ([Xu YL 2007](#)).

Three trials showed a statistically significantly better effect on BGP when compared with calcium supplementation:

- Bushen Huoxue capsule versus Caltrate plus Rocalirol after 12 months treatment (MD 0.93  $\mu\text{g}/\text{L}$ ; 95% CI 0.35 to 1.51) ([Analysis 3.9](#)) ([Zhang XJ 2008](#));
- Kanggusong capsule versus Caltrate after six months treatment (MD 1.78  $\mu\text{g}/\text{L}$ ; 95% CI 0.40 to 3.16) ([Analysis 3.9](#)) ([Wei RY 2011](#));
- Liuwei Dihuang pills versus calcium after 12 months treatment (MD 17.90  $\mu\text{g}/\text{L}$ ; 95% CI 12.43 to 23.37) ([Analysis 3.9](#)) ([Zhang J 2003](#)).

Three trials showed no significant effects of herbal treatments on BGP when compared to western medicines:

- Gukang oral liquid versus alendronate after six months treatment (MD -0.10  $\mu\text{g}/\text{L}$ ; 95% CI -0.93 to 0.73) ([Analysis 3.9](#)) ([Shao M 2003](#));
- Jianshenfang granule versus alendronate sodium tablets after six months treatment (MD 0.49  $\mu\text{g}/\text{L}$ ; 95% CI -1.59 to 2.57) ([Analysis 3.9](#)) ([Li BL 2007](#));

- Jiangu recipe versus alendronate sodium tablets after 12 months treatment (MD 1.81 µg/L; 95% CI -0.31 to 3.93) ([Analysis 3.9](#)) ([Qiu RB 2008](#)).

Five trials showed no significant effects of herbal treatments when compared with calcium supplementation:

- Strong Bone capsule versus Caltrate after three months treatment (MD -0.49 µg/L; 95% CI -2.17 to 1.19) ([Analysis 3.9](#)) ([Cui TH 1999](#));
- Yanghuo Sanzitang versus Caltrate after six months treatment (MD 2.71 µg/L; 95% CI -0.30 to 5.72) ([Analysis 3.9](#)) ([Qiu RB 2004](#));
- Shigu yin versus Caltrate after six months treatment (MD 0.80 µg/L; 95% CI -0.34 to 1.94) ([Analysis 3.9](#)) ([Zhang YP 2007](#));
- Jingujian granule versus Caltrate after three months treatment (MD 2.53 µg/L; 95% CI -0.38 to 5.44) ([Analysis 3.9](#)) ([Li YH 2008](#));
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD -1.50 µg/L; 95% CI -5.07 to 2.08) ([Analysis 3.9](#)) ([Zhou LZ 2001](#)).

Another trial showed a worse effect of Bushen Jianpi Huoxue recipe when compared to alendronate sodium tablets after six months treatment (MD -2.13 µg/L; 95% CI -2.74 to -1.52) ([Analysis 3.9](#)) ([He MT 2007](#)).

### **Interleukin-6 (IL-6) levels**

There was no significant difference between herbal drugs and western medicine in interleukin-6 in three trials:

- Bushen Jianpi Huoxue recipe versus alendronate sodium tablets after six months treatment (MD -5.72 pg/ml; 95% CI -14.05 to 2.61) ([Analysis 3.10](#)) ([He MT 2007](#));
- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD -3.50 pg/ml; 95% CI -15.93 to 8.93) ([Analysis 3.10](#)) ([Shao M 2003](#));
- Jianshenfang granule versus alendronate sodium tablets after six months treatment (MD -12.56 pg/ml; 95% CI -29.26 to 4.14) ([Analysis 3.10](#)) ([Li BL 2007](#)).

Three trials showed statistically significantly better effects on interleukin-6:

- Jiangu recipe versus alendronate sodium tablets after 12 months treatment (MD -19.99 pg/ml; 95% CI -30.92 to -9.06) ([Analysis 3.10](#)) ([Qiu RB 2008](#));
- Yanghuo Sanzi tang versus Caltrate after six months treatment (MD -20.29 pg/ml; 95% CI -35.67 to -4.91) ([Analysis 3.10](#)) ([Qiu RB 2004](#));
- Bushen Huoxue capsule versus Caltrate plus Rocalirol (MD -18.70 pg/ml; 95% CI -34.16 to -3.24) ([Analysis 3.10](#)) ([Zhang XJ 2008](#)).

### **Parathyroid hormone (PTH) levels**

Four trials showed no significant effects of herbal treatments on PTH when compared to common western medicines:

- prescription for tonifying kidney versus ipriflavone (MD -13.00 µg/L; 95% CI -41.67 to 15.67), kidney meridian sticking versus ipriflavone (MD -13.01 µg/L; 95% CI -41.95 to 15.93), urinary bladder meridian sticking versus ipriflavone (MD -3.01 µg/L; 95% CI -31.44 to 25.42), Gushukang granule versus ipriflavone (MD -3.02 µg/L; 95% CI -30.91 to 24.87) after six months treatment ([Analysis 3.11](#)) ([Wu MS 2007](#));
- Kanggusong granule versus ipriflavone after three months treatment (MD 11.81 µg/L; 95% CI -14.64 to 38.26) ([Analysis 3.11](#)) ([Wu MS 2001](#));
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD -10.63 µg/L; 95% CI -140.92 to 119.66) ([Analysis 3.11](#)) ([Xie YM 1997](#));
- Gujian capsule versus alfacalcidol after six months treatment (MD -22.57 pg/ml; 95% CI -60.92 to 15.78) ([Analysis 3.11](#)) ([Meng XD 2003](#));
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD -2.06 pg/ml; 95% CI -6.74 to 2.62) ([Analysis 3.11](#)) ([Ou L 2011](#)).

In another trial, TPF capsule showed a better effect than calcium granule after six months treatment (MD -254.00 pg/ml; 95% CI -399.06 to -108.94) ([Analysis 3.11](#)) ([Zhang YL 1996](#)).

### **Calcitonin (CT) levels**

Five trials showed no significant effects of herbal treatments on calcitonin when compared to common western medicines:

- prescription for tonifying kidney versus ipriflavone (MD 0.96 ng/L; 95% CI -3.71 to 5.63), kidney meridian sticking versus ipriflavone (MD -1.01 ng/L; 95% CI -5.44 to 3.42), urinary bladder meridian sticking versus ipriflavone (MD -0.01 ng/L; 95% CI -4.68 to 4.66), Gushukang granule versus ipriflavone (MD -0.01 ng/L; 95% CI -4.44 to 4.42) after six months treatment ([Analysis 3.12](#)) ([Wu MS 2007](#));
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (MD 15.93 ng/L; 95% CI -24.16 to 56.02) ([Analysis 3.12](#)) ([Xie YM 1997](#));
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD -6.18 ng/L; 95% CI -12.89 to 0.52) ([Analysis 3.12](#)) ([Zhou LZ 2001](#));
- Gujian capsule versus alfacalcidol after six months treatment (MD -12.77 ng/L; 95% CI -70.92 to 45.38) ([Analysis 3.12](#)) ([Meng XD 2003](#));

- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 0.11 ng/L; 95% CI -0.04 to 0.26) ([Analysis 3.12](#)) ([Ou L 2011](#)).

Three trials showed a statistically significantly better effect on calcitonin when compared with calcium supplementation:

- Strong Bone capsule versus Caltrate after three months treatment (MD 16.25 ng/L; 95% CI 10.43 to 22.07) ([Analysis 3.12](#)) ([Cui TH 1999](#));
- Jingujian granule versus Caltrate after three months treatment (MD 21.98 ng/L; 95% CI 17.01 to 26.95) ([Analysis 3.12](#)) ([Li YH 2010](#));
- TPF capsule versus calcium granule after six months treatment (MD 17.71 ng/L; 95% CI 11.53 to 23.89) ([Analysis 3.12](#)) ([Zhang YL 1996](#)).

#### Chinese herbal medicines plus western medicine versus western medicine (Comparison 04)

##### Oestradiol (E2) levels

Eight trials showed positive effects of Chinese herbal medicines plus western medicine treatments on E2 when compared to the same western medicines:

- Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol after six months treatment (MD 4.54 pg/ml; 95% CI 0.47 to 8.61) ([Analysis 4.6](#)) ([Chen FS 2001](#));
- Shugan zhen huoxue tang plus Caltrate and alendronate sodium tablets versus Caltrate and alendronate sodium tablets after six months treatment (MD 26.99 pg/ml; 95% CI 18.44 to 35.54) ([Analysis 4.6](#)) ([Han XL 2007](#));
- Ziyin Bushen Zhuanggu prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after eight months treatment (MD 23.21 pg/ml; 95% CI 14.46 to 31.96) ([Analysis 4.6](#)) ([Li HW 2004](#));
- Zhuanggu capsule plus Caltrate versus Caltrate after six months treatment (MD 4.06 pg/ml; 95% CI 2.56 to 5.56) ([Analysis 4.6](#)) ([Li SL 2004](#));
- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD 11.00 pg/ml; 95% CI 8.14 to 13.86) ([Analysis 4.6](#)) ([Wang SW 2003](#));
- Zhen prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin (MD 23.21 pg/ml; 95% CI 14.46 to 31.96) ([Analysis 4.6](#)) ([Zhao G 2002](#));
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks treatment (MD 6.04 pg/ml; 95% CI 4.61 to 7.47) ([Analysis 4.6](#)) ([Zhang XZ 2004](#));
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 40.85 pg/ml; 95% CI 33.61 to 48.09) ([Analysis 4.6](#)) ([Zhang RH 2004](#)).

Compared with Caltrate alone, Bushen Qiangshen pill plus Caltrate did not have significant effect on oestradiol (MD 7.60 pg/ml; 95% CI -0.51 to 15.71) ([Analysis 4.6](#)) ([Mu G 2001](#)).

##### Serum calcium (Ca) levels

Three trials showed positive effects of Chinese herbal medicines plus western medicine treatments on calcium when compared to the same western medicines:

- Bushenyiqihuoxue soup plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD 0.37 mmol/L; 95% CI 0.32 to 0.42) ([Analysis 4.7](#)) ([Zhang DS 2011](#));
- Chinese medicine (combinations of 10 herbs) plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD 0.37 mmol/L; 95% CI 0.32 to 0.42) ([Analysis 4.7](#)) ([Cao W 2010](#));
- Huangqi plus Caltrate versus Caltrate after six months treatment (MD 0.28 mmol/L; 95% CI 0.11 to 0.45) ([Analysis 4.7](#)) ([Yang B 2007](#)).

While Yigu capsule plus calcium versus placebo plus calcium had a negative effect on calcium after six months treatment (MD -0.07 mmol/L; 95% CI -0.13 to -0.01) ([Analysis 4.7](#)) ([Zhang RH 2004](#)).

Eight trials did not show positive effects of herbal treatments plus western medicines when compared to the same western medicines:

- Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol after six months treatment (MD 0.05 mmol/L; 95% CI -0.02 to 0.12) ([Analysis 4.7](#)) ([Chen FS 2001](#));
- Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.01 mmol/L; 95% CI -0.09 to 0.07) ([Analysis 4.7](#)) ([Chen ZX 2002](#));
- Zhuanggu capsule plus Caltrate versus Caltrate after six months treatment (MD 0.01 mmol/L; 95% CI -0.07 to 0.09) ([Analysis 4.7](#)) ([Li SL 2004](#));
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after three months treatment (MD -0.02 mmol/L; 95% CI -0.06 to 0.02) ([Analysis 4.7](#)) ([Ma CZ 2011](#));
- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD -0.03 mmol/L; 95% CI -0.09 to 0.03) ([Analysis 4.7](#)) ([Wang SW 2003](#));

- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD -0.05 mmol/L; 95% CI -0.11 to 0.01) ([Analysis 4.7](#)) ([Zheng WK 2007](#));
- Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD 0.03 mmol/L; 95% CI -0.09 to 0.15) ([Analysis 4.7](#)) ([Dong Y 2010](#));
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD -0.02 mmol/L; 95% CI -0.10 to 0.06) ([Analysis 4.7](#)) ([Zhang ZF 2011](#)).

### **Phosphorus (P) levels**

Nine trials did not show positive effects of herbal treatments plus western medicines when compared to the same western medicines:

- Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol (MD -0.13 mmol/L; 95% CI -0.27 to 0.01) ([Analysis 4.8](#)) ([Chen FS 2001](#));
- Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.02 mmol/L; 95% CI -0.11 to 0.07) ([Analysis 4.8](#)) ([Chen ZX 2002](#));
- Zhuanggu capsule plus Caltrate versus Caltrate (MD 0.01 mmol/L; 95% CI -0.06 to 0.08) ([Analysis 4.8](#)) ([Li SL 2004](#));
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after three months treatment (MD 0.06 mmol/L; 95% CI -0.22 to 0.34) ([Analysis 4.8](#)) ([Ma CZ 2011](#));
- Antai capsule plus Caltrate versus Caltrate (MD -0.01 mmol/L; 95% CI -0.23 to 0.21) ([Analysis 4.8](#)) ([Wang SW 2003](#));
- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD -0.02 mmol/L; 95% CI -0.09 to 0.05) ([Analysis 4.8](#)) ([Zheng WK 2007](#));
- Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD 0.01 mmol/L; 95% CI -0.12 to 0.14) ([Analysis 4.8](#)) ([Dong Y 2010](#));
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD -0.03 mmol/L; 95% CI -0.08 to 0.02) ([Analysis 4.8](#)) ([Zhang RH 2004](#));
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD -0.02 mmol/L; 95% CI -0.08 to 0.04) ([Analysis 4.8](#)) ([Zhang ZF 2011](#)).

### **Alkaline phosphatase (ALP) levels**

Seven trials did not show significant effects of herbal treatments plus western medicines on alkaline phosphatase levels when compared to the same western medicines:

- Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.50  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.70 to 0.70) ([Analysis 4.9](#)) ([Chen ZX 2002](#));
- Zhuanggu capsule plus Caltrate versus Caltrate after six months treatment (MD 0.00  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.55 to 1.55) ([Analysis 4.9](#)) ([Li SL 2004](#));
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after three months treatment (MD 0.31  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.48 to 1.10) ([Analysis 4.9](#)) ([Ma CZ 2011](#));
- Bushen Qiangshen pill plus Caltrate versus Caltrate after three months treatment (MD -0.31  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.72 to 1.10) ([Analysis 4.9](#)) ([Mu G 2001](#));
- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD 1.01  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.04 to 2.06) ([Analysis 4.9](#)) ([Zheng WK 2007](#));
- Chinese medicine (combinations of 10 herbs) plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD -0.26  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.64 to 1.12) ([Analysis 4.9](#)) ([Cao W 2010](#));
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD 0.08  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -0.54 to 0.70) ([Analysis 4.9](#)) ([Zhang ZF 2011](#)).

Six trials showed that herbal drugs plus western medicine could increase the alkaline phosphatase level when compared with the same western medicine:

- Antai capsule plus Caltrate versus Caltrate regarding alkaline phosphatase before and after six months treatment (MD 1.28  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.55 to 2.01) ([Analysis 4.9](#)) ([Wang SW 2003](#));
- Chinese decoction plus calcium gluconate versus calcium gluconate after nine months treatment (MD 1.77  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 1.20 to 2.34) ([Analysis 4.9](#)) ([Miu JQ 2008](#));
- Bushenyiqihuoxue soup plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD 3.54  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 1.68 to 5.40) ([Analysis 4.9](#)) ([Zhang DS 2011](#));
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 1.73  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.71 to 2.75) ([Analysis 4.9](#)) ([Zhang RH 2004](#));



- Huangqi plus Caltrate versus Caltrate after six months treatment (MD 0.82  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 0.63 to 1.01) ([Analysis 4.9](#)) ([Yang B 2007](#));
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks (MD 10.48  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI 9.81 to 11.15) ([Analysis 4.9](#)) ([Zhang XZ 2004](#)).

Two trials showed the opposite effect:

- Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD -0.99  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -1.52 to -0.46) ([Analysis 4.9](#)) ([Dong Y 2010](#));
- Kanggusong soup plus Caltrate versus Caltrate after three months treatment (MD -1.61  $\mu\text{mol s}^{-1}/\text{L}$ ; 95% CI -3.17 to -0.05) ([Analysis 4.9](#)) ([Li ZP 2011](#)).

### **Bone Gla protein (BGP) levels**

One trial showed a better effect of herbal drugs plus western medicine:

- Zhuanggu capsule plus Caltrate versus Caltrate (MD -2.30  $\mu\text{g}/\text{L}$ ; 95% CI -4.07 to -0.53) ([Analysis 4.10](#)) ([Li SL 2004](#)).

Seven trials showed a worse effect of herbal drugs plus western medicine:

- Traditional Chinese capsule plus calcium gluconate versus calcium gluconate after nine months treatment (MD 1.23  $\mu\text{g}/\text{L}$ ; 95% CI 0.88 to 1.58) ([Analysis 4.10](#)) ([Miu JQ 2008](#));
- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD 2.47  $\mu\text{g}/\text{L}$ ; 95% CI 1.44 to 3.50) ([Analysis 4.10](#)) ([Zheng WK 2007](#));
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 2.60  $\mu\text{g}/\text{L}$ ; 95% CI 1.66 to 3.54) ([Analysis 4.10](#)) ([Zhang RH 2004](#));
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks treatment (MD 6.24  $\mu\text{g}/\text{L}$ ; 95% CI 5.69 to 6.79) ([Analysis 4.10](#)) ([Zhang XZ 2004](#));
- Xianlinggubao capsules plus Caltrate versus Caltrate after 12 months treatment (MD 1.85  $\mu\text{g}/\text{L}$ ; 95% CI 0.87 to 2.83) ([Analysis 4.10](#)) ([Wu W 2005](#));
- Huangqi plus Caltrate versus Caltrate after six months treatment (MD 0.63  $\mu\text{g}/\text{L}$ ; 95% CI 0.50 to 0.76) ([Analysis 4.10](#)) ([Yang B 2007](#)).

There was no significant difference between Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD 0.56  $\mu\text{g}/\text{L}$ ; 95% CI -0.30 to 1.42) ([Analysis 4.10](#)) ([Dong Y 2010](#)).

### **Interleukin-6 (IL-6) levels**

Three trials showed a better effect of herbal drugs plus western medicine on interleukin-6:

- Erxian Yanggu tang plus alendronate sodium tablets versus alendronate sodium tablets (MD -16.18 pg/ml; 95% CI -19.62 to -12.74) ([Analysis 4.11](#)) ([Huang JW 2008](#));
- Kanggusong soup plus Caltrate versus Caltrate after three months treatment (MD -16.32 pg/ml; 95% CI -31.60 to -1.04) ([Analysis 4.11](#)) ([Li ZP 2011](#));
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks treatment (MD -133.30 pg/ml; 95% CI -139.94 to -126.66) ([Analysis 4.11](#)) ([Zhang XZ 2004](#)).

## **HISTORY**

Protocol first published: Issue 3, 2005

Review first published: Issue 3, 2014

Date	Event	Description
26 August 2008	Amended	Converted to new review format. C041-R

## **CONTRIBUTIONS OF AUTHORS**

Y Liu: drafted the protocol, developed the search strategy, selected trials, assessed trial quality, extracted data, performed data analyses and drafted the review.

Y Xia: updated the searches and selected trials, assessed trial quality, extracted data, performed data analyses and co-developed the review.

JP Liu: conceived the study, revised the protocol and the review, provided a methodological perspective and performed data analyses.

## DECLARATIONS OF INTEREST

We certify that we have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (e.g. employment, consultancy, stock ownership, honoraria, expert testimony).

## SOURCES OF SUPPORT

### Internal sources

- School of Public Health, Shandong University, China.
- Beijing University of Chinese Medicine, China.

### External sources

- National Basic Research Program ('973' program, grant number 2006CB504602), China.
- International Science & Technology Cooperation Project (grant number 2009DFA31460), China.
- The Program for Innovative Research Team of Beijing University of Chinese Medicine (no. 2011-CXTD-09), China.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Chinese diagnostic criteria for osteoporosis were added, besides the WHO criteria, as many trials used the Chinese criteria (these were adapted from the WHO criteria).

## INDEX TERMS

### Medical Subject Headings (MeSH)

Bone Density Conservation Agents [therapeutic use]; Drugs, Chinese Herbal [\*therapeutic use]; Osteoporosis [\*drug therapy]; Phytotherapy [\*methods]; Randomized Controlled Trials as Topic

### MeSH check words

Humans